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Abstract
Mismatch repair (MMR) defects results in widespread instability at repetitive
DNA in both coding and non-coding sequences. Repetitive tracts within the coding
sequences of genes including TGFBR2 and BAX are frequently mutated in MMR
deficient cancers and implicated in tumour progression. The Wnt pathway genes
APC and (3-catenin, are commonly mutated in MMR proficient cancers and are also
mutated in a lower proportion of MMR deficient cancers, suggesting they may also
be prone to mutation as a consequence of MMR defects. However, there has been
little study of the relative contribution of inherent instability and selection pressure at
such sequences in neoplasms. One explanation as to why sequences are mutated
frequently in MMR deficient colorectal cancer (CRC) is that they are inherently
prone to mutations. To investigate this hypothesis, MMR deficient cells (lbl-1260,
lbl-1261) derived from normal tissue (B-lymphocytes), have been utilised. Analysing
these cells minimises the effects of selection pressures that bias the apparent
frequency of mutations in cancer cells and "unmasks" inherent stability of given
sequences. Using this system, the research aims were to identify whether factors
independent of tumourigenesis, influence the manifestation of the mutator phenotype
at repetitive tracts. Also, whether mutations in the coding sequences of genes
implicated in tumourigenesis, can occur as a consequence of MMR defects when
selection pressure is minimal.
A SP-PCR technique was employed and demonstrated that lbl-1261 and lbl-1260
exhibit microsatellite instability. At the D2S123 locus, the sequence of the
constitutional allele itself is shown to be a determinant of instability in the absence of
MMR activity. Presence of an interruption within the (CA)n repeat, is common
within the Scottish population and confers differential stability at individual
microsatellite alleles in MMR deficient cells. At a second microsatellite locus (BAT-
40), extreme sensitivity to mutation in the presence of MMR deficiency is observed.
This is further indicated by analysis of the mutation frequency within families and
also from sperm DNA where germline instability at this poly(A) locus is revealed. A
combination of SP-PCR, allele cloning and restriction digest methods were employed
to determine whether differences in mutation frequencies of the TGFBR2 and BAX
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genes in MMR deficient CRC, may be due to differential stability in the presence of
MMR defects. MMR deficiency is shown to be associated with an excess of
mutations at the poly(A)io tract of TGFBR2 in cells of a normal lineage. Surprisingly,
at the poly(G)8 tract of the BAX gene, an excess of mutations is not observed. The
inherent stability of Wnt pathway gene sequences frequently mutated in MMR
proficient CRC was addressed. Mutations of CTNNB1 and APC are observed in a
small proportion of MMR deficient CRCs. However, despite rigorous mutation
analysis of exon 3 of the CTNNB1 gene, there is no indication that this region is
particularly prone to mutation consequent of MMR defects. Extensive analysis of
inherent mutability was also performed for the APC gene. Interestingly, an
unexpectedly high level of instability was detected in exon 15 in both normal and
cancer cells, proficient in MMR. But in lbl-1261 the instability was markedly lower
suggestive of complex relationship between MMR defects and mutation frequency at
this locus.
In this thesis, the importance of inherent instability in the accumulation of
mutational events observed in MMR deficient CRC has been investigated. The work
shows conclusively that the nature of the repeat in non-coding and coding sequences
affects the manifestation of the mutator phenotype. Differences in the mutation
frequency of genes mutated in CRC are influenced by inherent instability at such
sequences in the presence of MMR defects even in non-neoplastic cells.
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The research described in this thesis has addressed how defects in mismatch repair
(MMR) and the consequent elevation in mutation rate, contributes to the initiation
and progression of colorectal cancer (CRC). In particular this project has investigated
how inherent instability at both non-coding and coding sequence can influence the
frequency with which mutations accumulate in cancers with MMR defects. Specific
factors independent of the tumourigenic process itself, which affect the propensity to
mutation, have also been determined.
Inherent instability and selection pressures are believed to be important influences
in tumourigenesis. However, the specific consequences of these factors and the
relative contribution made to the acquisition of genetic changes observed in cancers,
are not well understood. Therefore, the examination of molecular events that arise
exclusively as a result of MMR defects has considerable relevance to understanding
the effects of inherent instability and increased mutation rate in cancer development.
The significance in elucidating the molecular mechanisms that underlie CRC is
underscored by the fact that cancer of the colon is a major health problem. In this
chapter the incidence of CRC is discussed and the contribution from aetiological and
genetic factors is reviewed. Evidence that an increase in instability is an important
and necessary feature of cancer is presented. In addition, the notion that selection
pressure represents the major driving force in tumourigenesis is also considered.
Malignancies associated with MMR defects are described, to exemplify the spectrum
of cancers in which genomic instability is involved. This includes a description of
syndromes associated with extra-colonic cancers. The mechanism by which MMR
maintains genome integrity is detailed, with emphasise on how inactivation of this
system results in the drastic elevation of mutations that are observed in the associated
cancers. The genetic and epigenetic mechanisms of inactivation of MMR are then
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presented. Current understanding of the consequences of MMR defects in terms of
widespread microsatellite instability and the manifestation of a mutator phenotype is
described and the evidence suggesting that instability results in tumourigenesis, via
mutation of specific cancer causing genes is detailed. Finally the aims of the project
are presented and the experimental approach is described.
1.2 Environmental and Genetic Factors in Colorectal Cancer
1.2.1 Incidence of colorectal cancer
Cancers of the colon and rectum (CRCs) represent a major health problem in the
western world. Despite advances in modern medicine the prevalence of CRC remains
second only to lung cancer in developed countries (Parkin et al., 1999). In the United
Kingdom (UK) there are 34,000 new cases of CRC and more than 20,000 deaths
annually (Farrington and Dunlop, in press) presenting a significant financial burden
to the National Health Service. In the United States (US), CRC accounts for 10% of
all cancer mortality (Pisani et al., 1999). In 2001 alone there will be an estimated
135,400 new cases in the US including, 98,200 of colon cancer and 37,200 of rectal
cancer with an estimated 56,700 deaths (American Cancer Society,
www.cancer.org). The prognosis for patients with CRC is relatively poor. Data from
the Scottish information and statistics division reveal that an average of just 44.5% of
patients are still alive 5 years after presentation (ISD Scotland;
www.show.scot.nhs.uk/isd/index.htm). CRC is the only cancer to occur with
approximately equal frequencies in men and women (Parkin et al., 1999). Although,
the age adjusted rates in men exceed woman by as much as 20%, in high incidence
areas such as North America and Australia (Parkin et al., 1999).
Colorectal cancer has a multifactorial aetiology that involves environmental
factors and genetic susceptibility. Environmental factors are evidenced by the
marked differences in world prevalence of the disease. Carcinoma of the colon and
rectum is predominantly a disease of westernised societies (Burkitt, 1971; Haenszel
and Correa, 1971; Parkin et al., 1999; Pisani et al., 1999) and age standardised rates
(ASR) suggest that in industrialised countries, bowel cancer is more than fifteen
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times more common than it is in developing countries (Burkitt, 1971; Parkin et al.,
1999). Australia and New Zealand have the highest ASR of CRC incidence
(89/100,000) (Parkin et al., 1999), whereas the lowest rates are reported in central
Africa (5/100,000) (Haenszel and Correa, 1971; Parkin et al., 1999; Potter, 1999).
CRC has long been known to occur more frequently in certain families and some
20-25% of all cases are hereditary (Bonelli et al., 1988). A number of hereditary
syndromes have now been defined and the last ten years has seen an increase in the
number of cancer predisposition genes being isolated, which have moderate to high
risk penetrance (Farrington and Dunlop, in press).
1.2.2 Aetiological factors in colorectal cancer
The increased incidence of CRC in developed countries indicates a contribution
from environmental factors. This is exemplified by studies of migrants from low to
high incidence countries, who attain cancer incidence rates similar to those of their
adopted country within a single generation (Haenszel, 1961; Stemmermann, 1970
McMichael and Giles, 1988). American Africans now have an incidence of bowel
cancer that is comparable to that of Caucasians rather than that of native Africans
(Burkitt, 1971; Parkin et al., 1999). In addition, Japanese who have immigrated to
America have a raised incidence of bowel cancer, compared to that observed in
Japan (Burkitt, 1971; Stemmermann, 1970). In most cases, these migrants have
accepted the dietary customs of their country of adoption indicating that the 15-fold
international difference may be explained in large part by dietary factors.
Furthermore rates of CRC incidence are increasing in countries with previously low
rates, possibly due to lifestyle changes (Parkin et al., 1999; Potter, 1999).
Although there is little doubt that diet and/or lifestyle are importance risk factors
contributing to the high incidence of CRC in the western world, there is both
contradictory and negative evidence regarding what the exact risks may be.
Numerous studies have addressed the causality of various dietary and lifestyle
components ranging from carcinogenic effects of smoking, alcohol and excess meat
and fats as well as protective effects from fruit and fibre intake and exercise. These
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studies have been reviewed extensively elsewhere (Gertig and Hunter, 1998; Potter,
1999) but the main themes will be presented here.
One of the most notable differences between the diet of the western world where
bowel cancer is most prevalent, and that of less developed countries, is the
proportions of un-absorbable fibre and refined carbohydrate in the food ingested.
Burkitt, originally proposed that a decrease in dietary fibre in western diets might act
by increasing bowel transit time and increasing the faecal concentrations of
carcinogens (Burkitt, 1971). However, while the consumption of fibre in terms of
increased fruit and vegetable intake has been related to lower risk of colon cancer (
Willett, 1989; Trock et al., 1990; Levi et al., 1999), the consumption of cereal
products has not (Willett, 1989). In addition, Giovannucci et al reported no inverse
relationship with either vegetables or fibre and CRC incidence in a prospective study
of over 50,000 US men (Giovannucci et al., 1994), indicating that while there is
strong evidence that fruit and vegetables are protective this is not necessarily
conclusive.
Increased consumption of red meat has also been associated with increased risk of
CRC in prospective and case-control studies (Willett, 1989; Willett et al., 1990
Giovannucci et al., 1994; Levi et al., 1999). The association has been explained in
terms of its fat content, bile acid production or by carcinogens developed by cooking
(Willett, 1989; Willett et al., 1990). However, there are also negative studies and a
number of European reports have shown no consistent association between red meat
consumption and CRC (Goldbohm et al., 1994; Franceschi et al., 1997).
Red meat and vegetable intake represent the two best-recognised dietary
correlates of CRC (Willett, 1989; Potter, 1999). Nonetheless, the possibility of an
association of CRC with other dietary and lifestyle factors such as alcohol
consumption, physical activity, smoking and NSAID intake has been suggested.
Levi et al found a moderate association between alcohol drinking and CRC in a
case-control study comprising 223 patients and this supported epidemiological
evidence from Longnecker et al who concluded a weak overall association (
Longnecker et al., 1990; Levi et al., 1999). Le Marchand et al evaluated the
contribution of a number of factors predominantly associated with a western lifestyle
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to CRC, including that from increased alcohol intake (Le Marchand et al., 1997). A
correlation between alcohol and CRC incidence in Asian immigrants to the US was
observed (Le Marchand et al., 1997). Le Marchand et al also reported that obesity,
high caloric intake and little physical activity were each independently associated
with an increased risk of CRC (Le Marchand et al., 1997).
Long-term aspirin intake has been consistently demonstrated to have a
preventative role in cancer risk (Muscat et al., 1994; La Vecchia et al., 1997). The
mechanism for this protective effect has not been precisely established although
evidence suggests that the anti neoplastic activity of aspirin and other NSAIDS is
predominantly mediated by inhibition of the cyclooxygenase (COX) enzymes
(Williams et al., 1999). However, it has also been suggested that aspirin induces the
activation of NF-KB, necessary for its anti tumour activity and this may also
contribute to the protective effect of aspirin that has been observed (Stark et al.,
2001).
In spite of the evidence that non-genetic influences account for high rates of colon
cancer in industrialised countries, few factors have been definitively proven to offer
the potential for prevention. Current evidence suggests that a variety of exogenous
agents (e.g., alcohol intake and meat consumption) may increase the risk while others
(e.g. NSAIDS and vegetables) may reduce the risk (Potter, 1999). However, it is
clear that the potential for preventing CRC by changes in diet needs to be more
clearly defined.
1.2.3 Genetics factors in colorectal cancer
The multifactorial aetiology of CRC involves genetic susceptibility as well as
environmental factors. Up to one quarter of all CRC cases are associated with a
family history (Bonelli et al., 1988). In addition, common genetic changes in subsets
of sporadic CRCs have also been elucidated (Fearon and Vogelstein, 1990). The last
ten years has seen significant advances in understanding the key molecular events
involved in susceptibility to CRC and these are now beginning to have real clinical
impact on the disease.
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Hereditary non-polyposis colorectal cancer (HNPCC) represents one of the major
familial CRC syndromes. HNPCC accounts for 5-8% of cancers of the colon
(Mecklin et al., 1995; Lynch and de la Chapelle, 1999). However, other reports on
the percentage of CRC caused by HNPCC have provided varying figures of between
-0.5-10% (Aaltonen et al., 1994; Bellacosa et al., 1996; Aaltonen et al., 1998;
Cunningham et al., 2001). Highly penetrant germline mutations in MMR genes are
associated with tumour microsatellite instability (MSI) and are responsible for the
majority of HNPCC cases (Aaltonen et al., 1993; Aaltonen et al., 1998). The clinical
aspects and genetics of this disorder are discussed in detail later.
Germline mutations in the adenomatous polyposis coli (APC) gene also confer an
extremely high risk of developing CRC as part of the disorder, familial adenomatous
polyposis (FAP) (Groden et al., 1991; Joslyn et al., 1991; Kinzler et al., 1991;
Nishisho et al., 1991). In contrast to HNPCC, this disease is characterised by
hundreds to thousands of colorectal polyps that develop at an early age. Although
these polyps are benign, their frequency and early onset invariably means that one or
more will progress to malignancy (Kinzler and Vogelstein, 1996). However,
germline mutations at the APC gene are somewhat less frequent than those in MMR
genes and FAP accounts for less than 1% of CRC (Bisgaard et al., 1994; Farrington
and Dunlop, in press).
Other gene mutations have been elucidated that underlie a number of rarer
disorders, associated with an elevated risk of CRC although the risk of CRC is
markedly lower in these syndromes compared to either HNPCC or FAP. The clinical
phenotypes of these disorders are heterogeneous, but each is characterised by benign
polyps of the intestine. The rare autosomal dominant disorder Puetz-Jeghers
syndrome (PJS) is associated with mutations of a novel serine threoinine kinase
known as LKB1 or STK1 (Hemminki et al., 1998; Jenne et al., 1998). Mutations of
the putative tyrosine phosphotase gene PTEN have been identified in families with
the autosomal dominant disorder, Cowdens disease (Liaw et al., 1997) and also
within a small number of Juvenile polyposis coli families (Lynch et al., 1997;
Olschwang et al., 1998). Juvenile polyposis coli, which has a very early age of onset,
usually under 10 years, has also been associated with germline mutations of
SMAD4/DPC4 in a number of families (Howe et al., 1998).
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In addition to genes predisposing to an increased risk of CRC, somatic genetic
alterations arising during colorectal tumour development have been identified and it
is established that cancer cells contain many genetic abrogation's (Peinado et al.,
1992; Lengauer et al., 1998). The sequence from adenoma to carcinoma is well
understood on a clinical level and the molecular changes are becoming increasingly
well-defined (Figure 1.1) (Vogelstein et al., 1988; Fearon and Vogelstein, 1990;
Kinzler and Vogelstein, 1996; Boland, 2000). Initiation, promotion and progression
of colorectal tumourigenesis are believed to result from a series of genetic alterations
leading to progressive dis-regulation of the normal mechanisms controlling growth.
Vogelstein et al, demonstrated a median of four or five allelic losses in a study of 92
colorectal carcinomas (Vogelstein et al., 1988) and the mutation of at least five genes
has been proposed as necessary for the formation of a malignant tumour (Fearon and
Vogelstein, 1990). In addition, it appears that the accumulation of changes rather
than their order with respect to one another is of primary importance (Fearon and
Vogelstein, 1990). However, some alterations are consistently associated with
specific stages of the adenoma to carcinoma sequence, such as early loss or mutation
of APC (Kinzler and Vogelstein, 1996; Boland, 2000). Alterations observed
frequently in subsets of CRC include mutations of the C-K-RAS oncogene
(Vogelstein et al., 1988 Delattre et al., 1989) and mutations or loss via chromosomal
deletions, of tumour suppressor genes p53, DCC and APC, on chromosomes 5q, 17p
and 18q (Figure 1.1) (Delattre et al., 1989; Fearon and Vogelstein, 1990). These
changes are accompanied by aneuploidy in most cases (Fearon and Vogelstein,
1990). However, the timing, the mechanisms by which such mutations arise and the
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Figure 1.1 Genetic changes associated with the adenoma to carcinoma sequence of colorectal
cancer. Tumourigenesis preceeds through a series of genetic changes involving oncogenes
(K-RAS) and tumour supressor genes such as those on chromosome 5q, 17p and 18q. The
clinical stages of this sequence are well defined. Abberent crypt foci (ACF) are thought to be
the precursors of adenomas and the three stages of adenomas represent tumours of increasing
size, dysplasia and villous content. The overall accumulation of changes seems of greater
importance than the order in which they occur. Both selection and instability underlie this
process to varying degrees. Adapted from Fearon and Vogelstein, 1990 and Kinzler and
Vogelstein, 1996.
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1.2.4 Selection and mutation in tumourigenesis
The mechanisms that lead to the high frequency of mutations observed in CRC
remains controversial. It is widely accepted that the process of adenoma to carcinoma
progression is a continuum, resulting from successive waves of clonal expansion
(Nowell, 1976). However, the relative importance of selection for growth advantage
and of genomic instability in this process is unclear. Loeb, originally proposed that
the expression of a mutator phenotype is an early and necessary step in tumour
progression (Loeb et al., 1974). This concept was formulated to explain the disparity
between the rarity of mutations in normal cells and the large numbers of mutations,
including chromosomal instability, microsatellite instability and anueploidy that are
present in a variety of human malignancies such as CRC (Loeb et al., 1974; Peinado
et al., 1992; Lengauer et al., 1998; Loeb, 2001). In the "mutator model" of
tumourigenesis, initiating mutations are proposed to occur in genes that insure the
stability of the genome such as those involved in DNA repair, or those encoding
DNA polymerases or helicases (Loeb, 2001). From the population of mutant cells
that result consequent of an elevated mutation rate, there is then selection for cells
that escape regulatory mechanisms for the control of cell replication, invasion and
metastasis. It follows from this model, that genes, which are inherently susceptible to
mutation, are more likely to be mutated frequently in cancers. Observations that
MMR genes are mutated somatically in a subset of sporadic CRCs and other
malignancies, in addition to tumours from HNPCC patients, lends support to the
mutator hypothesis (Borresen et al., 1995; Ma et al., 2000). An elevated level of
mutation is clearly associated with a variety of familial and non-familial cancers
(Merlo et al., 1994; Orth et al., 1994; Kinzler and Vogelstein, 1996).
In disagreement with the mutator hypothesis, Tomlinson and Bodmer have argued
that a raised mutation rate in itself does not cause cancer, and that selection is the
driving force behind tumour growth (Tomlinson and Bodmer, 1999). They have used
mathematical models of tumourigenesis based on CRC to analyse the role of
mutation rate in the growth of sporadic tumours. These models demonstrate that
selection alone is sufficient and more likely to explain the evolution of tumours, than
an increase in intrinsic mutation rate (Tomlinson et al., 1996). They have also found
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evidence that mutations in cancer genes such as APC occur prior to MMR defects
suggesting that an increased mutation rate is not necessary for tumour initiation
(Homffay et al., 1998). It has also been suggested that a raised mutation rate may be
a disadvantage, particularly in early tumours, since cells with a high mutational load
tend to undergo apoptosis (Cahill et al., 1999; Tomlinson and Bodmer, 1999). Under
the selection model, the most frequently observed mutations in CRC are those that
confer the strongest selectable advantage to the tumour cell. Tomlinson and Bodmer
have also highlighted the fact that excision repair mutations rarely occur in sporadic
cancers, despite leading to an increased cancer risk via genomic instability in the
presence of homozygous germline mutations. This might suggest that there is not a
direct association between increased mutation rate and tumourigenesis.
It is likely that both selection and increased mutation contribute to the
development of CRC, but the relative balance between these factors in the initiation
and progression of colorectal tumourigenesis remains unclear.
Understanding of the genetic consequences of MMR defects may go some way in
addressing the relative contribution of genomic instability to the development of
CRC.
1.3 Cancers Associated with MMR Defects
1.3.1 Hereditary non-polyposis colorectal cancer (HNPCC)
HNPCC, also known as Lynch Syndrome, was originally called cancer family
syndrome after it was noted as a hereditary condition with an autosomal dominant
mode of inheritance (Lynch et al., 1966). The first description of such a family
(Family G), was made in 1895 by the pathologist Aldred Warthin (Warthin, 1913).
Family G was re-studied by Lynch and Krush in 1971 and found to have features of
HNPCC (Lynch and Krush, 1971). Within the last ten years the molecular basis of
this disorder has been elucidated and has been linked to germline defects in the
MMR genes (Lynch and Smyrk, 1996). To date seven human genes that participate
in the MMR process have been identified (Fishel et al., 1993; Leach et al., 1993;
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Nicolaides et al., 1994; Bronner et al., 1994; Papadopoulos et al., 1994; Konishi et
al., 1996). These are MLH1, MLH3 PMS2, PMS1, MSH2 and MSH6, MSH3 and
germline mutations in at least five of these genes have been found in HNPCC
kindreds (Leach et al., 1993; Bronner et al., 1994; Nicolaides et al., 1994; Miyaki et
al., 1997a; Kolodner and Marsischky, 1999; Lipkin et al., 2000). Affected family
members inherit one mutant allele of the relevant MMR gene and one wild type
allele. During the early stages of tumour development, the wild type allele is
inactivated through somatic mutation resulting in complete loss of MMR activity.
This leads to a mutator phenotype, which can be visualised in tumours as
microsatellite instability, in which short repeated sequences are characteristically
altered. Inactivation of MMR leads to the rapid accumulation of somatic mutations
once tumourigenesis is initiated (Lynch and Smyrk, 1996). Tumour progression is
thus accelerated and HNPCC patients consequentially develop CRCs at an average
age of 45, more than two decades earlier than the general population (Lynch et al.,
1985; Bellacosa et al., 1996; Dunlop, 1997). These genetic mechanisms of HNPCC
are detailed below.
An autosomal dominant mode of inheritance and early onset of CRC are two of
the clinically defining features of HNPCC. CRC develops in gene mutation carriers
without the myriads of adenomas seen in FAP (Lynch et al., 1985). Although,
adenomatous polyps are detected in HNPCC patients, these are in numbers
comparable to the general population (usually <10) and it is the increase in genomic
instability within these adenomas that results in their rapid progression to malignancy
(Aaltonen et al., 1994; Lynch and Smyrk, 1996). In HNPCC families there is
preferential involvement of the proximal colon with approximately 70% of HNPCC
colon cancers versus 30% of sporadic tumours being located proximal to the splenic
flexure (Aaltonen et al., 1994; Lynch and Smyrk, 1996). Multiple CRCs may
develop and these may be synchronous or metachronous. Pathological features of
CRC include poor differentiation, increased signet cells, crohns like reaction,
peritumourol lymphocytic infiltration and tumour infiltrating lymphocytes mixed
with tumour cells (Jass, 2000). In addition to an increased risk of cancer of the colon
and rectum, gene carriers are also at high risk of malignancy at extracolonic sites
(Watson and Lynch, 1993; Aaltonen et al., 1994; Bellacosa et al., 1996). These
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specifically include the endometrium, ovary, stomach, small bowel, hepatobiliary
tract, pancreas, ureta and renal pelvis (Watson and Lynch., 1993; Lynch and Smyrk,
1996). An excess of breast cancer has also been noted in some HNPCC families
(Risinger et al., 1996). The penetrance for developing HNPCC in gene carriers can
approach 100%. Dunlop et al reported a risk for gene carriers to age 70 for all
cancers of 91% in males and 69% in females (Dunlop et al., 1997). It is of interest
that the risk of developing CRC was observed to be significantly greater for males
than for females (74% vs 30%) but that the risk of uterine cancer exceeded that for
CRC in females (42%) (Dunlop et al., 1997). This suggests that females are
protected from CRC in some way, perhaps due to environmental factors or sex linked
modifier genes (Dunlop et al., 1997).
Overall the prognosis for individuals from HNPCC families is better than for
those with sporadic CRCs. In a Finnish based population study based on patients
from the nation-wide Finnish cancer registry, Sankila et al found that the five year
survival rate for HNPCC patients was 65% compared to 44% for those with sporadic
CRC (Sankila et al., 1996).
Since large families are uncommon minimum criteria were drawn up to define
HNPCC for research purposes and to establish the frequency of HNPCC in the
population, (Vasen et al., 1991). The original criteria known as the Amsterdam
Criteria stated that; 1) At least three relatives should have histologically verified
CRC; one of them should be a first degree relative to the other two. FAP should be
excluded. 2) At least two successive generations should be affected. 3) In one of the
relatives CRC should be diagnosed under the age of 50. (Vasen et al., 1991).
However, when using these criteria on small families or in cases where little pedigree
information is available, there is less likelihood that the definition of HNPCC will be
fulfilled and these families may be inappropriately excluded. Furthermore, the
Amsterdam criteria require CRC in all affected family members and thus ignore
cases where key members are affected by other HNPCC cancers such as those of the
endometrium (Vasen et al., 1991; Watson and Lynch, 1993). Evidence from the
analysis of the genes responsible for the majority of HNPCC, has therefore lead to
the expansion of these criteria to include extra-colonic HNPCC cancers (Vasen et al.,
1999). It has been proposed that the presence or absence of a germline mutation in a
12
MMR gene should also be incorporated into the definition of HNPCC. But this may
also be problematic in that not all families fulfilling the Amsterdam criteria are
positive for MMR gene mutations (Aaltonen et al., 1994; Liu et al., 1996; Moslein et
al., 1996). In an analysis of 74 Amsterdam positive families in which all five MMR
genes were analysed, germline mutations were identified in 70% of the kindreds (Liu
et al., 1996). Those cases in which MMR mutations have not been identified may be
due to failure to detect all mutations as a result of the techniques used. In addition, it
is possible that MMR may be inactivated by some other unidentified mechanism or
there may be germline defects in as yet undefined genes. The identification of the
causative factors in such cases, and further development of rigorous methods of
mutation detection will facilitate further systematic assessment of the prevalence of
HNPCC on a whole population basis.
1.3.2 Turcots syndrome
In addition to HNPCC, germline defects in MMR contribute to several other rare
disorders that are associated with CRC. Turcots syndrome (TS) is characterised by
the concurrence of primary brain tumours and multiple adenomas or CRCs that occur
at an early age. The malignant transformation of these lesions occurs even earlier
than in FAP or HNPCC (Crail, 1949; Turcot et al., 1959) To date over 130 cases of
TS have been described but as yet, it has not been established whether the mode of
inheritance is dominant or recessive (Matsui et al., 1998; De Rosa et al., 2000).
Clues as to the molecular basis of TS were revealed by analysis of dominantly
inherited cases by Hamilton et al (Hamilton et al., 1995). In this study, the
association between brain tumours and multiple colorectal adenomas was
demonstrated to result from two distinct germ line defects; mutation of the APC gene
or mutation of MMR genes, specifically PMS2 or MLH1 (Hamilton et al., 1995). The
clinical phenotypes of TS associated with either of these defects are broadly
distinguishable. TS individuals with germline APC mutations have large numbers of
colorectal adenomas characteristic of FAP and brain tumours that are predominantly
medulloblastomas (Hamilton et al., 1995). TS individuals with germline defects in
the MMR genes tend to have small numbers of colorectal neoplasms as found in
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HNPCC, that develop in childhood or early adolescence. In addition they are prone
to developing glioblastomas or cafe au lait spots (Hamilton et al., 1995). However,
on purely clinical grounds there appears to be some overlap between the phenotypes
associated with APC or MMR gene mutations. Hamilton et al, reported that in one of
their TS families and in the family originally described by Turcot et al (Turcot et al.,
1959), large numbers of adenomatous polyps were present despite the identification
of MMR germline mutations rather than of the APC gene (Hamilton et al., 1995).
The tumours of TS patients with germline MMR gene mutations have been
demonstrated to show MSI, characteristic of the MMR defects present in HNPCC
tumours (Hamilton et al., 1995; De Rosa et al., 2000). In addition a number of
reports have also demonstrated MSI within the normal tissue of these patients, a
phenotype not generally observed in patients with classical HNPCC (Parsons et al.,
1995a; De Rosa et al., 2000). It has been suggested that this high level of DNA
instability in the normal tissues, might trigger the early development of cancer in
these TS patients (De Rosa et al., 2000). This disease represents an interesting cancer
syndrome in which an elevated mutation rate consequent of MMR defects is
associated with a clinical phenotype that shares phenotypic characteristics with
HNPCC.
1.3.3 Muir-Torre syndrome
Muir-Torre Syndrome (MTS) is an autosomal dominant cancer susceptibility
syndrome also associated with defects in the MMR genes. There have been over 150
reported cases of MTS, which is defined by the coincidence of at least one sebaceous
skin tumour and one internal malignancy (Muir et al., 1967; Torre, 1968). Although
these may occur between the ages of 23 to 90, the average age of presentation is
around the age of 50 (Cohen et al., 1991). The skin tumours include sebaceous
adenomas, epitheliomas and carcinomas. These sebaceous gland tumours, which are
rare in the general population, are considered to be the hallmark of MTS. The
spectrum of internal malignancy is similar to that in HNPCC and patients with MTS
have also been identified in HNPCC families (Cohen et al., 1991). CRCs are the
most common internal malignancy accounting for over 50% of primary cancers,
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while endometrial cancers occur with a frequency of about 15% in females (Cohen et
al, 1991).
Germline mutation in the MMR genes MSH2 and MLH1, have been identified in
some families with this syndrome (Kolodner et al., 1994; Bapat et al., 1996; Kruse et
al., 1996; Kruse et al., 1998). Kruse et al detected germline mutations in 9/13 (69%)
MTS patients ascertained on the basis of sebaceous skin tumours and occurrence of
CRCs. All nine of these patients with MMR defects, also exhibited MSI in at least
one skin tumour (Kruse et al., 1998). Significantly more mutations were identified in
the MSH2 gene than in MLH1 and this has also been noted in several other studies
(Kolodner et al., 1994; Kruse etal., 1996; Kruse et al., 1998).
It has been suggested that MTS consist of two subgroups. The first being those
patients without CRC and the second being those MTS patients with CRC. This
second group of patients, who are affected by CRC, may be allelic variants of
HNPCC and be associated with defects in MMR. It remains to be determined
whether MTS constitutes a distinct genetic entity or whether the observed skin
lesions are merely a pleiotropic effect of a MMR deficiency. MTS represents another
interesting example in which a raised mutation rate consequent of repair defects is
associated with both CRC and diverse extracolonic cancers.
1.3.4 Sporadic cancers
MSI arises in around 13% of sporadic CRCs (Kinzler and Vogelstein, 1996) and
these are also associated with defects in MMR genes (Liu et al., 1995a; Liu et al.,
1995b). In a more recent prospective study of 257 unselected CRC patients, 20%
were found to have MMR defects with 2% being accounted for by familial cases
(Cunningham et al., 2001). This indicates that the frequency of defective DNA MMR
in CRC is relatively common.
Since neither MMR gene allele is mutated in the germline of sporadic CRCs,
inactivation of both alleles occurs somatically and mutation of MLH1, MLH3 MSH2,
MSH3, MSH6 and PMS2 has been demonstrated in sporadic cases of CRC (Liu et al.,
1995b; Malkhosyan et al., 1996; Lipkin et al., 2000; Ma et al., 2000).
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Sporadic CRCs with MMR defects share certain features with CRCs from
HNPCC patients (Liu et al., 1995b). Both tend to be right sided and relatively
diploid, unlike MMR proficient CRCs that usually have an anueploid phenotype. In
addition, both have a relatively good prognosis. However, while HNPCC patients
often manifest left sided CRCs and extra-colonic cancers sporadic cases of CRC
almost always occurs singly and in the proximal colon (Aaltonen et al., 1994; Liu et
al., 1995b). In addition, the age of onset of sporadic CRCs with MMR defects is later
than in HNPCC patients by more than 20 years (Liu et al., 1995b). Interestingly,
there is a subset of CRC patients who develop the disease at a very young age (under
35 years) but do not have a family history of HNPCC and the majority of these have
MMR defects (Liu et al., 1995a).
MSI has been identified in a variable fraction of several other types of neoplasm's
including those of the lung, breast, pancreas, endometrium and ovary (Risinger et al.,
1993; Han et al., 1993; Orth et al., 1994; Merlo et al., 1994; Gurin et al., 1999;
Caldes et al., 2000; Ottini et al., 2000). MMR defects have also been identified in
some of these cases (Orth et al., 1994; Chung et al., 1997). These reports provide
evidence that an increased mutation rate consequent of MMR defects is associated
with a wide spectrum of primary malignancies.
1.4 Mismatch Repair
Elucidating the mechanism of MMR has proved essential in understanding how
its dys-regulation contributes to the accumulation of mutations during
tumourigenesis. MMR is critical for maintaining the overall integrity of the genome
and enhances the fidelity of chromosome replication by 100 to 1000 times (Modrich,
1991). The basic features of the MMR system have been highly conserved during
evolution and homologues of the bacterial MutS and MutL proteins have been
identified in yeast, mammalian and other eukaryotic cells (Harfe and Jinks-
Robertson, 2000). These proteins play key roles in mismatch recognition and
initiation of repair. The primary function of the MMR system is to eliminate
base:base mismatches and insertion:deletion loops. Such lesions arise in DNA by
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physical damage to existing nucleotides, polymerase mis-incorporation errors during
DNA replication, and as a result of forming heteroduplex intermediates during the
process of genetic recombination (Freidberg et al., 1995). Failure to repair base:base
mis-pairs typically affects non-repetitive DNA and leads to single base substitutions
(e.g. G->T). Failed correction of insertion:deletion loops affects repetitive DNA,
resulting in the gains or losses of short repeat units within microsatellites manifesting
as a characteristic phenotype known as MSI.
The mechanism of MMR comprises several universal features. Initially, error
correction involves the efficient recognition of mismatches. This is followed by the
selective removal of the newly synthesised strand containing the incorrect
information and then re-synthesis of the correct strand (Harfe and Jinks-Robertson,
2000). Strand discrimination is an essential feature of all MMR systems since it
ensures the incorrect strand is not used as the template. However, this latter feature
appears to be less well conserved between MMR systems in prokaryotes and
eukaryotes.
1.4.1 Prokaryotic mismatch repair
Since the key proteins in MMR are highly conserved from bacteria to mammals,
much of what is understood about MMR mechanisms in eukaryotes is based on
studies of the prokaryotic system. In prokaryotes the best understood MMR pathway
is the DNA adenine methylase (DAM) instructed MutHLS pathway in E.coli also
known as long patch repair (Modrich, 1991). This pathway is responsible for the
repair of most nucleotide mispairs and has been studied extensively in vitro and in
vivo (Modrich, 1991). The idea that this pathway suppresses misincorporation error
is supported by the observation that mutS, mutL, mutH, mutU (uvrD) and dam
mutations result in E. coli strains with elevated frequencies of spontaneous mutation
(Glickman and Radman, 1980). Characterisation of the functions of the mut genes in
correcting replication errors was facilitated by the purification of the protein products
and in vitro reconstruction of the E.coli MMR reaction (Lahue et al., 1989; Modrich
and Lahue, 1996).
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Briefly, MutS is an ATPase that drives mismatch recognition. MutL is also an
ATPase, that couples mismatch recognition to MutS by downstream processing steps
and MutH is involved in targeting MMR to the newly synthesised strand, being a
methylation sensitive endonuclease (Modrich and Lahue, 1996) (Figure 1.2).
MutS is a 95kD ATPase that acts as a homodimer to bind base:base mismatches
or small insertion:deletion loops (Su and Modrich, 1986). Almost all mismatches are
recognised by MutS and subsequently repaired, although there is some variation in
the affinity and efficiency of repair depending on the nature of the mismatch and the
sequence context (Su and Modrich, 1986; Fishel and Kolodner, 1995; Modrich and
Lahue, 1996). The elucidation of the crystal structure of the E.coli and T. aquaticus
MutS homodimers each bound to a mismatch, has provided considerable insight into
the function of this protein (Lamers et al., 2000; Obmolova et al., 2000). Both
reports show that the overall structure of the MutS dimer is asymmetric with the two
MutS monomers assuming different conformations (Lamers et al., 2000; Obmolova
et al., 2000). This finding is significant as it explains why the eukaryotic MutS
complexes (described below) exist only as heterodimers. The crystal structure also
reveals that the mismatch is specifically recognised by just one of the monomers,
which is ADP bound (Lamers et al., 2000). However both monomers contact the
DNA forming a clamp-like structure (Lamers et al., 2000; Obmolova et al., 2000).
The strand discrimination signal in the E.coli MMR system is provided by the
transiently unmethylated state of the newly synthesised DNA. The role of the 25kD
endonuclease MutH protein, is to cleave the unmethylated strand of a hemi-
methylated GATC dam methylation site thereby introducing a nick in the nascent
strand for exonucleolytic removal and re-synthesis (Modrich, 1991; Au et al., 1992).
The distance separating the strand signal and the mismatch can be substantial. The
recognition d(GATC) site, can direct mismatch correction from a kilobase away but
the strength of this signal is greatly reduced when separation distances exceed 2kb
(Modrich and Lahue, 1996). However, the E. coli system of strand discrimination is
not universal among prokaryotes and is not conserved in eukaryotic systems
(Modrich, 1991). It has been demonstrated that in the absence of MutH activity a
pre-existing nick on one strand of a duplex is sufficient to confer strand specific
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repair in vitro and this applies to eukaryotic systems (Lahue et al., 1989; Harfe and
Jinks-Robertson, 2000).
The binding of MutS to a mismatch is followed, by ATP dependent binding of the
ATPase MutL homodimer (Grilley et al., 1989; Ban and Yang, 1998). This results in
an enhancement of bi-directional scanning until a strand discrimination signal is
encountered. Although genetic studies have demonstrated that the 70kD MutL
protein is essential for MMR, its precise role is less well defined than that of MutS
and MutH (Lahue et al., 1989). However a number of studies have indicated that it
serves as a molecular matchmaker, coupling mismatch recognition and downstream
MMR events. MutL homodimers have been demonstrated to form a complex with
MutS (Grilley et al., 1989; Galio et al., 1999) and enhance ATP hydrolysis (Modrich
and Lahue, 1996) and this is probably as part of the identification of the strand
discrimination signal. MutL then stimulates MutH endonuclease in an ATP
dependent manner (Ban and Yang, 1998; Hall and Matson, 1999). Finally MutL is
required to load MutU (Uvrd) at the site of the MutH induced nick, thus facilitating
DNA unwinding which proceeds towards the mismatch and directs subsequent
removal of the nascent strand (Modrich and Lahue, 1996).
Proteins involved in general DNA metabolic processes complete the latter steps of
MMR. The excision step of MMR appears to require any one of four single stranded
DNA specific exonucleases, RecJ, ExoVII, Exol, or ExoX since MMR is inactivated
only when all four exonucleases are inactivated both in vitro and in vivo (Modrich,
1991). Polymerase II holoenzyme and DNA ligase complete re-synthesis and ligation
(Lahue et al., 1989)
In addition to the long patch repair system, E.coli possesses a second short patch
system that shares some components with the MutHLS system (Harfe and Jinks-
Robertson, 2000). Furthermore a third system, the very short patch (VSP) system,
specifically repairs G/T mismatches to G/C in the context of DNA cytosine
methytransferase (DCM), and its primary role is thought to be in correction of















SSDNA exonuclease I Excision
ch3
Pol III holoenzyme I ResynthesisI ch3
Figure 1.2 Model for mismatch repair of DNA replication errors in E.coli. Adapted from Modrich,
1991, Fishel and Kolodner, 1995 and Harfe and Jinks-Robertson, 2000.
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1.4.2 Eukaryotic mismatch repair
The function of the eukaryotic MMR system is best understood in the budding
yeast S. cerevisiae and human MMR appears to share genetic and functional
similarities with this system. Like bacteria, mutation of the S. cerevisiae MMR genes
was observed to result in yeast strains with mutator phenotypes, providing
considerable insight into the specific roles of the MMR proteins (Marsischky et al.,
1996).
All eukaryotic organisms characterised to date posses multiple MutS homologues
(MSH proteins) and multiple MutL homologues (MLH proteins) and the yeast and
human homologues are shown in Table 1.1. However, convincing MutH homologues
have yet to be identified and there is no evidence to suggest that strand
discrimination is methyl-directed (Harfe and Jinks-Robertson, 2000).
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Table 1.1 Eukaryotic MutS and MutL homologues. Adapted from Harfe and Jinks-
Robertson, (2000). The human nomenclature is used and primary functions are shown
based on data from both yeast and mammalian cells. Nl indicates not identified
E.coli S.cerevisiae Humans Eukaryotic Primary Function
MutS MSH1 Nl Mutation avoidance in mitochondria
MSH2 MSH2 Hetrodimerises with MSH3 and MSH6 to:
Repair base:base mispairs and insertion:deletion
loops
Responds to DNA damage (humans)
MSH3 MSH3 Heterodimerises with MSH2 to form MutSp
MSH4 MSH4 Hetrodimerises with MSH5 and promotes crossing
over in meiosis
MSH5 MSH5 Heterodimerises with MSH4
MSH6 MSH6 Heterodimerises with MSH2 to form MutSa
MutL PMS1 PMS2 Hetrodimerises with MLH1 to form MutLa and:
Repairs base:base mispairs and insertion:deletion
loops
Responds to DNA damage? (humans)
MLH1 MLH1 Heterodimerises with PMS2 (humans), PMS1
(humans) and MLH3
MLH2 PMS1 Heterodimerises with MLH1 to form MutLfJ and:
Repairs insertion:deletion loops
MLH3 MLH3 Heterodimerises with MLH1 to:
Repair insertion:deletion loops
Yeast possess six homologues (MSH1-6) of the bacterial MutS protein and with
the exception of the mitochondrial protein MSH1, human homologues of all the yeast
MSH genes have been identified (Tablel.l). These are named according to the yeast
designations (Harfe and Jinks-Robertson, 2000). In S.cerevisae MSH4 and MSH5 are
not involved in MMR but are required for crossing over during meiotic
recombination (Kolodner and Marsischky, 1999). Consistent with their role in yeast,
human MSH4 and MSH5 are most highly expressed in meiotic tissue (Kolodner and
Marsischky, 1999).
Hetrodimers formed between yeast MSH2 and either MSH3 or MSH6 recognise
mis-paired bases in DNA (Acharya et al., 1996). In humans these complexes have
been termed MutS(3 and MutSa respectively and their recognition properties are
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largely similar to the corresponding S.cerevisae complexes (Acharya et al., 1996;
Genschel et al., 1998). Marsischky et al measured the rate of accumulating mutations
and mutation spectrum in yeast strains containing different combinations of MSH2,
MSH3 and MSH6 mutations and suggested that two pathways of MSH2 dependent
mismatch repair exist (Marsischky et al., 1996). This has been confirmed by the
identification of the recognition specificities of the two MSH complexes in both S.
cerevisiae and humans (Acharya et al., 1996; Alani, 1996; Johnson et al., 1996;
Palombo et al., 1996; Genschel et al., 1998; Umar et al., 1998). These studies have
also revealed functional redundancy between MSH3 and MSH6 (Acharya et al.,
1996; Johnson et al., 1996; Marsischky et al., 1996; Palombo et al., 1996; Genschel
et al., 1998; Umar et al., 1998). While MSH2-MSH6 binds preferentially to base
substitutions and small insertion:deletion mismatches, MSH2-MSH3 is specific for
insertiomdeletion mismatches (Figure 1.3) (Alani, 1996; Habraken et al., 1996;
Johnson et al., 1996; Palombo et al., 1996; Umar et al., 1998). The redundancy
between MSH3 and MSH6 in the repair of insertion:deletion loops is suggested to
explain the prevalence of MSH2 mutations in HNPCC CRCs over those in the other
two MSH proteins and also as to why germline mutations in MSH6 have been
detected in patients whose tumours exhibit a mild form MSI.
The in vitro interaction between the human MutSa complex with mismatch
containing duplexes has been characterised in detail and there are two predominating
models to explain the structural changes elicited by ADP-ATP exchange (Gradia et
al., 1997; Blackwell et al., 1998). The first model suggests that the MSH complex
functions as a nucleotide regulated molecular switch and that ADP and ATP have
opposing effects in MutSa mis-pair binding (Gradia et al., 1997). MutSa complexed
with ADP is proposed to bind to the mispair with near irreversible affinity. This tight
binding acts as a flag for the assembly of the excision repair machinery and
subsequent exchange of ADP-ATP results in the release of MutSa from the DNA
allowing excision and re-synthesis to take place. On release, the intrinsic ATPase of
MutSa hydrolyses ATP resulting in a form that is again competent for mispair
binding (Gradia et al., 1997). This is substantially different from the translocation
model proposed by Modrich et al, that invokes the notion of ATP binding and
hydrolysis in movement away from the mismatch containing site (Blackwell et al.,
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1998). This study demonstrates that ADP is not required for mismatch recognition
and that dissociation of MutSa occurs at DNA ends in a reaction dependent on DNA
hydrolysis (Blackwell et al., 1998).
Four MutL homologues have been identified in both yeast and humans. In yeast
these are PMS1, MLH1, MLH2 and MLH3 however in humans the same yeast
names are not applied and this can be a source of confusion (Table 1.1). In both S.
cerevisae and humans MLH1 is the major MutL homologue and has been
demonstrated to form heterodimers with the other three MutL proteins (Prolla et al.,
1994; Li and Modrich, 1995; Raschle et al., 1999; Lipkin et al., 2000). PMS1 in
yeast is homologous to PMS2 in humans. In yeast, the MLH1-PMS1 complex is
proposed to act as a molecular matchmaker, co-ordinating activities between the
MSH complexes and downstream MMR events in a role similar to that of MutL in
bacteria (Prolla et al., 1994). Interactions between yeast MLH1-PMS1 (MLH1-
PMS2 in humans) and MSH2 complexes have been demonstrated in both humans
and yeast supporting the role of this MLH complex as a molecular matchmaker
(Figure 1.3) (Kolodner and Marsischky, 1999). In humans the MLH1-PMS2 complex
is known as MutLa and has been shown to restore repair proficiency on
heteroduplex DNAs containing base:base mispairs or insertiomdeletion loops, in cell
extracts that are deficient for MLH1 (Li and Modrich, 1995). Human PMS1 exhibits
homology to both yeast MLH2 and MLH3 and mammalian MLH1-PMS1
hetererodimers are referred to as MutL(3 (Raschle et al., 1999). Although the role of
MutLf3 in MMR remains to be demonstrated, the fact that few HNPCC families have
been identified with either PMS1 or PMS2 mutations has lead to the suggestion that
there may be partial redundancy in function between these two proteins (Kolodner
and Marsischky, 1999; Raschle et al., 1999; Harfe and Jinks-Robertson, 2000). The
human MLH3 protein has been more recently identified and demonstrated to interact
with MLH1 (Lipkin et al., 2000). Human MLH3 shows most homology to yeast
MLH3 which appears to be involved in the repair of a subset of insertiomdeletion
mispairs recognised by the MSH2-MSH3 complex (Figure 1.3) (Flores-Rozas and
Kolodner, 1998). The role of the human MLH1-MLH3 complex remains to be
elucidated, although over expression of an MLH3 N-terminal deletion protein is
associated with an MSI phenotype (Lipkin et al., 2000).
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The assembly of the MLH and MSH complexes subsequently recruits a number of
proteins that are not specific to MMR activity but are involved in completing the
later stages of MMR. These include DNA polymerase 8, replication protein A,
proliferating cell nuclear antigen (PCNA), replication factor C (RFC), exonuclease 1,
Fenl and the DNA polymerase 8 and e associated exonucleases (Prolla, 1998a;
Kolodner and Marsischky, 1999).
The human MED1 protein, also known as MBD4 has been speculated to represent
a bacterial MutH functional homologue on the basis that it interacts with MLH 1 and
displays endonuclease activity (Bellacosa et al., 1999). Frameshift mutations have
also been identified in MED1 in colorectal tumours exhibiting MSI (Bader et al.,
1999; Riccio et al., 1999). However, although MBD4 binds to methyl-CpG-
containing DNA, it has greater affinity for fully methylated rather than
hemimethylated DNA and there is no evidence that it is involved in strand
discrimination (Bellacosa et al., 1999; Hendrich et al., 1999). Furthermore, in the
second study by Hendrich et al, it was revealed that MBD4 is a mismatch specific
T/U glycosylase and no functional evidence for the endonuclease activity reported by
Bellacosa et al was identified (Hendrich et al., 1999). Rather than being a homologue
of bacterial MutH, MBD4 appears to function in the minimisation the mutability at
methyl CpG sites (Hendrich et al., 1999). In any case it is widely accepted that strand





5' — TAGCJGCTA— 3' 5'— GTAGCACACACACACACACACTACG — 3'
3' —ATCGGCGAT— 5' 3'— CATCGTGTGTGTGTGTGTGTGTTGC—5'




Figure 1.3 Interaction of human MMR proteins in the repair of base:base mispairs and insertion:
deletion loops. Adapted from Kolodner and Marsischky, 1999 and Harfe and Jinks-Robertson,
2000.
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1.4.3 Role of MMR in the response to DNA damage
The MMR proteins have an additional function in mediating the activation of cell
cycle checkpoints and apoptosis in response to DNA damage (Fink et al., 1998;
Harfe and Jinks-Robertson, 2000). The elucidation of this role, came from the
discovery that MMR defective bacteria are tolerant to alkylating agents (Karran and
Marinus, 1982) and this phenomenon was subsequently found to be a characteristic
of mammalian cells (Fink et al., 1998). Interestingly yeast MMR proteins do not
appear to be involved in response to DNA damage.
Alkylating agents such as N-methyl-N'-nitro-N-nitrosanguanidine (MNNG) and
N-methyl-N-nitosourea (MNU) generate a variety of adducts in DNA of which O6-
methyl-guanine (06-MeG) is the most cytotoxic. In mammalian cells treatment with
MNNG triggers an MMR-dependent G2-M arrest (Hawn et al., 1995), followed by a
MMR dependent apoptotic response (Wu et al., 1999a; Zhang et al., 1999). In MMR
proficient cells erroneous incorporation of a thymine opposite 06-MeG is thought to
initiate futile cycling of MMR, since the thymine containing strand rather than the
06-MeG containing strand is excised and the Oe-MeG lesion persists. Continued
rounds of MMR at the 06-MeG lesion, increase the risk of a double strand break at
the time of the next S phase, thus inducing apoptosis (Fink et al., 1998). In addition
to 06-MeG lesions, MMR proteins are responsible for triggering apoptosis in
response to a wide variety of DNA damaging agents (Fink et al., 1998).
It has been shown that MutSa and MutLp are specifically required for signalling
the initiation of apoptosis in response to alkylating agents (Duckett et al., 1999;
Hickman and Samson, 1999). However, Zhang et al demonstrated that over
expression of MSH2 or MLH1 induced apoptosis in either repair proficient or
deficient cells, whereas over-expression of MSH3, MSH6 and PMS2 did not (Zhang
et al., 1999).
The precise mechanism by which MMR triggers apoptosis has not been
elucidated, although both p53 dependent and p53 independent mechanisms have
been demonstrated (Duckett et al., 1999; Hickman and Samson, 1999). It has been
suggested that MMR components may be involved in sensing DNA damage and
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transducing the damage signal to downstream signalling components. Indeed, a large
multisubunit complex termed the BRCA1-associated genome surveillance complex
(BASC) has been identified (Wang et al., 2000). Using immunoprecipitation and
mass spectrometry, Wang et al partially purified a complex containing BRCA1 and a
variety of other components all of which are consistent with a function for this
complex, in sensing DNA damage (Wang et al., 2000). These components include
the MMR proteins MSH2, MSH6 and MLH1.
The identification of a role for MMR in the response to DNA damage has clinical
implications in terms of the chemotherapeutic treatment of MMR deficient cancers.
Chemotherapeutic agents induce DNA damage specifically to trigger cell death thus
destroying cancerous cells. However, MMR deficient cells that are no longer
responsive to damage, acquire resistance to this type of treatment (Fink et al., 1998).
1.5 MMR Gene Inactivation
1.5.1 Identification of the MMR genes
Although HNPCC has been recognised as a hereditary condition for over 25
years, the molecular basis of this disease has only been determined in the last eight.
Of the six major human MMR genes that have been identified (MSFI2, MLH1,
MLH3, PMS1, PMS2, MSH6, MSH3), germline and somatic mutations in all but
MSH3 and MLH3 have been associated with HNPCC and a subset of sporadic CRCs
(Fishel et al., 1993; Leach et al., 1993; Bronner et al., 1994; Nicolaides et al., 1994;
Papadopoulos et al., 1995; Miyaki et al., 1997a; Loukola et al., 2000).
The genetic basis for HNPCC was initially reported by Peltomaki et al in 1993
(Peltomaki et al., 1993). In this study, a panel of 345 microsatellite markers,
covering the whole genome was used in linkage analysis of two families who met the
HNPCC criteria (Vasen et al., 1991). Highly significant linkage to marker D2S123
led to the mapping of the first HNPCC locus at 2pl 5-16 (Peltomaki et al., 1993).
This was followed by the identification of a second HNPCC locus by Lindblom et al
who combined restriction fragment length polymorphisms with microsatellite
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markers to link cancer occurrences with markers on chromosome 3p (Lindblom et
al., 1993).
Fishel et al cloned the first human MMR gene located at the HNPCC locus on
chromosome 2 (Fishel et al., 1993). MSH2 was localised to 2p21-22 and mutations
were identified in sporadic tumours and within the germline of individuals from two
HNPCC kindreds (Fishel et al., 1993). A similar observation was made in a second
study (Leach et al., 1993). The knowledge that multiple genes function in MMR,
indicated that HNPCC might be associated with defects in any one of them. In 1994
the mutL homologue MLH1 was cloned and located to the second HNPCC locus at
3p21 (Bronner et al., 1994). PMS1 and PMS2 were also identified, by homology to
the bacterial and yeast proteins and were localised by fluorescent in situ
hybridisation to 2q31-33 and 7p22 respectively (Nicolaides et al., 1994). Mutations
in both genes were identified in the germline of HNPCC patients (Nicolaides et al.,
1994). MSH6, originally named GTBP for G/T binding protein, was localised to
2pl6 and demonstrated to function in MMR (Palombo et al., 1995; Papadopoulos et
al., 1995). However, the unusual phenotype associated with MSH6 mutations meant
that it was several more years before germline mutations in this gene were identified
in HNPCC families (Miyaki et al., 1997a).
The MMR genes are generally accepted to function as tumour suppressors in that
heterozygous cells have normal repair activity and loss or mutations of the wild type
allele is necessary for inactivation of MMR and subsequent tumour development. In
the inherited MMR defective disorders, one allele is already mutated in the germline
and somatic inactivation of the remaining wild type allele must take place. In
sporadic cases both alleles are intact in the germline and thus two somatic
inactivation events must occur.
1.5.2 Germline mutations of the MMR genes
A database of HNPCC associated mutations is maintained at http://www.nfdht.nl
which to date, contains information on over 300 germline mutations occurring in
over 500 HNPCC families from all parts of the world (Peltomaki, 2001). Around
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50% of germline mutations occur in MLH1 and 40% in MSH2 (Peltomaki, 2001)
(www.nfdht.nl). The predilection for mutations in these two genes is due to the fact
that loss of either results in the complete inactivation of base:base mispairs and
insertions:deletion loops as described (Figure 1.3). As a consequence, a strong
mutator phenotype and high levels of MSI are observed in the tumours of MSH2 and
MLH1 kindred's (Liu, 1996). Mutations in MLH1 and MSH2 are quite evenly
distributed although some clustering has been observed in exon 12 of MSH2 and
exon 16 of MLH1 (Peltomaki and Vasen, 1997). In the 1996 version of the mutation
database, Peltomaki noted that the mutations in MLH1 were mainly frameshift (40%)
or missense (31%) alterations, whereas germline changes in MSH2 were mainly
frameshifts (60%) or non-sense (23%) mutations (Peltomaki and Vasen, 1997).
Most of the reported mutations are unique with no real detectable hotspots.
However, there have been some notable cases of founder mutations that account for a
number of HNPCC families. One example is the exon 16 deletion of MLH1 known
as the Finland 1 mutation. It occurs in around 40 unrelated families in Finland and
Sweden. Genealogical studies have demonstrated that in a geographical cluster in
south central Finland, most of the affected individuals carrying this mutation belong
to different families descended from an ancestor who was one of a small number of
"founders" of this Finnish subpopulation around 500 years ago (Lathi et al., 1994).
Due to the functional redundancy between human MutSa and MutS(3 in the repair
of insertion:deletion mispairs (Figure 1.3), MSH3 mutations would not be expected
to result in a mutator phenotype. Consistent with this, no MSH3 kindred's have been
reported to date (www.nfdht.nl).
The number of HNPCC families in which germline MSH6 mutations have been
identified, has rapidly increased over the last five years (Peltomaki and Vasen, 1997;
Peltomaki, 2001). Due to the functional redundancy between MSH6 and MSH3,
MSH6 mutations predispose to an atypical form of HNPCC and this lead to MSH6
kindreds being overlooked in initial studies (Akiyama et al., 1997b). Inactivation of
MSH6, results in high rates of accumulation of base substitution mutations, since the
MSH2-MSH3 complex can still efficiently repair insertion:deletion mispairs.
Dinucleotide repeat markers were initially used to examine HNPCC families who
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showed the characteristic MSI+ phenotype. Loss of MSH6 would not result in
insertions or deletions at such loci and thus exclusion of potential MSH6 mutant
families from study resulted. The tumours of patients with MSH6 mutations typically
have a weaker MSI phenotype compared to the tumours from patients with MLH1 or
MSH2 defects (Kolodner et al., 1999). It has been suggested that this reduced level of
MSI may be the cause of the late onset, low penetrence form of HNPCC that typifies
patients with germline mutations of MSH6 (Akiyama et al., 1997b; Kolodner et al.,
1999).
Despite the fact that the numbers of families with mutations in MSH2, MLH1 and
MSH6 is steadily growing only five PMS2 germline mutations have been detected
and a single incidence of an HNPCC family with a germline PMS1 mutation
identified (Nicolaides et al., 1994) (www.nfdht.nl). The involvement of PMS1
mutations in a cancer family is intriguing in itself since the protein apparently plays
no role in MMR (Raschle et al., 1999). Furthermore, of the five PMS2 mutations
detected, only two occurred in classical HNPCC families (Nicolaides et al., 1994).
The remaining mutations were discovered in patients with familial CRC but also
phenotypic evidence of TS (Hamilton et al., 1995; Miyaki et al., 1997b; De Rosa et
al., 2000). This may indicate that germline mutations in PMS2 predispose individuals
to more atypical forms of HNPCC, as is the case for mutations ofMSH6.
1.5.3 MMR defects in mice
The generation of MMR defective mice has provided significant insight into the
role of the MMR proteins in the development of cancer, as well as in the mechanisms
of repair itself (Heyer et al., 1999).
Msh2 was the first MMR gene to be inactivated in the mouse. (De Wind et al.,
1995; Reitmair et al., 1995). Although Msh2~'~ mice are fertile (Reitmair et al., 1995),
they have a significantly decreased survival compared to both Msh2+/+ and Msh2+/~
mice. Around 50% are dead by 6 months and 100% die by one year of age (Reitmair
et al., 1996). Interestingly these mice do not develop early-onset CRC, as do HNPCC
individuals, but are predisposed to lymphomas early in life. (Reitmair et al., 1995;
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Reitmair et al., 1996). However, mice surviving beyond 6 months do develop
gastrointestinal tumours and these demonstrate MSI, characteristic of defects in
MMR. In addition, MSI was also detected in subclones from embryonic fibroblast
cell lines established from Msh2~/~ mice (Reitmair, et al., 1997). A small percentage
of Msh2 deficient mice also develop skin neoplasms, similar to the type occurring in
MT syndrome (Reitmair et al., 1996).
Mlhlmice show a similarly reduced survival to Msh2'/~ mice. Like Msh2
deficient mice, Mlhl deficient mice have a pre-disposition predominantly for
lymphomas and also for GI tumours and again MSI is detected in these tumours
(Prolla et al., 1998b; Edelmann et al., 1999). The fact that Mlhl'f' mice are infertile
supports other lines of evidence that suggest MLH1 has a role in meiosis (Edelmann
et al., 1996).
The MMR mutations in both Msh2''~ and Mlhlmice are clearly compatible with
normal development, but loss of MMR function leads to a predisposition for cancer
that is manifested by lymphoid tumours. Although a large number of tissue types are
involved in the tumours of HNPCC patients, lymphoid tumours are infrequent.
However, they have been observed in cases from MT and TS families, both of which
are associated with MMR defects (Hamilton et al., 1995; Kruse et al., 1998). The
propensity for lymphomas in Msh2 and Mlhl deficient mice, may reflect intrinsic
differences between mice and humans to lymphoma susceptibility. Alternatively, the
high turnover of maturing T-cells that exists in the developing immune system of
new-born mice, may offer a window in which MMR deficiency can strongly
accelerate the accumulation of transforming events (De Wind et al., 1995). This
explanation is indicative of a raised mutation rate having a major role in
carcinogenesis within expanding cell populations.
The idea that defects in MSH6 lead to an atypical form of HNPCC is supported by
the phenotype of the Msh6~'~ mouse (Edelmann et al., 1997). While these mice
developed B and T- cell lymphomas and GI cancers, these tumours do not display
MSI. Extracts of Msh2~/~ ES cells were demonstrated to be completely defective in
the repair of base:base mispairs, but not in the repair of insertiomdeletion mispairs
consistent with the predicted redundancy between human and yeast MSH6 and
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MSH3 (Edelmann et al., 1997). In addition the life span of these animals, while
reduced, is longer than that observed for Msh2'A and Mlhl" mice. By 10-11 months
50% are dead and 100% die by 18 months (Edelmann et al., 1997). Generation of the
Msh6~'~ mouse has provided evidence that the severity of the cancer pre-disposition
reflects the severity of the causative MMR defect. That MSH3 may co-operate with
MSH6 in tumour suppression was demonstrated by the generation of a double Msh6"
AMsh3'A mouse (Edelmann et al., 2000). In contrast to the atypical phenotype of the
Msh6~A mouse, the double mutant was indistinguishable in terms of tumour
predisposition phenotype to MlhPA and Msh2'A mice (Edelmann et al., 2000).
Mice deficient in Pmsl are not prone to cancer supporting the idea that human
PMS1 is either not involved in MMR or shares redundancy with another MutL
homologue, possibly MLH3 (Prolla et al., 1998b). The lack of cancers in the Pmsl~A
mouse makes the observation of an HNPCC family with a germline PMS1 mutation
even more intriguing (Nicolaides et al., 1994).
Consistent with the observation of PMS2 mutations in HNPCC kindreds
(Nicolaides et al., 1994), mice deficient in PMS2 are prone to cancer. Pms2'A mice
are pre-disposed to lymphomas like Msh2~A and MlhPA mice, but they do not develop
GI lesions (Prolla et al., 1998b). Furthermore Pms2~A mice have a level of MSI at
mononucleotide repeats that is 2-3 fold lower than in MlhPA mice (Yao et al., 1999).
This suggests that MLH1 can act in the repair of a subset of insertion:deletion loops
either alone or with another partner, perhaps MLH3. In addition, the data
demonstrate that MLH1 and PMS2 deficiencies have subtle, but differing effects on
mutation avoidance and this may in turn have dramatic effects on tumour
development. This might explain the different tumour spectrum between MLH1 and
PMS2 deficient mice (Yao et al., 1999).
1.5.4 Somatic inactivation of the MMR genes
Patients with HNPCC have one inherited MMR gene mutation and the remaining
wild type allele is inactivated somatically during tumourigenesis, thus disrupting
MMR activity. In HNPCC patients, inactivation of the second allele commonly arises
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by somatic mutation (Leach et al., 1993; Nicolaides et al., 1994; Papadopoulos et al.,
1994). In kindreds with germline MLH1 mutations, deletion of the wild type allele
has also been observed, a mechanism know as loss of heterozygosity (LOH)
(Hemminki et al., 1994; Wheeler et al., 2000). Evidence for LOH occurring at the
MSH2 locus has been examined using the closely linked marker, D2S123 but it
appears that this locus is not as susceptible to deletion (Aaltonen et al., 1993;
Wheeler et al., 1999). In sporadic CRCs with MSI, the inactivation of both MMR
alleles must occur somatically and mutational inactivation of MLH1, MSH2, MSH3,
MSH6 and PMS2 has been detected (Borresen et al., 1995; Liu et al., 1995b; Ma et
al., 2000; Mai et al., 1999; Malkhosyan et al., 1996). However, in contrast to the
situation in familial tumours, LOH is not observed at either MSH2 or MLH1,
suggesting this may represent a mechanism of gene inactivation specific to HNPCC
related cancers. (Wheeler et al., 1999). There is also disparity between the frequency
with which the MMR genes are mutated in familial and sporadic MSI+ tumours.
While MLH1 and MSH2 mutations predominate in HNPCC, inactivation of MLH1
accounts for the majority of sporadic cases (Cunningham et al., 1998; Herman et al.,
1998; Cunningham et al., 2001). This is explained by the relative contribution from
epigenetic inactivation ofMLH1, in familial and sporadic CRCs.
It has been established that epigenetic mechanisms contribute to gene inactivation
and in particular, silencing of gene expression by DNA methylation has been
observed at MLH1 in many MSI+ CRCs (Cunningham et al., 1998; Herman et al.,
1998; Jones and Laird, 1999; Lynch and de la Chapelle, 1999; Wheeler et al., 2000).
CpG islands are areas of about lkb, commonly found near the promoters of widely
expressed genes (Bird, 1986; Cross and Bird, 1995). They are usually unmethylated
thus allowing gene expression, but de novo methylation of these regions, results in
the silencing of the associated gene (Boyes and Bird, 1992; Cross, 1995).
Hypermethylation of the 5'CpG island of the MLH1 promoter has been detected in
the majority of sporadic primary CRCs with MSI and this is generally associated
with loss of MLH1 protein expression (Cunningham et al., 1998; Herman et al.,
1998; Wheeler et al., 1999; Cunningham et al., 2001).
Wheeler et al addressed the relative contribution of different mechanisms of
MMR gene inactivation by analysing sporadic MSI+ CRC cell lines for mutations,
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promoter methylation and LOH (Wheeler et al., 1999). Mutation of MLH1 together
with hypermethlation of the promoter region was found to account for the majority of
sporadic MSI+ tumours (Wheeler et al., 1999) and hypermethylation of the MLH1
promoter represents the most significant mutational difference between sporadic and
familial MSI+ CRCs (Wheeler et al., 2000). Although methylation of the MLH1
promoter has been detected in some HNPCC CRCs the overall contribution is
believed to be small (Cunningham et al., 1998; Wheeler et al., 2000).
1.6 The Mutator Phenotype
1.6.1 Microsatellite instability
Gross genetic alterations such as LOH and chromosomal gains in anueploid CRCs
are well documented and have demonstrated that cancer cells contain many genetic
changes in comparison to normal tissue (Peinado et al., 1992). However, the link
between MMR gene mutations and widespread instability at simple sequence repeats
(SSRs) furthered the notion that a high mutation rate makes a significant and
necessary contribution to the development of cancer (Loeb, 1994).
Microsatellites are tandem repeats of simple sequences that occur ubiquitously
throughout the human genome. These SSRs occur in both coding and non-coding
sequence, although they are most common in non-coding DNA (Toth et al., 2000).
SSRs comprise ~ 10-50 copies of l-6bp motifs that can occur as perfect tandem
repeats, imperfect (interrupted) repeats or as a combination of the two types (Weber,
1990). Microsatellites are often highly polymorphic in terms of length but are
normally transmitted through mitosis and meiosis without alteration (Weissenbach et
al., 1992; Weber and Wong, 1993) Although no specific function has been
demonstrated for non-coding microsatellite sequences, they do not necessarily
represent "junk" DNA. Non-coding repetitive tracts have been suggested to be
binding sites for DNA topoisomerase (Spitzner et al., 1990). In addition, there is
some evidence that the length of the SSR within promoter regions may influence
transcriptional activity (Kashi et al., 1997).
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MSI was initially described in independent publications from three groups that
appeared almost simultaneously in 1993 (Aaltonen et al., 1993; Ionov et al., 1993;
Thibodeau et al., 1993). Each study used PCR based assays to compare loci between
normal and tumour tissue and reported frequent alterations in the length of
mononucleotide and dinucleotide repeats in tumour DNA (Aaltonen et al., 1993;
Ionov et al., 1993; Thibodeau et al., 1993). These alterations varied in nature and
were observed as substantial changes in repeat length (often heterogeneous in
nature), or as minor changes (typically 2bp) (Thibodeau et al., 1993). In addition, the
number of microsatellite loci that displayed length alterations varied from tumour to
tumour. While changes were observed at a single locus in some tumours, alterations
at many were detected in others (Thibodeau et al., 1993). MSI was demonstrated to
occur in most familial CRCs and 13% of sporadic cases, indicating the phenotype is
a significant factor in CRCs and is characteristic of tumours from HNPCC families
(Aaltonen et al., 1993). It was recognised that although many of the changes may be
silent, some may occur within coding regions and thus result in the significant
alteration of gene products (Aaltonen et al., 1993). The presence of generalised
deletions at poly(A) and (CA)n repeats also correlated with a number of clinical
features. The presence of MSI is negatively associated with mutations in p53 and C-
K-RAS but positively associated with poorly differentiated right-sided tumours
(Ionov et al., 1993).
The link between MSI and MMR defects was made by Strand et al who
demonstrated that inactivating mutations in the yeast MMR genes, MSH2, MLH1 and
PMS1 lead to a 100 to 700 fold increase in repeat tract instability (Strand et al.,
1993). It was proposed that a high rate of DNA polymerase slippage occurs in vivo at
templates that contain simple repeats. The resulting alterations are usually corrected
by MMR, but in the majority of HNPCC CRCs and a subset of sporadic tumours,
defects in MMR means these errors remain un-repaired (Strand et al., 1993). Parsons
et al subsequently made the association in humans (Parsons et al., 1993).
These studies dramatically contributed to the elucidation of the genetic
mechanisms that cause CRC in HNPCC families and highlighted a role for an
elevated mutation rate in tumourigenesis.
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1.6.2 Classification of MSI status
Since almost all CRCs harbouring defects in MMR genes display MSI,
establishing tumour MSI status has become an important tool in molecular pathology
(Liu etal., 1996).
Around 90% of CRCs from HNPCC patient's display MSI and thus, the
assessment of MSI status is an important aspect of HNPCC screening (Aaltonen et
al., 1993). Exclusion criteria are applied that subsequently direct strategies to further
screen the MMR genes for germline alterations (Rodriguez-Bigas et al., 1997). Since
up to 20% of sporadic tumours also display MSI, assessment of tumour MSI status is
of great value in non-familial cases (Aaltonen et al., 1993; Cunningham et al., 2001).
In a study of CRCs from non-HNPCC patients under 35 years of age, the majority
(58%) exhibited a mutator phenotype and the underlying MMR gene mutations were
also identified in a proportion of these patients (Liu et al., 1995a). This suggests that
an MSI pathway of tumourigenesis is of particular significance in certain subsets of
sporadic CRCs especially in early onset cases.
MSI and MSS appear to characterise two different pathways of carcinogenesis
and the determination of MSI status can have relevance to predicting the clinical
course of a particular tumour. It is well documented that patients with MSf1" tumours
have a better prognosis than those whose tumours are MSS (Lothe et al., 1993;
Thibodeau et al., 1993). Although, more recent evidence suggests that this may not
always be the case (Farrington et al submitted). The fact that defects in MMR may
result in resistance to DNA damaging agents has been discussed. Since MSI is
indicative of MMR defects, identification of instability within a tumour may be
predictive of its responsiveness to chemotherapy (Fink et al., 1998).
Accurate determination of MSI status is critical in order to implement effective
screening strategies and to make clinical and molecular predictions with confidence.
However, it has been demonstrated that some microsatellite markers are more
efficient than others in detecting tumours with MSI (Dietmaier et al., 1997;
Thibodeau et al., 1998; Frazier et al., 1999). While some markers are very unstable
in MSI tumours, others show low levels of mutability. It has been suggested that the
likelihood of a microsatellite being susceptible to instability relates to the inherent
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mutation rate at that locus (Thibodeau et al., 1998). This is supported by the
observation of variation in mutation rates at di- tri- and pentameric markers within
CEPH families (Weber and Wong, 1993). Variation in marker susceptibility to
mutation can potentially affect the number of tumours that are scored positive for
MSI. To address this problem, a number of studies have sought to identify a panel of
markers that are the most efficient for detecting instability (Dietmaier et al., 1997;
Hoang et al., 1997; Frazier et al., 1999). At the National Cancer Institute (NCI)
workshop in 1997, five markers were recommended for use as part of international
guidelines for the evaluation of MSI in CRC (Boland et al., 1998). This panel
comprises, two mononucleotide markers, BAT25 and BAT26, and three dinucleotide
markers D5S346, D2S123 and D17S250. A set of alternative loci was also suggested
as part of an expanded panel and these include the poly(A) marker BAT40 (Boland
et al., 1998). Little is understood about factors independent of tumourigenesis that
may influence the susceptibility of these markers to mutation in the absence of
MMR. Elucidation of such factors is clearly of importance and further analysis is
necessary, to fully characterise the nature of alterations that take place at these
microsatellite loci in both tumour and normal cells (Boland et al., 1998).
There is evidence that tumours themselves show differences in susceptibility to
MSI and that MSI+ actually represents two classes of tumours with distinct mutator
phenotypes and different molecular aetiologies (Dietmaier et al., 1997; Thibodeau et
al., 1998). Thibodeau et al noted two categories of tumours that either showed
instability at a single repeat locus or showed instability at many (Thibodeau et al.,
1993). These two distinct groups have now been classified as tumours with high
levels of MSI (MSI-H) or those with low MSI frequency (MSI-L) (Boland et al.,
1998). The international guidelines recommend that a tumour is classified as MSI-H
if instability is detected at >2 of the recommended panel of five markers (Boland et
al., 1998). If one marker displays instability the tumour is classified as MSI-L and if
all the markers are stable the tumour is MSS. However, the use of just five markers
can result in cases of mis-classification between MSI-L and MSI-H (Frazier et al.,
1999). A more reliable analysis can be made by extending the number of loci used
and classifying MSI-H tumours as those shifting at > 30-40%, MSI-L as those
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shifting at <30-40% and MSS as those displaying no microsatellite alterations
(Boland et al., 1998).
The sub-classification of MSI tumours into MSI-L and MSI-H is particularly
useful as it can assist in screening strategies for MMR mutations. While most
tumours with an MSI-H phenotype have defects in MLH1 and MSH2 (Liu et al.,
1996), mutations in MSH6 appear to contribute to a substantial proportion of patients
with MSI-L tumours and result in a more atypical HNPCC phenotype (Wu et al.,
1999b). In addition, the clinical phenotype of MSI-L tumours seems more similar to
MSS tumours. For example, the predilection for right-sided tumours in MSI-H cases
is not observed in MSI-L. Such observations suggest that the level of instability
directly influences the clinical development of CRC (Thibodeau et al., 1998).
Further characterisation of factors that can affect stability of microsatellite
markers will improve the robustness of using these tools in the classification of MSI
in CRCs. In turn this will allow more effective conclusions to be made with regard to
the associations of relative levels of mutation within tumours and the association
with clinical phenotype.
1.6.2 Role of MSI in tumourigenesis
The subtle changes in the DNA sequence caused by MSI, provide an alternative
mutational mechanism to the cytogenetically visible changes such as chromosomal
losses, gains and translocations that are well documented in the majority of solid
tumours (Peinado et al., 1992; Lengauer et al., 1998). Tumours that show instability
at the sequence level (MSI+) are termed MIN, whereas those that are unstable at the
chromosomal level (MSS) are known as CIN. These two types of instabilities are
rarely found to co-exist in tumours and thus it appears that one form of instability is
sufficient to promote tumourigenesis. The exact mechanisms leading to a CIN
phenotype are largely unclear, however the relationship between MMR and MSI is
well established and is clearly associated with the development of MIN tumours.
Therefore, MIN tumours are of particular use in the investigating the function of
increased genetic instability in tumourigenesis.
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Since the discovery of MSI in CRCs, a number of studies have addressed the
timing of this event and the role that an abnormally elevated mutation rate plays in
the development of cancer (Aaltonen et al., 1994; Shibata et al., 1994). Shibata et al
examined patterns of MSI at different regions of colorectal carcinomas and
adenomas and detected MSI in colorectal adenomas, suggesting that genomic
instability is a very early event (Shibata et al., 1994). That MSI arises early in
tumour development is supported by the detection of genetic alterations in aberrant
crypt foci (ACF), which represent morphologically abnormal crypts, believed to be
the precursors of adenomas (Augenlicht et al., 1996; Heinen et al., 1996). Since
alterations in SSRs are not generally observed in normal tissue the activation of MSI
appears strongly associated with histological transformation and is implicated as
having a critical role in tumour initiation (Aaltonen et al., 1994; Shibata et al., 1994).
There are some exceptions in which MSI has been detected in non-cancerous tissue
but these cases are generally associated with constitutional defects in MMR (Parsons
et al., 1995a; Hackman et al., 1997; Narayanan et al., 1997; De Rosa et al., 2000).
MSI has been demonstrated to display different degrees of instability within
different regions of a given tumour and these regions comprise areas showing
distinct clonality. In addition more advanced cancers display greater instability
compared to early adenomas (Shibata et al., 1994). These observations provide
evidence that genomic instability is a dynamic process, which persists throughout
tumour development and likely contributes to both tumour progression and initiation
(Shibata et al., 1994).
A model of tumourigenesis driven by genomic instability has been proposed
(Figure 1.4). In this model, tumours initiate as a result of inactivation of a single
MMR gene. Consequently, mutations accumulate in the offspring of this cell and
waves of clonal expansion give rise to daughter cells that have a growth advantage
typical of cancer (Nowell, 1976; Fearon and Vogelstein, 1990; Cahill et al., 1999;
Loeb, 2001). The mutational targets of this multistep progression are oncogenes and
tumour suppressor genes that when mutated, directly affect the rate of cell growth or
cell death. The increase in mutation rate in MIN tumours provides variation for
selection to act upon. However, it is reasonable to predict that the intrinsic level of
instability may be critical (Cahill et al., 1999). If the mutation rate is too low, cells
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will be unlikely to contain an alteration that provides them with a selective
advantage. Conversely, if the mutation rate is too high and the cell becomes
overloaded with damage, programmed cell death will ensue (Cahill et al., 1999).
Advocates of the mutator phenotype propose that MSI is one of the earliest events
that drives tumour progression and furthermore, is necessary to generate the level of
mutational alterations on which selection may then act (Loeb, 2001).
The molecular pathogenesis of MIN tumours remains to be fully elucidated
although some causative genes have been isolated. Identification and functional
understanding of the mutations that accumulate in coding sequences in MMR
defective tumours, will be crucial to understanding mechanisms by which genomic



















Figure 1.4 Generalised model of the mutator pathway of colorectal cancer. The thickness of
the arrows is intended to convey the gradual increase in the probability of occurance of mutation
in genes required for tumour progression. The mutational events indicated are not definitive
but represent probable targets as suggested from the literiture. It is highly likely that many more
mutations than indicated here, contribute to this pathway of tumour development. Gene
alterations are different to those recognised in the initial pathway proposed by Vogelstein and
Fearon, 1991, as is the speed with which changes arise once tumourigenesis is initiated
(Figure 1.1). Adapted from Perucho, 1996; Eshleman and Markowitz, 1996 and Boland, 2000.
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1.7 Molecular Consequences of Mismatch Repair Defects
1.7.1 Coding sequence mutations in MMR deficient tumours
Microsatellite repeats are clearly hotspots for mutation in MMR deficient
tumours. Repeat regions in coding sequence have been identified and their
mutational status evaluated in MSI+ CRCs, in order to elucidate critical oncogenes
and tumour suppressor genes involved in the mutator pathway of CRC (Parsons et
al., 1995b; Duval et al., 2001). Repetitive tracts, particularly poly(A/T)
mononucleotide repeats and CA:GT dinucleotides are common in human coding
sequence although, they tend to be much shorter than in non-coding sequences (Toth
et al., 2000) (Taylor pers. comm.). However, due to the high background of genetic
instability that characterises MSI+ tumours, it is often difficult to establish which
alterations play a crucial role in the initiation and progression of MSI+ CRCs. An
elevated frequency of mutations within a gene in MSI+ tumours does not necessarily
imply a causal role for the mutation in CRC development.
To distinguish between mutations occurring in target genes and those that are
merely bystanders, a set of five criteria has been established (Boland et al., 1998). In
addition to (1) having a high mutational frequency in MSI+ CRCs, genuine targets
involved in tumourigenesis should (2) also demonstrate biallelic inactivation. It is
reasonable to suggest that only when both alleles of the putative target are
inactivated, is it highly likely that protein function will be completely abrogated. (3)
A role for the candidate gene within a tumour suppressor pathway should be
apparent, indicating a potential mechanism by which inactivation of the gene
provides the cell with a growth advantage. (4) The occurrence of alterations within
the same gene or same functional pathway in MSS tumours may also be expected if
the target is critical for tumour suppression. Finally, (5) functional studies carried out
in vitro and in vivo, should be consistent with a role for the protein, in growth
suppression (Boland et al., 1998). This set of criteria is not without limitations. By
suggesting that a role for the gene in a tumour suppressor pathway should be
implicated (point 3), this assumes that all important tumour suppressor pathways are
known. Clearly this is not the case. In addition, genes inactivated in MSI+ tumours
43
may not also be inactivated in MSS tumours (point 4) if the genetic pathways
involved in the development these tumours is different and there has been several
studies to suggest this may be the case (Olschwang et al., 1997; Perucho, 1999).
Models for the progression of CRC have been presented as an ordered sequence
of mutations in oncogenes and tumour suppressor genes, each associated with a
defined step in tumourigenesis (Figure 1.1) (Vogelstein, 1988; Fearon, 1990).
Flowever, a mutator phenotype may not be in accord with a set order of mutation
during tumour evolution, due to the large numbers of apparently different and
random mutations that occur and confer potential selective advantage (Loeb, 2001).
Nonetheless, a number of genes have been implicated as critical targets in a mutator
pathway of CRC development. It may follow that certain gene mutations may arise
more readily if particular sequences are inherently susceptible to mutation
consequent of MMR defects.
1.7.2 TGFBR2 mutations in MSI+ CRCs
The transforming growth factor beta type 2 receptor (TGFBR2) has been
implicated as having a major role in the development of MSI+ CRCs (Markowitz,
2000). There are several lines of evidence that suggest the TGFBR2 gene is
genuinely inactivated in CRCs with MMR defects and that this inactivation directly
contributes to tumourigenesis.
The transforming growth factor beta, (TGFB) signalling pathway results in potent
antiproliferative responses (Wang et al., 1995). Loss of this negative regulatory
mechanism causes excess cell growth, suggesting that the TGFBR2 gene behaves as
a tumour suppressor. Antiproliferative responses triggered by TGFB include,
induction of growth arrest in late G1 phase of the cell cycle (Alexandrow and Moses,
1995) and induction of apoptosis (Wang et al., 1995) and these activities have been
demonstrated in non-transformed colon epithelial cells (Wang et al., 1995). That
TGFBR2 is functionally a colon cancer suppressor gene has been demonstrated by
the restoration of wild type function by addition of wild type TGFBR2 into TGFBR2
mutant CRC cell lines (Grady et al., 1999).
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TGFB signals, by contacting the two distantly related transmembrane
serine/threonine kinases called receptors I and II (TGFBR1 and TGFBR2) (Figure
1.5) (Lin et al., 1992; Wrana et al., 1994). TGFB binds directly to TGFBR2, a
constitutively active kinase. TGFB bound to TGFBR2 is recognised by TGFBR1 and
this second receptor is then recruited to form a heteromeric receptor complex. On
formation of this complex, TGFBR1 is phosphorylated by TGFBR2 (Wrana et al.,
1994; Massague, 1996; Markowitz, 2000). The resultant activated receptor, signals to
the nucleus via members of a family of signal transduction molecules called SMADs,
which are related to the Drosophila gene, Mothers against dpp (Mad) and the C.
elegans sma homologues (Zhang et al., 1996; Nakao et al., 1997; Wrana and
Pawson, 1997; Attisano and Wrana, 1998; Kretzschmar and Massague, 1998).
Specific receptor activated SMADs, (SMAD2 and SMAD3) are recognised by the
activated TGFB receptor complex and are phosphorylated at carboxy-terminal serine
residues (Eppert et al., 1996; Nakao et al., 1997; Wrana and Pawson, 1997). These
molecules are then able to associate with a co-SMAD, (SMAD4) and translocate to
the nucleus where Smad2-Smad4 complexes have been demonstrated to regulate
TGFB signalling responses by specifically interacting with DNA-binding proteins
such as the transcription factor FAST-1 (Figure 1.5) (Kretzschmar and Massague,
1998; Nakao et al., 1997; Wrana and Pawson, 1997). The regulatory activities of
TGFB include inhibiting expression and activation of cyclins, inhibiting expression
of cyclin dependent kinases, inducing various cyclin-dependent kinase inhibitors
such as pi5, p27 and p21, inhibiting phosphorylation of Rb and inhibiting induction
of c-myc (Moses et al., 1990; Ewen et al., 1993; Hannon and Beach, 1994;
Markowitz, 2000). Inactivation of any of these targets could explain why human
cancer cells show resistance to TGFB mediated growth arrest.
Inactivating mutations have been identified in TGFBR2 in over 90% of MSI+
CRCs (Markowitz et al., 1995; Parsons et al., 1995b). These mutations are
principally ffameshift mutations that insert or delete one or two adenine bases within
a lObp polyadenine repeat poly(A)io that is present in exon 3 of the TGFBR2 gene
(Markowitz et al., 1995; Lu et al., 1996). The mutations observed introduce stop
codons in the TGFBR2 transcript. These result in a truncated protein that lacks the
wild type cytoplasmic domain and is therefore functionally inactive.
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Parsons et al, analysed 111 MSI+ primary CRC tumours and cell lines specifically
for mutations within the poly(A)io tract of TGFBR2 and identified ffameshift
mutations in 100 (90%). In most cases, biallelic inactivation of TGFBR2 was
observed (Parsons et al., 1995b). Since the mutations were found in tumour DNA,
i.e.) not in corresponding normal DNA, these mutations must have been somatic.
Furthermore, although poly(A) tracts are generally unstable in MSI+ tumours (Ionov
et al., 1993; Thibodeau et al., 1993), the poly(A)io tract of TGFBR2 appeared
significantly more unstable than other poly(A) tracts of the same size (Parsons et al.,
1995b).
Further studies have addressed the timing of the TGFBR2 poly(A)io mutations
observed in MSI+ CRCs. Those genetic changes critical for carcinogenesis, are likely
to be shared by all cells in an expanding tumour and thus be detectable at all sites
(Abdel-Rahman et al., 1999). Consistent with this notion, TGFBR2 poly(A)io
mutations were identified at all tumour sites sampled in 9 MSI+ CRCs (Abdel-
Rahman et al., 1999). Furthermore, TGFBR2 poly(A)io mutations have also been
detected in early colorectal lesions (Lu et al., 1996; Akiyama et al., 1997a; Grady et
al., 1998). Akiyama et al revealed altered TGFBR2 poly(A)io repeats in all 5
adenomas sampled with moderate atypia (Akiyama et al., 1997a). It was suggested
that mutation of TGFBR2 occurs early in tumourigenesis, functioning to allow MMR
defective cells to proceed to adenoma formation (Akiyama et al., 1997a). Grady et al
also detected TGFBR2 poly(A)io mutations in 75% of late stage MSI+ adenomas, not
significantly different to the frequency observed in carcinomas. This observation
suggests that the inactivation of TGFBR2 is tightly correlated with the progression of
late stage adenomas to cancer (Grady et al., 1998). Mutations at this region have not
been observed in normal cells, even those with constitutive defects in MMR,
although few studies have analysed this locus in non-cancerous tissue (De Rosa et
al., 2000). Therefore the nature of the mutations (predominantly frameshifts) at this
microsatellite locus and their timing is consistent with them having arisen early in
tumourigenesis, but subsequent to the loss of MMR (Grady et al., 1998; Abdel-
Rahman et al., 1999).
Further evidence that mutation of TGFBR2 is a key event in tumours defective in
MMR, is suggested by the observation of inactivating point mutations in TGFBR2 in
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MSS CRCs (Grady et al., 1999). Inactivation of other components of the TGFBR2
pathway has also been identified in a number of MSS cancers. SMAD4, also known
as DPC4, was originally isolated as a tumour suppressor gene on 18q21 that was
either deleted or mutated in large numbers of human pancreatic carcinomas (Hahn et
al., 1996). SMAD2 is also located at 18q21 and is mutated in MSS CRCs (Eppert et
al., 1996). These observations further suggest that inactivation of the TGFB
signalling pathway is an important step in the development of CRC.
Taken together the evidence suggests that mutations arise frequently in the
poly(A)io tract of the TGFBR2 gene and are critical to MSI+ associated
tumourigenesis. The mutational inactivation of TGFBR2 may be involved in
initiating events of CRCs with MMR defects and loss of TGFBR2 likely confers a
strong selective advantage to the developing tumour.
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Figure 1.5 General model of TGFB/SMAD signalling. TGFB signalling induces phosphorylation
of TGFBR1 by TGFBR2 leading to the transient association with specific receptor activatable
SMADS (2 and 3). On phosphorylation they associate with a co-SMAD (SMAD4) and move
to the nucleus. Formation of a complex with DNA binding transcription factors such as FAST-
1 leads to stimulation of target gene expression. Adapted from Nakao etal., 1997; Kretschmar
and Massague, 1998, and Markowitz, 2000.
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1.7.3 BAX mutations in MSI+ CRCs
Around 50% of MSI+ CRCs contain ffameshift mutations of a poly(G)s tract in
exon 3 of the pro-apoptotic BAX gene and in some cases bi-allelic inactivation has
been detected (Rampino et al., 1997; Ouyang et al., 1998). Although the overall
frequency of these mutations is not as high as mutations of the poly(A)io tract in
TGFBR2, the prevalence of mutations observed in the repetitive tract of BAX are still
in excess of those observed in sequences of similar size in MSI+ tumours (Rampino
et al., 1997; Ouyang et al., 1998; Zhang et al., 2001). In addition, there is evidence
that mutational inactivation of the BAX gene confers a selective advantage during
clonal evolution of the tumour (Ionov et al., 2000).
BAX is a member of an extended family of proteins that are activated by
cleavage. This cleavage may be carried out by caspases, by inhibition of protein
kinases and/or activation of phosphatases and by an increase in cellular pH
(Pawlowski and Kraft, 2000). BAX molecules reside in the cytoplasm and respond to
apoptotic stimuli by migration to the mitochondria (Figure 1.6). BAX contains a
hydrophobic membrane anchor at its C-termini that is necessary for mitochondrial
insertion (Goping et al., 1998). Attachment to the mitochondria allows BAX to
directly trigger the release of cytochrome C, by inducing the formation of ion-
permeable pores that disrupt the mitochondrial membrane barrier (Jurgensmeier et
al., 1998; Marzo et al., 1998). Upon entering the cytosol, cytochrome C promotes the
assembly of a multiprotein complex containing APAF-1, that induces proteolytic
processing and activation of cell death proteases, known as caspases. Bcl-2 is an
antagonist of BAX that prevents the release of cytochrome C, and while BAX and
Bcl-2 can function independently, their balance regulates the apoptotic response of
the cell to the same apoptotic stimuli (Oltvai et al., 1993; Pawlowski and Kraft,
2000). Thus, the function of BAX suggests that its inactivation may play a direct role
in tumourigenesis since cells lacking a functional protein may have diminished
capacity to trigger apoptosis upon receiving a death signal (Figure 1.6) (Oltvai et al.,
1993; Rampino et al., 1997; Yin et al., 1997).
The p53 protein plays a role in triggering apoptosis in response to DNA damage
and has been demonstrated to transactivate BAX (Miyashita and Reed, 1995;
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Thornborrow and Manfredi, 1999). Therefore, the finding of an appreciable
frequency of BAX mutations in MSI+ CRCs may explain why in contrast to MSS
tumours, those of the mutator pathway do not contain p53 mutations (Fearon and
Vogelstein, 1990; Ionov et al., 1993; Kim et al., 1994; Konishi et al., 1996;
Olschwang et al., 1997; Yagi et al., 1998). In an MMR defective cell, mutations at
the BAX poly(G)8 repeat are more likely to occur than other ffameshift or missense
mutations in p53. Inactivation of BAX thus eliminates the selective pressure for p53
mutations in MSI+ CRCs, since an apoptotic signalling molecule downstream of p53
has already been lost (Rampino et al., 1997; Yagi et al., 1998).
While TGFBR2 mutations appear to occur relatively early in tumourigenesis, the
lack of clonality ofBAX poly(G)8 mutations in some MSI+ carcinomas, indicates that
these changes are unlikely to be such an early event (Abdel-Rahman et al., 1999).
BAX poly(G)8 mutations have been observed in only 15% of adenomas, significantly
less than observed in adenocarcinomas (54%), suggesting that these mutations show
a high mutation rate in the transition to carcinomas (Yagi et al., 1998). It has also
been suggested that BAX mutations might not exert a critical role in tumour
initiation, but may aid tumour progression (Abdel-Rahman et al., 1999).
The high frequency of mutations of the repeat tract of the BAX gene in MSI+
tumours along with the functional evidence that inactivation can confer a selective
advantage during selection, suggests that the BAX poly(G)s tract is an important
mutational target in MSI+ CRCs. The difference in mutation frequency of the repeat
regions in TGFBR2 and BAX may reflect differences in inherent stability of the
repeats in the presence of repair defects or differences in selectable advantage
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Figure 1.6 Cascade of the BAX mediated apoptotic response. Major componants involved in
the pro-apoptic response by BAX are illustrated. p53 and BID represent examples of effector
molecules stimulated by apoptitic stimuli. On release of cytochrome C from the mitochondria
the two caspase 9 molecules are brought together by APARF-1 thus activating this initiator
caspase. Activated caspase 9 induces cleavage of effector proteases, caspase 3 and 7
activating their protease activity. These are responsible for the controlled degredation process
characteristic of apoptotic cell death including activation of the DNA cleavage nuclease (CAD).
Adapted from Pawlowski and Kraft, 2000 and Macleod, 2000.
1.7.3 Inactivation of the (3-catenin/TCF pathway in MSI+ CRCs
The tumour suppresser gene APC was shown to cause the syndrome FAP by
observing co-segregation of mutant APC alleles in affected kindreds (Groden et al.,
1991; Kinzler et al., 1991; Nishisho et al., 1991). Following this report, mutations of
the APC gene were demonstrated to occur in around 80% of sporadic CRCs and
adenomas, indicating that the APC gene plays a major role in the early development
of colorectal neoplasms (Miyoshi et al., 1992; Powell et al., 1992). It has been
suggested that APC acts as a gatekeeper of colonic epithelial cell proliferation and
that inactivation of this gatekeeper is required for an overall increase in cellular
proliferation in the majority of CRCs (Kinzler and Vogelstein, 1996). Although p53
and C-K-RAS mutations are also frequently observed in sporadic CRCs, germline
mutations in these genes do not pre-dispose to colon cancer, suggesting they cannot
initiate tumourigenesis in a manner similar to inactivation of APC (Kinzler and
Vogelstein, 1996).
Insights into APC function were gained from studies of the interaction between
APC and (3-catenin (Rubinfeld et al., 1993; Su et al., 1993) Interestingly, the
majority of somatic mutations in the APC gene occur in the mutation cluster region, a
666bp region that contains two classes of (3-catenin binding repeats (Figure 8.2).
These comprise 3, 15 amino acid (aa) signature repeats that provide binding sites for
(3-catenin and seven 20aa repeat motifs that allow (3-catenin binding and down
regulation (Miyoshi et al., 1992; Rubinfeld et al., 1996; Fearnhead et al., 2001). At
least three of the 20aa repeats are necessary for partial down regulation of (3-catenin
by APC and four or more for a complete effect (Su et al., 1993; Munemitsu et al.,
1995; Fearnhead et al., 2001). In CRCs containing APC mutations, five or more of
these repeats are typically deleted (Rubinfeld et al., 1997). This suggests that
abrogation of APC binding and regulation of (3-catenin is selectively disrupted in
colorectal tumours (Munemitsu et al., 1995; Rubinfeld et al., 1997).
(3-catenin plays a role in cadherin mediated cell adhesion. Binding to cadherins is
mutually exclusive to binding of APC, indicating that APC could modulate such
adhesion as part of its gatekeeping role (Barth et al., 1997). (3-catenin and APC also
52
play major roles in the (3-catenin/TCF signalling pathway (Figure 1.7) (Munemitsu et
al., 1995; Barth et al., 1997; Morin et al., 1997) and it is the disruption of this
pathway that is thought to be of particular significance in CRC development.
Abrogation of the (3-catenin/TCF pathway leads to tumour formation most likely via
the constitutive activation of oncogenic targets that include cyclin Dl, c-myc and c-
jun (Munemitsu et al., 1995; Mann et al., 1999; Tetsu and McCormick, 1999
Behrens, 2000). Understanding of this signalling pathway in humans, has been
elucidated from studies of the Wingless (Wg) and Wnt pathways, in Drosphila and
mouse respectively, where [3-eatenin has been established as the central signal
transducer in this pathway (Behrens, 2000). The control of cytoplasmic (3-catenin
levels is an essential regulatory mechanism that prevents inappropriate Wnt signal
transmission to the nucleus when Wnt factors are not present (Munemitsu et al.,
1995; Behrens, 2000). In the absence of Wnt signalling, a cytoplasmic multisubunit
complex is assembled that targets (3-catenin for degradation. Components of this
complex include conductin/axin, a serine/threonine kinase called glycogen
synthase3(3 (GSK3(3) and APC (Rubinfeld et al., 1996). Degradation of (3-catenin is
induced by the phosphorylation of specific serine/threonine residues in its N-
terminus probably by GSK-3(3. This leads to ubiquitination of (3-catenin and
subsequent proteosome degradation (Orford et al., 1997). Degradation is restricted to
the cytoplasmic pool of the (3-catenin and does not involve protein bound to
cadherins. In the presence of Wnt signals, cytoplasmic (3-catenin is stabilised. When
present at high levels in the cytoplasm, (3-catenin binds to cytosolic T cell factor-
4/lymphoid enhancer factor (TCF/LEF) proteins and the resulting complex is
shuttled to the nucleus (Behrens et al., 1996). As a consequence, the (3-catenin/TCF
complexes, activate transcription of specific target genes (Mann et al., 1999).
The essential function of APC in the (3-catenin regulatory complex has not been
fully elucidated. However, the finding that protein products of mutant APC genes
that are present in colorectal tumours, loose their ability to down-regulate
transcriptional activation mediated by (3-catenin and T-cell transcription factor,
indicates that regulation of (3-catenin is critical to APCs tumour suppressive effect
(Morin et al., 1997). Furthermore, in sporadic CRCs lacking APC mutations,
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activating mutations in the (3-catenin gene, CTNNB1, have been identified that alter
functionally significant phosphorylation sites (Morin et al., 1997). These CTNNB1
mutations have been demonstrated to encode proteins that circumvent the tumour
suppressive effect of APC (Morin et al., 1997).
The role of the [3-catenin/TCF signalling pathway in tumourigenesis of CRCs with
MMR defects is unclear. Evidence from mice studies has suggested that the loss of
APC is involved in HNPCC. For example, Msh2'/~ mice show loss of detectable APC
protein in their tumours (Reitmair et al., 1996). In addition, when an APC mutation
was bred into the MlhP/~ mouse, the incidence of GI tumours increased 40-100 fold
(Edelmann et al., 1999). However, in humans the reported frequency of APC
mutation in MSI+ CRCs differs markedly. A number of studies have demonstrated
that APC mutations occur infrequently in MSI+ CRCs and that these tumours involve
the abrogation of alternative genes and genetic pathways compared to MSS CRCs
(Heinen et al., 1995; Konishi et al., 1996; Olschwang et al., 1997; Salahshor et al.,
1999). Salahshor et al also screened MSI+ tumours for CTNNB1 mutations since
these can substitute APC mutations in MSS CRCs (Morin et al., 1997; Salahshor et
al., 1999). However, in 22 MSI+ tumours no CTNNB1 mutations were identified
furthering the argument that activation of the (3-catenin/TCF pathway is not critical
for tumour development when MMR is defective (Salahshor et al., 1999). In
contrast, a number of reports have demonstrated that the frequency ofAPC mutations
in MSI+ CRCs is similar to that of MSS CRCs (Huang et al., 1996; Homfray et al.,
1998) and CTNNB1 mutations have been detected in a number of MSI+ tumours
lacking APC mutations (Sparks et al., 1998; Mirabelli-Primdahl et al., 1999; Miyaki
et al., 1999;). Abrogation of (3-catenin has even been suggested to be an event
specific to MSI+ CRCs (Mirabelli-Primdahl et al., 1999).
Where APC mutations have been observed frequently in MSI+ CRCs, there is
uncertainty as to whether they occurred prior to inactivation of MMR or as a
consequence of these defects. This brings into question the role of an increased
mutation rate being necessary for initiation and development of MSI+ CRCs (Huang
et al., 1996; Homfray et al., 1998; Lamlum et al., 2000). Although the APC gene
does not contain a specific repetitive tract that may be particularly prone to mutation
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consequent of repair defects, it does contain many sites of short repeated sequences,
especially poly(A) mononucleotide repeats (Joslyn et al., 1991). Huang et al found
that although the frequency and distribution of mutations at the APC gene was
similar between MSI+ and MSS CRCs, the mechanism of mutation varied. Mutations
in MSS tumours were predominantly point mutations, whereas in MSI+ tumours the
mutation spectrum was significantly biased towards frameshift mutations within
poly(A) tracts, characteristic of defects in MMR (Ionov et al., 1993; Strand et al.,
1993; Thibodeau et al., 1993). In contrast, Homffay et al reported no difference in
the mutational spectrum between MSI+ and MSS CRCs (Homffay et al., 1998). The
same group also detected APC or |3-catenin mutations in early adenomas from
sporadic CRCs but no evidence of MSI (Lamlum et al., 2000). These observations
suggests that APC mutations arise before MMR mutations as a consequence of
selection and are of greater significance in tumourigenesis than the elevated mutation
rate that may occur later due to MMR defects (Homfray et al., 1998; Lamlum et al.,
2000; Sieber et al., 2000).
Mutations of repetitive elements within the coding sequence of other components
of the (3-catenin/TCF pathway in MSI+ CRCs have been reported. There is some
evidence that mutations in TCF-4 and AXIN2 (Conductin) may contribute to
disruption of this pathway. Mutation of TCF-4 appears almost exclusive to MSI+
tumours and lbp deletions of an (A)9 repeat have been detected in 50% of MSI-H
cell lines (Duval et al., 1999). However the cell lines, in which these mutations were
identified, also had either APC or CTNNB1 mutations and thus the relative
contribution from the TCF-4 mutations is unclear (Duval et al., 1999). AXIN2, the
human homologue of mouse Conductin, was also mutated in 11 out of 45 MSI+
CRCs (Liu et al., 2000). Mutations were detected in one of the four mononucleotide
repeats located in exon 7 and were demonstrated to activate [Lcatenin/TCF
dependent transcription. APC and CTNNB1 mutations were not found in tumours
with AXIN2 mutations suggesting that it was the AXIN2 mutations that contributed to
the development of CRC in these patients (Liu et al., 2000).
Although activation of the p-catenin/TCF pathway is a critical event in the
development of the majority of CRCs, its role in MSI+ tumourigenesis remains
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unclear. Conclusive evidence is required to define whether abrogation of this
'gatekeeper' pathway is necessary in MSI+ tumourgenesis and whether inactivation
















Figure 1.7 The p-catenin/TCF pathway. In the absence of a Wnt signal the phosphorylation
of p-catenin by the APC/GSK3-P complex leads to proteosome mediated degredation. In the
presence of Wnt signaling the degredation machinery is blocked leading to the accumulation
of cytosolic p-catenin which then interacts with TCF-4 /LEF transcription factors. Nuclear targets
are involved in the regulation of the cell cycle and apoptosis. Adapted from Behrens, 2000 and
Macleod, 2000.
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1.7.5 Mutation of other genes in MSI+ CRCs
TGFBR2 and BAX are mutated with consistently high frequency in MSI+ CRCs
and various lines of functional and genetic evidence suggests that the p53/BAX and
TGFB/SMAD pathways are involved in both MSI+ and MSS tumourigenesis, albeit
via different mechanisms of abrogation. Constitutive activation of the (3-catenin/TCF
pathway is clearly important in MSS CRCs and there is some evidence that its
disruption can occur in a mutator pathway of tumourigenesis.
There are a growing number of other genes whose frequency of mutation at short
coding repeat sequences in MSI+ CRCs suggests they may also confer a selective
advantage (Duval et al., 2001). Such candidates include the PTEN tumour suppresser
gene (Guanti et al., 2000), the insulin like growth factor II receptor (IGFRII) (Souza
et al., 1996; Ouyang et al., 1997) and the candidate DNA repair gene MBD4 (Bader
et al., 1999; Riccio et al., 1999). Interestingly, ffameshift mutations within an (A)g
repeat in MSH3 and a (C)g tract in MSH6 have been demonstrated exclusively in
around 30-40% of MSI+ CRCs (Malkhosyan et al., 1996; Yamamoto et al., 1999;
Cunningham et al., 2001). This has led to a hypothesis in which the mutator
phenotype unfolds in a series of consecutive steps. Initial inactivating mutations in
MMR genes such as MLH1 and MSH2 result in MSI leading to the mutation of other
genes containing repetitive tracts that are susceptible to mutation. The somatic
inactivation of secondary MMR genes such as MSH3 and MSH6 may subsequently
contribute to genomic instability by enhancing or broadening this phenotype (Figure
1.4) (Malkhosyan et al., 1996; Yamamoto et al., 1999).
There is considerable variation in the frequency with which candidate genes are
mutated and widespread intra-tumoural heterogeneity has been detected in MSI+
CRCs with respect to the spectrum of genes that are mutated (Barnetson et al., 2000).
Even non-coding repeated sequences show great variability in their mutation
frequency in MSI+ cells, suggesting that the inherent stability of a sequence may
significantly contribute to its mutation frequency in the presence of MMR defects
(Zhang et al., 2001).
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1.8 Research Aims
The central theme of this project was to define the molecular consequences that
accumulate exclusively due to defects in MMR and to identify factors that may
influence the manifestation of the resultant mutator phenotype. In particular to
address whether the frequency of mutations detected in CRCs with MMR defects
may be influenced by inherent instability at both non-coding and coding sequences
In view of the evidence in the literature, it was hypothesised that sequences
frequently mutated in MMR deficient CRCs, may be inherently prone to mutation.
This could explain the heterogeneity in mutation frequency observed at repetitive
tracts in both non-coding and coding sequence. If the inherent stability of a given
sequence significantly contributes to its mutation frequency in MSI+ cancers, this
would suggest that an increased mutation rate consequent of MMR deficiency,
represents a driving force in tumourigenesis. Factors independent of the
tumourigenic process itself, which may affect the inherent stability of repeat
sequences, would consequently be expected to affect the manifestation of the mutator
phenotype. Mutations in the coding sequences of genes, implicated in the progression
of MSI+ tumourigenesis, are thus predicted to occur exclusively as a consequence of
MMR defects even when selection pressures are minimised.
It was specifically aimed to investigate the inherent stability of sequences mutated
frequently in CRC. Initially at non-coding microsatellite repeats D2S123 and BAT-
40 due to their relevance in the assessment of MSI status in colorectal tumours.
Differences in inherent stability between different marker loci were predicted to give
insight into factors that can affect or modify susceptibility to mutation in the
presence of MMR defects. It was also aimed to investigate whether coding sequence
mutations frequently detected in CRC arise exclusively when MMR is defective as a
result of failure to repair spontaneous mutations. This was with a view to
understanding the contribution from inherent instability at such sequences in tumour
progression. Specific investigation was carried out at repeat loci in the TGFBR2 and
BAX genes due to the high frequency with which they are mutated in MSI+ CRCs. In
addition, inherent stability of regions within the APC gene and CTNNB1 gene in the
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presence of MMR defects was also analysed to address whether MMR deficiency
contributes to their mutation in MSI+ CRCs.
MMR defects are associated with a substantial proportion of CRCs as well as
cancers of extracolonic origin. Understanding of the molecular basis that underlies
these cancers is clinically important in terms of revealing potential therapeutic targets
and novel rational for preventative strategies. Furthermore, since cancers with MMR
defects display an elevated mutation rate, elucidation of the events that arise
exclusively as a result of increased genomic instability may provide new insight into
the contribution that an elevated mutation frequency makes to tumourigenesis. This
may shed light on the relative balance between selection and inherent instability in
the initiation and progression of cancer.
1.9 Experimental Approach
The research presented in this thesis specifically utilises two cell lines, lbl-1260
and lbl-1261. These cell lines are derived from normal tissue and have been
previously characterised and demonstrated to be completely deficient in MMR as a
consequence of constitutive heterozygous dominant negative MMR mutations
(Parsons et al., 1995a). Since lbl-1260 and lbl-1261 are non-cancer derived but have
constitutional defects in MMR they provide an excellent system with which to
investigate molecular events that arise as a result of such defects and thus address the
hypothesis and aims outlined above.
Cancer cell lines are invariably subjected to selection pressures for mutations that
provide the cell with a growth advantage, resulting in successive waves of clonal
evolution. Secondary defects that may contribute to the mutation rate and additional
molecular variability's also occur consequent of tumourigenesis itself. These factors
bias the apparent frequency of mutations, making the dissection of events dependent
solely on MMR defects difficult. In cells derived from normal tissue these factors are
minimised and the presence of MMR defects can then effectively "unmask" inherent
stability at given sequences.
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In this thesis, lbl-1260 and lbl-1261 are shown to be derived from normal tissue
and further evidence is provided that confirms the presence of the MMR defects
demonstrated previously (Parsons et al., 1995a). This analysis is presented in
Chapter 3. These cell lines are then utilised in the following chapters to address
specific questions relating to the hypothesis. While Chapters 4 to 6 focus on the
consequences of MMR defects at non-coding microsatellite sequences, Chapters 7
and 8 focus on the effects of such defects at coding sequences within genes
implicated in the initiation and development of MSI+ CRC.
In Chapter 4 the MMR defects in lbl-1260 and lbl-1261, derived from normal
tissue, are shown to be associated with low level MSI similar to that observed in
MMR defective cancers. This is revealed, by employing a small pool PCR approach
to detect mutations in individual alleles. The MSI phenotype is shown to display
heterogeneity on a number of different levels and the data indicates that factors
independent of tumourigenesis, contribute to inherent stability of the specific repeat
sequences analysed. These factors are investigated in Chapters 5 and 6.
Data presented in Chapter 4 reveals striking heterogeneity in the susceptibility of
individual alleles to mutation at the microsatellite marker D2S123. In view of this
finding, factors that may contribute to allele bias in mutation at D2S123 are
investigated in Chapter 5. Individual alleles at this locus have been characterised and
their inherent susceptibility to mutation consequent of MMR defects investigated.
Allele specific determinants of instability at this locus have been identified and in
addition, patient constitutional genotype is specifically demonstrated to affect the
manifestation of MSI in MMR deficient tumours.
Observations in Chapter 4 also suggest that the poly(A) marker BAT-40, is
particularly prone to mutation in the presence of MMR defects. In Chapter 6 the
notion that BAT-40 may be frequently mutated in MMR deficient cells due to its
extreme susceptibility to mutation, is further investigated by analysis of this locus in
the germline. This is carried out by study of population allele frequencies, mutation
frequency in families and mutation frequency in sperm DNA.
Chapter 7 addresses whether differences in the mutation frequencies observed at
the repetitive tracts within the TGFBR2 and BAX genes in MSI+ CRC, may be due to
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differential stability in the presence of MMR defects. The repeat regions within these
genes, frequently mutated in MSI+ CRCs, are analysed to examine whether low level
mutation can be detected in cells that are not derived from cancer tissue but that have
defects in MMR. This analysis is carried out using a combination of cloning, SP-
PCR and restriction digest based methods to investigate the mutational status of
individual alleles.
Finally an extensive appraisal of the inherent stability of p-catenin/TCF pathway
genes in the presence of MMR defects is presented in Chapter 8. This chapter
addresses whether the CTNNB1 and APC genes are inherently prone to mutation in
the absence of MMR activity. Regions of these genes, mutated frequently in MMR
proficient cancers, are analysed in lbl-1261 and lbl-1260 using a cloning based
approach to determine whether mutations can occur exclusively as a consequence of
MMR defects.
Although detailed discussion of the results is provided in each relevant chapter,
Chapter 9 summarises the main themes and conclusions that have emerged during




The following chapter documents the methods used during the course of this
thesis. Where appropriate, specific detail is included in methodological overviews in
the relevant result chapter. Where standard protocols have been used, these have
been referred to, and any adjustments made to the cited method have been
documented in the text. Standard safety procedures and COSH regulations were
adhered to. Stock solutions and media marked with an asterisk (*) were prepared by
the solution and media preparation service at the MRC HGU and sterilised by
autoclaving. Where the pH of solutions was adjusted this was done by adding cone.
HC1 or NaOH as appropriate and monitoring pH using a microprocessor pH meter
(Hanna Interments).
2.1 Biological Material
2.1.1 Summary of cell lines
The following cell lines were used during the course of this PhD; Epstein-Barr
virus (EBV) transformed lymphoblast cell lines lbl-1261 and lbl-1260 were a
donation from Prof. Vogelstein (John Hopkins Oncology Centre, Maryland). These
cell lines were previously established from two patients with CRC. Both had a family
history of the disease as well as phenotypic evidence of Turcots syndrome. Cell line
lbl-1261 harbours a dominant negative mutation in the human PMS2 gene. (Hamilton
et al., 1995; Parsons et al., 1995a; Nicolaides et al., 1998). Cell line lbl-1260 has a
germline MLH1 gene mutation that is speculated to be dominant negative (Parsons et
al., 1995a). Lbl-1261 and Lbl-1260 are described in more detail in Chapter 3.
Control EBV transformed lymphoblast cell lines (lbl-c5, lbl-cl, lbl-a, lbl-c8),
were established previously by Sheila Mcbeath (MRC, Human Genetics Unit,
Edinburgh) from healthy anonymous donors. These control cell lines are maintained
as laboratory stocks.
All colorectal carcinoma cell lines are available from the American/European
Type Culture Collections (ATCC/ECACC).
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Table 2.1 Summary of cell lines.
Cell line Cell type Mutation Reference
lbl-1260 EBV transformed lymphoblast MLH1 see 2.1.2 (Parsons et al.,
1995a)
lbl-1261 EBV transformed lymphoblast PMS2$ee2.1.2 (Parsons et al.,
1995a)
Ibl-a EBV transformed lymphoblast Control Lab stock
Ibl-c5 EBV transformed lymphoblast Control Lab stock
Ibl-cl EBV transformed lymphoblast Control Lab stock
Ibl-c8 EBV transformed lymphoblast Control Lab stock
LoVo Colorectal carcinoma MSH2 (Liu et al., 1995b)
SW480 Colorectal carcinoma 4PC and p53 (Leibovitz et al., 1976)
HCT116 Colorectal carcinoma MLH1 (Papadopoulos et al.,
1994)
HCT116 + Colorectal carcinoma Restoration of (Koi etal., 1994)
chr3 MMR activity due to
Introduction of wild
type MLH1 allele on
chromosome 3
2.1.2 Maintenance of EBV transformed lymphoblast cell lines
Media, solutions and additives;
Freezing medium
8% w/v Dimethysulfoxide (DMSO) in new-born calf serum
Tissue culture medium
RPMI (Gibco BRL)
10% w/v Foetal calf serum (FCS)
1% w/v Penicillin and streptomycin








Maintenance of EBV transformed cell lines was carried out by Sheila McBeath
and myself. All tissue culture was carried out under sterile conditions in a class 2-
containment hood.
In order to grow cells for DNA extraction, protein purification or FACS analysis,
cell lines were defrosted by rapid thawing in warm water followed by direct transfer
to 5mls of RPMI tissue culture medium and then fed as required. To retain the cell
lines as renewable sources at least 3 x 106 were split from the main culture,
centrifuged at 1200rpm in a Wifug lab centrifuge and the cell pellet re-suspended in
1.5ml freezing medium. The cells were then sequentially frozen at -70°C and -
140°C.
2.1.3 Maintenance of adherent cell lines
Adherent cell lines were maintained as for EBV transformed lymphoblast cell
lines. Cells were detached from culture flasks using either a cell scraper or by
washing with PBS and incubating with l-3ml TV for 3 minutes. RPMI culture
medium was then added accordingly.
2.1.4 Semen samples
Sperm sample MD-cl was donated anonymously from a healthy control
individual. Sperm sample MD-949 carries a germline mutation in the mismatch
repair gene, human MLH1 resulting in a deletion of exon 12 (codons 347-470).
Constitutional (blood) samples were also donated from both individuals.
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2.2 DNA and RNA Purification Protocols
2.2.1 Purification of DNA from cell lines and blood lymphocytes
Isolation of genomic DNA from cell cultures and blood was carried out using a
Nucleon II extraction kit (Scotlab Bioscience, Strathclyde) according to the
manufacturer's instructions. This procedure was carried out in a class 2-containment
hood
2.2.2 Purification of DNA from sperm
Solutions;
20 x Salt and Sodium citrate buffer (SSC)*
3M NaCl
3.3M Sodium citrate -2H2O
pH7.0
10% Sodium dodecyl sulphate (SDS)*
10% w/v SDS crystals
pH7.2
DNA was extracted from sperm as described by Jeffrey's et a\ (Jeffreys et al.,
1990) in a biological class 2 cabinet. Semen was pelleted by spinning at 1200rpm in
a Wifug lab centrifuge for 1 Omin. Semen pellets were rinsed 3 times with 20ml 1 x
SSC followed by 6 washes with 20ml lx SSC and 1% SDS to lyse any seminal
leukocytes and epithelial cells. Centrifugation after each wash was for 5 min at
3500rpm in a Wifug centrifuge. The residual sperm pellet was incubated in lx SSC
and 1M 2-mercaptoethanol (Sigma) at room temperature for 5 minutes and the
reduced sperm lysed by addition of SDS to 1%. Sperm DNA was collected after
phenol chloroform extraction and ethanol precipitation.
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0.5M Disodium ethylenediaminetetraacetate^FEO (Na^EDTAl*
0.5M Na2EDTA
pH8.0
1 x Tris EDTA (TE)*
1M Tris (pH 7.7),
0.5M Na2EDTA (pH8.0)
3M Sodium acetate (NaOAc)
3M Na0Ac-3H20
pH4
Phenol Chloroform extraction was carried out in a biological class 2 cabinet. An
equal volume of phenol chloroform solution (Gibco BRL) was added to the DNA
solution. This was inverted and spun for 5 minutes at 2000rpm in a Wifug lab
centrifuge. Supernatant containing the DNA was carefully removed with a pipette.
An equal volume of chloroform was then added to the supernatant, inverted and spun
for 5 min at 2000rpm. The supernatant was again removed.
For ethanol precipitation a 1:10 volume of 3M NaOAc (pH4) was added to the
DNA solution along with 2-3 volumes of 100% ethanol. The solution was incubated
for 30min at -70°C and then centrifuged for 15min at 2000rpm a Wifug lab
centrifuge. The residual DNA pellet was re-suspended in an appropriate volume of 1
x Tris EDTA pH7.7.
2.2.4 Purification of DNA from bacterial plasmids
Plasmid DNA was extracted on small scale using a QIAprep miniprep kit
(QIAGEN Ltd, Crawley, UK) according to the manufacturers. For DNA extraction
from a large number of plasmid samples (in 96well plates), a BioMek® 2000
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workstation robot was used, operated by Dr. Stewart Mckay (MRC, Human genetics
Unit, Edinburgh) according to manufacturers instructions.
2.2.5 Estimation of DNA concentration
5|il of genomic and sperm DNA samples were run on an agarose gel at stock
concentration and 1:10 dilution (see 2.4.6 for gel electrophoresis) against DNA
standards of known concentration (lfig/fil, 750ng/|al, 500ng/|il, 250ng/'(il, lOOng/pl).
To confirm the concentration indicated by agarose gel electrophoresis, DNA was
then measured by optical densomitery on a UV spectrophotometer (Pharmecia).
DNA samples were diluted in triplicate and placed in quartz cuvettes. The
absorbency at 260nm and 280nm was then measured.
DNA concentration was calculated from the readings as follows;
DNA flg/ml = A260 x dilution factor x 50
The A / A ratio of 1.8 taken as optimum purity of DNA. Readings were taken
in triplicate for each sample and repeated if inconsistent. Following determination of
concentration, stock DNA samples were then diluted to 100-200ng/fil or where
starting concentration was less than this, (in the case of sperm DNA), to an
appropriate concentration for handling.
2.2.6 Purification of RNA from cell lines
Isolation of RNA from cell cultures was carried out using an RNeasy mini kit
(QIAGEN Ltd, Crawley, UK) according to the manufacturer's instructions.
2.3 DNA Samples
The following were obtained directly as DNA samples. Where samples are
prefixed with MD- this represents the laboratory identification code used.
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2.3.1 CEPH family DNA
CEPH family DNA was obtained from the Foundation Jean Dausset Centre
D'Etude Du Polymorphisme Humain by Prof. Alan Wright (MRC, Human Genetics
Unit, Edinburgh). DNA from CEPH families was provided in microtiter plates
containing lypholized DNA. The families used in this study were randomly selected
and were; 66, 1331, 1341, 1346, 1362, 1377, 1423, 13293, and 13294 as indicated by
CEPH family identification numbers. Each sample was re-suspended to a final
concentration of lOOng/pi in d^O and shook gently for 24 hours.
2.3.2 Constitutional DNA from a Scottish cohort
DNA samples of a Scottish cohort were available as laboratory stocks. These
originated from the blood of 100 unrelated Scottish individuals. Prof. Malcolm
Dunlop (MRC, Human Genetics Unit, Edinburgh) collected these samples from
healthy individuals and they were labelled anonymously. They were all diluted and
used at 100ng/(il concentration.
2.3.3 Colorectal tumour DNA
Prof. M. Dunlop and Dr. S. Farrington (MRC, Human Genetics Unit, Edinburgh)
had previously collected a panel of colorectal tumour DNA samples. These were
available as a laboratory resource. Analysis of tumour MSI status had also been
determined by Dr. S. Farrington previously, by comparison of matched normal and
tumour DNA using a panel of 8 microsatellite markers that included the
recommended panel of 5 (Rodriguez-Bigas et al., 1997; Boland et al., 1998). Tumour
DNA samples were diluted to a concentration of 100ng/|il for use.
2.3.4 Constitutional DNA from colorectal cancer patients
Prof. M. Dunlop and Dr. S. Farrington collected a panel of constitutional DNA
previously, from the blood of patients with CRC. These were available as a
laboratory resource. These DNA samples were diluted to approximately 100ng/|Ltl for
use.
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2.3.5 Constitutional DNA from a Scottish HNPCC family (K-453)
Constitutional DNA was available from laboratory stocks of a Scottish Family, K-
435. This family had been previously identified as an HNPCC kindred with affected
individuals displaying tumour instability. Dr. S. Farrington has previously confirmed
family relationships by genotyping, using a panel of microsatellite markers. DNA
samples diluted to lOOng/p.1 were available from 20 individuals from this family.
2.4 PCR Protocols
Manipulation of oligonucleotides and all PCR techniques were carried out in a
biological class 2 cabinet. Pipettes specifically designated for PCR usage were also
employed to minimise the possibility of contamination of PCR products.
2.4.1 Oligonuclotides for PCR
Primers were supplied by Genosys as precipitates and re-suspended in dH20 to a
stock concentration of l|lg/|ll. Amplification was performed using an omnigene PCR
system thermal cycler (Hybaid) under the following standard conditions unless stated
otherwise: 94°C for 3min for 1 cycle, 94°C for lmin, 55°C for lmin, 72°C for lmin
for 35 cycles, 72°C for 5min for 1 cycle.
Primers were specifically designed unless otherwise referenced (Table 2.2). For
certain experiments, primers were fluorescently labelled with 6-carboxyfluorescein
(FAM) or 4, 7, 2', 4', 5', 7'-hexachloro-6-carboxyfluorescein (HEX) and in such
instances this is indicated in the appropriate results chapter. F and R refer to forward
and reverse respectively.
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Table 2.2 Oligonucleotides used for PCR
Primer Sequence 5'-3' Cycling Reference
Conditions
MLH1-ex15F CTACCAGATACTCATTTATG See 2.4.3 Farrington,
MLH1-ex18R CATTCCTTTTCTTCGTCCC pers. com.
D2S123F AAACAGGATGCCTGCCTTTA standard (Parsons,
D2S123R GGGGACTTTCCACCTATGGGAC 1995b)
BAT-40F AATAACTTCCTACACCACAAC standard (Liu etal.,
BAT-40R GTAGAGCAAGACCACCTT 1995a)
TGFBassayF CACTCTAGGAGAAAGAATGACG anneal at (Mironov et al.,
TGFBassayR GAAAGICICAGCAGGCI I I I I GAI I 55-60°C 1999)
TGFBR2ex3F CCTCGCTTCCAATGAATCTC standard (Lu et al.,
TGFBR2ex3R TTGGCACAGATCTCAGGTCC 1996)
TGFBR2ex4F CCACGTGTGCCAACAACATCAACC standard Farrington
TGFBR2ex4R CAGCCGTCAGGAACTGGAGTA pers.com.
BAXex3F ATCCAGGATCGAGCAGGGCG anneal at (Rampino et
BAXex3R ACTCGCTCAGCTTCTTGGTG 60°C al., 1997)
APCexlOF AAACATCATTG CTCTTCAAATAAC standard (Farrington
APCexlOR TACCATGATTTAAAAATCCACCAG and Dunlop,
1999)
CTNNB1ex3F TCGTATTTATAG CTGATTTG anneal at Farrington
CTNNB1ex3R TAATACTCTCTTACCAGCTAC 50°C pers. Com.
APCex15B1 AAGTACAAGGATG CCAATATTATG anneal at (Groden etal.,
APCex15D2 TGTTTGGGTCTTGCCCATCTTT 50°C 1991)
APCex15G1 AAGAAACAATACAGACTTATTGTG 1.5min (Groden et al.,






PCR reactions were performed in either a final volume of 25(_tl using the Expand
High Fidelity PCR system (Boehringer Mannheim, Germany) or a final volume of
50(j.l using AmpliTaq (Roche). Final reaction concentrations for the Expand High
Fidelity system were 1 x PCR buffer II, 0.2mM dNTPs, lOOng oligonucleotide
primer, lOOng DNA and 0.87 Units of Expand High Fidelity PCR mix. Final reaction
concentrations for the AmpliTaq system were as for the Expand system but using lx
AmpliTaq buffer instead of Expand buffer II, 2.5mM MgCl and 1.25 units of
AmpliTaq. Where PCR analysis was directly from bacterial plasmid DNA, bacterial
colonies were stabbed into the PCR reactions on the bench by a bunsen flame using a
sterile tooth pick, in place of lOOng DNA. The colony was then stabbed into a
storage culture in a 96 well culture plate (see 2.6)
2.4.3 Reverse transcription and PCR amplification (RT-PCR)
RT-PCR was performed on purified RNA using a Promega Access RT-PCR
system (Promega) according to the manufacturer instructions. Specific amplification
conditions for MLH1 RT-PCR (Chapter 3) using MLHl-exl5F and MLHl-exl8R
primers were: 1 cycle of 48°C for 45min, 94°C for 2min, followed by 40 cycles of
94°C for 30s, 60°C for lmin, 68°C for 2min followed by 1 cycle of 68°C for 7 min
and 4°C infinity.
2.4.4 Dilution protocol for SP-PCR
An assay was devised to genotype individual alleles, using a Small Pool PCR
strategy (SP-PCR). A similar approach has been used previously to detect mutations
within populations of wild type alleles (Jeffreys et al., 1994; Monckton et al., 1995;
Parsons et al., 1995a; Vilkki et al., 2001).
DNA from cell lines was extensively diluted to a final concentration of 15-20pg
per PCR reaction to give up to 3 input molecules of each allele per amplification
(assuming 6pg DNA per diploid genome). This was carried out by serial dilution of
DNA in dH20 as follows;
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From the concentration of DNA determined as described above (2.2.5), dHaO was
added to a final concentration of 40ng/|R. This was followed by 1:10 serial dilutions
giving to give aliquot of 4000pg/|Lil, 400pg/|il, 40pg/(al. This was followed by 1:2
dilution to 20pg/|ul. Prior to aliquoting for each dilution, DNA was repeatedly
inverted to ensure homogenisation throughout the sample. Limiting dilution SP-PCR
reactions (see 2.4.5) were carried out initially using the 40pg/jil and 20pg/|il dilution
aliquots in approximately 25 reactions to check the accuracy of the dilution
procedure. If SP-PCR products were detected in too many reactions (>40%) the
20pg/|fi dilution was further diluted to 15pg/(il and re-tested in preliminary SP-PCR
reactions. Due to the dilute nature of the final 15-20pg/(il aliquot some PCR
reactions contained no product. Final dilution concentrations resulted in the detection
of alleles in -30% of SP-PCR reactions by mutation analysis suggesting that most
products represented single molecules (Parsons et al., 1995a; Vilkki et al., 2001).
This was further indicated by the detection of single alleles by mutational analysis of
SP-PCR products amplified from individuals who were constitutionally heterozygous
at the given locus (See Chapter 4).
2.4.5 Small pool PCR
PCR amplifications were performed in a final volume of 25|il. Final reaction
concentrations were as described in 2.4.2 but using l|al (15pg) of diluted DNA rather
than lOOng DNA. Avoidance of contamination was paramount when amplifying
dilute DNA. Therefore all reactions were prepared in a class 2-containment hood. All
pipettes and plastics used in preparation of the SP-PCR reactions were UV irradiated
for 20 minutes in a Template Tamer (Oncor). Buffer solutions and sterile water were
opened under sterile conditions and also subject to UV irradiation. All Reactions
were prepared in 96 well plates. DNA free controls were prepared in 16 of the wells
in each plate (columns 3 and 10) and positive controls containing lOOng-cell line





10 x Tris-Acetate EDTA (TAE)*
2M Tris
5.7% w/v Glacial acetic acid
50mM Na2EDTA (pH8.0)






0.25% w/v Bromophenol blue
30% w/v Sucrose.
Standard agarose gels were prepared using routine electrophoresis grade agarose
(Flowgen) and lx TAE electrophoresis buffer. Separation of large fragments required
low % gels (typically 1.5%) whereas smaller fragments were separated on higher %
gels (typically 3%). If DNA fragments were being isolated from the gel for
sequencing, a 3% Nusieve GTG agarose (Bioproducts, Rockland, ME), 1% 'Hi Pure'
low EEO agarose (Biogene, Kimbolton, UK) gel was prepared using lx TBE
electrophoresis buffer.
5-10pl standard PCR products were loaded onto the gel with 2(il of loading
buffer. Size markers used were generally a lkb ladder (Gibco BRL) or a lOObp
ladder (Promega). The DNA was electrophoresed at 30-60V until the dye front was
lcm from the end of the gel although this varied with the size of fragments being
investigated. Visualisation of the DNA was by staining with ethidium bromide
(Biorad) followed by UV trans-illumination using a Herolab trans-illuminator
(Herolab, Wiesloch). Images were captured using a Herolab Camera and Easywin 32
version 2.00 software.
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2.5 Mutation Analysis Protocols
2.5.1 Fragment size analysis using an ABI310 genetic analyser
PCR products and SP-PCR products were size analysed using an ABB 10
automated genetic analyser with Genescan 350 data collection software version
1.0.4. PCRs were carried out using primers labelled with either FAM or HEX to
allow detection by ABB 10 analysis and are specified in the appropriate result
chapters. Detection of fluorescent labels by the ABB 10 is very sensitive, allowing
efficient visualisation and sizing of SP-PCR products. PCR products were prepared
for analysis by adding 11.5|li1 deionised formamide (PE Applied Biosystems,
Cheshire) and 0.5fil TAMRA 350 size standard (PE Applied Biosystems, Cheshire)
to 2|al of PCR product. Samples were denatured by heating for 5min at 95°C and
then placed on ice for 2min. Samples were run according to standard protocol using
module GS STR POP4 (1ml) with virtual filter set C (PE, Applied Biosystems,
Cheshire). Injection time was extended from 5 to 10 seconds for analysis of SP-PCR
products and negative controls from SP-PCR plates in order to increase sensitivity.
For analysis of SP-PCR products, all 16 negative controls were run from every SP-
PCR plate analysed and if a product was observed in any negative sample, the entire
plate was discarded. Positive controls from every plate were also analysed to ensure
reproducibility of the ABB 10 profiles. The size of each allele was taken to be the
predominant peak in each peak complex as determined from the Genescan analysis
data.




0.1M Triethylammonium acetate (TEAA) solution pH7.0
Buffer B*
0.1MTEAA
25% Acetonitrile (ACN) pH7.0
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The Wave™ (Transgenomic Inc., SanJose USA) was employed to detect
mutations in PCR and SP-PCR fragments. Mutations are visualised as a
characteristic pattern of peaks corresponding to a mixture of heteroduplexes and
homoduplexes formed when wild type and mutant DNA are hybridised. This method
has been shown to be highly sensitive at detecting over 97% mutations and is
especially appropriate for detecting single base pair changes (Giordano et al., 1999;
Taliani et al., 2001).
For detection of SP-PCR products by Wave™ analysis, 3(il of the primary SP-
PCR product was subjected to a second round of PCR identical to the first but with
the number of cycles reduced from 35 to 25.
10-20|il of PCR or secondary SP-PCR products were prepared for analysis by
hybridisation to form heteroduplexes. Samples were heated to 95°C for 3min and
then cooled to 25°C in stepwise decreases of 1°C over 45 min using a PCR system
thermal cycler (Hybaid). The Wave™ instrument was set up for each run according
to manufacturer instructions with default settings. Adjustments made were to
maximum noise and drift settings in the sample table, setting them at 500. An
injection volume of 10|Ltl was used in all runs. Optimal gradients and temperatures
were determined for each different fragment being analysed. A universal gradient
was run and the parameters adjusted accordingly to give a total run time of 7.3min
with fragment elution at approximately 5.3min. A series of melting curves was then
performed at 1-2°C increments between 50°C-65°C to determine the optimal
temperature for mutation detection. These standard procedures were carried out
according to manufacturer instructions. Optimal gradients and temperatures were
confirmed by the detection of heteroduplex peaks in samples containing known
mutations. The separation gradients and temperatures used for each fragment
analysed in this study are given in 2.5.3.
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Slope of 2% increase in buffer B per minute
BAX exon 3
For analysis of a 96bp fragment amplified using primers BAXex3F and
BAXex3R (2.4.1). Melting temperature; 60°C










For analysis of a 227bp fragment amplified using primers APCexlOF and
APCexlOR (2.4.1). Melting temperature; 55°C










2.5.4 Determination of allele origin
In instances where origin of new alleles was determined (highlighted specifically
in the appropriate result chapter) this was done in accordance with the literature e.g.
(Weber and Wong, 1993). The origin of "new/mutant" alleles is such that if there
were two possibilities, the shortest mutational step was considered to be the actual
one. For example if one progenitor allele differed by one repeat and the other by two
repeats, when compared to the mutant, a one step mutation was inferred. If two
progenitor alleles exhibited the same difference when compared to the new/mutant
one, the origin was declared ambiguous.
2.5.5 TGFBR2 restriction digest assay
A restriction digest based assay was adapted from Mironov et al, (Mironov el al.,
1999) specifically for the detection of lbp deletions in the poly(A)io tract of the
TGFBR2 gene (Figure 7.1). The reverse primer introduces a Hinfl site in the
presence of a lbp deletion in the poly(A)io tract, whereas in the presence of wild type
sequence no Hinfl restriction site is introduced during the PCR step (Mironov, et al.,
1999). The forward primer is fluorescently labelled with FAM allowing detection of
digestion products using an ABB 10 genetic analyser. Wild type undigested
fragments are visualised at 14lbp and mutant Hinfl digest fragments at 118bp.
PCR of TGFBR2 assay fragments from genomic DNA was performed as
described above using TGFBassayF and TGFBassayR primers (2.4.1) and the
Expand High Fidelity PCR system (2.4.2). 5pl of PCR product was digested at 37°C
overnight in a total volume of 15pl with 5 units Hinfl restriction enzyme and 1 x
buffer H (Boehringer Mannheim). Products were analysed on an ABI 310 Automated
Genetic Analyser, using Genescan software as described above (2.5.1).
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2.6 Cloning and Bacterial Culture
Media;
Luria Broth (L-broth)*
0.1% w/v Tryptone (Difco)
0.05% w/v Yeast extract (Difco),
171mM NaCl
Luria Agar (L-agar)*
0.1% w/v Tryptone (Difco)
0.05% w/v Yeast extract (Difco),
171mM NaCl
0.15% w/v Agar (Oxoid Ltd)
Terrific Broth (Ter-Broth)*
0.12% Tryptone (Difco)
0.24% w/v Yeast extract (Difco)
0.04% w/v Glycerol
1 x TB phosphate










2.6.1 TA cloning and transformation
Individual alleles were cloned using a TOPO TA Cloning kit version K2
(Invitrogen BV, Groningen, The Netherlands). Genomic DNA was PCR amplified as
described above (2.4.2) using the Expand High Fidelity PCR system (Boheringer
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Mannheim). The final extension step in the PCR reaction was extended to 10 minutes
to ensure addition of the single deoxyadenosine (A) to the 3' ends of PCR products
necessary for efficient ligation into the cloning vector. PCR products were cloned
into pCR 2.1-TOPO vectors (Invitrogen BV) according to the manufacturers
instructions. Clones were then chemically transformed into either TOP 10 or
TOPI OF' E.coli strains (Invitrogen BV) according to manufacturer's instructions. 10-
50|li1 of each transformation was spread onto selective L-agar plates containing amp
(50|j.g/|il) and X-gal (40|ig/ml) and/or IPTG (0.2mM) as appropriate. Plates were
incubated upturned overnight at 37°C
2.6.2 Colony selection and storage
White and light blue bacterial colonies, indicative of positive transformants, were
picked using sterile cocktail sticks or pipette tips. Presence of a correct sized insert
was determined by direct PCR amplification using M13F and M13R primers as
described above (2.4.1 and 2.4.2) and extending the PCR hot start to 94°C for 6min
to burst bacterial walls prior to amplification of plasmid DNA.
Bacteria were stabbed into PCR reaction mixtures after first inoculating a stock
culture. For analysis of small numbers of clones, 15ml cultures of L-broth containing
50|ig/ml ampicillin were inoculated. These were incubated at 37°C and shook at
225rpm for approximately 16 hours. Stocks for long-term storage were made by
mixing 0.85ml of this culture with 0.15ml of sterile glycerol (Sigma). These were
transferred to a cryovial and stored at -70°C. DNA was extracted from the remaining
culture as described above for small-scale bacterial DNA extraction (2.2.4).
For analysis of large numbers of clones, individual colonies were picked into 96
well plates containing 175|ll/well L-broth and 50(lg/ml ampicillin. These were
incubated at 37°C, and shook at 225rpm for approximately 10 hours. These 96 well
stock plates were then stored at -70C after addition of 25|fi sterile glycerol to each
well. PCR analysis as described above, indicated clones containing an insert and
these were cultured for DNA purification. 96 well culture plates containing
1.2mls/well Ter-broth with 50|j,g/ml ampicillin were inoculated from the original 96
well stock culture. These were incubated at 37°C for approximately 18 hours,
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shaking at 300rpm. DNA was then purified from plasmids on large scale using a
Biomeck robot as described above (2.2.4).
2.7 Sequence Analysis
2.7.1 Purification of PCR products
PCR products were cleaned for sequencing analysis using a QIAquick PCR
purification kit with a microcentrifuge (QIAGEN Ltd., Crawley, UK) according to
the manufacturer's instructions. PCR products cut out of agarose gels were cleaned
using a QIAquick gel extraction kit (QIAGEN Ltd., Crawley, UK) again, according
to manufacturers instructions. In both cases DNA was eluted in 30|ll1 of elution buffer
to increase DNA concentration.
2.7.2 DNA sequencing
All sequencing reactions were performed using ABI PRISM Ready Big Dye
Terminator cycle Sequencing Kit with AmliTaq DNA polymerase FS (Taq-FS;
Perkin Elmer /Applied Biosystems, Cheshire, UK) and Applied Biosystems DNA
sequencer models 373A, 377 or 3700 for 96 well format.
Sequencing of purified PCR products was carried out in 10|ll reactions using
lOOng purified DNA, 40ng primer and 4pl big dye terminator (PE/Applied
Biosystems). Amplification was performed on a PCR system thermal cycler (Hybaid)
at 96°C for 30 sec, 50°C for 15sec, 60°C for 4 min for 25 cycles.
Sequencing of plasmid DNA was carried out in 22fil reactions using
approximately lOOng plasmid DNA, lOOng primer, 4(il Big Dye (Taq-FS; Perkin
Elmer /Applied Biosystems, Cheshire, UK) and 0.36mM MgCl. Amplification was
performed on a PCR system thermal cycler (Hybaid) at 96°C for 5min for 1 cycle,
96°C for 30sec, 55°C for 15sec, 60°C for 4min for 25 cycles. All sequencing
reactions were stored at 4°C prior to precipitation
Sequencing reactions were carried out in either individual epindorf tubes or in 96
well plates.
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2.7.3 Precipitation of DNA from sequencing reactions
After amplification, standard precipitation of sequenced DNA was carried out by
adding 55|il 95% ethanol and 2|ft 3M NaOAC (pH 4) to the sequencing reaction mix.
The mixture was incubated on ice for lOmin and then spun at 15000rpm in an IEC
Micromax centrifuge for 30min. The DNA pellet was re-suspended in 70% ethanol
and spun at 15000rpm for a further lOmin. Ethanol was removed and the DNA pellet
dried at room temperature ensuring complete evaporation of the alcohol. The cell
pellet was stored at -20C.
For precipitation of DNA in 96 well format the above procedure was carried out
except samples in 96 well plates were incubated at room temperature for 30 mins.
Plates were spun in a Sorvell RT6000 centrifuge at 2000rpm for 30 minutes and
supernatant was removed by inverting the plate and then, pulse spinning the upturned
plates on paper towels at 800rpm. 70% ethanol was added to the cell pellets down the
side of each well and rapidly inverting the plate immediately. The pellets were dried
by a further pulse spin at 800rpm in a Sorvell RT6000 centrifuge. Cell pellets were
again stored at -20°C.
2.7.4 Gel electrophoresis of sequenced DNA
Precipitated cell pellets were re-suspended in 2-4|fi loading dye (PE applied
Biosystems) and heated at 90°C for 2min by Agnes Gallagher (MRC, Human
Genetics Unit, Edinburgh). Samples were then incubated on ice until loading.
Samples were analysed using Applied Biosystems DNA sequencer models 373A,
377 or in the case of analyses of samples in 96 well formats an ABI 3700 all
according to manufacturer's instructions.
2.7.5 Analysis of sequence data
Raw sequence data was analysed using Sequencing Analysis Version 3.0 (PE
Applied Biosystems).
For alignment of multiple sequences of the same fragment, sequence data was
imported into the Sequencher program Version 3.0.1 (Gene Codes Corp., Michigan).
Up to 100 fragments at a time were aligned with the default assembly parameters
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adjusted to allow 75-85% minimum match. The relevant reference sequence was also
imported from GenBank and incorporated in alignments to allow comparison of the
sequenced fragments to the published sequence.
Alignments were trimmed of vector sequence and poor quality end sequences
prior to further analysis. Individual base pairs highlighted by the Sequencher
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1 x Resolving buffer
7% w/v Acrylamide
0.15% w/v Ammonium persulphate (APS)
0.01% w/vN, N, N', N' tetramethyl-l-2-diaminomethane (TEMED)
5% Stacking Gel




2.8.1 Preparation of nuclear extracts
Nuclear levels of MLH1 and PMS2 protein were detected by western blotting.
Approximately 250 x 10"4 confluent cells were used to prepare each extract. Cells
were spun at 1200rpm in a Wifug lab centrifuge for 15min. Cell pellets were washed
twice in PBS followed by a spin at 1200rpm for 5min after each wash. Nuclear
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extracts were prepared by lysing cells in approximately 3x cell volume of lysis buffer
(-lOOjul), Complete™ protease inhibitor cocktail at 1:1250 dilution (Roche
Diagnostics, Mannheim, Germany), ImM pepstatin A (Sigma) and lOOmM Pefabloc
(Roche Diagnostics). Lysis reaction was blocked on ice, shaking occasionally, for
15min and the cytosolic extract removed by centriLigation at 13000rpm in an IEC
micromax centrifuge for lmin. Nuclei were then lysed by re-suspension in
approximately 1.5x cell volume (50|il) hypertonic buffer, protease inhibitors and
pefabloc as above and incubated on ice for 30min. Debris was cleared by
centrifugation at 13000rpm for 5min. Total protein concentration of nuclear extracts
was determined by Bradford assays (Biorad, Hercules, Calif) and the nuclear extracts
adjusted to the same concentration.
2.8.2 Western analysis
10|ig-20pg of nuclear extract was added to a 1:6 dilution of sample buffer boiled
for 5min and placed on ice. Samples were resolved by denaturing SDS-PAGE on a
7% polyacrylamide gel in 1 x running buffer. Pre-stained molecular weight markers
(Biorad) were run in parallel. Protein was transferred to a nitro-cellulose membrane
using a Biorad mini Trans-blot semi-dry Transfer cell for 30 minutes at 10 volts.
Prior to transfer, gels were pre-soaked in semi-dry transfer buffer and the nito-
cellulose membrane prepared by coating first in 100% methanol and then also in
transfer buffer. Successful transfer of proteins was established by covering the nitro¬
cellulose membranes with Ponceau solution (Sigma). Blots were blocked in 5% dried
milk (Marvel) and 0.3% Tween (Sigma) in PBS, overnight at 4°C. Blots were then
incubated for 1 hour with monoclonal antibodies PMS2 clone 37 at 1:500 dilution
(Transduction laboratories, KY), MLH1 clone G168-15 at 1:250 dilution
(Pharmingen Int.) or a-tubulin clone DM 1A (Sigma) at 1:1000 dilution. Blots were
washed in 5% dried milk (Marvel) and 0.3% Tween (Sigma) in PBS for 20 min then
incubated for 1 hour with horeseradish preoxidase conjugated sheep antimouse IgG
secondary antibody. Blots were again washed as previously with a final wash
containing just 0.3% Tween in PBS. Protein bands were detected using ECL western




2.9.1 Flow cytometry protocol
Assistance with flow cytometry was given by Dr. Martin Waterfall (John Hughe
Benett Laboratories, Dept. Oncology, University of Edinburgh).
Cells were harvested, washed twice in PBS (supplemented with 0.1% BSA and
0.1% sodium azide), counted and finally re-suspended at 2 x 106 cells/ml for use.
Aliquots of 2 x 105 cells were incubated for 40mins at 4°C with optimum
concentrations of appropriate monoclonal antibody (determined previously by Dr. M.
Waterfall by titration), washed twice to remove unbound antibody and re-suspended
in PBS for acquisition. Where a second step-detecting antibody was used, incubation
and washing steps were repeated as above. Data for 10,000 cells was acquired and
analysed using a FACS Caliber and CellQuest software (Becton Dickinson).
The following markers were used in the FACS analyses; PE conjugated anti-
human CD 19, anti-human CD la, anti-human CD 16, anti-human CD20, anti-human
CD80 and anti-human CD83 (Caltag). FITC conjugated anti-human CD3, anti-
human CD 14, anti-human CD38, anti human CD40, HLA-DR and anti-human CD86
(Caltag). Tricolour conjugated anti-human CD45RO (Caltag). Unconjugated anti-
cytokeratin antibody (clone BER-EP4, Dako), detected using a second step FITC
conjugated anti-mouse IgG clone (BIOSOURCE, Camarillo, CA, USA).
Excitation of the conjugates is at 488nm. Different emission wavelengths were
detected as follows: FL-1, detects emission for FITC at 525nm, FL-2, detects
emission for PE at 575nm and FL-3, detects emission for tricolor at 667nm.
2.10 Calculations and Statistics
2.10.1 Statistical analysis
Statistical advice was provided by Dr. Peter Teague (MRC, Human Genetics Unit,
Edinburgh). This was primarily in the form of confirming that the most appropriate
statistical test was being employed to address any given null hypothesis. Chi squared
analyses were carried out to test whether the frequency of a given event was
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observed more often than would be expected by chance using the minitab statistical
package (Minitab V. 13). Where expected counts were less than five, a Fishers Exact
test was more appropriate and this was carried out on the following web site
http://home.clara.net/sisa/fisher.htm taking a two sided p value for p(0>E | 0<E)
where 0= observed and E= expected. To test for significant differences between the
distributions of any two non-parametric data sets, a Mann-Whitney U test was
performed using the minitab statistical package (Minitab V.13)
Specific statistical calculations and methodology of data analysis is described in
more detail in the relevant results chapters.
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Chapter 3
Characterisation of Cell Lines Derived from Normal Tissue
with Defects in MMR
3.1 Introduction
HNPCC is an autosomal dominant disorder and thus non-cancerous cells of
affected patients contain one mutant and one wild type allele (Leach et al., 1993).
These phenotypically normal cells are assumed to be MMR proficient since, studies
have shown they are microsatellite stable and display no evidence of biochemically
measurable MMR deficiency (Parsons et al., 1993; Modrich, 1994). However rare
individuals have been identified with congenital defects in MMR due to bi-allelic or
dominant negative germline mutations (Parsons et al., 1995a; Ricciardone et al.,
1999; Wang et al., 1999; Vilkki et al., 2001)
Lbl-1260 and lbl-1261 are EBV transformed cell lines derived from the B cell
lymphocytes of two such patients. These cell lines have been previously isolated and
shown to be completely defective for MMR despite being derived from normal tissue
(Parsons et al., 1995a). The laboratory of Prof. Bert Vogelstein kindly donated lbl-
1260 and lbl-1261, EBV transformed lymphoblastoid cell lines. These cell lines
provide an ideal system with which to investigate the consequences of MMR defects
at both non-coding and coding sequences in vivo, while minimising the other effects
from tumourigenesis that can bias the apparent frequency of mutations.
Cell line lbl-1260 has a germline MLH1 mutation such that an amino acid is lost
through a 3-nucleotide deletion at codon 618 (AAG AAG AAG GCT->AAG AAG
GCT, lys deletion). Parsons et al refers to lbl-1260 as patient 4 (Parsons et al.,
1995a).
Cell line lbl-1261 harbours a germline truncating point mutation at codon 134 in the
PMS2 gene (CGA—>TGA, arg 134->stop). Lbl-1261 is patient 6 as referred to by
Parsons et al (Parsons et al., 1995a; Hamilton et al., 1995; Nicolaides et al., 1998).
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Both cell lines have been demonstrated to lack measurable MMR activity by
analysis of nuclear extracts (Parsons et al., 1995a). In addition the truncating
mutation in lbl-1261 has been shown to exert a dominant negative effect (Nicolaides
et al., 1998). In an earlier report the MLH1 mutation in lbl-1260 was also speculated,
to be dominant negative (Parsons et al., 1995a) but this has not been confirmed.
Both patients from whom these cell lines were derived had a family history of
CRC. Besides developing CRC they also displayed extra colonic lesions (Hamilton
et al., 1995). The male patient from whom cell line lbl-1260 was derived developed
CRC by the age of 30 and a gliobastoma at the age of 33 and thus displayed
phenotypic characteristics of TS (Hamilton et al., 1995). The female patient from
whom cell line lbl-1261 was derived, developed CRC that was detected when she
was 11. Phenotypic evidence of adenomatous polyposis was detected at the age of 14
and cutaneous cafe au lait spots were also evident (Hamilton et al., 1995). Despite
phenotypic evidence of adenomatous polyposis, no germline mutations of the APC
gene were detected in lbl-1261 (Hamilton et al., 1995).
The cell lines lbl-1260 and lbl-1261, which have constitutional defects in MMR
and are derived from phenotypically normal tissue, represent an excellent tool with
which to analyse the inherent stability of particular sequences. They provide many
advantages over investigation using cancer cell lines, which are subject to selection
pressures and clonal evolution (Nowell, 1976). In addition, cancer cell lines by their
nature accumulate multiple molecular variability's making it difficult to dissect the
contribution of events resulting directly and exclusively from MMR defects.
The experiments in this chapter were carried out to further characterise cell lines
lbl-1261 and lbl-1260. The lineage of origin of these cell lines was determined in
order to demonstrate they are indeed derived from B-lymphocytes. Furthermore,
expression of MLH1 and PMS2 proteins was evaluated to gain further insight into
the nature of the constitutive MMR defects in these cell lines, particularly in cell line
lbl-1260 where the mechanism by which the constitutive MLH1 mutation confers
complete loss of MMR activity, has not been definitively established.
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The data presented in this chapter thereby allows lbl-1260 and lbl-1261 to be
utilised with confidence in subsequent investigations that address specific questions
relating to the consequences of MMR defects.
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3.2 Methodological Overview
3.2.1 Maintenance of cell lines
EBV transformed lymphoblastoid cell lines, lbl-1260, lbl-1261 and lbl-a (2.1.1)
were maintained as described in 2.1.2. The adherent cancer cell line HCT116 was
maintained as described in 2.1.3
3.2.2 Flow cytometry
Dr. Martin Waterfall provided assistance with FACs analysis.
Cell lines lbl-1261, lbl-1260 and control lymphoblastoid cell line lbl-a, were
evaluated by FACS analysis as described in 2.9. Cancer cell line HCT116, provided
a positive control for epithelial cell marker BER-EP4. The cell surface markers used
are described in 2.9.1 and listed in Table 3.1.
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Table 3.1 Cell surface markers used in FACS analysis. These markers were used to
determine the origin of cell lineage of MMR deficient cell lines, lbl-1261 and lbl-1260.
Marker Cellular Expression
CD1a Thymocytes, langerhans cells, interdigitating cells
CD3 Thymocytes, T cells
CD14 Peripheral blood monocytes, macrophages, granulocytes
CD16 NK cells and neutrophils, macrophages
CD19 B cells- all stages of differentiation except plasma cells
CD20 B cells- pre, resting and activated except terminally differentiated
plasma cells
CD38 Early B and T cells, activated T cells, germinal centre B cells,
plasma cells
CD40 B cells, monocytes, dendritic cells
CD45RO Thymocytes, activated T cells, monocytes, granulocytes. Weakly
expressed on activated B-cells and in lymphoblastoid cell lines
CD80 B cell subset, macrophages, dendritic cells, activated T cells
CD83 Activated B cells, putative dendritic cell marker, some germinal
centre B cells.
CD86 Activated B cells, monocytes, dendritic cells
HLA-DR B cells, monocytes, macrophages, activated T cells
BER-EP4 Anti-cytokeretin, epithelial cell marker
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3.2.3 Western analysis
Western analysis was carried out as described in 2.8 using monoclonal antibodies
PMS2 (Transduction laboratories, KY) or MLH1 (Pharmingen Int.). Monoclonal
antibody a-tubulin (Sigma) was also used as a loading control.
Cell lines lbl-1261 and lbl-1260, which harbour constitutive mutations in PMS2
and MLH1 respectively, were evaluated for the nuclear expression of both proteins.
In addition nuclear extracts were analysed from positive control, MMR proficient,
lymphoblastoid cell lines, lbl-a and lbl-c8. In addition, nuclear extracts from a HeLa
cell line (Transduction laboratories) provided an additional positive control for
PMS2 expression. Cancer cell line HCT116 provided a negative control for loss of
MLH1 expression. A negative control for the PMS2 protein was not available. Each
analysis was carried out in triplicate. The concentration of nuclear protein loaded
onto each gel was evaluated by Bradford Analysis as described in 2.8.1 or by probing
the gel with a-tubulin antibody as described in 2.8.2.
3.2.4 RT PCR and cloning
RNA was extracted from cell line lbl-1260 as described in 2.2.6. RT-PCR carried
out as described in 2.4.3 using MLH1 primers 15F and 18R (2.4.1) to amplify a
335bp region around the known MLH1 mutation in lbl-1260 at codon 618. The
products were then cloned into TA cloning vectors (Invitrogen) as described (2.6.1
and 2.6.2). Sequencing and analysis of individual alleles was carried out using M13F
and M13R primers (2.4.1) as detailed in 2.7
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3.3 Results
3.3.1 Cell lines lbl-1260 and lbl-1261 are derived from a B-Lymphocyte
cell lineage
Cell surface marker expression of lbl-1260, lbl-1261 and lbl-a was analysed by
flow cytometery using the panel of markers described in Table 3.1. Cancer cell line
HCT116 was analysed specifically as a positive control for epithelial cell surface
marker BER-EP4.
To analyse the FACS data, gates were set on unstained cell populations and
applied to subsequent analyses. This minimises distortion of the data from cell auto-
fluorescence. Gated cells represent approximately 70% of the total, in all cases.
Representative FACS profiles are shown in Figure 3.1 and the data for all analyses is
given in Table 3.2.
CD 19 and CD20 are classic markers for determining B cell lineage and were
detected on >99% gated cells in each of the lymphoblastoid cell lines (Figure 3. IB
and Table 3.2). Cancer cell line, HCT116 was also tested for expression of CD 19 and
as expected CD 19 expression was not detected (Table 3.2). All three lymphoblastoid
cell lines were positive for five other B cell associated markers (CD38, CD40, CD80,
CD86 and HLA-DR) (Figure 3.IB, C, G, H, K-L and Table 3.2). Furthermore, dual
staining with CD-19 and CD-20 (Figure 3.1K+L) demonstrated that approximately
100% of the cell population express both markers to the level of detection.
The cell lines were also analysed using markers specific to Thymocytes and T
cells (CD1 and CD3), to blood monocytes and macrophages (CD 14, CD 16) and to
NK cells and neutrophils (CD 16). These markers provided a panel of negative
controls (Table 3.1). No expression of these markers was detected in the
lymphoblastoid cell lines (Figure 3.ID, E, I and J and Table 3.2). CD45RO and
CD83 were weakly expressed on all three lymphoblastoid cell lines (Table 3.2).
Expression of these markers is generally characteristic of activated T cells and
dendritic cells. However, germinal centre B cells and lymphoblastoid cell lines have
been reported to express low levels (Waterfall, pers. comm.). Expression in a subset
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of the lymphoblastoid cell populations as seen here, is entirely consistent with them
being of B-lymphocytic origin.
Of further importance, the three lymphoblastoid cell lines were negative for
epithelial (anti-cytokeratin) cell specific marker BER-EP4 (Figure 3.1M-N and Table
3.2). Epithelial cancer cell lines, such as those derived from primary CRCs, would be
expected to be positive for expression of this marker. Indeed, expression of BER-
EP4 was detected on approximately 100% of HCT116 cells (Figure 3.10-P). The
fact that expression of an epithelial cell marker was not detected in the three-
lymphoblastoid cell lines indicates they are not of primary tumour origin.
This comprehensive analysis of cell surface marker expression, reveals that cell
lines lbl-1261, lbl-1260 and control cell line lbl-a are derived from B-cell
lymphocytes, and display no evidence of contamination with epithelial tumour cells.
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Figure 3.1 Representative histograms and scattergrams from FACS analysis cell surface
marker expression. All analyses with the exception of 0 and P show expression of cell
suface markers in MMR deficient cell line lbl-1261. A and F show unstained gated cells
detected in the wavelength of emmission for PE (FL-2 height) or FITC (FL-1 height).
Subsequent histograms show detection of a panel of B-cell specific (B-C, G-H), and B-cell
negative (D-E, l-J) markers. K and L show lbl-1261 cells unstained (K) and dual stained (L)
with CD38 (FL-1) and CD19 (FL-2). The cells in the upper right gate (L) represent those in
which expression of both markers is detected. Analysis of cells for epithelial cell marker
expression is shown in M-P. Comparison to unstained lbl-1261 (M) and HCT116 (O) cells
respectively indicates that lbl-1261 cells are negative for BER-EP4 expression (N) whereas
cancer cells, HCT116 clearly express this marker (P). M1 is the marker set to identify the
% of unstained cells for the appropriate emmision and M2 is set to identify the % of positively
stained cells.
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3.3.2 Abnormal MMR gene expression in lbl-1260 and lbl-1261
The constitutive mutations harboured by the patients from which cell lines lbl-
1260 and lbl-1261 were derived, have been determined previously (Hamilton et al.,
1995). The PMS2 mutation in cell line lbl-1261 results in truncation of the wild type
protein from 862 to 134 amino acids (Nicolaides et al., 1998). Cell line lbl-1261 was
analysed for expression of PMS2 using an antibody that specifically detects the wild
type protein. As expected, expression of full length PMS2 is reduced by half, in lbl-
1261 compared with positive control cell lines (Figure 3.2A) supporting previous
analyses of the PMS2 defect in lbl-1261 (Hamilton et al., 1995; Nicolaides et al.,
1998). Lbl-1260 also showed approximately twice the level of PMS2 expression
compared to lbl-1261 (Figure 3.2A).
The underlying cause of the MMR defect in lbl-1260 has not been concluded
functionally and thus western analysis was carried out to determine whether the
MLH1 mutation in lbl-1260 is associated with aberrant expression of the protein.
MLH1 expression was observed in both lbl-1261 and a control cell line, lbl-a,
whereas expression was absent in a negative control cell line, HCT116 (Figure 3.2B).
Intriguingly cell line lbl-1260 also demonstrated loss of MLH1 protein (Figure 3.2B).
These data are surprising since, the germline MLH1 mutation in lbl-1260 induces a
single amino acid deletion (Hamilton et al., 1995). Nonetheless, the extreme
reduction of MLH1 in lbl-1260 suggests that the defects in MMR activity observed
previously on a biochemical level, may not be due to a dominant negative effect as
speculated (Parsons et al., 1995a). Instead the profound loss of MLH1 protein likely
confers the MMR deficiency in this cell line.
These data support the previous evidence that demonstrates cell lines lbl-1260 and
lbl-1261 have defects in MMR (Parsons et al., 1995a; Hamilton et al., 1995;
Nicolaides et al., 1998). Furthermore, they shed new light on the mechanism by
which the MMR defects in lbl-1260 arise.
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Figure 3.2 Western analysis of PMS2 and MLH1 expression in lbl-1261 and lbl-1260. (A)
Wild type PMS2 expression is reduced by half in cell line lbl-1261 compared with positive
control cell lines HeLa and Ibl-c8 and MMR deficient cell line lbl-1260. The HeLa nuclear
extract was comercially prepared and this likely explains why the HeLa PMS2 protein runs
slightly slower than those from extracts prepared in this study. Equal concentrations of protein
were loaded in each lane as determined by Bradford Assay. (B) lbl-1260 shows a severe
reduction in MLH1 compared to MMR proficient control cell line Ibl-a and MMR deficient cell
line lbl-1261. MMR deficient cancer cell line, HCT116 provides a negative control for MLH1
expression, a-tubulin expression is used as a loading control.
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3.3.3 Expression of mutant and wild type MLH1 mRNA transcripts in Ibl-
1260
The observation that lbl-1260 exhibits a severe reduction of MLH1, is particularly
intriguing. It may be speculated that the MLH1 mutation in lbl-1260 confers aberrant
expression of the mutant allele. Loss of the wild type protein may result from a
genomic deletion or an unidentified abrogation such as silencing of gene expression
by methylation of the MLH1 promoter (Herman et al., 1998; Veigl et al., 1998).
Since sequencing of MLH1 from the constitutional DNA of lbl-1260 around the 618
mutation, revealed mutant and wild type alleles, deletion of the wild type allele at the
genomic level cannot explain the results from the western analysis.
The hypothesis that loss of MLH1 protein in lbl-1260 may be due to gene
silencing was then addressed. RNA was extracted from lbl-1260 and subjected to
RT-PCR, amplifying a 335bp product containing the site of the 618 mutation that
was subsequently cloned. Sequencing of individual alleles from 6 clones revealed 3
mutant and 3 wild type alleles (Figure 3.3). The data suggests both MLH1 alleles are
transcribed in lbl-1260. Although a small number of transcripts were analysed, there
is no evidence to indicate over or under expression of either the mutant or wild type
mRNA. Since both mutant and wild type MLH1 alleles are expressed at the mRNA
level, the profound defect in MLH1 protein expression in lbl-1260 appears unlikely






Figure 3.3 Representative sequences of individual transcripts surrounding the mutation
at codon 618, cloned from lbl-1260 RNA by RT-PCR. (A) Clone 29 is wild type at codon 618
representing transcription of the wild type allele. (B) Clone 49 harbours the germline 618 mutation
resulting in a 3bp AAG deletion and is indicitive of transcription of the mutant allele.
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3.4 Discussion
Cell lines lbl-1260 and lbl-1261 were previously derived from the normal tissue of
two patients with CRC, a family history of the disease and phenotypic evidence of
TS (Hamilton et al., 1995). Lbl-1260 and lbl-1261 harbour germline mutations in the
MMR genes MLH1 and PMS2 respectively, and have been demonstrated to have
profound defects in MMR on a biochemical level (Parsons et al., 1995a). In this
chapter, evidence has been presented that confirms the "normal" lineage of origin of
these cell lines. Furthermore, the defects observed in the expression of the MLH1
and PMS2 proteins in lbl-1260 and lbl-1261 respectively, are in line with the
constitutive defects in MMR that have been previously reported (Parsons et al.,
1995a).
Since these cells are utilised in subsequent experiments specifically because they
are derived from non-cancerous tissue, demonstration of their lineage of origin is
clearly valid. By using a panel of cell surface markers including those associated
with B-cells, epithelial cells and a number of negative controls, it has been
demonstrated that lbl-1260 and lbl-1261 express surface proteins consistent with
them being of B-cell lymphocytic origin. In addition, there is no evidence that they
express epithelial cell surface proteins indicative of a primary cancerous phenotype
or micro-metastasis. Therefore, it is reasonable to conclude that lbl-1260 and lbl-
1261 are derived from normal, non-cancerous tissue.
The cause of the MMR deficiency in lbl-1261 has been determined previously to
be due to a dominant negative effect from the mutant PMS2 protein (Nicolaides et
al., 1998). The mutation results in a severe truncation of PMS2 and this is reflected
by the reduced expression of the wild type protein detected in the western analysis
here.
Interestingly, lbl-1260 does not express MLH1 to detectable levels. The data
strongly argues against the suggestion that the lbl-1260 MLH1 mutation encodes a
protein that confers a dominant negative effect (Parsons et al., 1995a). Rather, the
MMR defects are likely due to the loss of expression of both wild type and mutant
MLH1 proteins. Analysis of the MLH1 mRNA species from lbl-1260 by RT-PCR
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analysis revealed the presence of mutant and wild type transcripts. This analysis
suggests that gene silencing ofMLH1 by promoter hypermethylation is unlikely to be
the mechanism by which MLH1 protein expression is lost in lbl-1260. Promoter
methylation inactivates the MLH1 gene in the majority of MSI+ sporadic CRCs
(Cunningham et al., 1998; Veigl et al., 1998; Jones and Laird, 1999). However,
MLH1 silencing by methylation of the promoter region is correlated with decreased
expression of the mRNA transcript in addition to loss of the protein (Herman et al.,
1998).
It is possible that the MLH1 mutation in lbl-1260 affects the stability or translation
of the transcript and this could be tested in vitro. It should also be noted that the
region ofbinding, of the MLH1 antibody used in this study, has not been determined.
If the antibody specifically recognises the region of the MLH1 protein corresponding
to the 618 mutation, the mutant protein may not be detected. However, this does not
explain why the wild type protein is not detected. Further investigation is clearly
required and will be of interest in order to establish the nature of the loss of MLH 1
protein in lbl-1260. Unravelling the exact cause may reveal a novel mechanism of
MMR inactivation.
The experiments presented in this chapter demonstrate conclusively that lbl-1260
and lbl-1261 are derived from normal tissue and the western analyses of protein
expression is entirely consistent with MMR defects previously reported previously
(Hamilton et al., 1995; Nicolaides et al., 1998).
In the following chapters cell lines lbl-1260 and lbl-1261 have been utilised to
effectively unmask specific hypermutable loci, at both non-coding and coding
sequence in view of the fact that the frequency of mutations will not be biased by
other factors involved in tumourigenesis.
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Chapter 4
MMR Defects in Cells Derived from Normal Tissue Are
Associated with Microsatellite Instability
4.1 Introduction
Simple sequence repeats (SSRs) account for up to half of the human genome
(Toth et al., 2000). Many are highly polymorphic, making them of particular
importance to the study of evolution and the mapping of disease genes (Weissenbach
et al., 1992; Weber and Wong, 1993). New mutations occur at such sequences
predominantly as a result of slippage during replication (Levinson and Gutman,
1987) and failure to correct these errors in the presence of MMR defects results in
MSI (Ionov et al., 1993; Strand et al., 1993; Thibodeau et al., 1993). In view of the
susceptibility of microsatellites to mutation accumulation in the presence of MMR
defects, both poly(A/T) and (CA)n microsatellites are routinely employed to
determine the MSI status of colorectal tumours (Dietmaier et al., 1997; Rodriguez-
Bigas et al., 1997; Boland et al., 1998).
Differences in mutation rate are evident at alternative microsatellite loci both in
populations (Weissenbach et al., 1992) and in MMR deficient tumours (Thibodeau et
al., 1993; Shibata et al., 1994; Hoff-Olsen et al., 1998; Thibodeau et al., 1998;
Zhang et al., 2001). Variation in the repeat sequence itself can significantly affect
individual microsatellite stability (Weber and Wong, 1993; Bull et al., 1999).
Mononucleotide sequences are particularly prone to mutations (Chen et al., 1995) but
even these can display significant variation in mutation frequency dependent in part
on the nature of the mononucleotide tract (A/T vs G/C) (Zhang et al., 2001). In
addition, variations in microsatellite flanking sequence (Bichara et al., 1995;
Andreassen et al., 1996; Zhang et al., 2001), and in repeat length (Wierdl et al.,
1997; Xu et al., 2000) have been demonstrated to contribute to heterogeneity in
mutation rate.
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The use of MMR deficient cancer cells to investigate inherent stability of
microsatellites, and factors that may influence the manifestation of the mutator
phenotype, suffers from several limitations. Mutational homogeneity can arise at
microsatellites in cancer cells due to clonal evolution of the tumour (Nowell, 1976;
Shibata et al., 1994; Cahill et al., 1999). Additional mutations may accumulate
during expansion of the tumour cell population, but further waves of clonal selection
acting on advantageous coding sequence mutations, will again reduce the mutational
variation of non-transcribed microsatellite sequences. Consequently, the spectrum
and frequency of microsatellite mutations will be biased, due to the effects of
selection and other variability's that are dependent on the process of tumourigenesis.
This makes it difficult to identify mutational events that occur exclusively as a result
of MMR defects in cancer cells.
Data presented in Chapter 3 and elsewhere, has demonstrated that the germline
mutations in cell lines lbl-1260 and lbl-1261 result in complete loss of MMR activity
(Parsons et al., 1995a). In view of the fact that MSI is an excellent indicator of MMR
defects, these cell lines derived from normal tissue, were analysed by a small pool
PCR (SP-PCR) approach at two microsatellite repeat loci to address whether the
repair defects in lbl-1260 and lbl-1261, are associated with a mutator phenotype.
Microsatellite analysis was carried out at markers, D2S123 and BAT-40, in MMR
deficient lymphoblast cell lines lbl-1261 and lbl-1260 as well as MMR proficient
control lymphoblast cell lines lbl-cl and lbl-c5. D2S123 is a (CA)n microsatellite
marker (GenBank accession number; Z16551) and BAT-40 is a poly(A) marker
(GenBank accession number; M38180). D2S123 is one of the panel of five markers,
recommended for use in determination of microsatellite status of colorectal tumours
(Rodriguez-Bigas et al., 1997; Boland et al., 1998). BAT-40 is not one of the panel
of five, but is recommended for use in MSI analysis as part of an expanded panel of
markers (Boland et al., 1998).
It was anticipated that mutations in these cell lines would arise at a low frequency
within a population of predominantly wild type cells. Hence a sensitive small pool
SP-PCR strategy was adapted to genotype individual microsatellite alleles from these
cell lines. A similar approach has been used previously to detect mutations within
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populations of wild type alleles (Jeffreys et al., 1994; Monckton et al., 1995; Parsons
et al., 1995a; Vilkki et al., 2001)
This sensitised system was also utilised to investigate whether factors independent
of tumourigenesis, can influence stability at poly(A) and (CA) repeats when MMR is
absent. Identifying determinants of instability, which may affect the manifestation of
a mutator phenotype at repetitive sequences, is clearly merited in view of the
relevance to analysis of tumour MSI status. Since cell lines lbl-1260 and lbl-1261 are
derived from normal cells, the full spectrum of mutations arising consequent of
MMR defects was predicted to be available for analysis. This overcomes problems
associated with clonal evolution of microsatellite sequences in cancer cells and




DNA was extracted from patient cell lines lbl-1260 and lbl-1261 and control
lymphoblast cell lines lbl-cl and lbl-c5 as described in 2.2.1. DNA concentration was
determined as described in 2.2.5.
4.2.2 Small pool PCR
Limiting dilution experiments and SP-PCR was carried out as described
previously in 2.4.4 and 2.4.5 using primers BAT-40F and BAT-40R and D2S123F
and D2S123R (2.4.1). BAT-40 forward primers were fluorescently labelled with
HEX and D2S123 forward primers were fluorescently labelled with FAM. High
Fidelity Taq polymerase (Expand, Boehringer Mannheim) was used in all PCRs.
This has a three fold increased fidelity of DNA synthesis compared to Amplitaq (PE
Applied Biosystems) to achieve the most faithful replication of microsatellite alleles.
Since amplifications involved very dilute DNA, rigorous controls were employed
against contamination and these are detailed in 2.4.5 and 2.5.1.
4.2.3 Mutational analysis of SP-PCR products
SP-PCR products were size analysed using an ABI310 genetic analyser as
described in 2.5.1 and the size of each allele detected was recorded.
4.2.4 Data analysis
The frequency of mutant alleles in each cell line was expressed as the number of
alleles that were mutant in length divided by the total number of alleles detected
(normal and mutant). Accordingly, percentages are not exact contents of cells with
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alterations, but relative values of alleles. Differences in the frequency of normal and
2 ,
mutant alleles between cell lines were evaluated by a % test as described in 2.10.1
and significance taken at 5%.
Where mutant allele origin was assigned as having derived from one of two wild
type constitutional alleles (relating to analysis of D2S123 mutant profiles in cell line
lbl-1261), this was determined as described in 2.5.4. To subsequently evaluate
whether there was a bias in mutation at either wild type allele, this was carried out
using a %2 test to compare the number of mutant and wild type alleles at each
progenitor (2.10.1). To account for the possibility that some mutants did not derive
from the progenitor allele closest in size, a further more stringent assessment was
also performed and this is detailed in the results.
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4.3 Results
The results in this chapter have also been published in Bacon et al., 2000 and in
Bacon et al., 2001b.
4.3.1 Detection of mutant microsatellite alleles in lbl-1260 and lbl-1261
Genotyping of D2S123 alleles from MMR defective cell lines lbl-1261 and lbl-
1260 revealed constitutional allele sizes of 214/228bp (Figure 4.1) and 212/228bp
respectively. Genotyping of D2S123 alleles from MMR proficient cell line lbl-c5
revealed alleles of 212/214bp. At a second poly(A) marker, BAT-40, genotyping of
alleles from lbl-1261 and lbl-1260 revealed constitutional alleles of 120/124bp
(Figure 4.2) and 124/124bp respectively. At two-control cell lines, lbl-c5 and lbl-cl
constitutional allele sizes were 120/124bp and 120/124bp respectively.
Constitutional allele sizes as determined from the amplification of undiluted DNA
were subsequently confirmed during SP-PCR analysis. Individual alleles of the same
size as those determined from undiluted DNA were detected, validating the method
of genotyping used (Figures 4.1 and 4.2). In addition, reproducibility in the
amplification and sizing technique was evidenced by consistent sizing of positive
PCR samples from two wells on every SP-PCR plate.
For SP-PCR analysis, the extreme dilute nature of the DNA was evidenced in all
analyses by the absence of any peaks in the majority of PCRs or, the detection of
single alleles from heterozygous samples in others (Figures 4.1 and 4.3). In all,
between 54 and 270 alleles were typed by SP-PCR analysis in each of the cell lines
at both markers. Length variation in individual alleles was clearly detected at
D2S123 (Figure 4.3) and BAT-40 (Figure 4.4) in both MMR deficient cell lines, by








Figure 4.1 (A) Constitutional
genotype of DNA from lbl-1261 at
D2S123. Genotype is determined
from the preparation of undiluted
DNA. A short and a long allele of
214 and 228bp respectively are
clearly detected as the predominant
peaks in each peak complex. (B and
C) This is confirmed by genotyping
individual alleles from lbl-1261 using
SP-PCR where alleles of 214 and
228bp are those most frequently
detected. M = marker peak at 200bp.
Figure 4.2 (A) Constitutional
genotype of DNA from lbl-1261 at
BAT-40 determined from the
preparation of undiluted DNA. Wild
type allele sizes are taken as the
predominant peak in each peak
complex as determined from
genescan data. (B and C) the
constitutional allele sizes of 120 and
124bp are confirmed in SP-PCR
analysis. Individual alleles of 120
and 124bp are easily determined
and are the most frequently observed
allele sizes.
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Figure 4.3 Detection of mutant
D2S123 alleles in lbl-1261 by Sp-
PCR. (A) Constitutional genotype in
undiluted DNA. (B and C) In SP-PCR
analysis individual mutant alleles of
218 and 230bp are clearly detected
in lbl-1261 by comparison to
constitutional genotype. M = marker
peak at 200bp.
Figure 4.4 (B and C) Detection of
mutant BAT-40 alleles in lbl-1261 by
SP-PCR. Individual mutant alleles
of 129 and 116bp are detected in
lbl-1261 by SP-PCR. (A) The mutant
alleles are clearly identified by
comparison to the constitutional
genotype as determined from
undiluted DNA (A).
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4.3.2 Cells derived from normal tissue with MMR defects display a
mutator phenotype
The size profiles and frequency of individual D2S123 and BAT-40 alleles typed
from each cell line by SP-PCR are shown in Figures 4.5 and 4.6 and the frequency of
mutants detected in each cell line is summarised in Table 4.1.
Table 4.1 Summary of SP-PCR analysis at microsatellite markers. Mutant allele counts at
D2S123 and BAT-40 SSR loci in MMR deficient lymphoblastoid cell lines lbl-1261, lbl-1260
and MMR proficient lymphoblastoid cell lines, Ibl-c5, Ibl-c1 are shown. MMR deficient cell
lines are significantly more unstable than control cell lines (y2=84.032, p<0.001 MMR
deficient vs proficient cell lines at both markers.





lbl-1261 270 89 (0.330) 139 71 (0.51)
lbl-1260 120 10 (0.083) 54 13 (0.24)
Ibl-c5 109 2 (0.018) 55 1 (0.02)
Ibl-cl ND ND 99 5 (0.05)
Both MMR defective cell lines displayed elevated levels of mutation frequency
compared to MMR proficient cell lines at D2S123 (Figure 4.5) and BAT-40 (Figure
4.6). 89/270 (33%) D2S123 alleles and 71/139 (51.1%) BAT-40 alleles typed from
lbl-1261 were mutant as were 10/120 (8.3%) and 13/54 (24.1%) alleles typed from
lbl-1260. These mutation frequencies were significantly increased relative to the
control cell lines both at D2S123 (%2=41.2, p<0.001; %2=4.9, p=0.028 for lbl-1261
and lbl-1260 respectively) and BAT-40 (x2=85.02, p<0.001; %2 =19.9; p<0.001 for
lbl-1261 and lbl-1260 respectively)
The low number of mutants observed in control cell lines may be due to PCR
error or indeed could be genuine mutations. However their small number relative to
those in MMR deficient cell lines indicates that PCR artefacts do not interfere
significantly with the detection of mutants in the dilute DNA.
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Heterogeneity was observed in the level of mutation between the two MMR
deficient cell lines. Lbl-1261 displayed a significantly higher level of mutation
compared to lbl-1260 at both BAT-40 and D2S123 (%2=38.0, p<0.001; markers
combined). In addition clustering of mutants around wild type alleles was observed
suggesting the predominance of small mutations. A wide spectrum of insertion and
deletion mutant alleles was observed at both marker loci indicating that PCR bias
towards shorter alleles is not a significant factor of the technique used.
These results indicate that cell lines lbl-1261 and lbl-1260 that are derived from
normal tissue display a mutator phenotype similar to that observed in MMR deficient
tumours. These data demonstrate that the MMR defects in these cell lines are
associated with microsatellite instability and that when selection pressures and
confounding changes associated with cancer development are minimised, a wide























Figure 4.5 Microsatellite Instability at D2S123 in non-cancer derived cells with MMR defects.
Distribution of D2S123 allele sizes in MMR deficient (A and B) and MMR proficient (C)
lymphoblastoid cell lines as detected by SP-PCR. Asterisks indicate wild type alleles as identified
by analysis of undiluted DNA. A significantly elevated frequency of mutation is demonstrated
in MMR deficient cell lines lbl-1260 and lbl-1261, compared to control cell line Ibl-c5 (p<0.03,
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Figure 4.6 Microsatellite Instability at BAT-40 in non-cancer derived cells with MMR defects.
Distribution of BAT-40 allele sizes in MMR deficient (A and B) and MMR proficient (C)
lymphoblastoid cell lines as detected by SP-PCR. Asterisks indicate the predominant constitutional
alleles identified by analysis of undiluted DNA. Significant elevation in the frequency of mutations
is demonstrated in MMR deficient cell lines compared to MMR proficient controls (p<0.001,






4.3.3 Allele bias in mutation at D2S123 in MMR deficient cells
It was noticed that there was a substantial bias in the wild type constitutional
alleles from which mutants were derived, at microsatellite D2S123. This was
exacerbated in the most unstable cell line, lbl-1261. In all, 71 of 89 mutants (80%) in
lbl-1261 were clustered around the shorter (214bp) allele (Figure 4.5), indicating a
substantial bias for mutation at that locus (% =42.6, p<0.001). Mutant alleles were
assumed to be derived from the progenitor allele in the undiluted DNA that was
closest in size since, studies of microsatellite mutations in human pedigrees, human
cell lines and artificial constructs in yeast, have shown that mutations in most
microsatellites involve only one or two repeat units (Weber and Wong, 1993; Petes
et al., 1997; Olsen et al., 1998). Since mutant alleles in lbl-1261 ranged in size from
208-232bp and the progenitor alleles were 214 and 228bp, mutants of size <220bp
were assigned as derivatives from the 214bp-progenitor allele. Mutants of >222bp
were assigned as derivatives from the 228bp-progenitor allele. However, to ensure
that the observed bias was not due to mis-assignment of mutant alleles, the data was
re-analysed using a threshold to exclude large reductions in the 228bp allele. It was
assumed that only mutants of <216bp (a single repeat expansion of the short
progenitor allele) were derived from the shorter progenitor. This confirmed the
highly significant mutation bias at the shorter allele (% =9.43, p=0.002).
These observations are not due to PCR bias at the shorter allele, since equal
numbers of short and long alleles were detected in lbl-1261. Furthermore, insertion
and deletion mutants of both progenitor alleles were detected (Figure 4.5). These
observations indicate a substantial and statistically significant allele-specific bias in
mutation rate at D2S123. These observations are investigated further and discussed
in Chapter 5 where the nature of this mutational bias is determined.
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4.3.4 Evidence of increased instability at microsatellite BAT-40
Interestingly, instability was heterogeneous between the two microsatellites
D2S123 and BAT-40 (Table 4.1). The level of mutation at BAT-40 was significantly
elevated in comparison to D2S123 in both cell lines (%2=19.7, p<0.001) suggesting
differential susceptibility of SSRs for mutation. The increased frequency of mutation
at BAT-40 indicates the poly(A) tract has a significantly greater propensity to
mutation than the (CA)n repeat in D2S123, and may be inherently very unstable.
Further investigation to determine if BAT-40 is a hypermutable locus was carried out
and this is detailed and further discussed in Chapter 6.
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4.4 Discussion
In this chapter, data has been presented that demonstrates a substantial excess of
mutant microsatellite alleles can be detected in cell lines derived from normal tissue
with MMR defects.
Profound MMR defects in lbl-1261 and lbl-1260 have been demonstrated
previously (Parsons et al., 1995a; Nicolaides et al., 1998) and the levels of MMR
protein expression in these cell lines are consistent with such defects (Chapter 3).
Analysis of individual alleles by SP-PCR has shown that these defects in MMR are
associated with low level microsatellite instability in these cell lines, confirming a
previous report (Parsons et al., 1995a). Furthermore, this investigation demonstrates
that the mutator phenotype displays significant heterogeneity with regards to both the
spectrum and frequency with which mutations occur at microsatellite sequences and
suggests that D2S123 and BAT-40 have differential inherent susceptibilities to
mutation.
These data provide further support for a growing number of studies that show
constitutional MMR defects can result in widespread microsatellite instability in
normal tissue. High levels of DNA instability in non-cancerous tissues has been
demonstrated in cases of knockout mice with homologous mutations of Pms2 and
Msh2 genes (Baker et al., 1995; de Wind et al., 1995; Narayanan et al., 1997). In
addition rare individuals have been identified with biallelic germline mutations in the
MLH1 gene (Ricciardone et al., 1999; Wang et al., 1999; Vilkki et al., 2001) and
these also show instability at microsatellite loci in normal tissue. It is interesting to
note that the widespread MSI in the non-cancerous tissue of these patients is
associated with early malignancies, including extra-colonic cancers (Ricciardone et
al., 1999; Wang et al., 1999; Vilkki et al., 2001). The cell lines analysed in this study
were also derived from the normal tissue (Chapter 3) of patients, with early onset
cancer and who developed extra-colonic lesions displaying phenotypic evidence of
TS (Hamilton et al., 1995). In a separate study, a Turcots patient with a germline
PMS2 mutation also showed instability in normal tissue (Miyaki et al., 1997b).
Taken together these studies suggest that constitutive loss of MMR results in
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widespread MSI and this likely contributes to severe forms of early onset
malignancies. It will be of interest to establish how widespread this phenomenon
may be.
Insertion and deletion mutations were observed at both markers, with small
changes predominating. This is in agreement with previous studies in both yeast and
MMR deficient tumours demonstrating that most microsatellite alterations involve
the addition or subtraction of one or two repeating units (Brinkmann et al., 1998;
Sturzeneker et al., 2000). However a wide spectrum of mutations was also observed,
most dramatically in cell line lbl-1261. This suggests that mutational bias due to
selection and clonal expansion in these cell lines is not a significant factor.
The observed variation in the level of mutation between cell lines lbl-1260 and
lbl-1261, likely reflects the different mutations that they harbour. It is well
documented that defects in various MMR genes result in different levels of mutation
accumulation. MSH6 germline mutations are known to result predominantly in a
microsatellite instability low (MSI-L) phenotype due to redundancy between the
MSH6 and MSH3 proteins (Marsischky et al., 1996; Wu et al., 1999b). However, the
majority of tumours with high levels of microsatellite instability (MSI-H) are
accounted for by mutations of the MLH1 and MSH2 genes (Liu et al., 1996;
Thibodeau et al., 1998). In a study of Mlhl versus Pms2 deficient mice, the
mononucleotide repeat mutation frequency was consistently 2- to 3- fold higher in
the Mlhlcompared to the Pms2~/~ mice (Yao et al., 1999). Interestingly, this is in
contrast to the results presented here, in which a 3- fold increase in mutation was
observed in lbl-1261 (PMS2 mutation) compared to lbl-1260 (MLH1 mutation).
However, cell lines with mutations in the same gene have also been demonstrated to
show significant differences in the extent of mutation at dinucleotide repeats (Oki et
al., 1999), indicating the nature of the MMR mutation, as well as the specific gene,
influences the manifestation of the mutator phenotype. The increased frequency of
mutation observed in cell line lbl-1261 is also in agreement with a previous study
(Parsons et al., 1995a).
The statistically significant allele bias for mutation observed at D2S123 in cell
line lbl-1261, suggests that features of the sequence or chromatin structure at the
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shorter progenitor allele may contribute to the increased susceptibility for mutation.
Alternatively, some influence at the long progenitor allele may confer stability. Intra-
allelic heterogeneity for mutation adds further complexity to understanding the
manifestation of the mutator phenotype. That the locus genotype might determine
susceptibility to mutation, is of relevance when evaluating potential targets of the
mutator phenotype as well as in the use of such markers for the classification of MSI
status of colorectal tumours. This observation is also of interest since it conflicts with
the expectation that MSI correlates with increased repeat length and number of
repeating units (Sia et al., 1997; Wierdl et al., 1997). The nature of this allele bias for
mutation is further investigated in Chapter 5.
Heterogeneity in mutation frequency was observed between BAT-40 and D2S123
loci, with a statistically significant elevation in mutation at BAT-40 in both cell lines.
BAT-40 showed an overall 1.7 fold increase in mutation frequency over D2S123. In
lbl-1260, the level of BAT-40 mutation was 3 times that of D2S123. These data
indicate differences also exist in the inherent stability at alternative loci and that
BAT-40 is particularly prone to mutation. Previous studies have demonstrated that
microsatellite repeat loci containing mononucleotide repeat motifs particularly of the
type poly(A)n, are more susceptible to instability in MMR deficient tumours
(Dietmaier et al., 1997). Furthermore, BAT-40 has been reported to show mutation
in over 95% of MSI cancers (Parsons et al., 1995b). Extreme inherent instability at
this locus may explain the increased sensitivity to mutation in the presence of MMR
defects and this hypothesis is addressed in Chapter 6.
In summary, the data in this chapter indicates that defects in MMR in cells
derived from normal tissue are associated with microsatellite instability of the type
observed in MMR deficient tumours and are in agreement with a previous study
(Parsons et al., 1995a). This study illustrates that MMR deficient cell lines derived
from normal tissue are excellent tools in unmasking underlying mutation frequencies
and revealing factors that may affect the manifestation of a mutator phenotype or
result in the accumulation of new mutations at microsatellite sequences.
The fact that heterogeneity in the mutator phenotype was detected on a number of
different levels, suggests that the manifestation of MSI can be affected by a number
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of different factors. Variation in the mutation frequency at a given microsatellite loci
may be a result of the nature of the MMR mutation, or may be due to features of the
sequence within or surrounding individual repetitive tracts in both an allele specific
or locus specific manner. The contribution to mutability from inherent sequence
characteristics are of particular relevance when employing microsatellite markers in
the classification of MSI tumours and also in evaluating sequences that may be
potentially unstable consequent of MMR defects. These initial findings are addressed
in further detail in the next two chapters.
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Chapter 5
Sequence Interruptions Confer Differential Stability at
Microsatellite Alleles in MMR Deficient Cells
5.1 Introduction
In Chapter 4, SP-PCR analysis of cells with MMR defects, derived from normal
tissue at a (CA)n repeat marker, D2S123, demonstrated a substantial and statistically
significant allele-specific bias in mutation frequency. The shorter progenitor allele in
cell line lbl-1261 was found to be significantly more unstable than the longer allele,
conflicting with the expectation that instability correlates with repeat length (Sia et
al., 1997; Wierdl et al., 1997). This suggests that inherent features of the sequence
within or surrounding the (CA) repeat at individual D2S123 alleles may contribute to
the differential propensity to mutability observed at this locus.
The degree of perfection of a repeat has been demonstrated to correlate with
instability. In E.coli and yeast, presence of an interspersion within a dinucleotide
tract results in its stabilisation (Bichara et al., 1995; Petes et al., 1997). The
stabilising effect of repeat interspersion was also observed in yeast strains with
MMR defects (Petes et al., 1997). Locus by locus analyses reveal that interspersed
repeat markers are also relatively more stable in the ffuitfly Drosophila (Goldstein
and Clark, 1995), in the germline of human populations (Brinkmann et al., 1998) and
in tumours from cancer patients (Sturzeneker et al., 2000). Repeat sequence
interruption is also important on a clinical level. Expansion of triplet repeats in the
FMR1 gene, the HD gene and the SCA1 gene, gives rise to the human trinucleotide
disorders fragile X, Huntingdon's disease and spinocerebella ataxia type 1
respectively (Ashley and Warren, 1995; Gordenin et al., 1997). Stability of both
SCA1 and FMR1 alleles are conferred by interruption of the contiguous repeat
(Chung et al., 1993; Eichler et al., 1994; Hirst et al., 1994; Snow et al., 1994; Kunst
etal., 1997).
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The majority of these studies demonstrate variation in mutation frequency
between alternative loci. Mechanisms affecting mutation rate within a given locus
have been less extensively characterised, although such variation has been
documented. For example in a population study of meioses in pentameric and
tetrameric markers, it was shown that different alleles at a single locus varied in their
rate of mutation (Brinkmann et al., 1998).
In this chapter the nature of the allele specific mutational bias at D2S123 observed
in lbl-1261 (Chapter 4), was determined. The wider relevance of the initial
observations identified in lbl-1261 is established, by analysis of population D2S123
genotypes and the underlying cause of this mutational bias has been elucidated. The
question as to whether constitutional genotype can influence susceptibility to
mutation at D2S123 in MSI+ CRCs was then specifically addressed by analysis of
matched normal and tumour DNA. As well as providing considerable insight into
understanding the mechanisms that lead to instability at repetitive sequences, this
series of experiments has potential clinical relevance. The CA repeat marker studied
here is one of a panel of five markers recommended for use in MSI analysis in
colorectal cancer (Boland et al., 1998; Perucho, 1999). Therefore, establishing
whether patient genotype can influence the manifestation of MSI at this marker is of
considerable importance. In addition, uncovering factors that affect repeat stability in
the absence of MMR is important when considering other sequences, both coding or




The size distribution of D2S123 alleles within the population was determined by
genotyping blood DNA of 39 unrelated Scottish individuals described in 2.3.2.
Genotyping of matched normal and tumour samples was carried out using DNA's
previously isolated from 41 colorectal cancer patients shown to have defective MMR
and a mutator phenotype as described in 2.3.3 and 2.3.4. All patients with suitable
material whose tumours fulfilled MSI+ criteria were analysed in this study, regardless
of whether or not D2S123 showed length variation in tumour DNA. There is
potential bias because MSI criteria include D2S123 genotyping and so some patients
with homozygous long alleles may be underscored with respect to MSI status.
However this does not impact adversely on the finding of these investigations.
5.2.2 Genotyping samples at locus D2S123
For genotyping of DNA samples at the D2S123 locus, DNA templates were
amplified as described in 2.4.2 using FAM labelled fluorescent D2S123F and
D2S123R primers (2.4.1). The Expand High Fidelity PCR system (Boehringer
Mannheim) was used, to ensure faithful replication over the repetitive tract. Size
analysis of PCR products was carried out using an ABI310 genetic analyser as
described in 2.5.1. with allele size taken to be the most predominant peak in each
peak complex.
5.2.3 Sequencing of D2S123 alleles
D2S123 alleles were amplified from undiluted cell line or blood DNA as
described in 2.4.2. using non-fluorescent D2S123F and D2S123R primers (2.4.1).
Again, the Expand High Fidelity PCR system (Boehringer Mannheim) was used.
Individual progenitor alleles were visualised by gel electrophoresis as described in
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2.4.6 and gel purified as described in 2.7.1. Sequencing of purified products was then
performed as described in 2.7.2-2.7.4.
5.2.4 Cloning of individual D2S123 alleles
D2S123 alleles from lbl-1261 and lbl-c5 were cloned as described in 2.6.1 and
2.6.2. Genotyping and cycle sequencing of transformants was performed as described
in 2.5.1 and 2.7.1-2.7.5.
5.2.5 Determination of allele specific bias in MSI+ tumours
The D2S123 locus was amplified from lOOng of normal and tumour DNA
templates in 50pi PCR reactions with FAM labelled D2S123F and D2S123R primers
as described in 2.4.1 and 2.4.2. PCR products were size analysed using an ABI 310
genetic analyser as described in 2.5.1. Analysis of individual shifts was made by
comparison of normal and tumour Genescan profiles. Whenever there were doubts
about the veracity of a mutation, it was not included. On some occasions it was
questionable as to whether one or both alleles had mutated. Such cases were scored
as shifting at just one of the alleles. Mutation frequency may therefore be marginally
underestimated if both alleles had mutated and the presence of any wild type allele in
the tumour represented contamination from surrounding normal mucosa. Observed




The results presented here have been published in Bacon et al., 2000.
5.3.1 Determination of D2S123 allele size distribution in a Scottish
cohort
Since short (214bp) and long (228bp) progenitor alleles exhibited significant
differences in susceptibility to mutation in the MMR deficient, lymphoblast cell line
lbl-1261 (Chapter 4), the size distribution of D2S123 alleles in a Scottish cohort was
investigated to address whether large differences in constitutional allele size were
observed within a population. Thirty-nine Scottish individuals were genotyped at the
D2S123 locus. A total of eight different alleles were identified ranging from 210-
230bp. Sizes corresponded to variations in the core number of CA repeats rather than
single nucleotide changes. This was consistent with the published CEPH data to
which these results were compared (http://www.cephb.fr/cephdb/) (Figure 5.1 and
Table 5.1). The 198bp alleles, observed in the CEPH data, were not identified in this
cohort. However a previously undocumented allele size of 230bp was observed. The
allele sizes in this study (shown) genotyped exactly lbp longer than the
corresponding CEPH alleles. This is likely to be due to differences in primer length.
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Table 5.1 Comparison of D2S123 allele frequencies between CEPH database and 39
Scottish individuals. Genotyping data from the small Scottish cohort is in agreement with
those from CEPH family analysis. Number refers to that assigned by the CEPH database. A
198bp allele was not observed in the Scottish cohort, however a previously undocumented
allele size of 230bp (U) was observed. Allele sizes shown here (a) genotyped exactly 1bp
longer than the corresponding CEPH alleles.





1 228 0.304 0.244 Long
2 212 0.339 0.41 Short
3 216 0.107 0.089 Short
4 214 0.125 0.128 Short
5 216 0.054 0.026 Short
6 198 0.018 0.00 Short
7 226 0.018 0.064 Long
8 210 0.036 0.013 Short
U 230 0.00 0.026 Long
D2S123 alleles were noticed to cluster into two distinct size groups, long
(~228bp) or short (~214bp) and the frequency of alleles in each of these two groups
were almost identical between the Scottish cohort analysed here and the CEPH data
(Figure 5.1 and 5.2, and Table 5.1). In addition, it was noted that short alleles
predominate over long alleles in both the CEPH and Scottish cohorts (Figure 5.2)
Therefore the distinct long and short constitutional alleles in cell line lbl-1261
(Chapter 4) reflect two distinct allele size classes of D2S123, detected in the
population. Inherent differences in these two allele classes other than that of length,
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Figure 5.1 D2S123 allele size frequencies in 39 Scottish individuals and the CEPH database.




Figure 5.2 Comparison of frequencies of long and short D2S123 alleles in the Scottish cohort
and the CEPH database. The frequencies of the two allele classes are almost identical between
these two cohorts, with short alleles predominating.
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5.3.2 Mutation rate within the D2S123 CA repeat is predicted by
sequence content
The sequence for D2S123 logged in GenBank is (CA)i3(TA)(CA)i5 (GenBank
accession number; Z16551). Individual alleles from cell line lbl-1261 were
sequenced to determine whether sequence differences between long and short alleles
might explain the substantial mutation bias. Initially undiluted lbl-1261 DNA
amplified at the D2S123 locus was gel separated and individual alleles sequenced
independently. This demonstrated that the 228bp allele comprised a (CA)28 repeat
tract split into two runs of (CA)i3 and (CA) 15 by a TA dinucleotide concurring with
the sequence logged in GenBank. However, the shorter 214bp allele comprised an
uninterrupted (CA)22 repeat with no interspersing TA dinucleotide (Figure 5.3).
Genotyping and sequencing of 15 D2S123 alleles from template DNA of a cohort of
Scottish individuals showed that various length alleles classified as "long" always
contained the TA interspersion while, various lengths of "short" alleles were
invariably uninterrupted poly CA repeats (Table 5.2). This analysis indicated that
alleles clustered around 214bp (short) contain perfect uninterrupted CA repeats. In
contrast long alleles consistently contain a TA interspersion within the CA tract
(Figure 5.3 and Table 5.2).
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Figure 5.3 Sequence analysis of the progenitor D2S123 alleles cloned from lbl-1261. The short
allele (A) consists of an uninterrupted (CA)22 tract. The long wild type allele (B) consists of
(CA)-|3 repeats followed by a TA dinucleotide and then another run of (CA)-|5 repeats.
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Table 5.2 Analysis of D2S123 repeat in 15 alleles from 9 unrelated Scottish individuals.
Constitutive allele sizes were determined using an ABI310 and classified as either short (S)
or long (L). Sequencing of individual constitutive alleles revealed the presence (interspersed)





Ibl-c5 212 (S) perfect
214 (S) perfect
lbl-1260 212 (S) perfect
228 (L) interspersed
lbl-162 228 (L) interspersed
228 (L) interspersed
lbl-830 214 (S) perfect
228 (L) interspersed
lbl-2135 216 (S) NR
228 (S) interspersed
lbl-757 212 (S) perfect
212 (S) perfect
Ibl-c40 212 (S) perfect
218 (L) NR
lbl-55 216 (S) perfect
228 (L) interspersed
lbl-129 212 (S) perfect
216 (S) NR
In order to confirm definitively that mutant alleles detected in lbl-1261 (Chapter
4) arose predominantly from uninterrupted alleles, D2S123 alleles were PCR
amplified from lOOng lbl-1261 template DNA and cloned. Individual alleles were
then sized and sequenced. Analysis of alleles from 28 clones confirmed that every
long allele analysed (wild type or mutant) contained the TA interruption and every
short allele (wild type or mutant) contained perfect CA repeats, thereby confirming
that the presence of a TA interspersion confers stability on the CA repeats (Table 5.3
and Figure 5.4).
Mutation was due to length variation of the number of core CA repeats in every
case, implicating replication slippage as the causative mechanism of instability at this
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locus (Table 5.3 and Figure 5.4). Cell line lbl-c5 was heterozygous for two short
alleles and PCR cloning of undiluted DNA revealed two short uninterrupted alleles
of (CA)2i and (CA)22 repeats. As expected in this MMR proficient cell line, no
mutations were detected in the clones despite both alleles having no interspersion of
the repeat tract.
Taken together these data indicate that long alleles (~228bp) invariably contain a
TA interspersion in the repeat while short alleles (~214bp) contain uninterrupted
(CA)n repeats that are inherently more unstable. This instability was unmasked by the
analysis of MMR defective cell line lbl-1261 in Chapter 4.
Table 5.3 Sizing and sequencing of D2S123 alleles cloned from MMR deficient cell line,
lbl-1261. The sequences of the CA repeat region only are indicated. aSize of alleles as
determined by ABI 310 analysis. The allele sizes of 208-216 nucleotides are classed as
short and those of 224-230 nucleotides as long (see text and Chapter 4). All short alleles
contain perfect CA repeats in contrast to long alleles that have a TA interspersion. Variation
in allele size is wholly accounted for by differences in the number of CA repeats.
Allele Size3 Sequence Number of Clones Category
208 (CA)ig 3 Short
210 (CA)20 6 Short
212 (CA)2I 4 Short
214 (CA)22 5 Short
216 (CA)24 2 Short
222 (CA)12TA(CA)13 1 Long
226 (CA)12TA(CA)15 1 Long
228 (CA)13TA(CA)i5 5 Long
230 (CA)14TA(CA)15 1 Long
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Figure 5.4 Representative sequences of mutant D2S123 alleles cloned from lbl-1261 DNA. Clones
35 (A) and 1 (B) were genotyped as short with alleles sizes of 208 and 210bp respectively. Both
have an uninterrupted CA repeat tract. Clones 18 (C) and 21 (D) were 226 and 230bp in length and
thus classified as long. The TA interruption is evident in both.
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5.3.3 Allele specific bias of mutations at D2S123 in DNA MMR deficient
tumours
To determine whether allele bias might also influence the MSI phenotype in
MMR deficient tumours, D2S123 alleles were genotyped in matched normal and
tumour DNA samples from 41 colorectal cancer patients with MSI+ tumours. These
have been characterised previously and exhibit MSI at 4 or more markers. In some
cases the germline mutation has been identified (Farrington et al., 1998)
(unpublished data). Normal tissue was genotyped for D2S123 alleles and the stability
of each allele assessed in matched tumour DNA (Figure 5.5). Thirty of the 41
tumours exhibited mutation at one or more D2S123 alleles and overall 37 of the 82
alleles (45%) had mutations (Figure 5.6). There was a significant bias in the
frequency of mutations at the short alleles compared with long alleles (Figure 5.6).
Of 53 short wild type alleles identified, 32 (60%) displayed instability in the tumour
tissue compared with only 5 of 29 (17%) long alleles (%2 =12.4, p<0.001). Thus,
constitutional allele sequence is a determinant of the propensity for instability at a
given locus in the presence of defective mismatch repair. These data have important
implications for the classification of clinical material with respect to MSI status.
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Figure 5.5 Representative ABI 310 profiles of matched normal (N) and tumour (T) DNA from
two MSI+ patients. Patients (A) and (B) both show a shift at the short constitutive allele in the
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Figure 5.6 Tumour DNA instability at D2S123 alleles in 41 MSI+ CRC patients. Long and short
alleles were compared between matched normal and tumour DNA and assesed for stability.
There is a significant excess of mutations at short alleles (x^=12.4, p<0.001).
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5.4 Discussion
The data presented in this chapter investigate further, the initial observation made
in Chapter 4, that intra-allelic bias for mutational events occurs in a MMR deficient
cell line derived from normal tissue. The nature of the bias has been determined and
demonstrates that intra-allelic sequence variability for an interruption within the
repetitive tract, determines allele stability. Furthermore this analysis demonstrates
that accumulation of mutations at D2S123 is predicted by host genotype at each
allele.
By genotyping and sequencing of individual alleles, it has been demonstrated that
defective MMR results in insertion and deletions of CA repeat units, which accounts
for the variation in mutant allele sizes observed by SP-PCR in Chapter 4. In addition,
alleles without a TA interspersion within the repeat tract are significantly more
susceptible to instability as a consequence of defective MMR.
Other studies that have addressed differences between loci in human populations
and in CRCs, also show that perfect repeats are more susceptible to instability
(Goldstein and Clark, 1995; Petes et al., 1997; Brinkmann et al., 1998). However this
study goes further, by demonstrating that variant interruptions can occur between
alleles at the same marker loci and that these have a marked effect on individual
allele stability. These results indicate that the stabilising effect of a variant repeat is
apparent, even in the presence of defective MMR, supporting a previous report
(Petes et al., 1997). The data from this chapter and Chapter 4 provide compelling
evidence that different alleles at the same marker loci can display genotypic
variation, substantially affecting susceptibility to mutation. A factor independent of
tumourigenesis, namely allelic heterogeneity for a repeat interspersion has been
specifically shown to influence the manifestation of the mutator phenotype.
Several studies have suggested that the mechanism of microsatellite mutation in
MSI+ tumours shares similarity with the evolution of such sequences in the genome
(Di Rienzo et al., 1998; Sturzeneker et al., 2000). D2S123 population allele
frequencies from the Scottish cohort analysed here and that of the CEPH database
highlights higher frequencies of short alleles. The CEPH database,
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(www.cephb.fr/cephdb/), documents 6 short D2S123 alleles compared with 2 long
ones (Table 5.1, Figure 5.1). This would be expected if short alleles with perfect
repeats are more susceptible to mutation, as the results presented here in MMR
defective cells suggest. These mutations could then be fixed as new alleles. The
absence of many length variants of the long alleles is also consistent with the
sequence data here that demonstrate that long alleles invariably contain the
stabilising interspersion
It is generally accepted that replication slippage is the major mechanism causing
new mutations in microsatellites (Levinson and Gutman, 1987). The results are
consistent with models in which a variant interruption causes stabilisation by
encouraging the perfect realignment of the two strands, following their dissociation
during DNA replication slippage. However the possibility that interruption of the
repeat tract may alter some unusual structure associated with the repeats and
subsequently reduce the rate of slippage, cannot be wholly discounted (Petes et al.,
1997).
The majority of mutations occurring at CA microsatellites have been shown to
involve small length changes in which one or two repeats are altered (Henderson and
Petes, 1992; Petes et al., 1997; Brinkmann et al., 1998). Mutations of repeat tracts in
cancer genes of MSI+ colorectal tumours characteristically display small frameshift
mutations (Rampino et al., 1997; Parsons et al., 1995b). The mutations identified (in
Chapter 4) at the D2S123 locus, also involve the gain or loss of one or two repeat
units in the majority of cases. In the cell line lbl-1261, short mutant alleles always
contained perfect repeats, whereas long mutant alleles consistently possessed a TA
interruption. The absence of any short mutants with a repeat interruption, or long
mutants without an interruption or of mutants with duplicated TA interspersions,
argues against the occurrence of large sequence alterations in excess of a few repeats.
This is consistent with PMS2, the MMR gene mutated in lbl-1261, being involved in
the repair of small insertiomdeletion loops (Kolodner and Marsischky, 1999).
These data show that host genotype at CA repeat sequences, can influence the
ability of available marker sets to assign MSI status to any individual tumour.
Therefore these findings have important clinical relevance regarding MSI screening
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strategies and the effects of individual patient genotype on these analyses. Tumour
MSI status is used to determine if HNPCC may be discounted or if analysis of MMR
genes is required. Additionally, there have been a number of reports indicating MSI
status may be used as a predictor of survival and can be employed as a clinical tool
with which to give patient survival estimates and to predict responsiveness to
therapeutic treatment (Lothe et al., 1993; Fink et al., 1998; Gryfe et al., 2000). An
accurate assessment of MSI status is therefore of critical importance. The other four
microsatellite markers in the recommended panel (Boland et al., 1998) are entered in
GenBank as uninterrupted (CA)n or (A)n repeats. However the CEPH database
(www.cephb.ff/cephdb/) indicates that they are polymorphic for different sized
alleles. Such analysis by length may mask further underlying individual genotype
differences at these markers. Detailed characterisation of these microsatellite markers
will be of clinical relevance and of interest in establishing the extent of this intra
locus mutational bias. In any case, the phenomenon described here for D2S123 alone
is of importance and the influence of patient genotype at this particular marker may
be particularly critical in the diagnosis of borderline MSI cases especially when
using a small panel of markers. The data from these experiments highlights the need
for a well-characterised set of diagnostic markers in which allelic variance and the
intrinsic effect on stability is well understood. Suggestions that one or a few
microsatellite markers are sufficient to assess MSI status should perhaps be treated
with caution, especially when there may be significant implications for both the
patient and the family. (Boland et al., 1998; Frazier et al., 1999; Perucho, 1999). The
marker D2S123 is logged in GenBank as an interspersed microsatellite. However, it
has been shown that this does not reflect the underlying complexity of this locus.
Many other markers may share similar intrinsic variances in allelic stability and the
phenomenon may be widespread.
Finally, these studies have demonstrated that investigation into the consequences
of MMR defects in cells derived from normal tissue can unmask factors at repetitive
sequences that can dramatically affect mutation frequency in the absence of MMR.
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Chapter 6
Hypermutability at the BAT-40 poly(A/T) Tract in the Human
Germline
6.1 Introduction
In Chapter 4, analyses of MMR deficient cell lines lbl-1260 and lbl-1261 revealed
that the mutator phenotype exhibits heterogeneity on number of different levels.
Heterogeneity in mutation frequency was revealed between cell lines with different
MMR gene defects and between different alleles at the same microsatellite locus. In
addition, heterogeneity was observed between different microsatellites with a
statistically significant elevation in mutation at poly(A/T) microsatellite BAT-40,
compared with (CA)n microsatellite, D2S123 (4.3.4). This suggests that BAT-40 is
inherently more susceptible to mutation. This could be due to factors such as the
extreme length of the repeating unit, as well as the nature of the repeat and these
influences have been demonstrated previously to contribute to instability (Weber and
Wong, 1993; Sia et al., 1997; Wierdl et al., 1997; Zhang et al., 2001).
BAT-40 is highly sensitive to the effects of defective mismatch repair, since it is
susceptible to mutation in >95% MSI+ tumours and thus used routinely in the
analysis of MSI (Parsons et al., 1995b; Dietmaier et al., 1997; Boland et al., 1998).
In addition previous studies have revealed that BAT-40 exhibits significant
polymorphism within populations (Zhou et al., 1997; Samowitz et al., 1999). Along
with the data presented in Chapter 4, these observations suggest that BAT-40 is
inherently highly mutable. It has been demonstrated that mechanisms generating
mutations in microsatellite unstable (MSI+) tumours can have relevance to
understanding evolution of such sequences in the germline (Sturzeneker et al., 2000).
Therefore since inherent instability at this locus is suggested from its high mutation
frequency in MMR deficient cells, BAT-40 might also be unstable in the germline.
Investigation of determinants of germline mutation at SSR loci is laborious and
frequently requires analysis of many hundreds of meiosis in family studies (Weber
and Wong, 1993; Brinkmann et al., 1998). However the development of SP-PCR
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techniques to study germline stability at minisatellites, has facilitated investigations
of such mutations at other SSRs (Jeffreys et al., 1994; May et al., 1996).
To date many studies of germline mutation at SSR loci are focused on
understanding sequence instability of the trinucleotide repeat disorders (Mornet et
al., 1996; Kunst et al., 1997; Monckton et al., 1999; Crawford et al., 2000). In
addition a number of studies have investigated germline stability of dinucleotide
repeat markers, including long CA stretches (Weber and Wong, 1993). However
there has been little investigation of the stability of mononucleotide tracts in the
germline. This is surprising since poly(A/T) tracts are the most abundant simple
repetitive motif in the human genome, largely due to the poly(A/T) tails of scattered
retrotransposed sequences such as Alu, Line-1 and processed pseudogenes (Toth et
al., 2000; International human genome sequencing consortium, 2001). Coding
poly(A/T) sequence tracts have been identified with repeat lengths of up to 27bp and
within introns they may reach up to 70bp in repeat length (Toth et al., 2000). Any
process influencing the fidelity of replication at coding sequence mononucleotide
tracts, will clearly have important functional effects. For example the TGFBR2 gene
contains a poly(A/T)io tract in exon 3 and has been shown to be mutated in up to
90% of MSI+ tumours resulting in inactivation of the gene (Markowitz et al., 1995;
Parsons et al., 1995b; Lu et al., 1996; Markowitz, 2000).
In this chapter the stability of BAT-40 in the germline was investigated to
determine if the extreme inherent instability at this locus suggested by analysis of
MMR deficient cells, could also be revealed in non-somatic tissue. The microsatellite
BAT-40 is a paradigm mononucleotide marker consisting of 40 adenine repeats
located in intron 2 of the 3-beta-hydroxysteroid dehydrogenase (3-beta-HSD) gene
on chromosome 11. The stability of this paradigm poly(A/T) tract has been
determined by study of population allele frequencies, mutation frequency in families
and mutation frequency in sperm DNA.
It is of further importance that BAT-40 is used in the analysis of MSI in colorectal
tumours. It has already been demonstrated, in Chapter 5, that inherent influences at
such loci can direct their propensity for instability in the presence of MMR defects
(Bacon et al., 2000). Such studies highlight the need for markers used in these
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assessments to be extensively characterised in order for them to be employed with
confidence. Assessment of the degree ofmutability at a locus such as BAT-40 might





Genotyping was carried out on the constitutional DNA of 102 unrelated Scottish
individuals as described in 2.3.2, and 35 unrelated CEPH family individuals from the
nine families described in 2.3.1.
A Scottish Family, K-435, was used for pedigree analysis and is described in
2.3.5. DNA from the 9 CEPH families, described in 2.3.1 was used for further
pedigree analysis to provide a total of 187 germline transmissions for study.
SP-PCR was carried out on matched constitutional and sperm DNA samples from
two further unrelated individuals described in 2.1.5.
6.2.2 BAT-40 genotyping
Genotyping of constitutional DNA was carried out in triplicate by amplifying
BAT-40 alleles using HEX labelled BAT-40F and BAT-40R primers as described
2.4.1 and the Expand High Fidelity PCR system. These primers amplify a 126bp
product containing the standard 40(A)s according to the genomic sequence of the 3-
beta-HSD gene (GenBank; M38180) (Lachance et al., 1990). It was not possible to
assess the number of adenine repeats in a given sized allele directly, since repeated
attempts at sequencing across the BAT-40 locus were unsuccessful. Therefore repeat
length is based on the theoretical predicted amplified sequence both in this and in the
majority of other studies that report BAT-40 repeat length (Zhou et al., 1997;
Samowitz et al., 1999; Yokozaki, 2000).
PCR products were size analysed using an ABI 310 Genetic Analyser as described
in 2.5.1.
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6.2.3 Sperm DNA preparation and SP-PCR
DNA was extracted from sperm as described in 2.2.2 and 2.2.3 and from matched
constitutional DNA as described in 2.2.1. Limiting dilution experiments, SP-PCR
and analysis of products was carried out as described in 2.4.4 and 2.4.5. using BAT-
40 primers as above. Avoidance of contamination is paramount when preparing
DNA samples and amplifying dilute DNA templates and stringent measures against
contamination were taken as described in 2.5.4.
6.2.4 Origin of new alleles
Assessment of allele origin was carried out according to 2.5.4.
6.2.5 Statistical analysis
Statistical comparison of population allele size frequency at the BAT-40 locus
was carried out using a Mann Whitney U test on the Minitab (V.13) statistical
package. Significance was taken at the 5% level.
For comparison of mutation frequency between matched sperm and blood
samples, the frequency of mutant alleles in each sample was expressed as the number
of alleles which were mutant in length divided by the total number of alleles detected
(normal and mutant). Accordingly the frequency of mutants was not the exact
number of cells with alterations but represent relative proportions of alleles.
Statistical analyses were then performed using a chi-squared analysis on Minitab
(V.13) statistical package, and significance taken at the 5% level.
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6.3 Results
The results presented in this chapter have been published in Bacon et al., 2001a.
6.3.1 The BAT-40 poly(A/T) locus is polymorphic
For any inherently unstable locus, rapid generation of new alleles would be
expected to result in appreciable levels of polymorphism within a population.
Therefore, BAT-40 genotypes were defined in 104 unrelated Scottish individuals and
35 unrelated CEPH family members (Table 6.1). Representative ABI310 profiles are
shown in Figure 6.1. PCR products displaying single complex peaks with a near
normal distribution were counted as homozygous (Figure 6.1 A). Those with extra
peaks were regarded as BAT-40 heterozygous (Figure 6.1B-D).
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Table 6.1 Levels of heterozygosity at the BAT-40 locus. Frequency of individual BAT-40
genotypes in the Scottish and CEPH cohorts analysed are indicated. Allele sets are given in




























































The allele traces of the BAT-40 mononucleotide marker are complex with
"stutter" peaks evident due to DNA polymerase slippage. However, "bona fide"
allele sizes are taken to be the predominant peak in each separate peak complex in
accordance with previous studies (Samowitz et al., 1999; Yokozaki, 2000). The
predominant peak is that with the greatest peak area as indicated by the ABB 10
genetic analyser software. Analysis of BAT-40 by SP-PCR of multiple single alleles,
in three individuals in Chapter 4 has also validated this method of allele sizing at the
BAT-40 locus. The most predominant peaks as genotyped from constitutional DNA
are detectable as individual alleles by SP-PCR (Figure 4.2 and 4.6). If the true allele
size is not that of the predominant ABB 10 peak in SP-PCR products, then it must be
that almost every allele amplified from each sample has undergone PCR error to
exactly the same degree (Table 4.1 and Figure 4.6). This is an unlikely explanation
particularly in view of the allele profiles from MMR proficient cell lines lbl-c5 and
lbl-cl where almost no mutant alleles were detected.
PCR error is evident when amplifying BAT-40, by nature of the stutter bands that
are observed (Figure 6.1). However, reproducibility of the prominent peaks in a
given individual assures confidence in the sizes given (see methodology). Where the
genotype of an individual could not be confirmed by reproducibly detecting the same
peaks in the allele trace, these individuals were discarded from analysis (3 cases).
The distribution of BAT-40 heterozygous genotypes indicates that amplification
and detection of two BAT-40 alleles of different sizes, is due to the difference in
genotype and not technical artefact (Table 6.1).
Allele frequency and distribution for both the Scottish and the CEPH cohorts is
shown in Figure 6.2. Of the 139 samples analysed, a total of 83 demonstrated
heterozygosity at the BAT-40 locus (59.7%). Levels of heterozygosity were similar
between the cohorts, 58.7% (61/104) in the Scottish population and 62.9% (22/35) in
the CEPH cohort (Table 6.1). As expected for a highly polymorphic marker, the
overall distribution of allele sizes was not significantly different between these two
populations (p=0.056) (Figure 6.2). Allelic size variation was from -15 to +11 as
compared to the most frequent allele. Taking into account variation in the cohorts
studied, these data are in line with a previous study reporting polymorphism at this
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mononucleotide marker for a large number of different alleles (Zhou et al., 1997;
Samowitz et al., 1999) and are suggestive of the frequent generation of new alleles at
this locus. However, the BAT-40 heterozygosity reported here differs in both
frequency and size distribution to that observed in a Japanese study despite the use of
similar methodology (Yokozaki, 2000)
The most frequent allele in both cohorts in this study (123bp) corresponds to a 37-
adenine tract as calculated from the genomic sequence (GenBank; M38180).
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Figure 6.1 Representative ABI 310 traces of BAT-40 poly(A/T) PCR products. The polymorphic
nature of this microsatellite marker in samples from a Scottish cohort is clearly demonstrated.
Blood DNA (A) shows a single complex of peaks the maximum being 123bp. Samples B-D
show heterozygosity at BAT-40 as illustrated by seperate peak complexes.
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Figure 6.2 Comparison of BAT-40 allele frequencies between Scottish and CEPH populations.
Allele sizes are given in bp. The most frequent allele size (123bp) corresponds to a BAT-
40 allele containing 37 adenine repeats as estimated from the predicted PCR product size
(126bp) of the standard BAT-40 allele with 40 adenine repeats (Genbank; M38180). There
is no statistical difference in the distribution of alleles within the two cohorts (p=0.056).
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6.3.2 Germline hypermutability at BAT-40 in pedigree analysis
Since BAT-40 displays high levels of polymorphism in populations and has been
previously demonstrated to be extremely susceptible to instability in MMR deficient
tumours (Liu et al., 1995a; Dietmaier et al., 1997), it was reasoned that BAT-40 may
be inherently unstable and that germline mutations might be detectable in family
studies. A Scottish family (K-435) was used for pedigree analysis, as Dr. Farrington
in the laboratory had previously identified proband MD-473 as heterozygous at
BAT-40, with two distinct sized alleles at this locus (112/124) (Figure 6.3).
Analysing the meiotic stability of BAT-40 alleles that are easily distinguished by size
allows for the most accurate assessment of individual allele stability at a complex
locus such as BAT-40. DNA from 20 available individuals from K-435 was
genotyped at the BAT-40 locus (Figure 6.3). There were 11 germline transmissions
available for study. Within the family there was evidence of a germline mutation in
the allele transmission from MD-1303 to MD-449. MD-1303, is heterozygous for
BAT-40 with allele set 120/124 but her daughter (MD-449) is homozygous with two
112 BAT-40 alleles (Figure 6.3 and 6.4). DNA was unavailable from the father of
MD-449 who is highly likely to have carried a 112 allele, inferred from sibling and
progeny genotypes. Therefore, the mutation is implicated as being maternal in origin,
displaying loss of repeats at the BAT-40 locus.
The 112/112 homozygous genotype in MD-449 is unlikely to have arisen by
dropout of the larger 120 or 124bp allele during PCR, because four family members
including MD-439, the sister of MD-449, had 112/124 genotypes that were easily
detected under the PCR conditions used (Figure 6.4). This indicates that the
technique reliably detects larger alleles. Furthermore, the 120bp allele in MD-1303
was faithfully amplified (Figure 6.4). Genotyping for all members of this family
were confirmed in triplicate and previous genotyping at microsatellite markers
confirmed that MD-1301 was indeed the mother of the twins MD-449 and MD-439
(Dr. S. Farrington, pers. comm.).
This observation of a germline mutation in only 11 transmissions is striking, since
only one mutation event in 3000-5000 transmissions has been reported for CA
repeats (Weber and Wong, 1993). These data provide founding evidence for the
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notion that BAT-40 is inherently prone to mutation and is unstable in the germline.
This initial observation led to further investigation into the possibility that BAT-40 is
highly unstable in the germline and that mutant alleles might be transmitted in




Figure 6.3 BAT-40 genotypes of blood DNA from HNPCC pedigree K-435. A single incidence
of transmissible germline hypermutability is highlighted. Mother MD-1303 has allele set 120/124










Figure 6.4 Germline hypermutability in pedigree K-435. ABI 310 profiles of BAT-40 genotypes
are shown. (B) MD-1303 is the mother of MD-449 and alleles of 120 and 124bp are
detectable. (C) There is no indication of the presence of either of MD-1303s alleles in MD-
449, who is homozygous for allele 112.(A) Although DNA was not available from the father
it is likely that he carried at least one 112 allele as inferred from siblings such as his sister,
MD-436. (D) The profile of MD-439, who is the twin sister of MD-449, also demonstrates
that there is not a problem in detecting the 124 allele in the presence of the 112 allele.
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6.3.3 Germline hypermutability at BAT-40 in CEPH family analysis
To further explore germline instability at BAT-40, BAT-40 alleles were analysed
in a CEPH family panel. Nine CEPH families were genotyped at the BAT-40 locus,
totalling 176 germline transmissions and 12 putative mutations (6.8%) were
identified (Table 6.2 and Figure 6.5). It should be noted that 11 BAT-40 alleles were
counted as non-mutated by inference, due to the failure of two DNA samples to
amplify.
Table 6.2 Putative BAT-40 mutations detected in germline transmissions of CEPH
families. Transmissions in which a germline mutation was indicated are described and the
genotype of the child along with both parents is presented. The inferred origin is highlighted
with an asterisk. In one case (a) the sample failed to amplify and genotype was inferred from
the relatives. The CEPH pedigree number, individual identification number and family
relationship are given in standard CEPH nomenclature.
Family Genotype (father) Genotype (mother) Genotype (child)
66 122/123 (f, -01) 124/127 (m, -02)* 123/126 (c/m, -03)
123/123 (fm, -12)* 124/127, (mm, -14) 124/127 (m, -02)
1331 123/123 (f, -01)* 119/123 (m, -02) 119/124 (c/m, -17)
1341 120/123 (f, -01)* 123/125 (m, -02)a 119/125 (c/f, -05)
120/123 (f, -01)* 123/125 (m, -02)a 119/125 (c/f, -08)
1346 123/123 (f, -01)* 122/127 (m, -02) 124/127 (c/f, -08)
123/123 (f, -01)* 122/127 (m, -02) 124/127 (c/f, -09)
1362 120/120 (fm, -15) 121/123 (mm, -16)* 120/120 (m, -02)
121/123 (f, -01)*
t
120/120 (m, -02) 120/120 (c/f, -04)
1377 120/124 (ff, -10) 120/122 (mf, -11)* 120/121 (f, -01)
120/121 (f, -01)* 119/122 (m, -02) 122/123 (c/m, -08)
13293 120/123 (f, -01)* 108/109 (M, -02) 109/124 (c/m, -09)
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However, in all cases, heterozygous parental alleles differed by only a few base
pairs and the mutations indicated involved small (lbp) changes (Table 6.2 and Figure
6.5). Figure 6.6 illustrates an example of one of the BAT-40 germline mutations
detected in family 1346.
Of the 88 maternal transmissions analysed, 3 were mutant at BAT-40 (3.4%) and
of the 88 paternal transmissions analysed 9 were mutant (10.2%). This difference
was not statistically significant (%2=3.22, p=0.073). Insertions and deletions
appeared to occur equally.
The mutations identified in CEPH families provided further support for the initial
observation that BAT-40 is hypermutable in the germline. The CEPH data adds
further weight to the identification of the germline mutation in family K-435 and also
to the evidence from the high levels of heterozygosity at BAT-40 in the Caucasian
population study, demonstrating high levels of heterozygosity at BAT-40. However,
although the CEPH mutations were reproducible, the small changes observed in the
complex BAT-40 profile (Figure 6.6), led to a further, rigorous method being devised
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Figure 6.5 Genotyping of the BAT-40 locus in 9 CEPH families. Individuals from CEPH
families; 66 (A), 1331 (B), 1341 (C), 1346 (D), 1362 (E), 1377 (F), 1423 (G), 13293 (H) and
13294 (I) were genotyped at the BAT-40 locus. Both allele sizes are indicated for each
individual in bp. Identifying CEPH numbers are shown in green or where a putative mutation























Figure 6.6 Representative example of a putative BAT-40 germline mutation in CEPH family
1346. (A) While the mother -02 has a BAT-40 genotype of 122/127, (B) the father -01 appears
homozygous for a 123bp allele. (C) The mothers 127bp allele is detected in child -09 but the
most prominent peak in the first complex is at 124bp. This would indicate a 1bp mutation at
BAT-40 had occured in the germline of the father. Sizing of the extreme stutter peaks also
indicates a 1bp mutation in the fathers 123bp allele in c-09 and confirms the presence of the
127 allele derived from m -02.
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6.3.4 SP-PCR analysis of sperm DNA demonstrates that BAT-40 is
inherently hypermutable in the germline
SP-PCR analysis of germline DNA has important advantages over family studies
for analysing germline stability at complex loci (Jeffreys et al., 1994; Kunst et al.,
1997). This method overcomes the practical constraints encountered during pedigree
analyses, which suffer limitations from the small number of mutants that can be
identified. In contrast, many hundreds of gametes can be analysed from a single
semen sample and consequently, greater variations in size that can be easily detected,
should be available for identification. In addition the dilution of the DNA sample
aids unambiguous identification of both smaller and larger size changes at a
hypermutatble locus (Jeffreys et al., 1994).
Mutation frequency as detected in sperm DNA has been shown to reflect
estimations from studies in pedigrees (Jeffreys et al., 1994). Comparisons of sperm
DNA and constitutional DNA templates has shown that SP-PCR reliably
discriminates alleles in both and that there are no demonstrable differences in
technical artefact between the two sample templates (Jeffreys et al., 1994). In
addition SP-PCR has been demonstrated to reliably detect differences in intra-allelic
mutation frequency in sperm DNA (Mornet et al., 1996; Kunst et al., 1997; Jeffreys
et al., 1994; Crawford et al., 2000).
For SP-PCR of sperm DNA, study subjects were selected on being
constitutionally heterozygous at the BAT-40 locus with individual wild type alleles
easily distinguished by size. MD-cl had allele sizes 120/124 and MD-949 had alleles
of size 121/124. Correct identification of constitutional allele sizes was confinned in
the SP-PCR analysis where individual alleles of the same predominant allele size
were detected (Figure 6.7). Approximately 100 SP-PCR products were analysed per
sample. BAT-40 allele sizes typed from constitutional and sperm DNA templates by
SP-PCR are shown in Figure 6.8. Mutant alleles were detected in sperm DNA by
comparison to constitutional genotype (Figure 6.7). The frequency of mutant alleles
detected in each sample is summarised in Table 6.3.
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Table 6.3 Summary of mutant alleles detected by SP-PCR in matched sperm and blood
DNA from samples MD-949 and MD-c1.
Sample Total no. alleles Mutants
(frequency)
MD-c1 Sperm 164 44 (0.27)
MD-c1 Blood 99 5 (0.05) (%2 =19.32 p <0.001)
MD-949 Sperm 91 20 (0.22)
MD-949 Blood 99 4 (0.04) (y2 =13.82, p < 0.001)
In both MD-cl and MD-949 matched samples, there was a significantly higher
number of mutant alleles detected in sperm DNA compared to that of matched blood
leukocyte DNA samples (x2 =19.32, p<0.001; y2 =13.82, p<0.001 for MD-cl and
MD-949 respectively). A total of 9/198 (4.5%) alleles in the leukocyte DNA were
mutant compared to a total of 64/255 (25.1%) mutant alleles in the sperm templates,
indicating an almost 6 fold increase in mutation accumulation in the germline. The
proportion of mutant alleles in blood and sperm was equivalent in MD-cl and MD-
949 samples suggesting that the constitutional heterozygous DNA mismatch repair
gene mutation of MD-949, does not influence mutation rate in the male gamete.
Although both addition and deletion mutations were identified, a bias was
observed towards repeat losses over gains in the sperm, (%2=11.0, p<0.001; %2 =10.3,
p<0.001 for MD-cl and MD-949 sperm samples). While possibly an artefact of the
technique, both insertion and deletion mutations were detected in the cell lines lbl-
1260 and lbl-1261. These cell lines were evaluated by an identical method to that
used here suggesting the technique can detect both larger and smaller mutants.
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Figure 6.7 Representative ABI310 traces of BAT-40 alleles detected by SP-PCR in matched
blood (A) and sperm (B) DNA. (A) Almost all BAT-40 SP-PCR products amplified from blood
DNA revealed individual alleles with predominant peaks of the same size as those in the
undiluted (UD) DNA. For MD-949 these were 121 and 124bp. (B) The majority of BAT-40 SP-
PCR products amplified from sperm DNA were also of wild type allele size as shown. However,
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Figure 6.8 BAT-40 allele sizes in matched constitutional and sperm DNA detected by SP-
PCR. The predominant allele sizes for each individual as detected from analysis of undiluted
DNA are indicated by an asterisk . MD-949 is a CRC patient and has germline mutation in
the human MLH1 gene. MD-c1 is a normal healthy control individual.
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6.4 Discussion
This chapter has addressed the hypothesis that BAT-40 is inherently unstable by
defining the germline stability of this paradigm poly(A/T) repeat locus.
By analysis of two cohorts it is shown that that BAT-40 is a highly polymorphic
locus with an observed level of heterozygosity of 59.7%. This is similar to a previous
analysis of a CEPH cohort, in which a level of heterozygosity of 72% was reported
(%2=3.22, p=0.073) (Zhou et al., 1997). However, the level of BAT-40
heterozygosity detected here and by Zhou et al is considerably higher than that
observed in a Japanese cohort (14.6%) (Yokozaki, 2000). Although this might in part
be explained by variation in allele heterozygosity between populations, the Japanese
study cohort was from hospital derived samples and may not be representative of the
true Japanese population frequencies (Yokozaki, 2000). The confirmation here that
BAT-40 is a highly polymorphic locus suggests that generation of new alleles by
slippage and mutation at this locus might be quite common.
Further to the data presented in Chapter 4, high levels of instability at BAT-40 are
also well-documented in MMR deficient tumours (Parsons et al., 1995b; Dietmaier et
al., 1997) suggesting that this marker might be particularly unstable. Identification of
a germline mutation at BAT-40 in a Scottish pedigree suggests this locus is also
highly unstable in the germline. Failure to amplify larger alleles as an explanation for
apparent germline mutations such as that in MD-449, is unlikely. Larger alleles were
reliably detected in the presence of the 112 allele in other family members in
pedigree K-435. The initial observation in a single family is supported by pedigree
analysis of a further nine CEPH families, albeit with less dramatic examples, biased
in part by the nature of the parental genotypes. Hence, individuals were chosen with
easily distinguishable allele sizes for analysis of sperm DNA. Analysis of matched
sperm and blood DNA at BAT-40 by a SP-PCR technique demonstrated a
statistically significant increase in the proportion of mutant alleles in sperm
compared to somatic DNA. This argues strongly that the mutations detected by SP-
PCR of sperm DNA are indeed authentic. In addition rigorous controls were
employed to ensure against contamination (see methodology). The SP-PCR approach
used in this study has been shown previously to detect mutant alleles with equal
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fidelity in sperm and constitutional DNA templates as demonstrated by direct
comparisons between mutation rates detected by SP-PCR of sperm compared to
family studies (Jeffreys et al., 1994). Previous studies using this technique have
consistently validated the SP-PCR approach (Jeffreys et al., 1994; Crawford et al.,
2000).
The presence of an inactivating MLH1 mutation in the germline of one of the
individuals did not appear to further influence the level of instability at BAT-40 in
the sperm DNA. Since the mutation in MD-949 is heterozygous, this indicates that
constitutive loss of MMR is necessary to reveal instability.
Intriguingly, shorter mutant alleles predominated in the sperm DNA despite the
fact that the SP-PCR technique reliably detected both large and short constitutional
alleles.
The results provide compelling evidence that BAT-40 is inherently unstable in the
germline. Hypermutability at the BAT-40 locus provides an explanation for the wide
spectrum of allelic variants present in the Scottish and CEPH populations studied,
since transmission of new germline variants can become established within the
population. The evidence that BAT-40 represents a poly(A/T) tract within the
genomic structure of a gene and exhibits instability in the germline, might be of
importance in understanding mechanisms generating mutations at other such
polymorphic repeat loci. Indeed this phenomenon may be common to many
poly(A/T) tracts and further study of such sequences is merited to elucidate whether
this is a widespread phenomenon. Poly(A/T) tracts are ubiquitous at the 3'UTR of all
coding genes where the stability in length of the poly(A) tail is of known functional
importance to the stability of the mRNA species (Bernstein and Ross, 1989). Of
further relevance, these repetitive tracts are common in intronic sequence (Toth et
al., 2000), and shortening of intronic mononucleotides has been shown to have
functional consequences. Aberrant splice variants of the ATM gene that result in
mutations responsible for ataxia-telangiectasia, are generated as a consequence of
shortened intronic mononucleotide tracts (Ejima et al., 2000). A similar phenomenon
occurs in the cystic fibrosis transmembrane conductance regulator (CFTR) gene (Chu
et al., 1993). The shortened poly(T)5 variant in intron 8 of the CFTR gene causes
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congenital bilateral absence of the vas deferens when associated with a cystic fibrosis
mutation on the other allele (Chillon et al., 1995). Mutation of poly(A/T) tracts
within exonic sequences, has also been shown to contribute to carcinogenesis. This is
exemplified by mutation of the TGFBR2 gene in MSI+ CRCs (Markowitz et al.,
1995; Parsons et al., 1995b; Lu et al., 1996). Hence it seems reasonable to speculate
that the mechanism of inherent instability elucidated here, might also have relevance
to a number of genes containing such repeats. Similar investigation at other unstable
and/or polymorphic loci would reveal the extent of this phenomenon.
BAT-40 is used routinely as a marker in determining tumour genomic stability in
relation to defective DNA mismatch repair due to its extreme sensitivity to mutation
in the absence of MMR activity (Lothe et al., 1993; Liu et al., 1995a; Rodriguez-
Bigas et al., 1997; Boland et al., 1998; Gryfe et al., 2000). Microsatellite markers
such as BAT-40 that display extreme germline hypermutability should be used with
caution, in view of the likelihood of mitotic instability. Very unstable markers may
be too sensitive to provide the specificity to MMR defects that is clearly required in
such screening strategies. The evidence reported here supports a growing number of
studies, which highlight the importance of understanding inherent characteristics
influencing marker stability when they are used in clinical programs (Boland et al.,




Susceptibility of TGBFB2 and BAX Coding Repeat Sequences
to Mutation in Non-Cancer Derived cells with MMR Defects
7.1 Introduction
In addition to mutations accumulating at non-coding microsatellite sequences,
MMR defects also and more crucially, result in an increased mutation frequency
within the repetitive tracts of coding sequence in MSI+ tumours (Ionov et al., 1993;
Strand et al., 1993; Thibodeau et al., 1993; Markowitz et al., 1995; Rampino et al.,
1997). A mutator phenotype combined with selective pressure is believed to allow
the acquisition of mutations in key genes leading to progression of neoplasia from
cellular clones to invasive cancers (Vogelstein et al., 1988; Fearon and Vogelstein,
1990; Loeb, 1994; Kinzler and Vogelstein, 1996; Loeb, 2001). However, the relative
importance of selection for growth advantage and genomic instability in
tumourigenesis is not clear (Tomlinson, 1999; Sieber et al., 2000; Loeb, 2001). There
is little conclusive evidence in favour of either somatic natural selection being the
primary force behind tumour growth, or genomic instability being necessary to
explain the number of mutations found in cancers (Huang et al., 1996; Sieber et al.,
2000; Loeb, 2001). A number of studies have suggested that MSI is an early event in
the progression of a normal cell towards a malignant phenotype (Aaltonen, 1994;
Shibata et al., 1994; Pedroni et al., 2001). However, the significance and
contribution of this event to the accumulation of frequently observed mutations in
MSI+ CRCs is unclear.
The repetitive tracts of the TGFBR2 and BAX genes are mutated frequently in
MMR deficient tumours (Parsons et al., 1995b; Markowitz et al., 1995; Lu et al.,
1996; Ouyang et al., 1998; Yamamoto et al., 1998; Abdel-Rahman et al., 1999;
Markowitz, 2000) and the occurrence of these mutations are believed to be
significant events in tumourigenesis (Alexandrow and Moses, 1995; Parsons et al.,
1995b; Rampino et al., 1997; Grady et al., 1999). However there are notable
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differences in the frequency with which these two genes are mutated in MSI+ CRCs.
While the poly(A)io repeat of TGFBR2 is mutated in around 90% of MSI+ CRCs,
mutations of the BAX poly(G)g repeat is consistently detected in around 50% of such
cases (Markowitz et al., 1995; Parsons et al., 1995b; Rampino et al., 1997; Ouyang
et al., 1998; Markowitz, 2000). In addition, the timing of these mutations during
tumour progression also appears to be different. Mutations in TGFBR2 are thought to
be an early event, whereas BAX mutations seem to occur later (Akiyama et al.,
1997a; Grady etal., 1998; Yagi etal., 1998; Abdel-Rahman et al., 1999).
It was hypothesised that differences in mutational frequencies at the TGFBR2 and
BAX genes may reflect differences in the relative contributions of inherent mutation
and the effects of selection at these loci. Therefore, in this chapter the intrinsic
instability of these genes was investigated using cell lines lbl-1260 and lbl-1261
described previously, since MMR is completely defective but the cells are not subject
to the potentially extreme mutational bias due to molecular changes and selection
pressures that characterise the malignant phenotype. Repeat regions were analysed
specifically within TGFBR2 and BAX for mutations and this study provides




7.2.1 Restriction digest assay to detect 1bp deletions in the poly(A)i0
tract of TGFBR2
A restriction digest assay was adapted from that published by Mironov et al.,
(1999), to provide an initial analysis to detect lbp mutations in the poly(A)io tract of
TGFBR2 and this is illustrated in Figure 7.1. The assay was carried out as described
in 2.5.5 on DNA from lbl-1261 and lbl-1260. DNA from wild type control cell lines,
lbl-c5, lbl-cl and mutant control cell lines, HCT116 and LoVo were also analysed.
These assays were carried out in triplicate. In addition, 16 MSI+ tumour DNA
samples and 81 constitutional DNA samples from patients with both MSI+ and MSS
CRC were analysed in validating the use of this assay and these are described in





















Figure 7.1 Restriction digest assay for the detection of 1bp deletions in the poly(A)-|Q tract
of the TGFBR2 gene. Adapted from Mironov et1999. (A) In the presence of the wild type
poly(A)-|o sequence, no HINF1 restriction site is introduced during the PCR step. (B) In the
presence of a 1 bp deletion the reverse primer introduces a HINF1 site during amplification.
For deletion mutants of 2bp or greater amplification would not occur due to increased mis-
priming. Restriction digest products are subsequently visualised using an ABI310 genetic
analyser. A fluorescent peak at 141 bp is detected if the template DNA was wild type (A) and
a peak at 118bp will be detected if the template DNA contained a 1bp deletion (B).
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7.2.2 Cloning and sequencing
A 266bp region of the TGFBR2 exon 3 (nt599 -30 to nt789 +46) encompassing
the poly(A)io tract present in the TGFBR2 coding region, (codons 125-128)
(Markowitz et al., 1995; Parsons et al., 1995b), was PCR cloned from lbl-1261 and
MMR proficient control lbl-c5 using primers TGFBR2F and TGFBR2R as described
in 2.4.1, 2.6.1 and 2.6.2. A 245bp non-repetitive region of TGFBR2 exon 4 was also
cloned from lbl-1261 DNA using TGFBex4F and TGFBex4R primers (2.4.1, 2.6.1
and 2.6.2).
Sequencing was performed as described in 2.7.1-2.7.4. All clones were sequenced
in duplicate and mutants were re-confirmed by re-isolating and sequencing clone
DNA from bacterial stocks. The frequency of false positives and false negatives was
either zero or very low for each cell line. Any clone containing a putative mutation
that could not be confirmed in duplicate was discarded from the analysis, similarly
for any wild type sequence that could not be confirmed in at least duplicate.
Sequence data was analysed as described in 2.7.5.
The number of alleles with poly(A)io mutations from each cell line was
established and the difference in mutation frequency between cell lines evaluated for
significance by a chi squared test as described in 2.10.1. Mutation frequency for
individual loci analysed in different cell lines was expressed as follows;
Mutation Frequency (mutations/kb) = Total number of mutations detected
Total sequence analysed/kb
To test the significance of differences in mutation frequency between different
loci or at the same loci in different cell lines, a Chi Squared test or a Fishers exact
test was employed as described in 2.10.1. When using this method it is assumed that
mutations occur independently at any given base pair within the given locus.
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7.2.3 SP-PCR and DHPLC analysis of BAX poly(G)s tract
SP-PCR was carried out on DNA from lbl-1261 and control cell line lbl-c5 using
unlabelled BAXF and BAXR primers as described in 2.4.1. These primers amplify a
94bp region encompassing the poly(G)s repeat at codons 38 to 41 of the BAX gene
(Rampino et al., 1997). ABB 10 analysis was not sensitive enough to convincingly
pick up a 1 bp deletion in a known mutant due to the small size of this fragment.
Therefore 3p.l of SP-PCR product was subjected to a second round of PCR, allowing
visualisation of products on an agarose gel as described in 2.4.6. These were
subsequently analysed by DHPLC using a Transgenomic Wave™ machine as
described in 2.5.2 and 2.5.3. A known mutant control (LoVo) was also analysed to
ensure mutation detection. Any SP-PCR product resulting in a mutant wave profile
was sequenced to confirm the presence of the mutation indicated. In each case, a SP-
PCR product with a wild type profile was also sequenced as a control to confirm
these were indeed wild type sequences.
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7.3 Results
The results presented in this chapter have been published in Bacon et al., 2001b.
7.3.1 Adaptation of a TGFBR2 restriction digest based assay to detect
1bp deletions in the poly(A)10 tract
To address whether the mutator phenotype results in instability within genes
known to be involved in colorectal carcinogenesis, the poly(A)io tract of the
TGFBR2 gene was analysed for mutations in lbl-1260 and lbl-1261. Initial analyses
demonstrated that the TGFBR2 repetitive tract was not amenable for SP-PCR
analysis, as had been previously employed to detect low level mutation at
microsatellite loci. This was due to technical difficulties that were highlighted by the
failure to detect mutations in a known mutant cell line, LoVo, by DHPLC or size
analysis using an ABB 10 genetic analyser. Therefore a sensitive restriction digest
assay was adapted to detect lbp deletions occurring at low frequency within the
poly(A)io tract of TGFBR2 (Figure 7.1) (Mironov et al., 1999). Deletions of lbp are
commonly observed at this repeat tract in MSI+ tumours and thus it was reasonable
to use an assay that would specifically detect these lesions (Parsons et al., 1995b
Markowitz et al., 1995).
This assay reliably detected the presence of mutant TGFBR2 alleles in two
positive control cell lines (LoVo and HCT116) (Figure 7.2). LoVo has been
described previously to have A9 and Ag alleles at TGFBR2 (Carethers and Pham,
2000). This assay revealed only a mutant peak after HINF1 digestion of TGFBR2
PCR products amplified from LoVo DNA (Figure 7.2B). Since the TGFBR2 assay
primers amplify alleles of A9 or longer, (Figure 7.1) only the A9 mutant allele in
LoVo would be amplified and subsequently digested. MMR deficient cancer cell line
HCT116 has been previously demonstrated to be homozygous for a lbp deletion at
the poly(A)io repeat of TGFBR2 (Carethers and Pham, 2000). As expected, a single
mutant peak corresponding to the homozygous deletion was detected by this assay
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(Figure 7.2C). Finally, a peak corresponding to wild type template was detected by
the assay, in wild type control cell lines lbl-cl and lbl-c5 (Figure 7.2A).
To further validate the use of this assay a panel of 16 MSI+ CRC DNAs, and a
panel of 81 blood DNAs taken from patients with both MSI+ and MSS colorectal
tumours were analysed (Tables 7.1 and 7.2 and Figure 7.2). Mutations were detected
in 15/16 (93.8%) of the DNA samples from the MSI+ tumours (Table 7.1). This
frequency is in line with that observed in previous studies using alternative analyses
(Markowitz et al., 1995; Markowitz, 2000). No mutations were detected in the
constitutional DNAs (Table 7.2), even those from patients (e.g. MD-1699), who had
colorectal tumours with identified TGFBR2 mutations. These preliminary studies
indicate the assay adapted for this study can reliably detect known lbp deletions and
that the frequency of mutations observed in a panel of un-analysed MSI+ tumours is
in line with previously published frequencies.
Table 7.1 Summary of TGFBR2 poly(A)10 restriction digest analysis on DNA from MSI+
CRCs. Tumour identifying numbers are shown. The assay indicated that tumours were either
wild type (wt) at this region or that all or nearly all of the cells from the tumour material were






















Table 7.2. Summary of TGFBR2 poly(A)10 restriction digest analysis of constitutional
DNA from patients with CRC. One healthy control individual was also analysed. Laboratory
identifying MD number is given. The MSI status of patients tumours was determined
previously by Dr. S. Farrington and is given as microsatellite stable (MSS), microsatellite
















106 wt MSS 1385 wt MSS
177 wt MSS 1407 wt ND
329 wt MSI-H 1442 wt MSS
432 wt MSS 1452 wt MSI-L
528 wt MSI-H 1459 wt MSS
559 wt MSI-H 1460 wt MSS
611 wt MSS 1462 wt ND
615 wt MSI-H 1464 wt ND
621 wt MSS 1465 wt ND
622 wt MSS 1509 wt ND
633 wt MSI-H 1513 wt MSI-L
649 wt MSS 1523 wt MSS
660 wt MSI-H 1583 wt MSS
682 wt MSS 1596 wt ND
696 wt MSI-H 1597 wt MSS
708 wt MSS 1603 wt MSI-H
737 wt MSS 1622 wt MSI-H
757 wt MSS 1628 wt MSS
763 wt MSI-H 1629 wt ND
789 wt MSS 1634 wt ND
809 wt MSS 1666 wt MSS
812 wt MSS 1667 wt ND
813 wt MSI-H 1678 wt MSI-L
814 wt MSI-H 1699 wt MSI-H
815 wt MSI-H 1703 wt MSI-H
825 wt MSI-H 1705 wt ND
869 wt MSI-H 1708 wt MSS
871 wt MSI-H 1716 wt MSS
889 wt MSI-H 1724 wt ND
906 wt MSS 1733 wt MSS
932 wt MSI-H 1804 wt ND
949 wt MSI-H 1819 wt MSI-L
968 wt MSI-H 1851 wt MSS
982 wt MSI-H 1938 wt ND
1020 wt ND 1942 wt ND
1052 wt MSI-H 1989 wt ND
1311 wt ND 2050 wt ND
1323 wt MSS 2052 wt ND
1338 wt MSS 2145 wt MSS
















Figure 7.2 Validation of TGFBR2 assay to detect 1bp deletions in the poly(A)-|Q repeat. ABI
310 traces show peaks corresponding to the presence or absence of mutant template DNA
as revealed by this assay. (A) Only the wild type peak is detected in control cell line Ibl-c1 after
HINF1 digestion. (B and C) LoVo and HCT116 are cancer cell lines with known 1 bp deletions
at the TGFBR2 poly(A)-|Q repeat (see text), and accordingly only mutant peaks of 118bp are
detected after HINF1 digestion. D) and E) represent two of the assays performed on constitutional
DNA from patients with CRC and show only wild type peaks. The colorectal tumour from
patient MD-1699 has been demonstrated previously to be MSI-H and tumour from patient MD-
1513 has been demonstrated to be MSI-L. F) and G) represent two of the assays carried out
on DNA derived from the tumour material of CRC patients with MSI+ tumours. Mutant peaks
indicate that these tumours have 1bp deletions of the poly(A)-|Q tract in TGFBR2. A residual
fraction of the digestion products were wild type and these likely represent contamination of
the tumour material with normal tissue. This would suggest that the tumour cells have homozygous
TGFBR2 mutations.
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7.3.2 Excess mutations arise in the poly(A)i0 tract of TGFBR2 in lbl-1261
The TGFBR2 assay was then utilised to analyse DNA from lbl-1260 and lbl-1261
to address whether the mutator phenotype is associated with an excess mutation
frequency in the poly(A)io tract of TGFBR2 (Figure 7.3). Appreciable levels of
mutant alleles were detected in DNA from lbl-1261 as indicated by the detection of a
mutant peak in addition to that corresponding to wild type DNA in the undiluted
sample (Figure 7.3A). The wild type peak was more prominent, suggesting that
mutant alleles were present at a lower frequency in the template DNA. Intriguingly
the frequency of mutant alleles indicated for lbl-1260 was not significantly different
to that of wild type control DNAs (Figure 7.3B).
This analysis reveals that lbp deletions of the poly(A)io tract of TGFBR2 arise in
cells derived from normal tissue but which are defective for MMR. Heterogeneity in
mutation frequency between the two MMR deficient cell lines with different MMR
mutations was also observed at microsatellite sequences in Chapter 4. Lbl-1261
displayed increased mutation frequency compared to lbl-1260 at the repeat markers
BAT-40 and D2S123. This phenomenon also seems apparent within coding
sequence, since the poly(A)io repeat in TGFBR2 in lbl-1261 demonstrates an
















Figure 7.3 Analysis of MMR deficient cell lines lbl-1260 and lbl-1261 for 1bp deletions within
the TGFBR2 poly(A)-|Q repeat. Representative assays of the poly(A)-jotract in exon 3 of the
TGFBR2 gene from wild type (Ibl-c5) (C) and mutant (LoVo) (D) control cell lines showing ABI
310 traces corresponding to the presence or absence of mutant template DNA. (B) The TGFBR2
assay was performed on lbl-1260 DNA revealing only a wild type peak. (A) A mutant peak is
clearly visible for lbl-1261.
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7.3.3 Mutational heterogeneity at the TGFBR2 poly(A)10 tract in lbl-1261
To further characterise mutations at the poly(A)io repeat detected in lbl-1261 by
the restriction digest assay described above, exon 3 of TGFBR2 was PCR cloned
from lbl-1261 DNA. This region was also cloned from wild type control cell line lbl-
c5. Individual alleles were then sequenced across the poly(A)io repeat (Figure 7.4,
Table 7.3).
Of 56 lbl-1261 clones sequenced, 17 (30.3%) were mutated at the poly(A)io tract.
In contrast only 3 (6.8%) of the 44 wild type control clones were mutant. Therefore
mutation at the poly(A)io region of TGFBR2 was significantly increased in lbl-1261
relative to a control cell line (% =8.5, p=0.003). Most of the exon 3 poly(A)io
mutations detected in lbl-1261 were lbp deletions (82%), supporting the validity of
the results from the digestion assay described above. However a small number of lbp
insertions plus an A—>G transition within the poly(A) tract were also identified
(Figure 7.4 and 7.5). The frequency and the spectrum of these mutations suggest they
are not constitutional variants but arose somatically. Unfortunately tissue was not
available from the colorectal tumours of patient lbl-1261 to establish whether these
also harboured mutations in the TGFBR2 poly(A)io tract. However, the high
frequency of TGFBR2 mutations observed in the analysis of the MSI+ tumours,
indicates that this is highly likely.
These data provide compelling evidence that de-novo mutations can arise
frequently due to inherent instability of the poly(A)io repeat in TGFBR2 but these are
normally repaired by a proficient DNA MMR apparatus.
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Table 7.3 Cloning analysis of the poly(A)10 repeat in TGFBR2. Individual alleles were
sequenced from 56 lbl-1261 and 44 Ibl-c5 clones. The frequency and nature of mutations
detected at this 10bp repeat from nt709 to nt718 of TGFBR2 are detailed. A mutation
frequency is given by dividing the total number of mutations detected by the total amount of
sequence analysed at the poly(A)10 locus.
Cell line
lbl-1261 Ibl-c5
Total sequence analysed/Kb 0.56 0.44
Mutations identified 14 x 1 bp deletion 2 x 1bp deletion
2 x 1bp insertion 1 x 2bp deletion
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Figure 7.4 Representative sequence chromatograms of the poly(A)-|Q repeat of TGFBR2 in
individual alleles cloned from lbl-1261 template DNA. Along with wild type sequences (D),


























Ibl-c5, n=46 lbl-1261, n=56
cell line
Figure 7.5 Summary of mutation frequency and spectrum at the poly(A)-|Q tract of TGFBR2,
in alleles cloned and sequenced from cell lines lbl-1261 and Ibl-c5. The greater propotion of
mutant alleles in lbl-1261 was statistically significant (p=0.003).
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7.3.4 Determination of the relative susceptibility of regions within
TGFBR2 to mutation
The relative susceptibility to mutation of regions within the TGFBR2 gene was
determined. In particular to address whether the mutator phenotype results in
predilection for mutation at the poly(A)io repeat sequence or whether the
observations were simply the result of non-specific increase in mutation rate. Mutant
allele counts arising at non-repeat regions of the TGFBR2 gene in lbl-1261 were
compared to those arising in the poly(A)io tract.
A 216bp region of exon 3 flanking the repetitive poly(A)io region and a 245bp
non-repeat region of exon 4 were screened for mutations by PCR cloning and
sequencing of individual alleles. Exon 4 contains a site found to be mutated in MSS
colorectal cancer (Lu et al., 1998) but the region lacks long repeats. No mutations
were identified in this region of exon 4 in a total of 7.840kb of sequence from 32 lbl-
1261 clones sequenced (Table 7.4). However, in the non-repetitive region of exon 3,
6 transition mutations were identified in a total of 10.928kb of sequence analysed
from 49 lbl-1261 clones, a frequency of 0.55 mutations/kb (Figures 7.6 and 7.7 and
Table 7.4). There were no mutations in the non-repetitive region of exon 3 in a total
of 8.897kb from 40 control (lbl-c5) clones (Figure 7.6 and Table 7.4).
These data indicate that exon 3 of the TGFBR2 gene appears prone to mutation,
compared with exon 4 of the same gene (p=0.045), and also compared to the same
region in a control cell line (p=0.036). Nonetheless, the proportion of mutations
detected in the non-repeat region of TGFBR2 is significantly lower than that for the
poly(A)io tract (p<0.001) (Tables 7.3 and 7.4).
Taken together, these results suggest that exon 3 of TGFBR2 is inherently mutable
and that predilection for instability at the poly(A)io tract contributes to the frequent
observation of TGFBR2 mutations in MSI+ tumours.
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Table 7.4 Cloning analysis of two non-repeat regions in TGFBR2. The non-repeat region
in exon 3 analysed for mutations, comprised a 216bp region excluding the (A)10 repeat, from
nt599 -10 to nt789 +26. The region analysed in exon 4 comprised a 245bp region from
nt1021 to nt1266. Mutation frequency is given by dividing the total number of mutations
detected, by the total amount of sequence analysed. Sequencing of individual alleles was
carried out on MMR deficient cell line lbl-1261 and also for exon 3, MMR proficient control
cell line Ibl-c5.
TGFBR2 exon 3 non-repeat
region
TGFBR2 exon 4
Cell lines lbl-1261 Ibl-c5 lbl-1261 Ibl-c5
Total sequence
analysed/Kb




















Figure 7.6 Mutational analysis of the TGFBR2 gene comparing non-repetitive coding sequence
to the poly(A)-|o tract- The non-repetitive sequence of exon 3 was analysed in lbl-1261 and
Ibl-c5. Lbl-1261 sequence data for a second 245 bp control non-repeat region of TGFBR2 is
also presented. Mutation data are represented as mutations per kb sequenced, to account for
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Figure 7.7 Representative mutations (M), identified in the flanking sequence around the
poly(A)io tract of TGFBR2 in alleles cloned from lbl-1261 DNA. In clone 33 (A) an a to g
transition was identified at nt 142. In clone 56 (B) an a to g transition was also identified at
position 167 and in clone 16 (C), a t to c transition was identified at position 209.
Clones 32 (A), 57 (B) and 20 (C) provide examples of alleles with wild type sequence, detected
at each region.
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7.3.5 Analysis of inherent instability at the BAX gene in MMR deficient
cells
Since cell line lbl-1261 was particularly unstable at TGFBR2 and non-transcribed
microsatellite repeats, it was analysed for evidence that the mutator phenotype is
associated with a high level of mutation in the poly(G)s repeat of the pro-apoptotic
gene BAX. Analysis was limited to lbl-1261 in view of the more extreme phenotype
at BAT-40, D2S123 and TGFBR2. SP-PCR was employed to genotype alleles using
LoVo as a positive control (Figure 7.8). Of 164 SP-PCR products only 2 mutants
(1.2%) were detected by DHPLC of the 94bp products (Figure 7.8D). Sequencing of
one of these mutant SP-PCR products confirmed a lbp insert at the poly(G)s tract
(Figure 7.8E). No mutations were detected in 106 SP-PCR products analysed from a
control cell line. These data suggest that mutations do occur at the repetitive poly(G)8
tract of the BAX gene, but the frequency is much lower than that arising in TGFBR2
and is below the level of reliable detection.
Table 7.5 Summary of SP-PCR analysis of the poly(G)8 repeat in the BAX gene. SP-PCR
products were analysed for mutations by DHPLC using a Transgenomic Wave™. Analysis
was carried out on MMR deficient cell line lbl-1261 and MMR proficient cell line Ibl-c5







Figure 7.8 Analysis of the poly(G)g tract of the BAXgene in lbl-1261 DNA by SP-PCR and DHPLC. (A)
DHPLC trace of the BAXpoly(G)g region amplified from undiluted lbl-1261 DNA shows single homoduplex
peak corresponding to wild type template. (B) DHPLC trace of this region amplified from cancer cell line
LoVo, displays an additional heteroduplex peak corresponding to the presence of a known mutation in this
cell line (see text). (C) This SP-PCR product, amplified from lbl-1261 DNA has only a wild type homoduplex
DHPLC peak However, the DHPLC trace of the SP-PCR in (D), shows a flattened peak indicative of the
presence of homoduplex and heteroduplex products corresponding to a mutant template. (E) Sequencing
of SP-PCR product shown in D) reveals the presence of a heteroduplex product containing an allele with a
1 bp insertion in the poly(G)g tract. The reverse sequence is shown.
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7.4 Discussion
The data presented in this chapter demonstrate a substantial level of inherent
instability at coding sequences, as a consequence of MMR deficiency in cell line lbl-
1261 that is derived from normal tissue. These studies have provided evidence that
inherent mutability in the TGFBR2 gene contributes to the observation of similar
mutations in MSI+ tumours. The instability shows a clear propensity to the same
poly(A)io tract that is frequently mutated in MSI+ tumours. The analysis of the
poly(G)8 tract of the BAX gene indicates that there are varying degrees of inherent
mutational instability within coding regions known to have a high frequency of
mutation in tumours, and suggests differential contributions from mutational
mechanisms and the effects of the cancer phenotype itself.
Two independent experimental approaches were employed using the MMR
deficient cell line, lbl-1261, to demonstrate that the poly(A)io tract of TGFBR2 is
intrinsically hypermutable. These data show that mutations can be detected as a
consequence of MMR deficiency when the effects of selection pressure and other
confounding molecular variables normally present in tumour cells are minimised.
These studies were performed in cell lines that represent a model assay system
and as such, selection cannot be entirely negated. There is evidence that EBV
transformed lymphoblast cell lines are resistant to the effects of TGFB1 due to
selection against TGFBR2 expression (Inman and Allday, 2000). However, this
effect is unlikely to bias the frequency of mutations at the poly(A)io tract for a
number of reasons, 1) Cells used in this study were not treated with TGFB1 and thus
were not under heavy selection as in the previous study by Inman et al (Inman and
Allday, 2000), 2) Reduced expression of TGFBR2 in EBV transformed cell lines has
been shown definitively not to be due to mutation of the poly(A)io repeat in exon 3
(Inman and Allday, 2000), 3) The fact that the reduced TGFBR2 expression
previously observed is due to a mechanism other than mutation, underscores the fact
that selection does not contribute appreciably to the accumulation of inactivating
mutations, 4) The comparison with EBV transformed control lines subject to the
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same conditions in culture, shows conclusively that there is an important MMR
dependent effect.
Since a number of different TGFBR2 mutant alleles were detected, the findings
are also consistent with the occurrence of somatic events rather than pre-existing
constitutional heterozygous mutations or mosaicism. One bp deletions were the most
common mutation which is in line with the pattern of mutations observed at this
locus in MSI+ tumours (Markowitz et al., 1995; Parsons et al., 1995b). Finally, the
TGRBR2 poly(A)io mutations identified in cells derived from normal tissue, are
unlikely to reflect contamination from primary tumour DNA circulating in the blood.
These cell lines were specifically tested for the presence of epithelial cells in the
FACS analysis presented in Chapter 3. None of the cells in lbl-1261 were found to
express an epithelial cell specific marker, indicating that this cell line is not
contaminated with micro-metastasising cells. Furthermore, despite the fact that
TGFBR2 mutations were detected in the tumours of MD-1699 and MD-528 (Table
7.1), no mutations were identified in the matched normal DNA from these
individuals (Table 7.2) during analysis of matched normal and tumour DNA from
other CRC patients (7.3.1).
The fact that mutations in sequences encoding tumour suppressor genes were
detected in cells derived from a normal B-cell lineage is remarkable in itself. That
lbl-1261 appears particularly prone to mutation may be due to specific influences
from MMR genes. Indeed, a recent report (Vilkki et al., 2001) did not detect any
TGFBR2 mutations in non-cancerous autopsy material in a child with homozygous
MLH1 mutations. Interestingly, cell line lbl-1260, which contains a heterozygous
MLH1 mutation, displays a lower incidence of mutation at both coding and non-
transcribed SSRs (Chapter 4). The fact that excess mutations were not observed at
the poly(A)io tract in lbl-1260 may indicate a threshold effect of MMR activity in the
cell lines studied here, which has an influence on the ability for replication errors to
be repaired. Levels of MMR activity on a biochemical level in these cell lines has
been previously investigated with no discernible difference in repair activity of
nuclear extracts from lbl-1261 and lbl-1260 (Parsons et al., 1995a). However the
frequency of mutations measured at microsatellite loci was significantly elevated in
lbl-1261 compared to lbl-1260 observed both in this study (Chapter 4) and
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previously (Parsons et al., 1995a). This may reflect subtle differences in repair
capabilities in these two cell lines resulting from the different germline MMR
mutations that they harbour. A model implying that the threshold of repair activity
directly influences the spectrum of mutations observed has been recently proposed
(Cahill et al., 1999). Further analysis of low level MMR activity in these MMR
deficient cell lines would be merited to address if this hypothesis can account for the
mutational differences between lbl-1261 and lbl-1260 at the TGFBR2 gene.
Mutations revealed by cloning analysis in a control cell line may indicate a
background error rate or may be genuine mutations occurring at a level undetectable
by the restriction digest analysis. Indeed there is little investigation into low-level
mutation frequencies in cancer causing genes in either normal tissue or in control cell
lines. However, both analyses demonstrate a statistically significant excess of
mutations in lbl-1261 compared to a control cell line.
Few studies address the mutation frequency at the non-repetitive sequences
surrounding the mutable repeat tracts in genes implicated in tumourigenesis of MSI+
tumours (Takenoshita et al., 1997). In this chapter it has been specifically
demonstrated that non-repeat regions of TGFBR2 are subject to levels of instability
that are statistically significantly lower than at the poly(A)io repeat. These data
suggest that it is the repeat sequence and not the entire TGFBR2 gene, which is prone
to instability consequent of MMR deficiency.
Analysis of the poly(G)8 repeat region in the BAX gene, suggests that although
this is mutated frequently in MMR deficient tumours, it does not share the same
propensity for mutation observed at the poly(A)io repeat of TGFBR2. These results
give considerable insight into susceptibility of the BAX and TGFBR2 genes to
mutations rising exclusively as a result of MMR defects. The high mutability of the
poly(A)io tract in TGFBR2 is likely to be a consequence of increased replication
error at this region. Such error is well documented and is dependent on the number of
repeats in the tract (Parsons et al., 1995a; Dietmaier et al., 1997; Sturzeneker et al.,
2000). Chromatin structure within or surrounding such repetitive tracts has also been
suggested to contribute to mutability (Zhang et al., 2001). In this regard it is
interesting to note that a low frequency of mutation was observed in the flanking
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sequence surrounding the poly(A)io tract in lbl-1261, that was significantly greater
than that observed for a region of exon 4 of the same gene possibly indicating that
chromatin structure may play a role in the mutability of the poly(A)io tract.
That the TGFBR2 poly(A)io repeat is so readily prone to mutation in the absence
of MMR goes some way to explain why these mutations are observed with such a
consistently high frequency within MMR deficient tumours (Markowitz et al., 1995;
Markowitz, 2000) and also in early adenomas (Grady et al., 1998; Abdel-Rahman et
al., 1999). Taken together with previous studies, the data presented here supports the
notion that MMR inactivation occurs very early in neoplastic transformation and
results in accumulation of mutations in the TGFBR2 poly(A)io tract. Subsequently,
selection pressure for homozygous mutations would be anticipated to result in clonal
selection within the tumour.
Since only a very low level of BAX mutations were detected in the most unstable
cell line, lbl-1261, this suggests that BAX is inherently more stable and that selection
pressure may play a greater role in generating poly(G)8 mutations, than is the case for
TGFBR2 mutations. The data presented here suggests that BAX mutations arise
infrequently and this may explain why they are less frequently observed, and are not
detectable at such an early stage in tumourigenesis as TGFBR2 mutations (Rampino
et al., 1997; Yagi et al., 1998; Abdel-Rahman et al., 1999)
These findings indicate that intrinsic mutational instability is an important
determinant of mutation frequency observed in MSI+ tumours. Use of cells derived
from normal tissue has allowed analysis of the mutation frequency consequent upon
MMR deficiency, while minimising bias from the effects of selection and
confounding abnormalities. It will be of interest to further these studies and
determine which other coding gene sequences are similarly susceptible to mutation in
cell lines lbl-1260 and lbl-1261 as this might identify important genes involved in
MMR dependent tumour initiation and progression.
197
Chapter 8
Analysis of the Susceptibility of (3-catenin/TCF Pathway
Genes to Mutation in MMR Deficient Cells Derived from
Normal Tissue
8.1 Introduction
With the exception of TGFBR2 and BAX, there is conflicting evidence on the
repertoire of genes that when altered, contribute directly to the oncogenic properties
of MSI+ tumours. In addition, it is not clear whether such alterations arise as a
consequence of genomic instability or selection.
Abrogation of the p-catenin/TCF signalling pathway is an important step in the
development of the majority of CRCs (Miyoshi et al., 1992; Powell et al., 1992). In
particular, the gatekeeping role of the APC gene in CRC is well established (Kinzler
and Vogelstein, 1996; Fearnhead et al., 2001). However, there are conflicting data on
the contribution ofAPC mutations to the initiation and progression of MSI+ tumours
as discussed in Chapter 1. Whether APC mutations are associated with MMR defects
has not been definitively established (Heinen et al., 1995; Huang et al., 1996;
Konishi et al., 1996; Olschwang et al., 1997; Homfray et al., 1998). Where a high
frequency of APC mutations have been reported in MSI+ tumours, it is unclear as to
whether they arose prior to the loss of MMR or as a consequence of such defects
(Huang et al., 1996; Homffay et al., 1998). The conflicting data provide little
resolution of the selection vs mutation debate (Huang et al., 1996; Homfray et al.,
1998; Tomlinson and Bodmer, 1999; Loeb, 2001).
Activating mutations in the regulatory domain of P-catenin, have also been
observed in some MSS colorectal tumours that are wild type for APC (Morin et al.,
1997; Iwao et al., 1998; Sparks et al., 1998). However, it is unclear as to how
frequently CTNNB1 mutations substitute for APC mutations in MSI+ CRCs (Sparks
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et al., 1998; Mirabelli-Primdahl et al., 1999; Miyaki et al., 1999; Salahshor et al.,
1999). Again these contradictory observations make it difficult to conclude whether
or not mutational abrogation of the (3-catenin/TCF pathway is an important event in
MSI+ CRCs, albeit via alternative mechanisms to those in MSS cancers (Huang et al.,
1996).
In light of the conflict in the available data, the research presented in this chapter
set out to investigate the effect of defective MMR on the (3-catenin/TCF pathway. In
particular the work addresses whether mutations in (3-catenin/TCF pathway genes
can arise as a consequence of defects in MMR in the absence of selection pressure.
Differences in inherent susceptibility to mutation of (3-catenin/TCF pathway genes
may contribute to the frequency with which they are mutated in MSI+ tumours.
Therefore regions of CTNNB1 and APC were analysed for mutations, in cell lines
lbl-1260 and lbl-1261. It has already been demonstrated in previous chapters that
since these cell lines have defects in MMR but are derived from non-cancerous
tissue, the inherent instability of particular gene sequences can be effectively
revealed.
The inherent stability of exon 3 of the CTNNB1 was analysed since it
encompasses the regulatory phosphorylation sites that are mutated in some MSI+
CRCs, which lack APC mutations. For example, mutations at codons 32, 33, 34, 37,
41, 43, and 45 that are located within exon 3 have been previously reported (Miyaki,
et al., 1999; Mirabelli-Primdahl et al., 1999; Akiyama et al., 2000). Three regions of
the APC gene were also analysed (Figure 8.1). The poly(GT)4 repeat in exon 10 was
specifically analysed since it has been previously demonstrated to show mutational
mosaicism in the parent of an FAP patient (Farrington and Dunlop, 1999). The
mosaicism at this repeat region was speculated to have arisen due to genetic
instability (Farrington and Dunlop, 1999). In addition, two regions of exon 15 were
also examined. These were B1-D2 of exon 15 that spans codons 736 to 1054 and
region G1-I2 of exon 15 that spans codons 1256 to 1641. Mutations in both these
regions have been identified previously in MSI+ tumours. In particular, mutations
have been detected at SSRs within these loci and these represent potential sites of
mutation in the presence of MMR defects (Huang et al., 1996). Such repetitive sites
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include a poly(A)4 at nt2822-5, a poly(A)5 at nt2540-4, an (A)5T(A)3 at nt4363-71
and a poly(A)6 at nt4664-9. Furthermore, region G1-I2 encompasses the previously
reported mutation cluster region located at codons 1286-1513 (Miyoshi et al., 1992).
By utilising lbl-1261 and lbl-1260 to study these coding sequence loci for
susceptibility to mutation, the approach comprises an alternative to previous studies
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8.2 Methodological Overview
8.2.1 PCR of CTNNB1 and APC fragments
A 251 bp region from ntl4-12 to nt241+12 that encompasses exon 3, was
amplified from the CTNNB1 gene using primers CTNNBlex3F and CTNNBlex3R
(2.4.1) and lOOng of cell line DNA template as described in 2.4.2. A 955bp region of
exon 15 of the APC gene (B1-D2) from nt2206 to nt3161, was amplified using
primers APCexl5Bl and APCexl5D2 (2.4.1) and lOOng template DNA as described
in 2.4.2. A 1156bp region of exon 15 of the APC gene (G1-I2) from nt3767 to
nt4923 was also amplified using primers APCexl5Gl and APCexl5I2 (2.4.1) as
described in 2.4.2.
The Expand High Fidelity PCR system was used in all amplifications to allow the
most faithful replication of DNA templates.
8.2.2 Cloning of individual CTNNB1 and APC alleles
Individual alleles were cloned from PCR products described in 8.2.1 into TA
cloning vectors as described in 2.6.1. All clones were checked for the presence of an
insert of appropriate size by direct PCR analysis from each bacterial colony using
M13F and M13R primers as described in 2.4.2. Bacteria were grown and plasmid
DNA harvested as described in 2.6.2 and 2.2.4.
8.2.3 Sequencing of cloned alleles
Individual alleles were sequenced from plasmid DNA as described in 2.7. Each
insert was sequenced using M13F and M13R vector specific primers (2.4.1).
Sequence data was then analysed as described in 2.7.5. For APC exon 15 region Bl-
D2, nt2229-3139 was specifically analysed for mutations and for APC exon 15
region G1-I2, nt3791-4905 was specifically analysed for mutations.
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8.2.4 Estimation of PCR error
Observation of statistically significant differences in mutation frequency at a
given locus between alternative cell lines strongly suggests that PCR error does not
significantly bias the results obtained. In addition, observations of statistically
significant differences between the same cell lines at alternative loci are difficult to
reconcile with PCR error. However, to definitively rule out introduction of error
from Taq polymerase as a valid explanation of the results, the expected number of
PCR errors was specifically estimated. The number of polymerase errors expected
within the total amount of sequence analysed (nt) for alleles cloned from a given cell
line was calculated from the error rate of the Expand Taq polymerase, according to
the information provided with the Expand High Fidelity PCR system (Boheringer
Mannheim) (Table 8.1).
Table 8.1 Expected errors from Expand Taq polymerase. (Boheringer Mannheim)
Expand Taq Polymerase has an error rate of 8.5 x 10"6. The number of PCR fragments with
errors is expressed in % and depends on fragment length and cycle numbers. * Amplifying
up to 3kb, the effective cycle number is around 60% of the machine cycies, e.g.: 30-
programmed cycles correspond to 18 effective cycles. Table adapted from Table 1 of the
Expand product information sheet (Boheringer Mannheim).
PCR Fragment
size [kb]
PCR fragments with errors [%]
0.2
1.0




In all PCR reactions for which the number of errors was calculated, amplification
was for 35 machine cycles (21 effective cycles).
The effective number of fragments analysed for each sample was calculated
according to;
Total amount of sequence analysed per sample = Effective number of fragments
Individual fragment length
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The expected number of errors per sample was then calculated from the
percentage of fragments with an error as calculated using the table above. Malcolm
Sheppard, Technology Support Supervisor at Roche Diagnostics, verified these
calculations.
8.2.5 SP-PCR of APC exon 10
The PCR fragment encompassing the poly(GT)4 repeat in exon 10 of APC was
amenable to SP-PCR/Transgenomic Wave™ analysis and thus a 210bp region from
ntl313 -59 to ntl408 +55 encompassing exon 10 of the APC gene was amplified
using the SP-PCR technique described in 2.4.4 and 2.4.5. Primers APCexlOF and
APCexlOR were used for amplification as detailed in 2.4.1.
8.2.6 DHPLC of APC exon 10 using a Transgenomic Wave™
Analysis of APC exon 10 SP-PCR products was carried out by DHPLC using a
Transgenomic Wave™ as described in 2.5.2 using the APC exon 10 melting gradient
(2.5.3)
8.2.7 Statistical analysis
Relative mutation frequency was calculated at each locus for each sample
analysed. The total number of mutations observed was divided by the total amount of
high quality sequence analysed in kilobases to give a mutation ffequency/kb.
Sequencing with forward and reverse, vector specific primers gave high quality
sequence across all the CTNNB1 alleles included in this analysis. For inserts cloned
from the two APC exon 15 regions partial read-through of alleles occurred in some
instances since the inserts were longer. As this was observed to be a stochastic event
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with no apparent bias for alleles from any one sample, all good quality sequence data
was included for analysis.
It was assumed that a mutation might be equally likely to occur at any individual
base pair by chance. Differences in the number of nucleotides mutated out of the
total nucleotides analysed at any given locus from different DNA templates were
then evaluated for significance using a Chi-Squared analysis as described in 2.10.1.
Where observed counts were less than 5, a Fishers Exact test was employed as
described in 2.10.1
Chi-Squared or Fishers Exact tests were also employed appropriately (2.10.1) to
test whether the number of mutations observed in any given sample, differed
significantly to that expected from PCR error.
Significant differences in any given mutation occurring out of the total number of
mutations detected between different samples was evaluated by a Chi-Squared test
(2.10.1) or again, a Fishers Exact test if expected counts were less than 5.0.
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8.3 Results
8.3.1 MMR defects are not associated with excess mutations in the
regulatory domain of the CTNNB1 gene
Mutations arise at phosphorylation sites within exon 3 of the CTNNB1 gene in
CRCs that do not have APC mutations (Sparks et al., 1998; Morin et al., 1997;
Mirabelli-Primdahl et al., 1999; Miyaki et al., 1999). To address whether such
mutations can arise exclusively as a result of MMR defects without the selection bias
that occurs during tumourigenesis, the level of spontaneous mitotic mutations was
assessed in exon 3, in MMR defective cell line lbl-1261, which is derived from
normal tissue. Lbl-1261 was the focus of this analysis because of the high level of
instability demonstrated at both non-coding and coding SSRs in experiments
presented in previous chapters.
The cloning strategy used in the previous analysis of the TGFBR2 gene (Chapter
7), effectively detected both frameshift and mis-sense changes. Therefore, a similar
cloning strategy was employed to assess the mutational status of CTNNB1 in
individual alleles. A 251bp region encompassing exon 3 of CTNNB1 was PCR
cloned from lbl-1261 and from MMR proficient lymphoblastoid cell line lbl-a.
Sequencing of 89 alleles (22,339 bp) from lbl-1261 template DNA revealed 2
mutations in exon 3, a mutation frequency of 0.090 mutations/kb (Table 8.2). Both
mutations identified were T—>C transitions but did not occur on the serine/threonine
phosphorylation sites previously reported as being hotspots for mutation in colorectal
tumours (Table 8.3) (Kitaeva et al., 1997; Sparks et al., 1998; Mirabelli-Primdahl et
al., 1999; Miyaki et al., 1999; Akiyama et al., 2000). Sequencing of 74 alleles
(18,574bp) cloned from lbl-a template DNA, also revealed two transition mutations,
a mutation frequency of 0.108 mutations/kb (Table 8.2). Again these did not occur at
previously described mutational hotspots (Table 8.3). Hence, within the levels of
detectability there was no apparent difference in the frequency of mutations in
CTNNB1 alleles from lbl-1261 and the MMR proficient control cell line lbl-a
(p>0.99). The data here indicate, that a high level of inherent mutations that are
206
usually repaired by MMR, do not arise within the regulatory domain of CTNNB1.
These data strongly suggest that when selection pressure and other molecular
variabilities consequent of tumourigenesis are minimised, exon 3 of CTNNB1 is not
particularly prone to mutation even when MMR is defective.
Table 8.2 Mutational analysis of CTNNB~\ exon 3 alleles cloned from MMR deficient (Ibl-
1261) and MMR proficient (Ibl-a) cell lines. There is no significant difference in the frequency
of mutation between the two cell lines.
Cell line No. Full length Missing Total Number of Mutation freq
clones clones seq/kb Seq/kb Mutations (Mutations/kb)
lbl-1261 89 89 0 22.339 2 0.090
Ibl-a 74 74 0 18.547 2 0.108
Table 8.3 CTNNB1 mutations identified in individual alleles cloned from Ibl-a and MMR
lbl-1261.
Cell line Clone ID CTNNB1 change nt Codon Target
Sequence
lbl-1261 1 T-C 88 30 TpA
91 T-C 141 47 TpG
Ibl-a 7 C-T 90 30 CpC
36 A-G 107 51 ApA
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8.3.2 Analysis of APC exon 10 for inherent instability consequent of
MMR defects
The poly(GT)4 tract of APC exon 10 has been shown previously to exhibit
somatic mutational mosaicism in the unaffected parent of an FAP patient and thus it
was reasoned that this locus may be inherently unstable (Farrington and Dunlop,
1999). The mutational status of a 207bp region encompassing all 96bp of exon 10 of
the APC gene was analysed by SP-PCR followed by DHPLC using a Transgenomic
Wave™, from lbl-1261 and control (lbl-c5) template DNA. No mutations were
identified from the (GTfr repeat in APC exon 10 in 115 SP-PCRs amplified from
MMR deficient cell line lbl-1261, although a single transition mutation was
identified in the 5' intronic region in one reaction (Figure 8.2). After analysis of 26
SP-PCR products from MMR proficient cell line lbl-c5 template, no mutations were
identified and further assessment was abandoned.
There is no evidence from this data to suggest that the (GT)4 repeat of exon 10 of




Figure 8.2 Mutational analysis of exon 10 of the APC gene by SP-PCR and DHPLC. (A) Exon
10 amplified from undiluted lbl-1261 DNA shows a single homoduplex peak when analysed
using a Transgenomic WaveTm. (B) The same region amplified from an FAP patient with a
known mutation in the (GT)4 repeat in exon 10 displays an additional heteroduplex peak. (C)
Wild type SP-PCR products also show a single homoduplex peak. (D) One SP-PCR product
was identified as having an additional heteroduplex peak corresponding to the presence of a
mutant allele. (E) The mutant SP-PCR product was identified as having an intronic, T to C
transition at nt1331 -23 in one allele, by sequencing. The reverse sequence is shown.
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8.3.3 Analysis of inherent instability in exon 15 of the APC gene in MMR
deficient and MMR proficient lymphoblastoid cell lines
In order to further address whether the APC gene is inherently unstable and to
gain insight as to whether mutations arise in APC that are usually repaired by MMR
defects, two further regions of the APC gene were analysed. Region B1-D2 of exon
15 spans codons 736 to 1054 and region G1-I2 of exon 15 spans codons 1256 to
1641 and these regions are illustrated in Figure 8.1.
Individual alleles from regions B1-D2 and G1-I2 were cloned from MMR
deficient cell lines (lbl-1261 and lbl-1260) that are derived from normal tissue and
from control MMR proficient lymphoblastoid cell lines (lbl-c5, lbl-a). Due to the
amount of sequencing involved in these experiments, analysis of the second region
G1-I2 was focused towards the highly unstable MMR deficient cell line, lbl-1261
and a MMR proficient control cell line (lbl-a). Individual alleles were sequenced and
analysed for mutations from nt2229-nt3139 (B1-D2) and nt3791-nt4905 (G1-I2). A
total of 80,014 bp of sequence was analysed from 92 alleles at region, B1-D2, cloned
from lbl-1261 template DNA. 13 mutations were identified, a mutation frequency of
0.16 mutations/kb. (Table 8.4). A similar frequency of mutation was observed at the
second region, spanning the mutation cluster region of the APC gene. Eleven
mutations were identified in 85 G1-I2 alleles (85,090 bp) cloned from lbl-1261 DNA
(Table 8.4), a mutation frequency of 0.13 mutations/kb. There is no significant
difference in the level of mutation between the two regions of exon 15 analysed from
lbl-1261 DNA (%2=0.313; p=0.576). Furthermore, this level of mutation was not
significantly different from that observed in the analysis of exon 3 of the CTNNB1
gene (p=0.542), indicating that these two regions of APC are also not particularly
prone to mutation when MMR is defective.
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Table 8.4 Analysis of individual alleles cloned and sequenced from two regions of exon
15 of the APC gene, from lbl-1261, lbl-1260, Ibl-c5 and Ibl-a. B1-D2 = 910bp and G1-I2
=114bp.
Region Cell line No. Full Missing Total No. Mutation
clones length seq./kb seq./ mutations freq.
clones kb (mutations
/kb)
B1-D2 lbl-1261 92 77 3.706 80.014 13 0.16
lbl-1260 98 59 11.599 77.581 54 0.69
Ibl-a 71 63 2.451 62.159 39 0.63
Ibl-c5 48 40 2.028 41.652 24 0.58
G1-I2 lbl-1261 85 65 9.600 85.090 11 0.13
Ibl-a 38 23 8.210 34.122 20 0.59
In contrast to the lack of instability in lbl-1261 at the two regions ofAPC exon 15
that were analysed, a significantly higher level of mutational instability was observed
in two control lymphoblastoid cell lines (lbl-a and lbl-c5) (Figure 8.3 and Table 8.4).
A total of 62,159 bp of sequence from region B1-D2 of the APC gene was analysed
from 71 alleles cloned from lbl-a DNA. A total of 39 mutations were detected, a
mutation frequency of 0.63 mutations/kb (Table 8.4). Examples of the mutations are
illustrated in Figure 8.4. At the second region G1-I2, 20 mutations were detected in
34,122bp of sequence analysed from 38 alleles cloned from lbl-a DNA, (0.59
mutations/kb). There was no significant difference in the level of mutation at these
two regions in lbl-a (%2=0.061; p=0.804). A second control cell line (lbl-c5) was also
analysed at B1-D2 and the frequency of mutations did not differ significantly from
that observed for lbl-a (%2=0.108; p=0.743) (Figure 8.3 and Table 8.4). These results
are striking since they indicate that the MMR proficient cell lines, lbl-c5 and lbl-a,
display a level of mutation that is significantly higher than that of MMR deficient
cell line lbl-1261, at two regions of the^PC gene (x2=21.59, p<0.001 at B1-D2 and
X2=19.55; p<0.001 at G1-I2) (Figure 8.3).
Differences in mutation frequency between lbl-1260 and lbl-1261 at non-coding
and coding repeat sequences have been demonstrated in experiments presented in
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previous chapters. Therefore, it was not surprising that a significant difference in the
frequency of mutation between lbl-1260 and lbl-1261 at region B1-D2 of the APC
gene was also revealed, albeit with lbl-1260 displaying a higher frequency of
mutation. 54 mutations were detected in 98 alleles (77,58lbp) sequenced, a mutation
frequency of 0.69 mutations/kb (Table 8.5). This level of mutation is not
significantly different to observations in control lymphoblast cell lines (%2=0.55,
p=0.459) but is significantly increased compared to MMR deficient cell line lbl-1261
(p<0.001) (Figure 8.3).
The data presented from this extensive analysis of low level stability at two
regions of the APC gene in MMR proficient and MMR deficient lymphoblastoid cell
lines suggests three major points. Firstly, in cell line lbl-1261 there is no evidence to
indicate that mutations usually repaired by MMR accumulate within the APC gene.
The frequency of mutations detected in lbl-1261 does not differ significantly to the
level detected in either exon 4 of the TGFBR2 gene (p=0.297) analysed in Chapter 7
or in exon 3 of the CTNNB1 gene (p=0.542). These regions were also concluded not
to be particularly susceptible to mutation when MMR is defective.
Secondly, a statistically significant, four-fold difference in mutation frequency
was detected in control, MMR proficient cell lines, lbl-a and lbl-c5 compared to
MMR deficient cell line lbl-1261. This increased level of mutation in control
lymphoblastoid cell lines is also significantly different to that observed in these cell
lines in exon 3 of the CTNNB1 gene (p=0.002) and also in the non-repeat region of
exon 3 of TGFBR2 (p=0.004). The increased mutation frequency detected at two
regions of the APC gene in lbl-c5 and lbl-a cannot be accounted for by Taq
polymerase error in the PCR step during the allele cloning protocol (Table 8.5).
Twenty-nine of the mutations in the control cell lines were sequenced in duplicate
and all mutations were confirmed. Approximately half of each allele was also
sequenced in duplicate and no instances of discrepancy (false positives or false
negatives) were observed, indicating that sequencing error was not a significant
factor. In any case, the statistically significant difference in mutation frequency
between the control cell lines and lbl-1261 at these regions and also between the
APC gene and coding sequence in alternative genes in MMR proficient cell lines,
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argues that biological difference rather than artefactual error contributed to these
observations.
Finally, a statistically significant difference in the frequency of mutation at the
APC gene between lbl-1260 and lbl-1261 is revealed in this analysis. This
observation furthers the notion that there is a dosage dependent effect from the MMR
defects that these cell lines harbour, on the frequency of mutations detected at
alternative loci. Differences in underlying levels of instability in these cell lines, as
evidenced at non-coding microsatellites (Chapter 4), may be important in modulating
the frequency of mutation accumulation at many loci including the APC gene.
However, it is intriguing that at the APC gene, mutation frequency is higher in lbl-
1260 (and MMR proficient control cell lines) than in lbl-1261 in contrast to the
higher instability detected in lbl-1261 at other loci studied.
Table 8.5 Expected number of errors attributable to Taq polymerase, in alleles
sequenced and cloned from two regions of APC exon 15 from lbl-1261, lbl-1260, Ibl-c5 and
Ibl-a. Frequency of mutations observed in individual alleles cloned from APC gene regions
(observed errors) are compared to the frequency expected due to Taq polymerase error in
the PCR step (expected errors).
Cell line Expected Observed Significance
APC errors errors
Region
B1-D2 lbl-1261 6.7 13 *2=1.8, p=0.18
lbl-1260 6.5 54 *2=36.23 p<0.001
Ibl-a 5.2 39 *2=26.3 p<0.001
Ibl-c5 3.5 24 *2=14.21 p<0.001
G1-I2 lbl-1261 7.1 11 *2=0.89 p=0.346
Ibl-a 2.9 20 *2=12.56 p<0.001
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Figure 8.3 Relative mutation frequency detected in individual alleles cloned from lbl-1261, Ibl-
1260, Ibl-c5 and Ibl-a at two regions of the APC gene. (A) Mutation frequency over 910bp
encompassed by region B1-D2 of APC. (B) Mutation frequency over 1114bp encompased by
region G1-I2. At both regions the level of mutation is significantly elevated in MMR proficient
cell lines, Ibl-c5 and Ibl-a compared to MMR deficient cell line, lbl-1261 (p<0.001).
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Figure 8.4 Representative mutations (m) in two alleles cloned from Ibl-c5 template DNA at
APC exon 15, region B1-D2. (A) An A to G transition was identified at nt2647 in clone 41. The
top panel shows the wild type sequence at this site. The subsequent panels show the mutation
revealed in both the forward and reverse sequence. (B) A transition of G to A was identified
at nt2657 in clone 5. Again the top panel illustrates the wild type sequence at this site. Subsequent
panels show that the mutation was confirmed in both directions.
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8.3.4 Mutational spectrum at the APC gene in MMR proficient and MMR
deficient lymphoblast cell lines
It was hypothesised that if the differences in mutation levels observed between
lbl-1261 and MMR proficient cell lines were a result of different mechanisms of
mutation, then the spectrum of mutations may also show significant differences. A
propensity of ffameshift mutations in lbl-1261 may be indicative that they arose as a
consequence of MMR defects. Additionally if the inherent instability observed in the
MMR proficient cell lines and lbl-1260 were due to similar factors, then the
spectrum ofmutations may also be expected to show similarities.
A detailed and extensive comparison of the nature and location of all 162 APC
mutations in the lymphoblastoid cell lines analysed, is presented in Appendix A and
Figure 8.5. Forward and reverse sequencing overlapped 41 of the mutations,
confirming their presence in both directions. No false positives or false negatives
were identified in any of the sequencing.
Huang et al previously reported differences in the mutational spectrum at the APC
gene between MSI+ and MSS tumours (Huang et al., 1996). In contrast to the study
by Huang et al there was no observable propensity for ffameshift mutations within
either of the two MMR deficient cell lines and no observable tendency for mutations
to occur within simple repeated sequences in any of the cell lines analysed
(Appendix A and Figure 8.5). Except for a single transversion mutation in cell lines
lbl-1261 and lbl-a, all the identified mutations were transitions. However, Huang et
al also reported a predominance of C—>T changes in transition mutations in MSI+
tumours (Huang et al., 1996). It is of interest that in MMR deficient cell line lbl-1261
the frequency of both C—>T and G—»A transitions was significantly higher than in the
MMR proficient control cell lines, lbl-a and lbl-c5 at both B1-D2 and G1-I2
(p<0.0015 at both regions) (Appendix A and Figure 8.5). Indeed the propensity for
T—>C and A—>G transitions in lbl-a and lbl-c5 was not observed in lbl-1261 and this
was seen most dramatically at region G1-I2 (Figure 8.5). Therefore, the significant
difference in mutation frequency between lbl-1261 and MMR proficient control cell
lines appears to be associated with a significant difference in the frequency of C—>T
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and G—>A transition mutations. This may indicate underlying differences in the
mechanisms resulting in mutation at the APC gene in lbl-1261 and MMR proficient
lymphoblastoid cell lines. The similar frequency of APC mutations between lbl-1260
and MMR proficient control cell lines is also associated with a similar mutation
spectrum, with lbl-1260 sharing the predominance for T—>C and A—>G mutations
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Figure 8.5 Spectrum of mutations identified in individual alleles cloned from two regions
(B1-D2, G1-I2) of exon 15 of the APCgenein five lymphoblast cell lines. Ibl-a and Ibl-c5
are MMR proficient lymphoblastoid cell lines and lbl-1260 and lbl-1261 are MMR deficient
lymphoblastoid cell lines. The frequency of each mutation is given in each cell line as a
proportion of the total number (n) of mutations identified in that cell line.
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8.3.5 Inherent instability at exon 15 of the APC gene in MMR proficient
and MMR deficient cancer cell lines.
The initial data in 8.3.3 suggests that the APC gene is inherently prone to mutation
but that in a highly unstable MMR deficient cell line instability at the APC gene is
not detected. To further investigate this notion, inherent instability at the APC gene
was examined in cancer cell lines with and without MMR defects. MMR proficient
cell line SW480 (Parsons et al., 1993), was analysed for inherent instability at region
B1-D2 of the APC gene to address whether mutations were detected with a similarly
significantly high frequency, as observed in MMR proficient lymphoblastoid cell
lines lbl-a and lbl-c5. In addition, regions B1-D2 and G1-I2 were also analysed in the
cancer cells HCT116 and HCT116+chromosome3 (HCT116+chr3). HCT116 is
deficient for wild type MLH1 (Figure 3.2), exhibits MSI and is found to be defective
in MMR (Parsons et al., 1993; Koi et al., 1994). However, the cell line
HCT116+chr3 has restored MMR activity by the re-introduction of the MLH1 gene
on chromosome 3 (Koi et al., 1994). These cell lines were used to provide a direct
comparison of the effect from presence or absence of a functional MLH1 protein on
the predilection for mutation at the APC gene.
147 alleles (120,319bp) cloned from SW480 template DNA, were sequenced and
analysed at region B1-D2 (Table 8.6). A total of 79 mutations were identified, a
mutation frequency of 0.66 mutations/kb (Table 8.6 and Figure 8.6). This frequency
was very similar to that observed for MMR proficient lymphoblastoid cell lines and
significantly greater than that observed in MMR deficient cell line lbl-1261
(%2=25.52, p<0.001) (Figure 8.6 and Table 8.4). These data indicate that a MMR
proficient cancer cell line also exhibits instability at the APC gene at a level
significantly above that observed in a MMR deficient cell line derived from normal
tissue. A comparison of mutation frequency between all MMR proficient cell lines
analysed at the APC gene and other coding regions examined by identical
methodology in this thesis was made (Table 8.7). This revealed a statistically
significant difference between the frequency of mutation between the APC gene and
other regions analysed (%2=13.23, p<0.001). The statistically significant difference
219
in mutation frequency between MMR proficient cell lines at different loci strongly
suggests that the majority of mutations detected at the APC gene are genuine and
cannot be accounted for by explanations such as polymerase error.
At region B1-D2, a mutation frequency of 0.23 mutations/kb was determined for
MMR deficient cancer cell line HCT116. However, analysis of cell line
HCT116+chr3 did not reveal a significant increase in the number of mutations
compared to HCT116 at region B1-D2 despite having an intact MLH1 allele
(%2=0.214, p=0.644) (Table 8.6 and Figure 8.6). Furthermore, there was no
significant difference in the level of mutations between these cell lines at the second
APC region analysed (G1-I2) (%2=T.450, p=0.229) (Table 8.6, Figure 8.6). The
number of mutations at B1-D2 compared to G1-I2 also differed significantly
(pO.OOl, HCT116, p=0.031, HCT116+chr3). At region G1-I2, HCT116 and
HCT116+chr3 had an elevated frequency of mutations compared to that at region
B1-D2 (%2=0.473, p=0.491) (Table 8.6). Therefore, although striking differences in
inherent instability at the APC gene between HCT116 and HCT116+chr3 were
predicted from the initial experiments in lymphoblastoid cell lines, this was not
observed in the subsequent analysis.
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Table 8.6 Analysis of individual alleles cloned and sequenced from two regions of exon
15 of the APC gene in cancer cell lines SW480, HCT116 and HCT116+chr3 (B1-D2, 910bp
and G1-I2, 1114 bp). HCT116 is MMR deficient and SW480 and HCT116+chr3 are MMR
proficient.
Region Cell line No. No. Full Missing Total No. Mutation
clones length
clones
seq./kb seq./ kb mutations freq.
(mutations
/kb)
B1-D2 SW480 147 103 13.451 120.319 79 0.66
HCT116 96 77 1.836 85.497 20 0.23
HCT116 93 65 73 77.330 21 0.27
+chr3
G1-I2 HCT116 70 47 11.768 66.212 42 0.63
HCT116 82 59 12.973 78.375 38 0.48
+ch3
Table 8.7 Comparison of levels of inherent instability in MMR proficient cell lines at
coding sequence loci in the APC, CTNNB1 and TGFBR2 genes. HCT116+chr3 is not
included since it is MMR proficient only due to a chromosome transfer. CTNNB1 ex3 refers
to the region detailed in 8.3.1. TGFBR2 ex3 refers to the non-repetitive region of exon 3 in
TGFBR2 as detailed in Chapter 7.
Locus MMR proficient Mutation frequency APC vs
cell line (mutations/kb) non APC
APC B1-D2 Ibl-a 0.63 %2=13.23,
Ibl-c5 0.58 p<0.001
SW480 0.66
APC G1-I2 Ibl-a 0.59
CTNNB1 ex3 Ibl-a 0.108
TGFBR2 ex 3 Ibl-c5 Undetectable
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Figure 8.6 Relative mutation frequency detected in individual alleles cloned from cancer cell
lines HCT116, HCT116+chromosome 3 and SW480 at two regions of the APC gene. (A)
Mutation frequency over 910bp encompassed by region B1-D2. (B) Mutation frequency over
1114bp encompassed by region G1-I2.
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8.3.6 Mutational spectrum at the APC gene in cancer cell lines
Overall, the 79 mutations detected in region B1-D2 of SW480 displayed a similar
spectrum to those observed in MMR proficient lymphoblastoid cell lines lbl-a and
lbl-c5 (Figure 8.7 and Appendix A). Again transition mutations predominated
showing a propensity for T—>C and A—>G changes. A single transversion mutation
was detected in SW480 at region B1-D2.
In HCT116 and HCT116+chr3 a total 121 mutations were identified. Again the
majority were transition mutations in both HCT116 (59/62, 95%) and HCT116+chr3
(56/59, 95%) (Figure 8.7, Appendix A). Two transversions and a deletion were
identified in region G1-I2 of HCT116, a single insertion was identified in region Bl-
D2 of cell line HCT16+chr3 and an insertion and a deletion at G1-I2. Although
MMR deficient lymphoblast cell line lbl-1261 showed a significant difference in the
frequency of C—>T and G—>A transitions compared to MMR proficient cell lines,


























Figure 8.7 Spectrum of mutations in individual alleles at exon 15 of the APC gene in cancer
cell lines HCT116, HCT116+chromosome 3 and SW480. (A) Region B1-D2. (B) Region G1-
12. The frequency of each mutation is given in each cell line as a proportion of the total number
(n) of mutations identified.
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8.4 Discussion
The investigations presented in this chapter set out to address whether mutations
arise in specific coding sequences in (3-catenin/TCF pathway as a consequence of
DNA MMR defects. In this way it may be possible to infer the role of the (3-
catenin/TCF pathway in the progression of MSI+ CRCs.
The regulatory domain of the CTNNB1 gene and exon 15 of the APC gene have
been reported as being mutated in a proportion of MSI+ CRCs (Huang et al., 1996;
Homffay et al., 1998; Sparks et al., 1998; Mirabelli-Primdahl et al., 1999; Miyaki et
al., 1999). However, in this analysis, there is no evidence to suggest that these
regions are inherently prone to mutation exclusively as a result of MMR defects.
Nonetheless, several intriguing observations have been made that may provide
considerable insight into the susceptibility to mutation of sequences that are mutated
in both MSI+ and MSS colorectal cancers.
Analysis of individual alleles in exon 3 of the CTNNB1 gene did not reveal an
excess of mutations in a cell line derived from normal tissue with MMR defects (lbl-
1261). The data suggest that other factors consequent of the process of
tumourigenesis contribute to the observed accumulation of the mutations within this
region in some MSI+ CRCs (Akiyama et al., 1997; Kitaeva et al., 1997; Mirabelli-
Primdahl et al., 1999; Miyaki et al., 1999). It should be noted that although the
complete deletion of exon 3 has been observed in some MSI+ CRCs (Iwao et al.,
1998) these lesions would not be detected by the technique used here.
Excess mutations were not observed at a low level in the (GT)4 repeat of exon 10
of the APC gene. This region was previously shown to exhibit mutational mosaicism
in the parent of a patient with FAP (Farrington and Dunlop, 1999). It was suggested
that this repeat may be susceptible to mutation and the mosaicism might be
associated with genetic instability. However, there was no evidence that mutations
accumulate at this region consequent of MMR defects in this study. The previous
study did not find constitutional defects in the MMR genes MLH1 or MSH2,
although it is possible that mutation in one of the other MMR genes contributed to
the observed mosaicism. In addition, this APC repeat has not been reported as being
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particularly prone to mutation in either MSI+ or MSS cancers (Laurent-Puig et al.,
1998).
The observation that two MMR proficient (lbl-c5, lbl-a) lymphoblastoid cell lines,
and a MMR proficient cancer cell line (SW480) displayed a significantly greater
level of mutation at two regions of exon 15 of the APC gene compared to MMR
defective cell line, lbl-1261 is intriguing. Furthermore, the level of mutation in MMR
proficient control cell lines is significantly greater than that observed at other coding
sequence loci such as exon 3 of the TGFBR2 gene and exon 3 of the CTNNB1 gene
(Table 8.7). The data suggests that a region of the APC gene that is frequently
mutated in around 80% of CRCs (Miyoshi et al., 1992; Powell et al., 1992), is
inherently prone to mutations, even in cells that are derived from normal tissue. This
would indicate that low but appreciable levels of mutations occur at these regions but
that these are not corrected by MMR. Clearly, further validation of this result is
merited but it is tempting to speculate that inherent susceptibility to mutation across
the APC gene contributes to the frequent mutations found early during MSS
tumourigenesis (Miyoshi et al., 1992; Powell et al., 1992; Miyaki et al., 1994). The
mutations observed were mainly point mutations and these lesions are commonly
observed in CRCs (Miyoshi et al., 1992; Powell et al., 1992; Miyaki et al., 1994;
Huang et al., 1996; Laurent-Puig et al., 1998). However, whereas C—>T transitions
are the most often detected somatic APC point mutation in tumours (Laurent-Puig et
al., 1998), T—>C and A—>G transitions predominated here. A detailed analysis of the
mutation spectrum between MMR proficient and MMR deficient cell lines that are
non-cancer derived, did not identify any differences in the propensity for ffameshift
mutations or for mutation at SSRs within the APC gene as was reported previously
(Huang et al., 1996). However, in MMR deficient cell line lbl-1261, the frequency of
C—>T transitions differed significantly from MMR proficient cell lines, a similar
observation to that reported by Huang et al., (Huang et al., 1996). This may suggest
that the MMR defect in lbl-1261 modifies the mutation spectrum observed in this cell
line.
The statistically significant increase in APC mutations in MMR proficient cell
lines compared to lbl-1261 indicates that the majority of the mutations detected are
genuine. Furthermore the significant differences in mutation frequency in MMR
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proficient cell lines at alternative coding loci are difficult to reconcile with
explanations such as error introduced in the PCR step of the cloning protocol. Indeed
error attributable to Taq polymerase during PCR cannot account for the high
frequency of APC mutations observed in the MMR proficient cell lines (Table 8.5).
Repeated sequencing and re-isolation of plasmid stocks confirmed the identified
mutations in every case. No instances of false positive or false negative sequencing
errors were detected, suggesting sequencing error was not a major factor.
Statistical significant heterogeneity in mutation frequency has been demonstrated
between lbl-1260 and lbl-1261 at microsatellite markers BAT-40 and D2S123 and
also at the coding poly(A)io repeat of the TGFBR2 gene in experiments presented in
earlier chapters (Chapters 4 and 7). Further support for mutational heterogeneity
between lbl-1260 and lbl-1261 dependent upon the nature of the inherent MMR
defect is provided by the analysis of the APC gene at region B1-D2. At the poly(A)io
repeat in TGFBR2 lbl-1260 displayed a mutation frequency similar to that of control
MMR proficient lymphoblast cell lines. This is also seen in the analysis here at the
APC gene although it remains intriguing that the mutation frequency in lbl-1260 and
MMR proficient cell lines is greater than in lbl-1261 whereas at other loci analysed it
was lower.
Underlying differences in instability in lbl-1260 and lbl-1261 may contribute to
the differences in frequency of mutation at APC. Indeed influence from mutation
threshold may go some way to explaining the different frequency of mutations
observed in the MMR deficient cell lines lbl-1261 and lbl-1260 at region B1-D2 of
the APC gene. It has been proposed that the level of instability is crucial in
determining whether a cell will be provided with a selective advantage (Cahill et ah,
1999). It is envisaged that if the accumulated damage from cell division rises above
the threshold for viability, apoptotic pathways are activated and cell death ensues
(Cahill et al., 1999). Profound MMR defects in lbl-1261 as evidenced from the
analysis of microsatellite loci (Chapter 4) may lead to increased mutation
accumulation at the APC gene that is already inherently unstable. This combined
with mutations at other coding regions (such as TGFBR2) may raise the level of
mutation above the threshold for cell viability leading to apoptosis, with the remit
being selection against any further APC mutations. In lbl-1260, the lower level of
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instability observed at microsatellite sequences (Chapter 4), indicates a less profound
defect in MMR. This may result in an increased level of mutation at APC but not to a
level that exceeds the threshold for cell viability. It is of interest to note that of all the
cell lines analysed, lbl-1260 had the highest frequency of mutation, although the
mutational spectrum did not necessarily indicate that they were of the type associated
with MMR defects.
It is also possible that resistance to DNA damage in the case of lbl-1260 may play
an additional factor. Previous studies have suggested that the mismatch repair
proteins, particularly MLH1 and MSH2, may be components of a pathway that
influences apoptosis, since loss of apoptosis results from MLH1 or MSH2 deficiency
(Zhang et al., 1999). In addition, numerous studies have demonstrated that MLH1
deficient tumours are resistant to the DNA damaging agent MNNG and that this
resistance is conferred via apoptotic pathways (Fink et al., 1998; Duckett et al.,
1999; Hardman et al., 2001). Since lbl-1260 has a defect in the MLH1 gene,
resistance to DNA damage may allow the accumulation of excess mutations but fail
to induce apoptotic pathways. These may also be a factor in the analysis of cancer
cell line HCT116, which also has a defect in MLH1. In contrast, there is evidence
that apoptotic defects are not associated with defects in the PMS2 gene and thus
apoptosis in response to DNA damage in lbl-1261 may remain a viable mechanism
(Zhang et al., 1999). Therefore, it is speculated that a lower level of underlying
genetic instability and/or resistance to apoptosis may contribute to the increased
mutation frequency observed at the APC gene in lbl-1260 compared to lbl-1261.
The data from the two cancer cell lines HCT116 and HCT116+chr3 add further
complexity to the observations presented above. Despite the fact that HCT116+chr3
is proficient in MMR, it did not display a significantly increased level of mutation
compared to the same cell line in which MMR is deficient (HCT116). Furthermore,
the lack of consistency in the results from each cell line at the two APC regions
studied makes it difficult to draw conclusions from these results. These data illustrate
the limitations of using cancer cells to address the direct consequences of MMR and
point back to the conflicting reports of mutation at the APC gene in MSI+ CRCs
(Huang et al., 1996; Homffay et al., 1998). These data further justify the use of
MMR deficient cells derived from normal tissue to unmask inherent instability
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dependent on MMR defects. Another confounding factor is that although HCT116 is
MMR deficient due to MLH1 defects, it also has other abnormalities. Mutation in the
poly(C) tract of the MSH6 gene has been identified, and the MSH3 gene is also
known to be mutated (Farrington, pers. comm.). Additional variabilities may
contribute to the mutation frequency at any given locus making the dissection of
events resulting exclusively from the MLH1 defect difficult. In addition, inhibition of
wild type MLH1 expression in HCT116+chr3 using antisense RNA does not impair
MMR activity (Chauhan et al., 2000). This is suggestive of the presence of other
unidentified factors that may contribute to the results presented here.
The notion that the APC gene may be inherently unstable even when MMR is
intact clearly needs to be further clarified. Techniques such as single cell PCR may
provide a complementary method to confirm the inherent instability observed in
these cell lines. In addition, analysis of normal colon mucosa from MSS cancer
patients, and also analysis of normal tissue from MMR deficient and MMR proficient
mice, may also provide evidence that the APC gene is inherently susceptible to
mutation in primary tissue.
In this chapter an alternative approach has been used to evaluate the role of
mutations in (3-catenin/TCF pathway genes in MMR deficient tumourigenesis. By
utilising MMR deficient and MMR proficient cells derived from normal tissue, the
inherent level of instability at three regions of the APC gene and exon 3 of the
CTNNB1 has been unmasked. The results suggest that the APC gene may be
inherently susceptible to mutation at a low but appreciable level in cells that are
proficient in MMR. This may reflect the high level of somatic mutation in the APC
gene, observed in MSS colorectal cancers (Miyoshi et al., 1992; Powell et al., 1992)
and the high new mutation rate for FAP (Bisgaard et al., 1994). In the presence of
MMR defects, underlying influences from instability may then modify the frequency
with which mutations accumulate at the APC gene. Factors such as a mutational load
within the cell and resistance to apoptosis may contribute to the propensity for
further mutations to accumulate. The contribution of such factors would be
dependent on the nature of the underlying MMR defects and may explain the
conflicting frequencies of APC mutations identified in MSI+ tumours. The
relationship between MMR deficiency and susceptibility to mutation at the APC
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locus appears complex. It will be of considerable interest to address the hypotheses





The work presented in this thesis has focused on molecular events that accumulate
as a result of defects in MMR. Factors that influence the manifestation of MSI but
which are not dependent on the process of tumourigenesis have also been
determined.
The use of cell lines lbl-1260 and lbl-1261 has facilitated this research. In Chapter
3 these cell lines were demonstrated to be derived from B-cell lymphocytes and
abnormal MMR protein expression, consistent with the profound MMR defects these
cell lines are known to harbour, has been shown. The MMR defects in lbl-1260 and
lbl-1261 are demonstrated to be associated with low level MSI even though they are
not cancer derived (Chapter 4). This research has provided significant understanding
of the analytical characteristics of two microsatellite markers used in the assessment
of MSI status in CRCs (D2S123 and BAT-40). Examination of inherent instability of
BAT-40 and D2S123 in lbl-1260 and lbl-1261 has revealed that the MSI phenotype
exhibits significant heterogeneity. In particular, sequence susceptibility to mutation is
influenced by intra-allelic differences that are dependent on constitutional phenotype.
Allelic specific interruptions within the (CA)n repeat of microsatellite D2S123,
confer stability to mutation in the presence of MMR defects even in MSI+ tumours
(Chapter 5). In addition, extreme susceptibility to mutation of the poly(A/T) repeat in
BAT-40 has been revealed, by the demonstration that it is also inherently
hypermutable in the germline (Chapter 6).
Investigation into the occurrence of mutations that are usually corrected by MMR
at coding sequences in TGFBR2, BAX, APC and CTNNB1 has provided considerable
insight into the contribution that inherent sequence instability makes, to the
accumulation of mutations in genes implicated in the development of MSI+ CRCs.
Differences in the mutation frequency of the repetitive tracts in TGFBR2 and BAX in
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MSI+ CRCs has been demonstrated to reflect differences in the predilection of these
repeats to instability when MMR is defective but when other effects of
tumourigenesis are minimised. The poly(A)io repeat of TGFBR2 has been
specifically shown to be frequently mutated consequent of MMR defects in cells that
are derived from normal tissue. p-catenin/TCF pathway genes CTNNB1 and APC are
mutated frequently in MSS CRCs and in some MSI+ CRCs. Extensive analysis of
coding sequence within these genes has not found any evidence that they are
inherently prone to mutations as a direct result of MMR defects. However, the
relationship between inherent stability at the APC locus and MMR deficiency
appears to be complex. MMR defects may result in modification of the frequency
and spectrum of mutations at the APC gene which itself is suggested to be inherently
unstable even when MMR is proficient.
9.2 Study of molecular consequences of MMR defects using cell lines
derived from normal tissue: an effective assay system.
Few studies have evaluated the relative contribution of inherent stability and
selection, to the accumulation of mutations that are detected frequently in MMR
deficient CRCs. The research in this thesis has utilised a sensitised in-vivo system,
which effectively minimises selection and this has allowed inherent sequence
stability to be unmasked. The system has facilitated the detection of genetic events
that are specifically associated with defects in MMR, but that are not dependent on
other influences associated with tumourigenesis itself.
The experimental rationale, with respect to the use of cell lines lbl-1260 and lbl-
1261 has been validated during the course of the research. The use of these cell lines
that are derived from normal tissue, but are defective in MMR, has effectively
revealed molecular events that specifically accumulate, consequent of such defects.
This approach has provided an alternative to the analysis of MSI+ cancer cells, lbl-
1260 and lbl-1261 represent a model system and as such the effects from selection
cannot be entirely negated. However, the very fact that these cells are derived from
non-cancerous tissue means that mutational bias from selection will be much reduced
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compared to that in cancer cells. Furthermore, confounding molecular abnormalities
consequent of the tumourigenic process itself will be largely eliminated. Striking
differences in mutation frequency were detected between control (MMR proficient)
cell lines and lbl-1260 and lbl-1261, at microsatellite repeats (D2S123 and BAT-40)
and coding sequence (TGFBR2 and APC). Since all the cell lines used were subject
to the same conditions in culture, the data are not easily reconciled with explanations
relating to selection or culture effects and this point was specifically discussed in
Chapter 7. Furthermore, the stringent experimental controls and rigorous
methodological techniques used throughout the experiments, means that technical
error is likely at most, to be a minor contributor to the results presented. The most
significant biological difference between the cell lines analysed, is the presence,
absence or nature of MMR defects. The observed mutational differences are most
easily explained as being consequent of these cell line specific differences in MMR
status.
Previous reports have demonstrated MSI in normal tissues from patients with
constitutional MMR defects (Miyaki et al., 1997; Vilkki et al., 2001; Wang et al.,
1999). Flowever, these studies primarily focus on defining the clinical phenotype of
such patients at a molecular level. The research in this thesis goes further, exploiting
the value of these non-cancer derived MSI+ cells by utilising them as an in vivo assay
tool. Further to the characterisation of lbl-1260 and lbl-1261, these cell lines were
employed to address specific questions that were defined in the research aims
(Chapter 1), relating to inherent instability of sequences mutated frequently in MMR
deficient CRCs. These cell lines have provided an excellent model with which to
understand the molecular consequences of MMR defects.
Cell lines such as lbl-1260 and lbl-1261, have potential to be utilised for broader
investigation of inherent sequence instability. It will be of considerable interest to
carry out similar studies to those presented here at other loci to gain a greater insight
into the susceptibility of different sequences to mutation in the presence of MMR
defects. Furthermore, these cell lines could be employed to define the rate of
mutation at inherently unstable sequences, using techniques such as single cell
cloning or single cell PCR.
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9.3 Heterogeneity in MMR defects results in heterogeneity of the
mutator phenotype: insight into mechanisms of MMR
Both lbl-1260 and lbl-1261 have been demonstrated to lack MMR activity on a
biochemical level (Parsons et al., 1995a). However, the data presented throughout
this thesis consistently demonstrates that these cell lines derived from normal tissue
with different constitutional MMR defects have different mutator phenotypes in
terms of the frequency and spectrum of mutations that arise.
While the dominant negative effect of the PMS2 mutation in lbl-1261 has been
demonstrated previously (Nicolaides et al., 1998), the data in Chapter 3 provides
compelling evidence that the defect in lbl-1260 is conferred by a reduction in MLH1
protein expression. Further study is necessary to establish the precise mechanism that
prevents the translation of the MLH1 transcripts in this cell line and to determine the
contribution that the MLH1 mutation in lbl-1260 makes to the observed reduction in
protein expression. It will be of interest to establish whether expression of the wild
type lbl-1260 MLH1 allele at the protein level can be detected in the absence of the
mutant. This could be determined, by cloning and transfecting the wild type allele
into an MLH1 deficient cell line such as HCT116 and subsequent assay of nuclear
extracts by western analysis.
Lbl-1261 displays dramatic instability at coding and non-coding repeat sequences,
supporting previous evidence that shows MMR activity is completely abolished in
this cell line (Parsons et al., 1995a). Furthermore the detection of mutations at both
mononucleotide (BAT-40, TGFBR2) and dinucleotide (D2S123) repeats is consistent
with PMS2 functioning in the repair of base:base mismatches and insertion:deletion
loops (Figure 1.3) (Li and Modrich, 1995; Kolodner and Marsischky, 1999).
It is well established that MLH1 also functions in the repair of base:base mispairs
and insertion:deletion loops (Kolodner and Marsischky, 1999) and the observation of
mutation at BAT-40 and D2S123 in lbl-1260 is entirely consistent with this.
However, the lower level of instability in lbl-1260 compared to lbl-1261 at both
microsatellite repeat sequences and at the TGFBR2 poly(A)io tract is intriguing. This
may indicate that residual MMR activity is taking place, but that the expression of
functional MLH1 is below the level of detection.
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That the nature of the MMR defect contributes to heterogenity in the frequency
and spectrum of accumulating mutations is not only evident from the analyses at
non-coding and coding repeat sequences but also from the analysis at two regions of
the APC gene. Significant differences in mutation frequency between lbl-1260 and
lbl-1261 again suggest influence from differential repair capabilities in these two cell
lines. However, at APC the mutation frequency appeared to be greater in cell line lbl-
1260 than in lbl-1261 in contrast to the trend observed at other loci. Possible
explanations for such a phenomenon were considered in Chapter 8.
Analysis of cells derived from normal tissue containing different MMR mutations
to those in lbl-1260 and lbl-1261 will facilitate investigation into whether the nature
of the MMR mutation or the gene that is mutated, is of greater importance in
directing the frequency and spectrum of mutations that consequently accumulate.
Such studies could also be carried out, utilising normal tissue from MMR deficient
mice, especially since these tissue are relatively easy to acquire.
9.4 Susceptibility of microsatellite repeats to mutation is dependent on
inherent instability and can be modified by loci dependent factors
The work presented in Chapters 4-6 provides fundamental understanding of the
stability of non-coding microsatellite sequences in the human genome (Bacon et al.,
2000; Bacon et al., 2001a; Bacon et al., 2001b). Furthermore, since the loci
investigated are used in CRC MSI screening strategies, the results have relevance to
the effective implementation of such programs and to the correlation of cancer with
clinical outcome.
The data supports the notion that the likelihood a microsatellite will be susceptible
to instability may relate to the inherent mutation rate at that locus (Thibodeau et al.,
1998). The detection of mutations in lbl-1260 and lbl-1261 at BAT-40 and D2S123
that are specifically associated with MMR defects (Chapter, 4) indicates that these
loci are inherently unstable by nature of the fact that these cell lines are not cancer-
derived. Further evidence for the relationship between inherent sequence instability
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and susceptibility to mutation in MMR defective CRCs has been presented in
Chapters 5 and 6.
In Chapter 5, a TA interruption in the (CA)n repeat of D2S123 is demonstrated to
confer stability on the allele. Constitutional genotype is shown to determine the
inherent susceptibility of this locus to mutation and directly affects whether D2S123
will accumulate mutations in MMR deficient colorectal tumours (Bacon et al., 2000).
Due to the important clinical implications of this finding, it will be of considerable
interest to re-asses studies in which tumour MSI status was determined using the
panel of five recommended markers (Boland et al., 1998). MSI-L or MSS colorectal
tumours, from patients with inherently "stable" constitutional D2S123 genotypes,
may have been inappropriately classified. This can be easily confirmed by analysis of
tumour MSI at other microsatellite loci. Evaluating the extent of such mis-
classification will only underscore the importance of assessing the analytical
characteristics of microsatellite markers, prior to using them in assays for detecting
tumour stability.
It is clear from the CEPH database that many microsatellite markers used in MSI
analysis are polymorphic as determined by size analysis (www.cephb.fr/).
Determination of allele specific sequence differences may highlight those loci at
which constitutional genotype may influence susceptibility to mutation in MMR
deficient tumours. Identifying intra-allelic repeat sequence differences could direct
subsequent analysis of the inherent allele stability at a given locus, in cell lines such
as lbl-1260 and lbl-1261 and in MMR deficient tumours. Such studies can only serve
to increase the robustness of the MSI marker panel and the confidence with which
these microsatellites are used.
This work has further relevance to the identification of functionally important
coding sequences that may be susceptible to mutation in MMR deficient cancers.
Repeat sequences are prone to mutation in coding as well as non-coding sequences in
MSI+ CRCs (Ionov et al., 1993; Thibodeau et al., 1993; Markowitz et al., 1995;
Parsons et al., 1995b; Rampino et al., 1997; Duval et al., 2001). It is likely that
further, functionally important coding sequence repeat loci will be identified as being
frequently mutated in MSI+ CRCs and implicated as contributing to cancer
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development. Rigorous assessment of population polymorphism at such loci should
be carried out. If allelic stability similar to that observed at D2S123 is conferred on
such a coding sequence repeat, it could be envisaged that constitutional genotype
may not only confer resistance to mutation consequent of MMR defects, but may
also be functionally protective towards CRC development. It is also rational to assess
the mutational stability of coding sequence loci logged in GenBank as short
interspersed repeats e.g. (CA)nTA(CA)n or (A)nT(A)n. Allelic variants at such loci
that lack an interspersion, may reveal longer repetitive tracts that are highly
susceptible to mutation consequent of MMR defects and that are also functionally
important.
The importance of inherent sequence stability on the likelihood of mutation
accumulation in MMR deficient tumours is underpinned by the study in Chapter 6.
BAT-40 is one of the most highly mutable microsatellite markers in MMR deficient
CRCs (Parsons et al., 1995b) and the work presented has provided evidence that this
reflects extreme inherent instability at this locus. The profound susceptibility to
mutation at BAT-40, identified in Chapter 4 is confirmed by the finding that this
poly(A/T) repeat is highly unstable in the germline (Bacon et al., 2001a). It will be of
importance to further this founding observation, by defining the rate of mutation by
more rigorous analysis such as single sperm cell PCR. In addition, further
investigation as to whether this phenomenon is common to many poly(A/T) repeats,
both in coding and non-coding sequence, will strengthen the initial finding made here
and be both of considerable interest and fundamental importance.
BAT-26 is another poly(A/T) marker frequently employed in MSI analysis
(Boland et al., 1998). Despite being very sensitive to MSI in MMR deficient
tumours, BAT-26 has been described as showing quasi-monomorphic variation in the
population in contrast to the polymorphic nature of BAT-40 (Hoang et al., 1997;
Zhou et al., 1997). It will be of interest to address whether BAT-26 displays germline
instability as indicated by the high propensity for mutation in MMR deficient
tumours, or whether the quasi-monomorphic population variance is correlated with
stability in the germline (Hoang et al., 1997; Zhou et al., 1997).
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It has already been discussed in Chapter 6 that germline instability of poly(A/T)
loci may have functional consequences in view of the prevalence of poly(A/T)
repeats in coding and non-coding sequence. Available sequence from the human
genome was recently subjected to rigorous searching for coding sequence
mononucleotide and dinucleotide tracts over 8 repeat units in length. The results of
this search were filtered for redundancy and for the presence of pseudogenes. 215
coding sequence loci were identified containing poly(A/T) repeats of over lObp,
some with repeats over 30bp in length (Taylor pers. comm.). Many of these repeats
were within putative genes whose function has yet to be established (Taylor pers.
comm.). Thus if hypermutability of poly(A/T) sequences in the germline occurs
frequently, there are many potential loci at which functional impact from this
phenomenon could be conferred.
An in depth analysis of inherent stability at all the microsatellite markers that are
used in the analysis of MSI status of CRCs is not trivial task (Boland et al., 1998).
However, the data presented in this thesis have demonstrated that such investigations
are worthwhile and can significantly improve our understanding of how the mutator
phenotype manifests in CRCs, as well as offering more reliable molecular tools for
clinical and research purposes.
9.5 Inherent susceptibility of coding sequences to mutations
contributes to the frequency with which they are mutated in MMR
deficient CRCs.
The data presented in Chapters 7 and 8 has provided evidence that inherent
stability of coding sequences, contributes to the frequency with which they are
mutated in MMR deficient tumours and thus implicates a significant role for MMR
deficiency in the development of CRC. The results are consistent with the hypothesis
presented at the outset of this thesis that sequences mutated frequently in MMR
deficient CRCs are inherently prone to mutation. The data strengthens support for the
importance of an increased mutation rate in tumourigenesis (Loeb, 2001).
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In particular compelling evidence is presented in Chapter 7 (Bacon et al., 2001b).
The data demonstrate that MMR deficiency results in an excess of mutations,
specifically at the poly(A)io tract compared to other regions of the TGFBR2 gene
(p<0.001). Conversely, an excess of mutations does not appear to arise at the
poly(G)g tract of the BAX gene. These studies provide insight into the mechanism by
which TGFBR2 and BAX become mutated during tumourigenesis. The work has
suggested that differences in the mutation frequency observed at the repetitive tracts
within TGFBR2 and BAX in MSI+ CRCs, are associated with differences in the
susceptibility of these loci to mutation exclusively as a result of MMR defects. These
findings support the idea that the relative contribution from selection and mutation
may be different at alternative loci, which are mutated to appreciable levels in MSI+
CRCs. TGFBR2 in particular, is mutated with extreme consistency in MMR
defective colorectal tumours and is implicated as having a critical role in early stages
of tumourigenesis (Markowitz et al., 1995; Parsons et al., 1995b; Markowitz, 2000).
The fact that the poly(A)io tract within TGFBR2 is inherently susceptible to
mutation, indicates that inherent mutation frequency as unmasked by MMR defects,
plays a major role in the accumulation of these mutations in MSI+ CRCs and thus
contributes significantly to tumourigenesis (Bacon et al., 2001b).
It will be of importance to establish whether other coding poly(A) repeats also
accumulate mutations exclusively as a result of MMR defects, to a similar level as
that observed in TGFBR2. This may indicate the relative importance of the
predilection of the repeat in TGFBR2 to mutation, in MSI+ CRCs. Identification of
other loci that are similarly prone to mutation consequent of MMR defects may
reveal other functionally important loci that are abrogated in the progression of MSI+
CRCs. As described above many coding sequence loci in the human genome contain
poly(A) tracts over lObp in length. These represent potential functional targets for
mutation accumulation in MSI+ CRCs. This work has shown that MMR defects
specifically allow mutations to accumulate at one such coding poly(A) repeat.
However, a systematic analysis of inherent stability of all coding sequence repeats
and analysis of their frequency of mutation in MSI+ CRCs would provide
considerable insight into the role of MMR deficiency in tumourigenesis. Such
analysis would further understanding of the relationship between inherent sequence
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instability and the frequency of gene mutation in MSI+ tumours. Although the total
number of human coding repeat sequences, over 10 repeating units in length is
appreciable, extensive mining of the human genome suggests the number does not
pose an impossible research task (Taylor pers. comm.)
The examination of the susceptibility of two P-catenin/TCF pathway genes to
mutation consequent of MMR defects, highlights that the relationship between the
inherent instability of a sequence and the frequency with which it is mutated in MSI+
CRCs is likely to be complex in many cases. Further investigation of the preliminary
findings presented in Chapter 8 is clearly necessary. Nonetheless, this work adds to
previous studies that have investigated the role that abrogation of the P-catenin/TCF
pathway may play in the development of CRCs with MMR defects. The data
presented does not find any evidence to suggest that mutations arise in the APC gene
or the CTNNB1 gene exclusively as a consequence of repair defects. Although, the
initial research has resulted in the speculation that the APC gene is subject to a low
but appreciable level of mutation in MMR proficient cells. This is a radical
suggestion that clearly needs to be substantiated. Flowever, the notion that APC may
be readily prone to mutation even when MMR is functional, may explain why it is
mutated frequently in sporadic CRCs (Miyoshi et al., 1992; Powell et al., 1992) and
also the high new mutation rate in FAP patients (Bisgaard et al., 1994; Farrington
and Dunlop, 1999).
The work presented in this thesis provides insight into the relative contribution of
inherent instability at sequences mutated frequently in MMR defective cancers and
reveals that it is possible to dissect out those events that occur exclusively in the
presence of MMR deficiency. This research offers promise for new levels of
understanding of how MSI+ cancers develop and the role that an increased mutation
frequency may contribute to tumourigenesis. The revelation that loci specific and
allele specific factors modify sequence susceptibility to mutation, significantly
affecting the manifestation of the mutator phenotype, adds further complexity to the
study of events consequent of MMR defects. However, identification of such factors
at other loci will be critical in order to fully appreciate the contribution that
inactivation of MMR makes to the development of cancer. Detailed understanding of
the molecular consequences of MMR can only have a positive impact on
240
understanding how cancers associated with these defects develop and ultimately be
of clinical and public health benefit.
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Appendix A
Cell line, Clone, ID Mutation Nucleotide Codon Target
APC region position sequence
lbl-1261 Transitions
B1-D2 8 A-G 2242 748 ApG
56 A-G 2267 756 ApA
83 A-G 2458 820 ApG
31 C-T 2470 824 CpC
49 C-T 2626 876 CpG
12 G-A 3139 1047 GpA
16 G-A 2782 928 GpC
29 G-A 2329 777 GpA
49 G-A 2556 852 GpG
72 G-A 2863 955 GpA
101 G-A 3135 1045 GpA
30 T-C 2980 994 TpT
85 T-C 2980 994 TpC
lbl-1261 Transitions
G1-I2 117 A-G 3983 1328 ApC
122 A-G 3976 1326 ApG
46 C-T 4297 1433 CpC
49 C-T 3989 1330 CpC
167 C-T 3987 1329 CpC
168 C-T 4297 1433 CpC
18 G-A 4357 1453 GpT
71 G-A 4525 1509 GpC




162 T-G 4718 1573 TpT
Cell line, Clone, ID Mutation Nucleotide Codon Target
APC region position sequence
Ibl-c5 Transititons
B1-D2 1 A-G 2312 771 ApA
2 A-G 2370 790 ApA
7 A-G 2565 855 ApC
7 A-G 2972 991 ApA
9 A-G 2773 925 ApG
11 A-G 2272 758 ApA
11 A-G 2544 848 ApG
12 A-G 2525 842 ApT
18 A-G 2435 812 ApC
33 A-G 2456 819 ApT
35 A-G 2679 893 ApG
41 A-G 2647 883 ApC
17 C-T 3103 1035 CpA
5 G-A 2658 886 GpA
9 G-A 2915 972 GpT
17 G-A 2528 843 GpT
1 T-C 2961 987 TpG
4 T-C 2672 891 TpG
17 T-C 2352 784 TpC
17 T-C 2382 794 TpC
17 T-C 2931 977 TpC
27 T-C 2352 784 TpC
44 T-C 2781 927 TpG
46 T-C 2740 914 TpG
Cell line, Clone, ID Mutation Nucleotide Codon Target
APC region position sequence
Ibl-a Transitions
B1-D2 65 A-G 2263 755 ApG
53 A-G 2263 755 ApG
14 A-G 2267 756 ApA
46 A-G 2283 761 ApG
28 A-G 2330 777 ApC
4 A-G 2379 793 ApA
56 A-G 2469 823 ApC
5 A-G 2512 838 ApG
6 A-G 2540 847 ApA
27 A-G 2606 869 ApT
13 A-G 2710 904 ApG
5 A-G 2750 917 ApT
26 A-G 2926 976 ApG
32 A-G 2940 980 ApC
27 A-G 3118 1040 ApG
3 C-T 2727 909 CpA
54 G-A 2768 923 GpA
50 G-A 2987 996 GpT
61 T-C 2232 744 TpT
26 T-C 2235 745 TpG
6 T-C 2251 751 TpC
46 T-C 2305 769 TpT
14 T-C 2491 831 TpT
37 T-C 2506 836 TpC
6 T-C 2691 897 TpC
14 T-C 2751 917 TpG
42 T-C 2810 937 TpC
44 T-C 2818 940 TpC
11 T-C 2844 948 TpA
24 T-C 2875 959' TpC
62 T-C 2878 960 TpC
23 T-C 2922 974 TpA
67 T-C 2953 985 TpC
67 T-C 3048 1016 TpA
70 T-C 3093 1031 TpT
58 T-C 3093 1031 TpT




69 T-G 2298 766 TpC
Ibl-a Transitions
G1-I2 28 A-G 3799 1260 ApG
28 A-G 3864 1288 TpG
33 A-G 4359 1453 TpA
35 A-G 3917 1306 ApA
35 A-G 4370 1457 ApA
44 A-G 3997 1333 ApC
50 A-G 3927 1309 ApA
60 A-G 4006 1336 ApG
68 A-G 4349 1450 ApG
68 A-G 4370 1457 ApA
68 A-G 4401 1467 ApC
75 A-G 4688 1563 ApC
18 T-C 4586 1529 TpT
21 T-C 4842 1614 TpG
23 T-C 4698 1566 TpG
28 T-C 3865 1289 TpG
31 T-C 4842 1614 TpG
44 T-C 4680 1560 TpG
44 T-C 4842 1614 TpG
52 T-C 4629 1543 TpA
Cell line, Clone, ID Mutation Nucleotide Codon Target
APC region position sequence
lbl-1260 Transitions
B1-D2 93 A-G 2224 742 ApT
56 A-G 2242 748 ApG
39 A-G 2267 756 ApA
59 A-G 2274 758 ApG
25 A-G 2280 760 ApG
59 A-G 2283 761 ApG
12 A-G 2330 777 ApC
46 A-G 2368 790 ApG
63 A-G 2370 790 ApC
95 A-G 2380 794 ApG
85 A-G 2420 807 ApT
9 A-G 2423 808 ApT
P1-13 A-G 2425 809 ApA
93 A-G 2458 820 ApC
59 A-G 2546 849 ApT
26 A-G 2624 875 ApG
70 A-G 2702 901 ApG
15 A-G 2738 913 ApT
16 A-G 2788 930 ApC
17 A-G 2905 969 ApG
50 A-G 2908 970 ApG
65 A-G 2912 971 ApT
57 A-G 3008 1003 ApC
10 A-G 3118 1040 ApG
44 C-T 2285 762 CpA
70 C-T 2285 762 CpA
21 C-T 3009 1003 CpC
22 G-A 2519 840 GpC
6 G-A 2871 957 GpA
55 T-C 2460 820 TpG
22 T-C 2465 822 TpT
50 T-C 2500 834 TpC
93 T-C 2521 841 TpT
39 T-C 2529 843 TpT
P1-13 T-C 2535 845 TpT
19 T-C 2592 864 TpC
76 T-C 2592 864 TpC
91 T-C 2619 873 TpT
63 T-C 2649 883 TpG
84 T-C 2660 887 TpT
76 T-C 2690 897 TpT
16 T-C 2793 931 TpT
61 T-C 2827 943 TpC
50 T-C 2850 950 TpT
74 T-C 2850 950 TpT
32 T-C 2898 966 TpT
43 T-C 2958 986 TpT
95 T-C 2961 987 TpG
73 T-C 2991 997 TpG
2 T-C 3018 1006 TpA
24 T-C 3036 1012 TpC
2 T-C 3084 1028 TpC
37 T-C 3093 1031 TpT
37 T-C 3114 1038 TpG
Cell line, Clone, ID Mutation Nucleotide Codon Target
APC region position sequence
SW480 Transitions
B1-D2 19 A-G 2273 758 ApA
20 A-G 2872 958 ApG
22 A-G 2859 953 ApT
48 A-G 2338 780 ApG
51 A-G 2859 953 ApT
52 A-G 2859 953 ApT
63 A-G 2452 818 ApA
81 A-G 2268 756 ApC
89 A-G 2918 973 ApT
89 A-G 2928 976 ApG
93 A-G 2420 807 ApT
4' A-G 2415 805 ApC
8' A-G 2323 775 ApA
8' A-G 2410 804 ApA
9' A-G 2706 902 ApG
10' A-G 3053 1018 ApT
17' A-G 2969 990 ApT
19' A-G 2321 774 ApC
29' A-G 2755 919 ApG
34' A-G 3053 1018 ApT
40' A-G 2282 761 ApA
41' A-G 2773 925 ApG
55' A-G 2250 750 ApT
58' A-G 2274 758 ApG
61' A-G 2713 905 ApA
67' A-G 2644 882 ApC
73' A-G 2321 774 ApC
73' A-G 2332 778 ApA
78' A-G 2514 838 ApG
82' A-G 2294 765 ApT
85' A-G 2426 809 ApT
86' A-G 2324 775 ApT
96' A-G 2595 865 ApG
2 C-T 2795 932 CpA
44 C-T 2257 753 CpA
63 C-T 2365 789 CpA
89 C-T 3032 1011 CpA
39' C-T 2254 752 CpT
41' C-T 2687 896 CpC
42' C-T 2848 950 CpC
49' C-T 2955 985 CpT
51' C-T 2371 791 CpA
70' C-T 2848 950 CpC
72' C-T 2799 933 CpA
16 G-A 2888 963 GpT
22 G-A 2674 892 GpA
33 G-A 2357 786 CpG
37 G-A 2992 998 GpG
48 G-A 2903 968 GpT
51 G-A 2673 891 GpG
62 G-A 3116 1039 GpA
65 G-A 2662 888 GpC
78 G-A 2871 957 GpA
82 G-A 3115 1039 GpG
20' G-A 2630 877 GpT
33' G-A 2265 755 GpA
72' G-A 2422 808 GpA
53 T-C 3106 1036 TpT
1' T-C 2418 806 TpG
8' T-C 2765 922 TpT
29' T-C 2256 752 TpT






















































Cell line, Clone, ID Mutation Nucleotide Codon Target
APC region position sequence
HCT116 Transitions
B1-D2 84 A-G 2345 782 ApG
84 A-G 2366 789 ApG
59 A-G 2565 855 ApC
28 A-G 2624 875 ApG
86 A-G 2652 884 ApG
3 A-G 2274 758 ApG
10 A-G 2455 819 ApT
22 A-G 2924 975 ApA
33 C-T 2642 881 CpC
94 C-T 2688 896 CpA
61 C-T 3025 1009 CpA
44 C-T 2654 885 CpC
59 C-T 2783 928 CpC
22 C-T 2945 982 CpG
2 G-A 2749 917 GpA
16 T-C 2350 784 TpC
1 T-C 2350 784 TpC
23 T-C 2698 900 TpC
78 T-C 2818 940 TpC
76 T-C 2970 990 TpG
HCT116 Transitions
G1-I2 4 A-G 3852 1284 ApG
12 A-G 4573 1525 ApT
17 A-G 3852 1284 ApG
38 A-G 3794 1265 ApA
78 A-G 4760 1587 ApG
87 A-G 4114 1372 ApG
90 A-G 4598 1533 ApC
91 A-G 3794 1265 ApA
4' A-G 4309 1437 ApG
27' A-G 4222 1408 ApG
41' A-G 4071 1357 ApG
63' A-G 4317 1439 ApC
68' A-G 4071 1357 ApG
69' A-G 4049 1350 ApC
92' A-G 4299 1433 ApC
92' A-G 4486 1496 ApG
83 C-T 4526 1509 CpT
41' C-T 3875 1292 CpG
68' C-T 3875 1292 CpG
2 G-A 3895 1299 GpC
16 G-A 4391 1464 GpA
90 G-A 4791 1597 GpA
69' G-A 4221 1407 GpA
4 T-C 4295 1432 TpG
13 T-C 4177 1393 TpC
20 T-C 4266 1422 TpT
21 T-C 4469 1490 TpA
29 T-C 4586 1529 TpT
37 T-C 4095 1365 TpT
59 T-C 4266 1422 TpT
59 T-C 4581 1527 TpC
87 T-C 4873 1625 TpT
38' T-C 4266 1422 TpG
47' T-C 3825 1275 TpT
56' T-C 4854 1618 TpC
63' T-C 3905 1302 TpG
78' T-C 3841 1281 TpC







92' A-T 4606 1536 ApA
79' T-A 4691 1564 TpA
Cell line, Clone, ID Mutation Nucleotide Codon Target
APC region position sequence
HCT116 Transitions
+chr3 74 A-G 2312 771 ApA
B1-D2 36 A-G 2330 777 ApC
7 A-G 2433 811 ApG
21 A-G 2647 883 ApC
41 A-G 2708 903 ApC
90 A-G 2746 916 ApC
28 A-G 2746 916 ApC
40 A-G 2940 980 ApC
60 A-G 3132 1044 ApC
61 A-G 2564 855 ApA
23 C-T 2255 742 TpT
40 C-T 2278 760 CpT
59 C-T 2786 CpA
34 G-A 2449 817 GpG
58 G-A 2450 817 GpC
11 G-A 2528 843 GpT
83 G-A 2971 991 GpA
34 T-C 2505 835 TpT




14 G insertion 2359 787 ins
HCT116 Transitions
+chr3 20 A-G 4662 1544 ApG
G1-I2 57 A-G 4616 1539 TpC
85 A-G 3879 1293 ApC
78 A-G 4045 1349 ApG
83 A-G 4646 1549 ApC
2' A-G 4349 1450 ApG
r A-G 4000 1334 ApA
8' A-G 4374 1458 ApC
9' A-G 3929 1310 ApG
11' A-G 3961 1321 ApG
16' A-G 3852 1284 ApG
17' A-G 3861 1287 ApG
33' A-G 3797 1266 ApT
84 C-T 4044 1348 CpA
8 G-A 3889 1297 GpA
34 G-A 4414 1472 GpC
64 G-A 4426 1476 GpC
87 G-A 3974 1325 GpC
26 T-C 4320 1440 TpC
41 T-C 4177 1393 TpC
58 T-C 3801 1267 TpC
59 T-C 4101 1367 TpC
70 T-C 4177 1393 ApG
7' T-C 4197 1399 TpC
8' T-C 3980 1327 TpG
8' T-C 4177 1393 TpC
8' T-C 4320 1440 TpC
8' T-C 4562 1521 TpG
9' T-C 4148 1383 TpC
11' T-C 4329 1443 TpC
16' T-C 4332 1444 TpC
18' T-C 3791 1264 CpA
18' T-C 4167 1389 TpT
19' T-C 4020 1340 TpT







47' Adel 3823 1275 ApG
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Determinants of instability at a given microsatellite
repeat merits investigation in view of relevance to
understanding evolution of mutations at such
sequences in human populations. The microsatellite
D2S123 was studied as a paradigm CA repeat marker.
Furthermore, this marker is one of a recommended
panel used in molecular screening for hereditary
non-polyposis colorectal cancer (HNPCC). In this
investigation we show that the mutation rate at the
D2S123 locus is markedly influenced by intra-allelic
sequence variation within the repetitive tract itself.
We employed a novel approach to characterize the
nature of instability at D2S123, by utilizing cells
derived from a non-tumour lineage, which harbour a
dominant negative mismatch repair (MMR) mutation
and a mutator phenotype. Individual alleles were
typed using a semi-quantitative small pool PCR tech¬
nique and this demonstrated substantial allele-these
specific bias in susceptibility to mutation at the
D2S123 locus. In support of these in vitro data, bias
in allele mutation rate was also observed in tumours
from 41 HNPCC patients, which was dependent on
constitutional genotype. Sequencing of cell line and
patient DNAs revealed that short alleles are signifi¬
cantly more susceptible to mutation due to the pres¬
ence of uninterrupted CA repeats. Long D2S123
alleles are intrinsically more stable because of a TA
interspersion within the repetitive tract. In addition to
extending understanding of mutation at CA repeat
dinucleotide tracts, these findings have considerable
relevance both to screening programmes and to
correlation of microsatellite instability (MSI) with
colon cancer survival. The manifestation of tumour
MSI may be substantially influenced by constitu¬
tional genotype.
INTRODUCTION
Microsatellites occur ubiquitously throughout the genome and
mutations within these simple repetitive tracts are frequent as
evidenced by heterozygosity rates (1). In studies of poly(CA/
GT) repeats in humans, high rates of mutation per locus per
gamete per generation (5.6 x 1(H) have been revealed (2). The
inherently unstable nature of microsatellites results in frequent
alterations in the length of the repeat tracts making many of
them highly polymorphic (1,3). Differences in mutation rate
are evident at alternative microsatellite loci (1) and sequence
variation can significantly affect individual microsatellite
stability. Variations in microsatellite flanking sequences (4,5)
and in repeat length (6,7) have been demonstrated to contribute
to heterogeneity in mutation rate. In addition, correlation of
instability with the degree of perfection of a repeat has been
documented. In Escherichia coli and yeast, presence of an
interspersion within a dinucleotide tract results in its stabiliza¬
tion (5,8); this is also observed in the presence of defective
mismatch repair (MMR) (8). Locus-by-locus analyses reveal
that interspersed repeat markers are also relatively more stable
in the fruit fly Drosophila (9), in the germline of human popu¬
lations (10) and in tumours from cancer patients (11). Repeat
sequence interruption is also important at a clinical level.
Expansion of triplet repeats gives rise to the human
trinucleotide repeat disorders such as fragile X, Huntington's
disease and spinocerebellar ataxia type 1 (SCAl) (12,13).
Stability of both SCAl and FMR1 (fragile X gene) alleles are
conferred by interruption of the contiguous repeat (14-18).
The high degree of polymorphism makes microsatellites
invaluable tools for use in genetic mapping, in DNA forensic
studies, as population markers and in a variety of other appli¬
cations. Mechanisms affecting mutation rate within a given
locus have been less extensively characterized, although there
are studies documenting such variation. For example, in a
population study of meioses in pentameric and tetrameric
markers, it was shown that different alleles at single loci varied
in their rate of mutation (10). However, investigation of mech¬
anisms affecting microsatellite stability in family studies
requires very large numbers of meiosis to be screened in order
to identify mutations (2). This places severe practical limita¬
tions on such studies as well as on investigations using sperm
DNA (19).
To investigate factors influencing stability at given micro-
satellite alleles we employed a novel approach using a 'sensi¬
tized' system. We utilized a lymphoblast cell line from a
patient who developed colorectal cancer. The cell line is defec¬
tive in MMR and displays a mutator phenotype but is derived
from a non-tumourous tissue. There is evidence that mecha¬
nisms generating mutations in microsatellite unstable (MSI+)
tumours share similarities with those resulting in the evolution
+To whom correspondence should be addressed. Tel: +44 131 467 8439; Fax: +44 131 343 2620; Email: malcolm.dunlop@hgu.mrc.ac.uk



















Figure 1. Genotyping of individual D2S123 alleles in cell line lbl-1261.
(A) Constitutional genotype of DNA from lbl-1261 determined from the prep¬
aration of undiluted DNA. A short and a long allele of 214 and 228 bp, respec¬
tively, are clearly detected. (B and C) Individual mutant alleles of 230 and
220 bp detected in lbl-1261 by SP-PCR. M, marker peak at 200 bp.
of such sequences in the germline (11,20) and a mutator
phenotype might exacerbate the process of germline evolution
at repetitive markers. Hence, study of determinants of marker
stability in MSI+ MMR-defective cells has relevance to the
understanding of the process of evolution of repeat sequences
in human populations (11,20).
Defects in mismatch repair result in the accelerated accumu¬
lation of frameshift mutations within microsatellite sequences
(21-23) occurring predominantly at mononucleotide and
dinucleotide repeat tracts. Over 90% of hereditary non-poly-
posis colorectal cancer (HNPCC) cases display microsatellite
instability (MSI) (24,25), usually as a result of germline
defects in one of at least five MMR genes (hMLHl, hMSH2,
hPMS2, hPMSI and hMSH6) (26,27). During tumour develop¬
ment, the wild-type allele is inactivated by loss of heterozy¬
gosity (LOH), mutation or epigenetic silencing causing
complete loss of MMR activity. Some MSI+ sporadic color¬
ectal tumours are also defective in MMR by nature of somatic
mutations, LOH or by epigenetic silencing due to hypermeth-
ylation of the hMLHl promoter (28). Once inactivated, the
consequent failure to repair DNA replication errors that arise
due to DNA polymerase slippage manifests as MSI.
In a cell line defective in MMR due to a dominant negative
hPMS2 mutation, we show that alleles at a microsatellite repeat
locus are differentially stabilized and demonstrate the
sequence determinant of this mutation bias. The CA repeat
microsatellite studied here is one of a panel of five markers
recommended for use in MSI analysis in colorectal cancer
(29,30). In addition to having general importance in under¬
standing the mechanisms that lead to instability at repetitive
sequences, this work also has specific relevance to the influ¬
ence of patient genotype on the manifestation of tumour MSI
and also on correlation of MSI with clinicopathological
features.
RESULTS
Determination of allele bias in MMR-deficient cells
Genotyping of D2S123 alleles from MMR-defective lympho-
blast cell line lbl-1261 revealed alleles of 228 and 214 bp
(Fig. 1). In all, a total of 270 and 115 alleles were typed by
small pool PCR (SP-PCR) for lbl-1261 and a control lympho-
blast cell line (lbl-c5), respectively. Ninety alleles (33.3%)
from lbl-1261 templates exhibited length variation compared
with only two alleles (1.7%) of the control cell line (^2 = 42.3,
P < 7 x HP11) (Figs 1 and 2, Table 1). The small number of
mutants found in lbl-c5 may be due to PCR error or indeed
could be genuine mutations. However, their small number rela¬
tive to those in lbl-1261 indicates that PCR artefacts do not
interfere significantly with the detection of mutants in the
dilute DNA. These data are in accordance with a previous
study of mutation frequency in this cell line (31). However, we
noted a substantial bias in the alleles from which mutations
were derived. In all, 72 of 90 mutants (80%) in lbl-1261 were
clustered around the shorter (214 bp) allele (Fig. 2A), indi¬
cating a substantial bias for mutation at that locus (%2 = 42.3,
P < 0.00001). Mutant alleles were assumed to be derived from
the progenitor allele closest in size in the undiluted DNA, since
studies of microsatellite mutations in human pedigrees, human
cell lines and artificial constructs in yeast have shown that
most microsatellite mutations involve only one or two repeat
units (2,8,32).
To ensure that the effect was not due to misassignment of
mutant alleles, we re-analysed the data using a threshold to
exclude reductions in the 228 bp allele. We assumed that only
mutants of <216 bp (a single repeat expansion of the short
progenitor allele) were derived from the shorter progenitor.
This confirmed the highly significant mutation bias at the
shorter allele (%2 = 8.45, P < 0.0037). These observations are
not due to PCR bias at the smaller allele since equal numbers
of short and long alleles were detected in lbl-1261. Further¬
more, insertion and deletion mutants of both progenitor alleles
were observed (Fig. 2).
These observations indicate a substantial and statistically
significant allele-specific bias in mutation rate. We were inter¬
ested to determine the nature of this bias, especially since it
conflicts with the expectation that MSI correlates with
increased repeat length and number of repeating units (7,33)
Thirty-nine Scottish individuals were genotyped at the
D2S123 locus. A total of eight different alleles were identified
(210-230 bp) consistent with the CEPH data (http://
www.cephb.fr/cephdb/ ) (Table 2). Alleles were noticed to
cluster in two distinct size groups, long (-228 bp) or short
(-214 bp) and the frequency of alleles in each of these two
groups were almost identical between our cohort and the
CEPH data.
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Figure 2. Distribution of progenitor and mutant D2S123 alleles in MMR-
deficient (lbl-1261) (A) and -proficient (lbl-c5) (B) lymphoblast cell lines as
detected by SP-PCR. Arrows indicate wild-type alleles as identified by analy¬
sis of undiluted DNA. Equal numbers of short and long alleles and their
respectively assigned mutants were identified indicating that there is not a PCR
preference in detecting shorter alleles. A significant mutation bias at the 214 bp
progenitor allele in lbl-1261 is demonstrated (x2 = 42.3, P < 0.00001).
ently. This demonstrated that the 228 bp allele comprised of a
(CA)28 repeat tract split into two runs of (CA)I3 and (CA)I5 by
a TA dinucleotide, concurring with the sequence logged in
GenBank. However, the shorter 214b bp allele comprised of an
uninterrupted (CA)22 repeat with no interspersing TA dinucleotide
(Fig. 3). Genotyping and sequencing of 15 D2S123 alleles
from template DNA of a cohort of Scottish individuals showed
that various length alleles classified as long always contained
the TA interspersion, whereas various lengths of short alleles
were invariably uninterrupted poly(CA) repeats. This analysis
indicated that alleles clustered around 214 bp (short) contain
perfect uninterrupted CA repeats. In contrast long alleles
consistently contain a TA interspersion within the CA tract.
In order to confirm definitively that mutant alleles arose
predominantly from uninterrupted alleles in cell line lbl-1261,
D2S123 alleles were PCR amplified from undiluted lbl-1261
template DNA and cloned. Individual alleles were sized and
sequenced. Analysis of 28 clones confirmed that every long
allele analysed contained the TA interruption and every short
allele contained perfect CA repeats, thereby confirming that
the presence of a TA interspersion confers stability on the CA
repeats. Mutation was due to length variation of the number of
core CA repeats in every case, implicating replication slippage
as the causative mechanism of instability at this locus
(Table 3). Cell line lbl-c5 was heterozygous for two short
alleles and PCR cloning of undiluted DNA revealed two short
uninterrupted alleles of (CA)2I and (CA)22 repeats. As expected
in this MMR-proficient cell line, no mutations were detected in
the clones despite both alleles having no interspersion of the
repeat tract (data not shown).
Taken together these data indicate that long alleles (-228 bp)
invariably contain a TA interspersion in the repeat whereas
short alleles (-214 bp) contain uninterrupted (CA)„ repeats that
are inherently more unstable. This instability is unmasked in
MMR-deficient cell lines.
Table 1. Summary of mutant alleles detected by SP-PCR in cell lines lbl-1261
and lbl-c5
Cell line Total no. of alleles Mutants (frequency)
lbl-1261 270 90 (0.33)
lbl-c5 115 2(0.17)
lbl-1261 is significantly more unstable than control cell line lbl-c5 (x2 = 42.3,
P< 7x 10"").
Mutation rate within the D2S123 CA repeat is predicted
by sequence content
The sequence for D2S123 logged in GenBank is
(CA)i3(TA)(CA)|5 (GenBank accession no. Z16551). Indi¬
vidual alleles were sequenced to determine whether sequence
differences between long and short alleles might explain the
substantial mutation bias. Initially undiluted lbl-1261 DNA
was gel separated and individual alleles sequenced independ-
Allele-specific bias of mutations at D2S123 in DNA
MMR-deficient tumours
To determine whether allele bias might also influence MSI
phenotype in MMR-deficient tumours, we genotyped D2S123
alleles in matched normal and tumour DNA samples from 41
colorectal cancer patients with MSI+ tumours. These have been
characterized previously and exhibit MSI at four or more
markers. In some cases the germline mutation has been identi¬
fied (unpublished data) (34). Normal tissue was genotyped for
D2S123 alleles and the stability of each allele assessed in
matched tumour DNA. Thirty of the 41 tumours exhibited
mutation at one or more D2S123 alleles and overall 37 of the
82 alleles (45%) had mutations. There was a significant bias in
the frequency of mutations at the short alleles compared with
long alleles (Fig. 4). Of 53 small wild-type alleles identified,
32 (60%) displayed instability in the tumour tissue compared
with only 5 of 29 (17%) large alleles (x2i= 12.4, P = 0.00043).
Thus, constitutional allele sequence is a determinant of the
propensity for instability at a given locus in the presence of
defective MMR. This has important implications for the classi¬
fication of clinical material with respect to MSI status.
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Table 2. Comparison of D2SI23 allele frequencies between CEPH database and 39 Scottish individuals
Number Size of fragment" (bp) Frequency (CEPH data) Frequency (Scottish data) Category
1 228 0.304 0.244 Long
2 212 0.339 0.41 Short
3 216 0.107 0.089 Short
4 214 0.125 0.128 Short
5 215 0.054 0.026 Short
6 198 0.018 0.00 Short
7 226 0.018 0.064 Long
8 210 0.036 0.013 Short
u 230 0.00 0.026 Long
Our genotyping data for a small Scottish cohort is in agreement with those from CEPH family analysis. We did
not identify any 198 bp alleles; however, a previously undocumented allele size of 230 bp (u) was observed.
"Our allele sizes (shown) genotyped exactly 1 bp longer than the corresponding CEPH alleles. This is likely to
be due to difference in primer length.
A
ITdCHCHCHCnCHCRCHCflCflCaCflCflCnCflCncaCHCHCRLnCflTRr I
70 SO 90 100 110
B
Figure 3. Sequence analysis of the two progenitor D2SI23 alleles in lbl-1261.
The short allele (A) consists of an uninterrupted (CA)22 tract. The long wild-
type allele (B) consists of (CA)13 repeats followed by a TA dinucleotide and
then another run of (CA)15 repeats.
DISCUSSION
We studied a paradigm CA repeat microsatellite locus,
D2S123, and have shown that a cell line derived from non-
tumour tissue displays a mutator phenotype and that the
resultant accumulation of mutations is predicted by host geno¬
type at each allele. D2S123 is used routinely in tumour MSI
analysis and shows inter-allelic sequence variability for an
interruption within the repeat tract. By genotyping and direct
sequencing of individual alleles, we have demonstrated that
defective MMR results in insertion and deletions of CA repeat
units, which accounts for the variation in size of mutant alleles.
In addition, alleles without a TA interspersion within the repeat
tract are significantly more susceptible to instability as a
consequence of defective MMR. Equal numbers of long and
short alleles and their respectively assigned mutants were iden¬
tified. Furthermore, insertion and deletion mutants derived
from both progenitor alleles were detected. Such findings
argue strongly against the trivial explanation that these obser¬
vations are due to PCR bias in detecting shorter mutants at this
locus. The analysis of a cohort of MSI+ colorectal cancer
patients provides further confirmation that patient genotype
directly influences manifestation of a mutator phenotype and
the likelihood of MSI status being scored accurately.
Other studies that have addressed differences between loci in
human populations and in colorectal cancers also show that
perfect repeats are more susceptible to instability (8,9,11).
However, this study is the first to demonstrate that variant
interruptions can occur between alleles at the same marker loci
and that these have a marked effect on individual allele
stability. We show that the stabilizing effects of a variant
repeat is apparent even in the presence of defective MMR,
supporting a previous report (8). These results suggest that
different alleles at the same marker loci can display genotypic
variation, substantially affecting susceptibility to mutation.
Several studies have suggested that the mechanism of micro-
satellite mutation in MSI+tumours shares similarity with the
evolution of such sequences in the genome (11,20). D2S123
population allele frequencies from both our own data and that
of the CEPH database highlights higher frequencies of short
alleles. The CEPH database (http://www.cephb.fr/cephdb/ )
documents six short D2S123 alleles compared with two long
ones (Table 2). This would be expected if short alleles with
perfect repeats are more susceptible to mutation as our results
from MMR-defective cells suggest. These mutations could
then be fixed as new alleles. The absence of many length vari-
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Table 3. Sizing and sequencing of D2SI23 clones from lbl-1261
Allele size" (bp) Sequence No. of clones Category
208 (CA), 3 Short
210 (CA)2 6 Short
212 (CA), 4 Short
214 (CA), 5 Short
216 (CA), 2 Short
224 (CA)|,TA(CA), 1 Long
226 (CA)|,TA(CA), 1 Long
228 (CA)I3TA(CA), 5 Long
230 (CA)i4TA(CA), 1 Long
The sequences of the CA repeat region only are indicated.
"Size of alleles as shown by ABI 310 analysis. Allele sizes of 208-216 nucleo¬
tides are classed as short and those of 224—230 nucleotides are long (see text).
All short alleles contain perfect CA repeats in contrast to long alleles that have
a TA interspersion. Variation in allele size is wholly accounted for by differ¬
ences in the number of CA repeats.
M loss of heterozygosity □ stable 0 unstable |
Figure 4. Tumour DNA instability at D2SI23 alleles in 41 VISI' colorectal
cancer patients. Long and short alleles were compared between matched nor¬
mal and tumour DNA and assessed for stability. There is a significant excess of
mutations at short alleles (y2 = 12.4, P = 0.00043).
ants of the long alleles is also consistent with our sequence data
showing that long alleles invariably contain the stabilizing
interspersion.
It is generally accepted that replication slippage is the major
mechanism causing new mutations in microsatellites (35). The
results presented here are consistent with models in which a
variant interruption causes stabilization by encouraging the
perfect realignment of the two strands following their dissoci¬
ation during such DNA polymerase slippage. However, the
possibility that interruption of the repeat tract may alter some
unusual structure associated with the repeats and subsequently
reduce the rate of slippage cannot be wholly discounted (8).
The majority of mutations occurring at CA microsatellites
have been shown to involve small length changes in which one
or two repeats are altered (8,10,36). Mutations of repeat tracts
in cancer genes of MSI+ colorectal tumours characteristically
display small frameshift mutations (37,38). The mutations
identified here at the D2S123 locus also involve the gain or
loss of one or two repeat units in the majority of cases. In the
cell line lbl-1261, short mutant alleles always contained perfect
repeats, whereas long mutant alleles consistently possessed a
TA interruption. The absence of any short mutants with a
repeat interruption, or long mutants without an interruption or
of mutants with duplicated TA interspersions argues against
the occurrence of large sequence alterations in excess of a few
repeats. This is consistent with hPMS2 being involved in the
repair of small insertion/deletion loops (39).
Defects in MMR result in genome-wide accumulation of
mutations at repetitive microsatellite sequences. We have used
a cell line derived from a non-tumor lineage with a dominant
negative MMR mutation to investigate inter-allelic MSI. This
system has distinct advantages over using cancer cell lines.
Cancer cell lines are subject to selection pressures for muta¬
tions that provide the neoplastic cell with a distinct growth
advantage, thus evolving clonally and making them largely
homogenous for mutations at any given microsatellite. In addi¬
tion they accumulate multiple mutations and abnormalities,
making the dissection of events resulting directly and exclu¬
sively from MMR defects difficult.
These data show that host genotype at CA repeat sequences
can influence the ability of available marker sets to assign MSI
status to any individual tumour. Therefore, these findings have
important clinical relevance regarding MSI screening strategies
and the effects of individual patient genotype on these
analyses. Tumour MSI status is used to determine whether
HNPCC may be discounted or whether analysis of MMR
genes is required. Additionally there have been a number of
reports indicating that MSI status may be used as a predictor of
survival and can be employed as a clinical tool with which to
give patient survival estimates (40—41). An accurate assess¬
ment of MSI status is therefore of critical importance. The
other four microsatellite markers in the recommended panel
(29) are entered in GenBank as uninterrupted (CA)n or (A)n
repeats. However, the CEPH database (http://www.cephb.fr/
cephdb/ ) indicates that they are polymorphic for different
sized alleles. Such analysis by length may mask further under¬
lying individual genotype differences at these markers. In any
case, the phenomenon described here for D2S123 alone is of
importance and the influence of patient genotype at this partic¬
ular marker may be particularly critical in the diagnosis of
borderline MSI cases. The data from this study highlight the
need for a well-characterized set of diagnostic markers in
which allelic variance and the intrinsic effect on stability is
well understood. Suggestions that one or a few microsatellite
markers are sufficient to assess MSI status should perhaps be
treated with caution, especially when there may be significant
implications for both the patient and the family (29,30,42). The
marker studied here is logged in GenBank as an interspersed
microsatellite. However we have shown that this does not
reflect the underlying complexity of this locus. Many other
markers may share similar intrinsic variances in allelic stability
and the phenomenon may be widespread.
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MATERIALS AND METHODS
Lymphoblast cell lines and tumour samples
Epstein-Barr virus (EBV) transformed lymphoblast cell lines
were cultured from a healthy control individual (lbl-c5) and
from the non-tumour tissue of a patient with colorectal cancer
who had a family history of the disease (lbl-1261). Cell line
lbl-1261 is derived from patient 6 referred by Parsons et al.
(31) and displays a mutator phenotype due to a dominant nega¬
tive mutation in hPMS2 (31,43).
Matched tumour and normal DNAs were previously isolated
from 41 colorectal cancer patients shown to have defective
MMR and a mutator phenotype. The causative MMR gene
mutations have been defined in a number of cases (unpub¬
lished data) (34).
All patients with suitable material available whose tumours
fulfilled MSI criteria were analysed in this study, regardless of
whether or not D2S123 showed length variation in tumour
DNA. There is potential bias because MSI criteria include
D2S123 genotyping and so some patients with homozygous
long alleles may be underscored with respect to MSI status.
However, this does not impact adversely on the findings of
these studies.
SP-PCR
We devised an assay to genotype D2S123 alleles, using an SP-
PCR strategy in order to investigate the mutational behaviour
of individual alleles. A similar approach has been used previ¬
ously to detect mutations within populations of wild-type
alleles (44,45). DNA from EBV transformed cell lines was
diluted to a final concentration of 15-20 pg per PCR reaction
to give up to three input molecules of each D2S123 allele per
amplification (assuming 6 pg of DNA per diploid genome).
Due to the dilute nature of the DNA, alleles were detected in
-30% of analyses. Fluorescently labelled D2S123 primers
were used in all PCR reactions (31). PCR amplifications were
performed in a final volume of 25 pi. Final reaction concentra¬
tions were lx PCR Buffer II (Boehringer, Mannheim,
Germany), 0.2 mM dNTPs, 3.7 pM oligonucleotide primer and
0.87 U of Expand high fidelity PCR system enzyme mix. Reac¬
tions were prepared in 96 well plates. DNA-free controls were
prepared in 16 of the wells in each plate and positive controls
containing 100 ng of cell line DNA were prepared in 2 wells in
every plate. Amplification was performed using an Omnigene
PCR system thermal cycler (Hybaid) at 94°C for 3 min for
1 cycle, 94°C for 1 min, 55°C for 1 min, 72°C for 1 min for
35 cycles, 72°C for 5 min for 1 cycle. Two microlitres of each
PCR reaction, including positive and negative controls, were
analysed on an ABI 310 Automated Genetic Analyser, using
Genescan software. For each DNA sample 100-250 SP-PCR
products were generated and analysed. The frequency of
mutant alleles in each cell line was expressed as the number of
alleles which were mutant in length divided by the total
number of alleles detected (normal and mutant). Accordingly,
percentages are not exact contents of cells with alterations, but
relative values of alleles. Differences between MSI frequency
in the two cell lines was evaluated by y2 test and significance
taken at 5%. Mutant allele origin was determined by assign¬
ment to the progenitor allele closest in size according to
previous studies and our own experiments (2,8,32). Differ¬
ences in mutation frequency of each progenitor allele was eval¬
uated by x2 test. To account for the possibility that some
mutants did not derive from the progenitor allele closest in
size, a further more stringent assessment was performed by
assuming that only mutants of <216 bp were derived from the
smaller allele.
Sequencing D2S123 alleles
D2S123 alleles were amplified from undiluted cell line DNA
using non-fluorescent primers and the aforementioned high
fidelity PCR system and electrophoresed on a 3% Nusieve GTG
agarose (Bioproducts, Rockland, ME) 1% 'Hi Pure' low EEO
agarose (Biogene, Kimbolton, UK) gel in lx TBE buffer at 30 V
overnight and individual progenitor alleles gel purified (Qiagen,
Crawley, UK). Sequencing was performed using PRISM Ready
Big Dye Terminator Cycle Sequencing kit with AmpliTaq DNA
polymerase, FS (Taq-FS; Perkin Elmer/Applied Biosystems,
Branchburg, NJ) and Applied Biosystems DNA sequencer
model 373A or 377, according to the manufacturer's instruc¬
tions. D2S123 alleles from lbl-1261 and lbl-c5 were cloned into
the TA cloning vectors (Invitrogen, Groningen, The Nether¬
lands) according to the manufacturer's instructions. Genotyping
and cycle sequencing of transformants was performed as above.
Allele-specific bias in MSI tumours
One hundred nanograms of normal and tumour DNA templates
were used in 50 pi PCR reactions as described. Analysis of
individual allele shifts was made by comparison of Genescan
profiles on the ABI analyser from normal and tumour DNA.
Whenever there were doubts about the veracity of a mutation
we did not include it. This applied to cases where the patient
harboured two short alleles. On occasions it was questionable
as to whether one or both alleles had mutated. Such cases were
scored as shifting at just one of the alleles. Mutation frequency
may therefore be marginally underestimated if both alleles had
mutated and the presence of any wild-type allele in the tumour
was due to contamination from surrounding normal mucosa.
Observed differences in mutation frequency at each allele were
evaluated by a y2 analysis.
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ABSTRACT
Poly(A/T) tracts are abundant simple sequence
repeats (SSRs) within the human genome. They
constitute part of the coding sequence of a variety of
genes, encoding polylysine stretches that are impor¬
tant for protein function. Assessment of poly(A/T)
tract stability is also used to identify microsatellite
unstable colorectal cancers, which are characteristic
of tumours defective in DNA mismatch repair.
Despite their importance, little is known about the
stability of poly(A/T) SSRs in the human germline. We
have determined the stability of a paradigm poly(A/T)
tract, BAT-40, by study of population allele frequen¬
cies, mutation frequency in families and mutation
frequency in sperm DNA. We show that the locus is
polymorphic, with a level of heterozygosity of 59.7%.
Germline mutation was observed in 13 of 187 germ¬
line transmissions (7.0%) in 10 families suggesting
BAT-40 is unstable in the germline. Further evidence
for germline instability at BAT-40 was provided by
small pool PCR analysis of matched blood and sperm
DNA templates, revealing a significantly elevated
frequency of mutation in the germline (P < 0.001).
These findings provide insight into poly(A/T) tract
stability in the germline. They also have relevance to
the study of gene expression and to determination of
microsateliite instability in tumours.
INTRODUCTION
Simple sequence repeats (SSRs) occur ubiquitously
throughout the genome. Many are highly polymorphic, making
them of particular importance to the study of evolution and the
mapping of disease genes (1). SSRs such as poly(A/T) and
(CA)n are routinely used in determining microsatellite instability
(MSI) status in mismatch repair (MMR) deficient colorectal
cancers (CRCs) (2-5). The proportion of markers that display
mutational shifts in the tumour directs subsequent analysis for
germline MMR mutations that lead to this MSI phenotype (6).
Factors affecting the mutation frequency of microsatellites
have been studied in MMR deficient tumours since analysis is
rapid and material readily available (7,8). We have previously
demonstrated that constitutional genotype at a given micro-
satellite locus influences the propensity for instability in the
presence of defective MMR (7). Such studies highlight the
need for a well-characterised panel of markers to be used for
such assessments, in order for them to be employed with confi¬
dence.
It has been shown that mechanisms generating mutations in
microsatellite unstable (MSI+) tumours have relevance to
understanding the evolution of such sequences in the germline
(8). Investigation of determinants of germline mutation at SSR
loci is laborious and frequently requires analysis of many
hundreds of gametes in family studies (9,10). However, the
development of small pool PCR (SP-PCR) techniques in studying
germline stability at minisatellites has facilitated investigations
of such mutations at other SSRs (11,12).
To date, many studies of germline mutation at SSR loci have
focused on understanding sequence instability of the trinucleotide
repeat disorders (13-16). In addition, investigations have been
carried out on germline stability of dinucleotide repeat
markers, including long CA stretches (10). However, there has
been little investigation of the stability of mononucleotide
tracts in the germline. This is surprising since poly(A/T)
repeats are the most abundant simple repetitive sequence motif
in the human genome (17) largely due to the poly(A/T) tails of
scattered retrotransposed sequences such as long (LINEs) and
short interspersed elements (SINEs) (17,18). Coding poly(A/T)
sequence tracts have been identified with repeat lengths of up
to 27 bp and within introns they may occur up to 70 bp in
repeat length (17). Any process influencing the fidelity of
replication at coding sequence mononucleotide tracts will
clearly have important functional effects. The transforming
growth factor beta receptor type 2 (TGFBR2) gene contains a
poly(A/T)K) tract in exon 3 that has been shown to be mutated
in up to 90% of MSI+ tumours, resulting in inactivation of the
gene (19-21).
In view of the prevalence of poly(A/T) stretches and their
functional relevance we were interested to gain insight into the
inherent stability of such sequences. The microsatellite BAT-40 is
a paradigm mononucleotide marker consisting of 40 adenine
repeats located in intron 2 of the 3-beta-hydroxysteroid dehydro¬
genase (3-beta-HSD) gene on chromosome 11 (22). BAT-40 is
highly sensitive to the effects of defective MMR, since it is
susceptible to mutation in >95% MSI+ tumours and thus is
used routinely in the analysis of MSI (5,21,23,24). Previous
studies have also demonstrated that BAT-40 exhibits significant
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polymorphism within populations (25,26). Hence we hypothe¬
sised that BAT-40 and other long poly(A/T) repeats might be
unstable in the germline.
We analysed germline stability at the BAT-40 locus as a
paradigm poly(A/T) tract, in order to gain insight into the
generation of new mutations at such sequences. Assessment of
the degree of mutability at such a locus might have considerable




Genotyping was carried out on the constitutional DNA of 102
unrelated Scottish individuals and 35 unrelated CEPH family
members from the nine families listed below.
A Scottish Family, K-435, was used for pedigree analysis.
Family relationships were confirmed by genotyping, using a
panel of microsatellite markers (data not shown). This family
was identified previously as being an HNPCC kindred with
affected individuals displaying tumour instability as determined
using a panel of microsatellite markers. Proband MD-473 was
previously determined to be heterozygous at BAT-40 with two
alleles differing by 12 bp in length thus making individual
allele identification obvious. MD numbers represent our labora¬
tory sample identification system. DNA samples were avail¬
able from the peripheral blood leukocytes of 20 individuals
from this family.
DNA from nine CEPH families (66, 1331,1341, 1346, 1362,
1377, 1423, 13293 and 13294) was used for further pedigree
analysis to provide a total of 176 germline transmissions for
study.
SP-PCR was carried out on matched constitutional and
germline DNA samples from two further unrelated individuals.
MD-949 carries a germline mutation in the MMR gene, human
MLHl, resulting in a deletion of exon 12 (codons 347—470).
MD-cl is a healthy control individual.
Preparation of constitutional DNA and BAT-40 genotyping
Constitutional DNA was extracted from blood using Nucleon
II DNA extraction protocol (Scotlab Bioscience, Strathclyde).
BAT-40 alleles were amplified from DNA templates in tripli¬
cate using primers described previously (24). These primers
amplify a 126 bp product containing the standard 40 A residues
according to the genomic sequence of the 3-beta-HSD gene
(GenBank accession no. M38180) (22). We were not able to
assess the number of adenine repeats in a given sized allele
directly, since repeated attempts at sequencing across the
BAT-40 locus were unsuccessful. Therefore repeat length is
based on the theoretical predicted amplified sequence both in
this and in the majority of other studies that report BAT-40
repeat length.
PCR reactions were performed in a final volume of 25 pi
using the Expand High Fidelity PCR system (Boehringer
Mannheim, Germany). Final reaction concentrations were
lx PCR buffer II, 0.2 mM dNTPs, 100 ng oligonucleotide
primer, 100 ng DNA and 0.87 U of Expand high fidelity PCR
mix. Amplifications were performed using an Omnigene PCR
thermal Cycler (Hybaid) at 94°C for 3 min for 1 cycle; 94°C
for 1 min, 55°C for 1 min, 72°C for 1 min for 35 cycles; 72°C
for 5 min for 1 cycle. PCR products were size analysed using
an ABO 10 Automated Genetic Analyser, using Genescan soft¬
ware.
Sperm DNA preparation and SP-PCR
DNA was extracted from sperm as described by Jeffreys el ai.
(27). Pelleted semen was rinsed three times with 20 ml lx SSC
followed by six washes with 20 ml Ix SSC and 1% SDS to lyse
any seminal leukocytes and epithelial cells. The residual sperm
pellet was incubated in lx SSC and 1 M 2-mercaptoethanol at
room temperature for 5 min and the reduced sperm lysed by
addition of SDS to 1%. Sperm DNA was collected after phenol
extraction by ethanol precipitation and resuspended in Tris-
EDTA pH 7.7. DNA concentration was calculated using a
spectrophotometer to measure the optical density of DNA
samples in triplicate and also by running samples against
standards of known DNA quantity using gel electrophoresis.
SP-PCR and analysis of PCR products was performed as
described (7). DNA from matched blood and sperm samples
were serially diluted to a final concentration of 15-20 pg per
PCR reaction. This results in an estimated five to six template
BAT-40 alleles in total, per reaction (assuming 6 pg of DNA
per diploid genome). Limiting dilutions were carried out and
final DNA concentrations resulted in the detection of a product
in -30% of analyses corresponding to products that represent
single DNA templates (11,28). PCR reactions were then
performed as described above in 96 well plates using the
Expand High Fidelity PCR System (Boehringer Mannheim,
Germany). Avoidance of contamination was paramount when
amplifying dilute DNA templates. Therefore all reactions were
carried out in a Class-2 containment hood. All pipettes and
plastics used in the preparation of the SP-PCR reactions were
UV irradiated for 20 min in a Template Tamer (Oncor). Buffer
solution and sterile water were opened under sterile conditions
and also subjected to UV irradiation. On each plate, 16 wells
were DNA free to provide negative controls and positive
controls containing 100 ng of undiluted sample DNA was
prepared in two wells on every plate to ensure reproducibility
of ABT310 profiles between plates. Matched sperm and blood
DNA samples and SP-PCRs were prepared simultaneously,
using the same reagents to allow direct comparison. Amplifica¬
tions were performed as above and SP-PCR products and posi¬
tive controls were size analysed using ABO 10 Automated
Genetic Analyser and Genescan software. All 16 negative
controls from every SP-PCR plate were also analysed and if a
product was observed in any negative sample, the entire plate
was discarded.
Determination of the origin of new alleles
In instances where the origin of 'new/mutant' alleles was
inferred, this was done in the same manner as in published
studies (e.g. 10). The origin of'new/mutant' alleles is such that
if there were two possibilities, the shortest mutational step was
considered to be the actual one. For example, if one progenitor
allele differed by one repeat and the other by two repeats, when
compared to the mutant, a one step mutation was inferred. If
two progenitor alleles exhibited the same difference when
compared to the new/mutant one, the origin was declared
ambiguous.
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Statistical analysis
Statistical comparison of population allele size frequency at
the BAT-40 locus was carried out using a Mann-Whitney
U test on the Minitab (V.13) statistical package. Significance
was taken at the 5% level.
For comparison of mutation levels between matched sperm
and blood samples, the frequency of mutant alleles in each
sample was expressed as the number of alleles that were
mutant in length divided by the total number of alleles detected
(normal and mutant). Accordingly the frequency of mutants
was not the exact number of cells with alterations but repre¬
sents the relative proportions of alleles. Statistical analyses
were then performed using a chi-squared analysis on Minitab
(V.13) statistical package, and significance taken at the 5% level.
RESULTS
The BAT-40 poly(A/T) locus is polymorphic
BAT-40 genotypes were defined in 104 unrelated Scottish
individuals and 35 unrelated CEPFI family members (Table 1).
Representative ABO 10 profiles arc shown in Figure 1. PCR
products displaying a single complex of peaks with a near
normal distribution were counted as homozygous (Fig. 1A).
Those with extra peaks were regarded as BAT-40 hetero¬
zygous (Fig. 1B-D). The allele traces of the BAT-40 mononu¬
cleotide marker are complex with 'stutter' peaks evident due to
DNA polymerase slippage. However, 'bona fide' allele sizes
are taken to be the predominant peak in each separate peak
complex in accordance with previous studies (Fig. 1) (26,29).
The predominant peak is that with the greatest peak area as
indicated by the ABB 10 genetic analyser software. Our own
previous analysis of this locus by SP-PCR analysis of multiple
single alleles in three individuals has also validated this method
of allele sizing at the BAT-40 locus. The most predominant peaks
as genotyped from constitutional DNA are detectable as indi¬
vidual alleles by SP-PCR (Fig. 2). PCR error is evident when
amplifying BAT-40, by nature of the stutter bands that are
observed (Figs 1 and 2). However, reproducibility of the
prominent peaks in a given individual assures confidence in
the sizes given (see Materials and Methods). Where the geno¬
type of an individual could not be confirmed by reproducibly
detecting the same peaks in the allele trace, these individuals
were discarded from further analysis (three cases).
The distribution of BAT-40 heterozygous genotypes also
indicates that amplification and detection of two BAT-40
alleles of different sizes is due to the difference in genotype
and not technical artefact (Table 1).
Allele frequency and distribution for both the Scottish and
the CEPH cohorts are shown in Figure 3. Of the 139 samples
analysed, a total of 83 demonstrated heterozygosity at the
BAT-40 locus (59.7%). Levels of heterozygosity were similar
between the cohorts, 58.7% (61/104) in the Scottish population
and 62.9% (22/35) in the CEPH cohort. As expected for a
highly polymorphic marker the overall distribution of allele
sizes was not significantly different between these two popula¬
tions (P = 0.056) (Fig. 3). Allelic size variation was from -15
to +11 as compared to the most frequent allele. Taking into
account variation in the cohorts studied, these data are in
line with a previous study reporting polymorphism at this
Table 1. Levels of heterozygosity at the BAT-40 locus
Allele set Frequency detected in Frequency detected in
(bp) Scottish cohort CEPH cohort
(% n=104) (% n = 35)












































Frequency of individual BAT-40 genotypes in the Scottish and CEPH
cohorts analysed are indicated. Allele sets are given in base pairs and are
grouped according to whether or not the genotype is heterozygous.
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Figure 1. ABB 10 traces of BAT-40 poly(A/T) PCR products show the poly¬
morphic nature of this microsatellite marker in samples from a Scottish
cohort. Blood DNA shows a single complex of peaks, the highest being 123 bp
(A). (B-D) Heterozygosity at BAT-40 as illustrated by separate peak complexes.
Figure 2. Genotyping of the BAT-40 locus in constitutional DNA is validated
by SP-PCR analysis. (A) Constitutional BAT-40 allele sizes in cell line lbl-
1261 are revealed as 120 and 124 bp from analysis of undiluted DNA. (B and
C) In SP-PCR analysis of DNA from the same cell line, individual alleles of
120 and 124 bp are easily determined and confirm the genotype revealed from
the undiluted DNA. (Data taken from ref. 33).
mononucleotide marker for a large number of different alleles,
and are suggestive of the frequent generation of new alleles at
this locus (25). The most frequent allele in both cohorts in this
study (123 bp) corresponds to a 37-adenine tract as calculated
from the genomic sequence (GenBank accession no. M38180).
However, the BAT-40 heterozygosity reported here differs in
both frequency and size distribution to that observed in a Japanese
study despite the use of similar methodology (29).
Germline hypermutability at BAT-40 in pedigree analysis
Since BAT-40 displays high levels of polymorphism in popu¬















\ r"k _ p_ _ ■ 1 Irl _(1 _
108 110 112 114 116 118 1 20 1 22 12' 126 128 130 132 134
allele size
Figure 3. Comparisons of BAT-40 allele frequencies between Scottish and
CEPH populations. The sizes of each allele are given in base pairs. The estimated
size of the standard BAT-40 allele with 40 adenine repeats is 126 bp as calculated
from the predicted PCR product size (GenBank accession no. M38180). There
is no statistical difference in the distribution of alleles within the two cohorts
(P = 0.073).
susceptible to instability in MMR deficient tumours (21), we
reasoned that BAT-40 may be inherently unstable and that
germline mutations might be detectable in family studies. A
Scottish family. K-435, was chosen to determine whether a
high level of germline mutation occurs within this population.
Proband MD-473 had previously been identified as hetero¬
zygous at BAT-40, with two distinct sized alleles at this locus
(112/124). Analysing the meiotic stability of BAT-40 alleles
that are easily distinguished by size allows for the most
accurate assessment of individual allele stability at a complex
locus such as BAT-40. DNA from 20 available individuals
from K-435 was genotyped at the BAT-40 locus (Fig. 4A).
There were 11 germline transmissions available for study.
Within the family there was striking evidence of a germline
mutation in the allele transmission from MD-1303 to MD-449.
MD-1303 is heterozygous for BAT-40 with an allele set of
120/124 but her daughter (MD-449) is homozygous for two
112 BAT-40 alleles (Fig. 4). DNA was unavailable from the
father of MD-449 who is very likely to have carried at least one
112 allele, inferred from sibling and progeny genotypes.
Therefore the mutation is implicated as being maternal in
origin showing loss of repeats at the BAT-40 locus. The 112/112
homozygous allele is highly unlikely to have arisen by dropout
of the larger 120 or 124 bp allele during PCR because four
family members including MD-439, the sister of MD-449, had
112/124 genotypes that were easily detected under the PCR
conditions used (Fig. 4). This indicates that the technique reli¬
ably detects the larger alleles. Furthermore, the 120 bp allele in
MD-1303 was faithfully amplified (Fig. 4B). Genotyping for
all members of this family was confirmed in triplicate and
previous genotyping at microsatellite markers confirmed that
MD-1301 was indeed the mother of the twins MD-449 and
MD-439 (data not shown).
The observation of a germline mutation in only 11 allele
transmissions is striking, since only one mutation event in
3000-5000 transmissions has been reported for CA repeats
(10). This led us to further investigate the possibility that BAT-40
is highly unstable in the germline and that mutant alleles might
be transmitted in subsequent generations, to manifest as poly¬
morphism within the population.
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Figure 4. (A) BAT-40 genotypes of blood DNA from available samples of pedigree K-435. A single incidence of transmissible germline hypermutability is high¬
lighted. Mother MD-1303 has allele set 120/124 whereas daughter MD-449 (arrow) is homozygous for 112. (B) The ABI310 profiles of the BAT-40 alleles of MD-
1303 and MD-449 are shown. There is no indication of the presence of either of MD-1303's alleles in MD-449. Although DNA was not available from the father
it is likely that he carried at least one 112 allele as inferred from siblings such as his sister MD-436. The profile of MD-439 also demonstrates that there is not a
problem in detecting the 124 allele in the presence of the 112 allele.
(Jermline hvpermutability in CEPH family analysis
To further explore germline instability at BAT-40, we analysed
BAT-40 alleles in a CEPH family panel. Nine CEPH families
were genotyped at the BAT-40 locus, totalling 176 germline
transmissions analysed, and 12 putative mutations (6.8%) were
identified (Table 1). However, in all cases, heterozygous
parental alleles differed by only a few base pairs and the muta¬
tions indicated involved small (1 bp) changes (Table 1 and Fig. 5).
Of the 88 maternal transmissions analysed, three were mutant
at BAT-40 (3.4%) and of the 88 paternal transmissions
analysed, nine were mutant (10.2%). This difference was not
statistically significant (%2 = 3.22, P = 0.073). Insertions and
deletions appeared to occur equally.
The mutations identified in CEPH families provided further
support for our initial observation that BAT-40 is hypermut-
able in the germline. The CEPH data add further weight to the
identification of the germline mutation in family K-435 and
also to the evidence from the high levels of heterozygosity at
BAT-40 in the Caucasian population study demonstrating high
levels of heterozygosity at BAT-40. However, although the
CEPH mutations were reproducible, the small changes
observed in the complex BAT-40 profile led us to devise a
further, rigorous method to analyse susceptibility of this locus
to mutation in the germline.
Inherent hypermutablity of BAT-40 in the germline
demonstrated by small-pool PCR analysis of sperm DNA
SP-PCR analysis of germline DNA has important advantages
over family studies for analysing germline stability at complex
loci (11,15). The method overcomes the practical constraints
encountered during pedigree analyses, which suffer limitations
from the small number of mutants that can be identified. In
contrast, many hundreds of gametes can be analysed from a
single semen sample and consequently, a greater variation in
allele size changes may be available for identification. In addi¬
tion, the dilution of the DNA sample aids unambiguous allele
identification at a hypermutable locus. Mutation frequency as
detected in sperm DNA has been shown to reflect estimations
from studies in pedigrees (11). Comparisons of sperm DNA
and constitutional DNA templates have shown that SP-PCR
reliably discriminates alleles in both and that there are no
demonstrable differences in technical artefact between the two
sample templates (11). In addition SP-PCR has been demon¬
strated to reliably detect differences in intra-allelic mutation
frequency in sperm DNA (11,14—16). For SP-PCR of sperm
DNA, study subjects were selected as being constitutionally
heterozygous at the BAT-40 locus with individual wild-type
alleles easily distinguished by size. MD-cl had allele sizes
120/124 and MD-949 had alleles of size 121/124. Correct iden¬
tification of constitutional allele sizes was further supported in
the SP-PCR analysis where individual alleles of the same
predominant allele size were detected (Fig. 6). Approximately
100 SP-PCR products were analysed per sample. BAT-40
allele sizes typed from constitutional and sperm DNA
templates by SP-PCR are shown in Figure 7. Mutant alleles
were detected in sperm DNA by comparison with constitu¬
tional genotype (Fig. 6). The frequency of mutant alleles
detected in each sample is summarised in Table 3. In both MD-cl
and MD-949 matched samples, there was a significantly
greater number of mutant alleles detected in sperm DNA
compared to that of matched blood leukocyte DNA samples
(X2 = 19.32, P < 0.001 and %2 = 13.82, P < 0.001 for MD-cl
and MD-949, respectively). A total of 9/198 (4.5%) alleles in
the leukocyte DNA were mutant compared to a total of 64/255
(25.1%) mutant alleles in the sperm templates, indicating an
almost 6-fold increase in mutation accumulation in the germ¬
line. The proportion of mutant alleles in blood and sperm was
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Table 2. Putative BAT-40 mutations detected in germline transmissions of CEPH families
Family Genotype (father) Genotype (mother) Genotype (child)
66 122/123 (f, -01) 124/127 (m. -02)* 123/126 (c/m, -03)
123/123 (fm,-12)* 124/127, (mm,-14) 124/127 (m, -02)
1331 123/123 (f, -01)* 119/123 (m, -02) 119/124 (c/m,-17)
1341 120/123 (f,-01)* 123/125 (m, -02)a 119/125 (c/f, -05)
120/123 (f,-01)* 123/125 (m, -02)a 119/125 (c/f, -08)
1346 123/123 (f,-01)* 122/127 (m, -02) 124/127 (c/f, -08)
123/123 (f, -01)* 122/127 (m, -02) 124/127 (c/f, -09)
1362 120/120 (fm, -15) 121/123 (mm,-16)* 120/120 (m, -02)
121/123 (f,-01)* 120/120 (m, -02) 120/120 (c/f, -04)
1377 120/124 (ff,-10) 120/122 (mf,-11)* 120/121 (f,-01)
120/121 (f,-01)* 119/122 (m, -02) 122/123 (c/m, -08)
13293 120/123 (f, -01)* 108/109 (M, -02) 109/124 (c/m, -09)
Transmissions in which a germline mutation was indicated are described. The genotype of the child
along with both parents is presented. The inferred origin is highlighted by an asterisk. The CEPH pedigree
number, individual identification number and family relationship is given as standard CEPH nomenclature.
aIn one case the sample failed to amplify and genotype was inferred from the relatives.
equivalent in MD-cl and MD-949 samples suggesting that
constitutional heterozygous DNA MMR gene mutation does
not influence mutation rate in the male gamete in this case.
Although both addition and deletion mutations were identi¬
fied, we observed a bias towards repeat losses over gains in the
sperm (%2 = 11.0, P < 0.001 and %2 = 10.3, P < 0.001 for MD-cl
and MD-949 sperm samples, respectively).
DISCUSSION
Long poly(A/T) tracts are abundant in the human genome,
occurring at the 3' untranslated region (UTR) of genes (30) and
within intronic sequences as well as coding regions (17).
Length variation at such repetitive sequences has importance
with respect to gene expression and function (21,30-32). In
addition, poly(A/T) markers play an important role in the
classification of microsatellite unstable CRCs (6). Here we
report a series of studies aimed at defining germline stability of
a paradigm poly(A/T) repeat locus. By analysis of two cohorts
we show that BAT-40 is a highly polymorphic locus with an
observed level of heterozygosity of 59.7%. This is similar to a
previous analysis of a CEPH cohort in which a level of hetero¬
zygosity of 72% was reported. However, the level of BAT-40
heterozygosity detected here and in a CEPH cohort by Zhou
et al. (25) is considerably higher that that observed in a
Japanese cohort (14.6%) (29). Although this might be
explained in part by variation in allele heterozygosity between
populations, the Japanese study cohort were from hospital
based samples and may not be representative of the true
Japanese population frequencies. Our confirmation that BAT-40
is a highly polymorphic locus suggests that generation of new










Figure 5. Representative example of a putative BAT-40 germline mutation in
CEPH family 1346. While the mother -02 (A) has a BAT-40 genotype of 122/
127, the father -01 (B) appears homozygous for a 123 bp allele. The mother's
127 bp allele is detected in child -09 (C) but the most predominant peak in the
first complex is at 124 bp. This would indicate a 1 bp mutation at BAT-40 had
occurred in the germline of the father. Sizing of the extreme stutter bands also
indicates a 1 bp mutation of the father's 123 bp allele in c-09 and confirms the
presence of the 127 allele derived from m-02.
Instability at BAT-40 is well documented in MMR deficient
tumours (6,21) and we have also observed instability at this
locus in cells derived from normal tissue that are deficient in
MMR (33). These data also indicate that this repeat locus might
be particularly unstable. Identification of a germline mutation
at BAT-40 in a Scottish pedigree suggests that this locus is also























Figure 6. Representative ABI310 traces of BAT-40 alleles detected by SP-PCR
in matched blood (A) and sperm (B) DNA. Almost all BAT-40 SP-PCR prod¬
ucts amplified from blood DNA revealed individual alleles with predominant
peaks of the same size as those in undiluted (UD) DNA. For MD-949 these
were 121 and 124 bp. The majority of BAT-40 SP-PCR products amplified
from sperm DNA were also of wild-type allele size as shown. However, a sig¬
nificant number of mutant alleles were detected. Mutants of 117 and 119 bp are
illustrated here.
highly unstable in the germline. Explanations such as failure to
amplify larger alleles as an explanation for apparent germline
mutations, such as that in MD-449, are highly unlikely since
larger alleles were detected reliably in the presence of a 112
allele in other family members. Our initial observation in a
single family is supported by pedigree analysis of a further nine
CEPH families, albeit with less dramatic examples, biased in
part by the nature of the parental genotypes. Hence, we chose
individuals with easily distinguishable allele sizes for analysis
of sperm DNA. Analysis of matched sperm and blood DNA at
BAT-40 by SP-PCR demonstrated a statistically significant
increase in the proportion of mutant alleles in sperm compared
to somatic DNA. This argues strongly that the mutations
detected by SP-PCR of sperm DNA are indeed authentic. We
employed rigorous controls to ensure against contamination
(see Materials and Methods). The SP-PCR approach has been
previously shown to detect mutant alleles with equal fidelity in
sperm and constitutional DNA templates as demonstrated by
direct comparisons between mutation rates detected by
SP-PCR of sperm compared to family studies (11). These
studies have consistently validated the SP-PCR approach
(11,14).
The presence of an inactivating MLH/ mutation in the germ¬
line of one individual did not further influence the level of
instability at BAT-40 in the sperm DNA. Intriguingly, there
were shorter mutant alleles predominating in the sperm DNA
despite the fact that the SP-PCR technique reliably detected
both large and short constitutional alleles.
The results presented here provide compelling evidence that
BAT-40 is inherently highly unstable in the germline. It will be
of interest to determine whether this phenomenon is common
and what length of poly(A/T) tract represents a threshold at
which instability becomes likely.
Hypermutability at the BAT-40 locus provides an explana¬
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Figure 7. BAT-40 allele sizes in matched constitutional and sperm DNA detected by SP-PCR. The predominant allele sizes for each individual are indicated by
asterisks, as detected from analysis of undiluted DNA. MD-949 is a CRC patient with a germline mutation in the human MLHI gene. MD-cl is a normal healthy
control individual.
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Table 3. Summary of mutant alleles detected by SP-PCR in matched sperm
and blood DNA from samples MD-949 and MD-cl
Sample Total no. alleles Mutants (frequency)
MD-949 Sperm 91 20 (0.22)
MD-949 Blood 99 4(0.04) (x2= 13.82,/> <0.001)
MD-cl Sperm 164 44 (0.27)
MD-cl Blood 99 5 (0.05) (%2 = 19.32, P< 0.001)
Scottish, CEPH and other populations studied, since transmis¬
sion of new germline variants can become established within
the population.
The evidence that BAT-40 represents a poly(A/T) tract
within the genomic structure of a gene and exhibits instability
in the germline might be of importance in understanding the
mechanisms generating mutations at other such polymorphic
repeat loci. Indeed this phenomenon may be common to many
poly(A/T) tracts and further study of such sequences is merited
to elucidate whether this is a widespread phenomenon. Poly(A/T)
tracts are ubiquitous at the 3TJTR of all coding genes where
the stability in length of the poly(A) tail is of known functional
importance to the stability of the mRNA species (30). Of further
relevance, these repetitive tracts are common in intronic
sequence (17), and shortening of intronic mononucleotides has
also been shown to have functional consequences. For
instance, aberrant splice variants of the ATM gene that result
in ataxia-telangiectasia can arise as a consequence of shortened
intronic mononucleotide tracts (31). In addition the shortened
poly(T)5 variant in intron 8 of the cystic fibrosis transmembrane
conductance regulator gene causes congenital bilateral absence
of the vas deferens when associated with a cystic fibrosis muta¬
tion on the other allele (34). Mutation of poly(A/T) tracts
within exonic sequences have also been shown to contribute to
carcinogenesis and this is exemplified by mutation of the
TGFBR2 gene in MSP CRCs (20,21). Hence, it seems reason¬
able to speculate that the mechanism of inherent instability
elucidated here might also have relevance to a number of genes
containing such repeats.
BAT-40 is used routinely as a marker in determining tumour
genomic stability in relation to defective DNA MMR, due to
its extreme sensitivity to mutation in the absence of MMR
activity (5,21,23). Microsatellile markers that display such
germline hypermutability should be used with caution in view
of the likelihood of mitotic instability. Very unstable markers
may be too sensitive to provide the specificity to MMR defects
that is clearly required in such screening strategies. The
evidence reported here supports a growing number of studies
that highlight the importance of understanding inherent charac¬
teristics influencing marker stability when they are used in
clinical analyses (7,23,26,35).
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Mutation frequency in coding and non-coding repeat sequences in mismatch
repair deficient cells derived from normal human tissue
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Repetitive tracts within the coding regions of TGFBR2
and BAX are frequently mutated in mismatch repair
deficient tumours and are implicated in tumour progres¬
sion. However, there has been little study of the balance
between selection pressure and inherent instability at
sequences within these genes. To determine whether
TGFBR2 and BAX are inherently prone to mutations in
the presence of MMR defects, we studied MMR
deficient cells derived from B-lymphocytes. By analysing
cells derived from normal tissue we aimed to minimize
the effects of selection pressures that bias the apparent
frequency of mutation. We definitively show that certain
sequences, usually repaired by MMR, are inherently
unstable. Using a small pool PCR technique we
confirmed these cells exhibit microsatellite instability.
Additionally, we demonstrate that MMR deficiency
results in an excess of mutations, specifically at the
poly(A)io tract compared to other regions of the
TGFBR2 gene (P< 0.001). Conversely, an excess of
mutations does not appear to arise at the poly(G)8 tract
of the BAX gene. These studies provide insight into the
mechanism by which TGFBR2 and BAX genes become
mutated during tumorigenesis. These findings invoke the
notion of 'unmasking' specific hypermutable sequences in
particular genes adding further complexity to the concept
of the mutator phenotype. Oncogene (2001) 20, 7464-
7471.
Keywords: TGFBR2; mutation rate; BAX; mismatch
repair; colon cancer
Introduction
A mutator phenotype is well documented in tumours of
patients with hereditary non-polyposis colorectal cancer
(HNPCC), and also in a subset of sporadic cancers
(Aaltonen et al., 1993). Such genomic instability is
largely due to inactivation of one or more of the
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mismatch repair (MMR) genes (MLH1, MSH2,
PMS2, PMS1, MSH6) (Papadopoulos and Lindblom,
1997) by mutation or promoter hypermethylation
(Wheeler et al., 1999). Disruption of MMR leads to
accumulation of mutations at simple microsatellite
sequences and within the repetitive tracts of coding
sequence (Ionov et al., 1993; Parsons et al., 1995a). A
mutator phenotype, combined with selection pressure, is
believed to allow the accumulation of mutations in key
genes leading to progression of neoplasia from cellular
clones to invasive cancers (Cahill et al., 1999). However,
the relative contribution of selection pressure and
inherent instability at specific gene sequences is not clear.
Mutations in repetitive sequences within a number of
genes have been identified in microsatellite unstable
(MSG) tumours, including TGFBR2, BAX and IGFR2,
(Markowitz et al., 1995; Ouyang et al., 1997; Rampino
et al., 1997). However, the observation of gene
mutations in MMR deficient cancers does not prove
that such mutations are tumorigenic and not simply
bystander effects. Other lines of evidence are required
to establish pathogenicity (Boland et al., 1998).
Mutations in the poly(A)10 tract of the transforming
growth factor beta type 2 receptor (TGFBR2) gene are
observed in over 90% of MMR deficient colorectal
tumours (Markowitz et al., 1995). The transforming
growth factor beta (TGFB) signalling pathway results
in potent anti-proliferative responses (Wang et al.,
1995). Loss of this negative regulatory mechanism
results in excess cell growth suggesting that the
TGFBR2 gene behaves as a tumour suppressor. Bi-
allelic inactivation of TGFBR2 has been demonstrated
in most MSG colorectal cancers (CRC's) (Parsons et
al., 1995a). Furthermore, in microsatellite stable (MSS)
CRC's, inactivating point mutations in TGFBR2
(Grady et al., 1999) and, mutational inactivation of
other components of the TGFB signalling pathway
(SMAD2 and SMAD4), have also been observed
(Eppert et al., 1996). Together such studies suggest
inactivation of TGFBR2 and subsequent disruption of
the TGFB signalling pathway is an important step
during colon carcinogenesis.
Around 50% of MSI+ cancers contain mutations in
the poly(G)s tract of the pro-apoptotic BAX gene
(Rampino et al., 1997). Bi-allelic inactivation in some
cases suggests that BAX mutations are important
during progression of MMR deficient tumours. How-
Coding mutations in normal cells with MMR defects
AL Bacon ef a/
ever, inactivation of both alleles is not observed with
the same frequency as in the TGFBR2 gene (Rampino
et al., 1997). The prevalence of mutations observed in
the repetitive tracts of both TGFBR2 and BAX are in
excess of those at non-coding repeats in intronic
sequence, suggesting a clonal selection effect (Zhang
et al., 2001).
Mutations at microsatellites occur consistently in
adenomas with MMR gene defects (Shibata et al.,
1994) and have also been detected in the earliest lesions
known as aberrant crypt foci (Pedroni et al., 2001).
Such observations suggest that microsatellite instability
(MSI) is an early event in the progression of a normal
cell towards a cancerous phenotype. TGFBR2 muta¬
tions are similarly observed within MMR deficient
adenomas suggesting that these mutations also occur
early during tumorigenesis (Grady et al., 1998; Abdel-
Rahman et al., 1999). Although BAX mutations have
been observed in early tumours, there are also data
suggesting they occur at a later stage in tumour
development (Abdel-Rahman et al., 1999).
The relative contribution of inherent, sequence-
specific instability has not been studied extensively.
Early neoplastic lesions are subject to selection pressure
and so evolve clonally, analogous to more advanced
tumours. Furthermore, even early lesions have accu¬
mulated multiple mutations making it difficult to
dissect the contribution of events resulting directly
and exclusively from MMR defects.
We hypothesized that differences in mutational
frequencies at the TGFBR2 and BAX genes may reflect
differences in the relative contributions of inherent
mutation and effects of selection at these loci. There¬
fore we set out to investigate the intrinsic instability in
these genes using a system where MMR is defective but
cells are not subject to bias due to molecular changes
that characterize the malignant phenotype. We con¬
ducted a series of studies in lymphoblastoid cells that
are deficient in MMR, and we show sequence specific
hypermutability at the poly(A)|0 tract of the TGFBR2
gene arising in cells of normal lineage.
Results
Characterization of the mutator phenotype in eel/ lines
derived from lymphocytes with constitutive mismatch
repair defects
Lymphoblast cell lines lbl-1261 and lbl-1260 are
derived from lymphocytes of patients with germline
mutations of the MMR genes PMS2 and MLFI1
respectively (Parsons et al., 1995b). These mutations
have both previously been demonstrated to result in
the complete loss of MMR activity (Parsons et al.,
1995b). The PMS2 mutation in lbl-1261 exerts a
dominant negative effect (Nicolaides et al., 1998), while
we have shown that MLH1 expression is dramatically
reduced in lbl-1260 (data not shown).
We set out to characterize in detail the mutator
phenotype previously reported in these cell lines
7465
(Parsons et al., 1995b). Both cell lines were confirmed
to be derived from B-lymphocytes by demonstration of
the appropriate pattern of expression of lymphocyte
and epithelial cell specific markers, detected by flow
cytometry (data not shown).
We anticipated that mutations in these cell lines were
likely to arise at a low frequency within a population
of predominantly wild type cells. Hence, we employed
a sensitive, small pool PCR (SP -PCR) strategy to
genotype individual microsatellite alleles from lbl-1261
and lbl-1260 DNA plus control cell lines (lbl-c5 and
lbl-cl) at two microsatellite markers (BAT-40 and
D2S123) (Figure 1). Cell lines lbl-1260 and lbl-1261
both displayed a substantially greater proportion of
mutant alleles compared with control cell lines (Figure
1 and Table 1) in accordance with previous findings
(Parsons et al., 1995b). For lbl-1261, 89/270 (33%)
D2S123 alleles and 71/139 (51.1%) BAT-40 alleles were
mutant, as were 10/120 (8.3%) and 13/54 (24.1%)
alleles typed from lbl-1260. The proportion of mutant
alleles for lbl-1261 and lbl-1260 was significantly
greater than that observed in control cell lines, at both
BAT-40 (r = 50.5, P<0.001; = 15.4; P<0.001) and
D2S123 (r = 28.7, PcO.OOl; *2 = 4.4, P = 0.036) (Table
1). Notably lbl-1261 displayed a significantly higher
level of microsatellite instability compared to lbl-1260
Of = 25.2, P< 0.001). Insertion and deletion mutant
alleles were observed indicating that PCR bias for
reductions in tract length was not a major factor.
There was evidence of heterogeneity in the degree of
instability between microsatellite loci. The proportion
of mutant BAT-40 alleles was significantly greater than
that of D2S123 in both cell lines (^2 = 9.9, P< 0.001)
suggesting differential susceptibility of simple sequence
repeats (SSRs) to replication error.
These data show firstly, that lymphoblastoid cell
lines lbl-1260 and lbl-1261 with MLH1 and PMS2
mutations respectively, exhibit microsatellite instability.
Secondly, that there is considerable heterogeneity in the
degree of instability between the two MMR deficient
cell lines, presumably due to the MMR gene mutation
itself. Furthermore, the results demonstrate inherent
differences in instability between particular SSR's.
Excess mutations arise in the poly (A) 10 tract of
TGFBR2 in lbl-1261
To address whether the mutator phenotype described
above also results in instability within genes known to
be involved in colorectal carcinogenesis, we analysed
lbl-1261 and lbl-1260 for mutations in the poly(A)10
tract of TGFBR2. There were considerable difficulties in
reproducibly detecting mutations in alleles of the
TGFBR2 poly(A)]0 tract amplified by SP PCR using
FoVo as a positive control. Therefore we adapted a
sensitive assay to detect 1 bp deletions occurring at low
frequency within the poly(A)|0 tract of TGFBR2
(Mironov et al., 1999). In brief, the reverse primer
introduces a Hinf I site in the presence of a 1 bp
deletion in the poly(A)|0 tract, whereas in the presence
of wild type sequence no Hinf I restriction site is
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Figure 1 D2S123 (a-c) and BAT-40 (d f) alleles identified in MMR deficient (lbl-1261 (a and d) and lbl-1260 (b and e)) and
MMR proficient (lbl-c5 (c and f)) lymphoblastoid cell lines detected by SP-PCR. The predominant constitutional alleles (*) were
sized by analysis of undiluted DNA. Alleles for D2S123 (a and c) have been reported by us previously (Bacon et al., 2000) but are
shown here for comparison
Table 1 Summary data of alleles typed at DS2123 and BAT-40 SSR
loci in lbl-1261, lbl-1260 and controls. BAT-40 control allele data is
composed of pooled allele counts for lbl-c5 and second cell line lbl-cl
that was also typed at BAT-40
DS2123 BAT-40
Total Mutants Total Mutants
Cell line alleles (% alleles typed) alleles (% alleles typed)
lbl-1261 270 89 (33.0) 139 71 (51.1)
lbl-1260 120 10 (8.3) 54 13 (24.1)
Controls 109 2(1.8) 154 6 (3.9)
introduced during the PCR step (Mironov et al., 1999).
Digestion products are detected using an AB1310
genetic analyser. This assay reliably detected the
presence of mutant TGFBR2 alleles in positive control
lines, LoVo and HCT116 (Figure 2). Mutations were
also detected in lbl-1261 DNA, indicating an appreci¬
able level of mutant alleles in lbl-1261 (Figure 2).
Intriguingly, the frequency of mutant alleles indicated
for lbD 1260 was not significantly different to that of
wild type control DNAs (Figure 2).
In order to quantify and to characterize mutations
arising in lbl-1261. exon 3 of TGFBR2 was PCR cloned
(Figure 3 and Table 2). Of 56 clones sequenced, 17
(30.3%) were mutated at the poly(A)I0 tract. In
contrast only three (6.8%) of the 44 wild type control
clones were mutant presumably representing technical
artefact. These data demonstrate a significant excess of
mutations at the poly(A)|0 region of TGFBR2 in
lbl-1261 compared to a control cell line (^2 = 8.5,
P = 0.003). Most of the exon 3 poly(A)|0 mutations
detected in lbl-1261 were 1 bp deletions (82%),
supporting the validity of the results from the digest
assay described above. However a small number of
1 bp insertions, plus an A->G transition were also
identified. The frequency and the spectrum of these
mutations strongly suggests they are not constitutional
variants but arise somatically. These data provide
compelling evidence that de novo mutations arise
frequently due to inherent instability of the poly(A)|0
repeat in TGFBR2 but these are normally repaired by a
proficient DNA MMR apparatus.
Determination of the relative susceptibility to mutation of
regions within TGFBR2
Next we wished to determine the relative susceptibility
to mutation of regions within the TGFBR2 gene. In
particular to address whether the mutator phenotype
results in predilection for mutation at the poly(A)|0
repeat sequence or whether the observations were
simply the result of non-specific increase in mutation
rate. Therefore we compared mutant allele counts
arising at non-repeat regions of the TGFBR2 gene in
lbl-1261 to those arising in the poly(A)l0 tract. A
216 bp region of exon 3 flanking the repetitive
poly(A)i0 region and a 245 bp non-repeat region of
exon 4 were screened for mutations by PCR cloning
and sequencing of individual alleles. Exon 4 contains a
site found to be mutated in MSS colorectal cancer (Lu
et al., 1998) but lacks long repeats. No mutations were
identified in this region in a total of 7840 bp of
sequence from 32 lbl-1261 alleles sequenced for exon 4
Oncogene
(Figure 4 and Table 2). However, in the non-repetitive
region of exon 3, six transition mutations were
identified in a total of 10 928 bp of sequence analysed
from 49 lbl-1261 alleles, a frequency of 0.55 mutations/
kb (Figure 4 and Table 2). There were no mutations in
the non-repetitive region of exon 3 in a total of
8897 bp from 40 control (lbl-c5) alleles (Figure 4).
These data indicate that exon 3 of the TGFBR2 gene
appears particularly prone to mutation, compared with
Coding mutations in normal cells with MMR defects
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exon 4 of the same gene (P = 0.036), and also compared
to the same region in a control cell line (Z3 = 0.036).
Nonetheless, the proportion of mutations detected in
the non-repeat region of TGFBR2 is significantly lower
than that for the poly(A)l0 tract (P<0.001).
Taken together, these results show that exon 3 of
TGFBR2 is inherently mutable and that predilection
for instability at the poly(A)10 tract contributes to the




















Figure 2 Representative ABI 310 traces of the poly(A)i0 tract in
exon 3 of the TGFBR2 gene from wild type (lbl-c5) (c) and
mutant (LoVo) (d) control cell lines corresponding to the presence
or absence of mutant template alleles after Hinfl digestion. There
were only constitutional genotype peaks for lbl-1260 (b), but
mutant peaks were reproducibly detected for lbl-1261 (a)
Analysis of inherent instability at the BAX gene in MMR
deficient cells
Since lbl-1261 was particularly unstable at TGFBR2
and non-coding repeats, we wished to determine
whether this phenotype was associated with a high
level of mutation in the poly(G)8 repeat of the pro-
apoptosis gene, BAX. SP-PCR was employed to
genotype alleles using LoVo as a positive control. Of
164 SP-PCR products only two mutants (1.2%) were
detected by DHPLC analysis of the 94 bp products
(data not shown). Sequencing of mutant SP-PCR
products confirmed a 1 bp insert at the poly(G)g tract.
No mutations were detected in 106 SP-PCR products
analysed from a control cell line. These data suggest
that mutations do also occur at the repetitive poly(G)8















Ibl-c5, n=46 lbl-1261, n=56
cell line
Figure 3 Summary data showing an excess of mutations in the
poly(A)]0 tract of TGFBR2 in lbl-1261 as detected by allele
cloning and sequencing (T3 = 0.003)
Table 2 Summary of mutations detected, as a function of total bps sequenced, at three separate regions within the TGFBR2 gene in lbl-1261
and control cells
Region TGFBR2 exon 3 poly(A)io repeat TGFBR2 exon 3 non-repeal TGFRB2 exon 4
(nt 1021 to nt 1266,
analysed (nt 709 to nt 718, 10 bp) (nt 599-10 to nt 789, 216 bp) 245 bp)
cell lines lbl-1261 Control lbl-1261 Control lbl-1261 Control
Total sequence 0.56 0.44 11.016 8.967 7.840 ND
analysed/Kb
Mutations identified 14x1 bp del
2 x 1 bp ins
1 x a-g transition
2 x 1 bp del








Mutation frequency, Mutations/Kb 30.36 6.82 0.55 Undetectable Undetectable ND
Oncogene
Coding mutations in normal cells with MMR defects





Figure 4 Comparison of the non-repeat coding sequences to the
poly(A)10 tract in TGFBR2. Mutation data are presented as
mutations/kb sequenced, to account for variation in the length of
cloned fragments
than that arising in TGFBR2 and is below the level of
reliable detection.
Discussion
The data presented here demonstrate a substantial level
of inherent instability at SSRs and in coding sequences
as a consequence of MMR deficiency in cell lines
lbl-1260 and lbl-1261 that are derived from non-
tumour tissue. By analysis of alleles by SP-PCR we
have demonstrated that despite being of B-lymphocyte
lineage, lbl-1260 and lbl-1261 exhibit an appreciable
level of microsatellite instability, confirming previous
findings (Parsons et al., 1995b). We extend these
findings and show that there is significant heterogeneity
with regards to both the spectrum and frequency with
which mutations occur at microsatellite sequences in
these cells. We also provide evidence that inherent
mutability in the TGFBR2 gene contributes to the
frequent observation of mutations in MSI+ tumours.
The instability shows a clear propensity to the same
poly(A)i0 tract that is frequently mutated in MSI'
tumours. Our analysis of the poly(G)8 tract of the BAX
gene indicates that there are varying degrees of
inherent mutational instability within coding regions
known to have a high frequency of mutation in
tumours, and suggests differential contributions from
mutational mechanisms and effects of the tumour
phenotype itself.
We observed evidence of heterogeneity of instability
at microsatellite markers D2S123 and BAT-40, in
lbl-1260 and lbl-1261. Heterogeneity in mutation
frequency between BAT-40 and D2S123 indicates locus
specific influences, and suggests BAT-40 is an in¬
herently more unstable locus (Bacon et al., 2001).
Intrinsic sequence characteristics at given loci can
influence the manifestation of the mutator phenotype
and the mutation bias between alleles at D2S123 has
been previously reported (Bacon et al., 2000).
We employed two independent experimental ap¬
proaches using MMR deficient cells to demonstrate
that the poly(A)10 tract of TGFBR2 is intrinsically
hypermutable even in cells that are not tumour derived.
The data show that mutations can be detected as a
consequence of MMR deficiency when the effects of
selection pressure and other confounding molecular
variables present in tumour cells, are minimized. These
studies were performed in cell lines that represent a
model assay system and as such, selection cannot be
entirely negated. EBV transformed lymphoblast cell
lines are resistant to the effects of TGFB1 due to
selection against TGFBR2 expression (Inman and
Allday, 2000). However, it has been shown that this
is not due to mutation of the poly(A)|0 repeat in exon
3 (Inman and Allday, 2000). Furthermore, the
comparison with control lines shows conclusively there
is an important MMR dependent effect.
Since we detected a number of different TGFBR2
mutant alleles, the findings are consistent with the
occurrence of somatic events rather than pre-existing
constitutional heterozygous mutations or mosaicism.
The fact that excess mutations were not observed in
TGFBR2 in lbl-1260 might indicate a threshold effect
of MMR activity in the cell lines studied here, which
has an influence on the ability for replication errors to
be repaired.
The fact that we detected mutations in sequences
encoding tumour suppressor genes as well as non-
coding repeats in cells derived from a normal B-cell
lineage is remarkable in itself. That lbl-1261 appears
particularly prone to mutation may be due to gene
specific influences. Indeed, a recent report (Vilkki et al.,
2001) did not detect any TGFBR2 mutant alleles in
autopsy material from a child with homozygous MLH1
mutations. Interestingly, cell line lbl-1260 which
contains a heterozygous MLH\ mutation displays a
lower incidence of mutation at both coding and non-
coding sequence (Parsons et al., 1995b).
Few studies have addressed mutation frequency at
the non-repetitive sequences surrounding the mutable
repeat tracts in genes implicated in tumorigenesis in
MSI ' tumours (Takenoshita et al., 1997). Here we
demonstrate that non-repeat regions are not subject to
high levels of mutation, indicating that it is the repeat
sequence and not the entire TGFBR2 gene, which is
prone to instability consequent of MMR deficiency.
Analysis of the poly(G)s repeat in the BAX gene,
suggests that although this is mutated frequently in
MMR deficient colorectal tumours, it does not share
the same intrinsic propensity for mutation observed at
the poly(A)io repeat of TGFBR2. These results give
considerable insight into susceptibility of the BAX and
TGFBR2 genes to mutations arising exclusively as a
result of MMR defects. The high mutability of the
poly(A)l0 tract is likely to be a consequence of
increased replication error at this region. Such error
is well documented and, dependent on the number of
repeats in the tract (Parsons et al., 1995a; Dietmaier et
al., 1997). Chromatin structure within or surrounding
such sequences has also been suggested to contribute to
mutability at repeat tracts (Zhang et al., 2001). In this
regard it is interesting to note that we detected a low,
but appreciable, frequency of mutation in the flanking
Oncogene
sequence surrounding the poly(A)|0 tract in lbl-1261
that was significantly greater than that observed for
exon 4 of the same gene.
That the TGFBR2 poly(A)10 tract is so readily prone
to mutation goes some way to explain why these
mutations are observed with such a consistently high
frequency within MMR deficient cancers (Markowitz
et al., 1995) and also in early adenomas (Abdel-
Rahman et al., 1999). Taken together with these
previous studies, the data presented here supports the
notion that MMR inactivation occurs very early in
neoplastic transformation and results in accumulation
of mutations in the TGFBR2 poly(A)10 tract. Subse¬
quently, selection pressure for homozygous mutations
would be anticipated to result in clonal selection within
the tumour. Since we detected only a very low level of
BAX mutations in the most unstable line lbl-1261, this
suggests that BAX is inherently more stable and that
selection pressures may play a greater role than is the
case for TGFBR2 mutations. The data presented here
suggec'" that BAX mutations arise infrequently and
th: .iay explain why they are less frequently observed
a, arc not detectable at such an early stage in
tumorigenesis as TGFBR2 mutations (Rampino et al.,
1997; Abdel-Rahman et al., 1999).
Taken together these findings indicate that intrinsic
mutational instability is an important determinant of
mutation frequency observed in MSI tumours. Use of
cells derived from normal tissue has allowed analysis of
the mutation frequency consequent upon MMR
deficiency, while minimizing bias from the effects of
selection and confounding abnormalities. It will be of
interest to determine which other coding gene
sequences are similarly susceptible to mutation in cell
lines lbl-1260 and lbl-1261 as this might identify




Epstein-Barr virus (EBV) transformed lymphocytes from two
healthy control individuals (lbl-c5, lbl-cl) were cultured in
RPMI with 10% FCS 1% P/S. EBV transformed lympho¬
cytes from two patients with colorectal cancer and
phenotypic evidence of Turcots syndrome (lbl-1261,
lbl-1260) were a gift from Bert Vogelstein. These patients
carry germline defects in PMS2 and MLH1 respectively and
have been shown to lack MMR activity (Parsons et al.,
1995b).
Flow cytometry
Cells were analysed for the presence of B-cell specific and
epithelial cell specific markers. Antibodies used were PE
conjugated anti-human CD 19 (B-cell specific) (Caltag) and.
unconjugated anti-cytokeratin antibody (epithelial cell spe¬
cific) (Clone BER-EP4, DAK.O) detected using a second step
FITC conjugated anti-mouse IgG. Data for 10 000 cells was
acquired and analysed using a FACSCaliber and Cell Quest
Software (Becton Dickinson). Controls included were un-
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stained cells and cells stained with FITC conjugated anti-
mouse IgG alone. The cancer cell line HCT116 provided a
positive control for the epithelial marker BER-EP4.
Small pool PCR
DNA from cell lines was diluted to a final concentration of
15-20 pg per PCR reaction as previously described (Bacon et
al., 2000). Fluorescently labelled D2S123 and BAT-40
primers (Parsons et al., 1995a) were used for microsatellite
analysis. Non fluorescent primers were used to amplify a
94 bp region encompassing the poly(G)8 repeat at codons 38
to 41 of the BAX gene (Rampino et al., 1997).
High fidelity PCR amplifications were performed using
Expand high fidelity PCR system as previously described
(Bacon et al., 2000). Reactions were prepared in 96 well
plates. DNA free controls were prepared in 16 wells per plate
and positive controls containing 100 ng of cell line DNA
were prepared in two wells in every plate. Amplification was
performed on an Omnigene PCR system thermal cycler
(Hybaid) at 94°C (3 min) for 1 cycle, 94°C (1 min), 55°C
(1 min), 72°C (1 min) for 35 cycles, 72°C (5 min) for 1 cycle.
For microsatellite markers 2 pi of each PCR reaction
including positive and negative controls was analysed on an
ABI310 Automated Genetic Analyser, using Genescan soft¬
ware. For the BAX gene ABI310 analysis was not sensitive
enough to pick up a 1 bp deletion in a known mutant, LoVo
(Carethers and Pham, 2000 ), due to the small size of the
fragment. 3 pi of BAX SP-PCR products were subjected to
a second round of PCR allowing visualization of products on
an agarose gel. These were subsequently analysed by DHPLC
using a Transgenomic waverM machine along with the
known mutant control.
The frequency of mutant alleles in each cell line for both
microsatellite markers was expressed as the number of alleles
which were mutant in length, divided by the total number of
alleles detected (normal and mutant). Accordingly, frequen¬
cies are not exact contents of cells with alterations but
relative values. Differences between mutation frequency in the
two cell lines compared to controls, and between MSI
frequency at the two microsatellite markers was evaluated
using a Chi-squared test (Minitab V.13). Significance was
taken at the 5% level.
TGFBR2 restriction digest mutation detection assay
We adapted a sensitive assay (Mironov et a/., 1999) to
provide an initial analysis to detect 1 bp deletions in the
poly(A)|0 tract of TGFBR2. DNA samples from lbl-1261,
lbl-1260, control wild type (lbl-c5) and a control mutant cell
lines, LoVo and HCT116 (Carethers and Pham, 2000) were
amplified using a primer that induces a Hinf I restriction site




These primers would be expected to amplify alleles of
length Ay and longer. Since LoVo contains one Ay and one
Ax allele (Carethers and Pham, 2000) the primers used would
not be expected to amplify the A8 allele. PCR reactions were
performed in a final volume of 25 pi using the Expand high
fidelity PCR system as previously described (Bacon et al.,
2000 and above). Five p\ of PCR product was digested at
37°C overnight in a total volume of 15 p\ with 5 units Hinfl
restriction enzyme and IX buffer H (Boehringer Mannheim).
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Products were analysed on an AB1 310 Automated Genetic
Analyser, using Genescan software. Wild type undigested
fragments are visualized at 141 bp and mutant Hinf I digest
fragments at 118 bp. The analysis was performed on each cell
line in triplicate.
Cloning and sequence analysis
A 266 bp region of TGFBR2 exon3 encompassing the
poly(A)10 tract was PCR cloned from lbl-1261 and wild type
control, lbl-c5, DNA (primers described elsewhere, Lu et al.,
1996). A 245 bp non-repetitive region of TGFBR2 exon 4 was
also cloned from lbl-1261 DNA. PCR reactions were
performed as above using the following primers;
Forward: CCACGTGTGCCAACAACATCAACC
Reverse: CAGCCGTCAGGAACTGGAGTA
PCR fragments were cloned into TA cloning vectors using
TOPO TA Cloning kit version K2 (Invitrogen BV, Gronin-
gen, The Netherlands) according to the manufacturer's
instructions. Plasmid DNA was extracted from transformants
using a QIAprep miniprep kit (QIAGEN Ltd, Crawley, UK).
Sequencing was performed using M13 primers and PRISM
ready Dye Terminator Cycle Sequencing Kit with AmpliTaq
DNA polymerase, FS (Taq-FS: Perkin Elmer/Applied
Biosystems) on an Applied Biosystems DNA sequencer
model 373A or 377. DNA sequence analysis was performed
by use of Sequencing analysis 3.0 and Sequencher™ 3.0
(Gene Codes Corporation). All clones were sequenced at least
in duplicate and the majority of mutants were re-confirmed
by re-isolating and sequencing clone DNA from bacterial
stocks.
A two tailed fishers exact test (http://home.clara.net/sisa/
fisher.htm) with significance taken at the 5% level was used
to evaluate differences in the number of mutations observed
in the total amount of cloned sequences from different loci,
or the same loci between different cell lines. When using this
method it is assumed that mutations occur independently at
any given base pair within the given locus.
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